0000882104-18-000091.txt : 20180809 0000882104-18-000091.hdr.sgml : 20180809 20180809163139 ACCESSION NUMBER: 0000882104-18-000091 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 104 CONFORMED PERIOD OF REPORT: 20180630 FILED AS OF DATE: 20180809 DATE AS OF CHANGE: 20180809 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PDL BIOPHARMA, INC. CENTRAL INDEX KEY: 0000882104 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943023969 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-19756 FILM NUMBER: 181005531 BUSINESS ADDRESS: STREET 1: 932 SOUTHWOOD BLVD CITY: INCLINE VILLAGE STATE: NV ZIP: 89451 BUSINESS PHONE: 775-832-8500 MAIL ADDRESS: STREET 1: 932 SOUTHWOOD BLVD CITY: INCLINE VILLAGE STATE: NV ZIP: 89451 FORMER COMPANY: FORMER CONFORMED NAME: PROTEIN DESIGN LABS INC/DE DATE OF NAME CHANGE: 19930328 10-Q 1 pdli-2018063010qdoc.htm 10-Q Document


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
 
 (Mark One)
ý
Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
For the quarterly period ended June 30, 2018
OR
¨
Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
For transition period from               to            
Commission File Number: 000-19756
 
pdllogoa01.jpg
PDL BIOPHARMA, INC.
(Exact name of registrant as specified in its charter)
 
Delaware
94-3023969
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification No.)
932 Southwood Boulevard
Incline Village, Nevada 89451
(Address of principal executive offices and Zip Code)

(775) 832-8500
(Registrant’s telephone number, including area code)
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes  ý    No   ¨
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).   Yes  ý    No  ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ¨
Accelerated filer ý
Non-accelerated filer ¨
Smaller reporting company ¨
Emerging growth company ¨
(Do not check if a smaller reporting company)
 
 
 
 
 
If an emerging growth company, indicated by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ¨
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act)    Yes  ¨    No  ý
As of July 30, 2018, there were 145,400,381 shares of the registrant’s Common Stock outstanding.



 PDL BIOPHARMA, INC.
2018 Form 10-Q
Table of Contents
 
Page
PART I - FINANCIAL INFORMATION
 
 
 
ITEM 1.
FINANCIAL STATEMENTS (unaudited)
 
 
 
 
Condensed Consolidated Statements of Income for the Three and Six Months Ended June 30, 2018 and 2017
 
 
 
 
Condensed Consolidated Statements of Comprehensive Income for the Three and Six Months Ended June 30, 2018 and 2017
 
 
 
 
Condensed Consolidated Balance Sheets at June 30, 2018 and December 31, 2017
 
 
 
 
Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2018 and 2017
 
 
 
 
Notes to the Condensed Consolidated Financial Statements
 
 
 
ITEM 2.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
 
 
 
ITEM 3.
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
 
 
 
ITEM 4.
CONTROLS AND PROCEDURES
 
PART II - OTHER INFORMATION
 
 
 
ITEM 1.
LEGAL PROCEEDINGS
 
 
 
ITEM 1A.
RISK FACTORS
 
 
 
ITEM 2.
UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
 
 
 
ITEM 3.
DEFAULTS UPON SENIOR SECURITIES
 
 
 
ITEM 4.
MINE SAFETY DISCLOSURES
 
 
 
ITEM 5.
OTHER INFORMATION
 
 
 
ITEM 6.
EXHIBITS
 
 
SIGNATURES
We own or have rights to certain trademarks, trade names, copyrights and other intellectual property used in our business, including PDL BioPharma and the PDL logo, each of which is considered a trademark. All other company names, product names, trade names and trademarks included in this Quarterly Report on Form 10-Q are trademarks, registered trademarks or trade names of their respective owners.

2


PART I. FINANCIAL INFORMATION

 ITEM  1.         FINANCIAL STATEMENTS

 PDL BIOPHARMA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)
(In thousands, except per share amounts)
 
 
Three Months Ended
 
Six Months Ended
 
 
June 30,
 
June 30,
 
 
2018
 
2017
 
2018
 
2017
Revenues
 
 
 
 
 
 
 
 
Royalties from Queen et al. patents
 
$
1,218

 
$
16,285

 
$
4,001

 
$
30,441

Royalty rights - change in fair value
 
12,842

 
83,725

 
23,933

 
96,871

Interest revenue
 
751

 
5,460

 
1,500

 
10,917

Product revenue, net
 
31,761

 
18,829

 
55,085

 
31,410

License and other
 
3

 
19,536

 
574

 
19,636

Total revenues
 
46,575

 
143,835

 
85,093

 
189,275

Operating expenses
 
 

 
 

 
 

 
 

Cost of product revenue (excluding intangible asset amortization)
 
14,524

 
4,515

 
25,090

 
7,067

Amortization of intangible assets
 
6,384

 
6,148

 
12,677

 
12,163

General and administrative
 
14,529

 
11,288

 
26,190

 
23,864

Sales and marketing
 
5,385

 
3,616

 
10,898

 
6,200

Research and development
 
684

 
4,281

 
1,477

 
6,047

Impairment of intangible assets
 
152,330

 
—

 
152,330

 
—

Change in fair value of anniversary payment and contingent consideration
 
(22,135
)
 
1,207

 
(22,735
)
 
2,649

Total operating expenses
 
171,701

 
31,055

 
205,927

 
57,990

Operating income (loss)
 
(125,126
)
 
112,780

 
(120,834
)
 
131,285

Non-operating income (expense), net
 
 

 
 

 
 

 
 

Interest and other income, net
 
1,376

 
276

 
3,290

 
488

Interest expense
 
(2,811
)
 
(5,015
)
 
(6,396
)
 
(9,986
)
Gain on bargain purchase
 
—

 
6,271

 
—

 
6,271

Total non-operating income (expense), net
 
(1,435
)
 
1,532

 
(3,106
)
 
(3,227
)
Income (loss) before income taxes
 
(126,561
)
 
114,312

 
(123,940
)
 
128,058

Income tax expense (benefit)
 
(14,265
)
 
53,873

 
(13,246
)
 
60,425

Net income (loss)
 
(112,296
)
 
60,439

 
(110,694
)
 
67,633

Less: Net loss attributable to noncontrolling interests
 
—

 
—

 
—

 
(47
)
Net income (loss) attributable to PDL’s shareholders
 
$
(112,296
)
 
$
60,439

 
$
(110,694
)
 
$
67,680

 
 
 
 
 
 
 
 
 
Net income (loss) per share
 
 

 
 

 
 

 
 

Basic
 
$
(0.76
)
 
$
0.39

 
$
(0.74
)
 
$
0.42

Diluted
 
$
(0.76
)
 
$
0.39

 
$
(0.74
)
 
$
0.42

Weighted average shares outstanding
 
 

 
 

 
 

 
 

Basic
 
146,923

 
155,654

 
149,186

 
159,677

Diluted
 
146,923

 
156,394

 
149,186

 
160,168

 
See accompanying notes.

3


PDL BIOPHARMA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(Unaudited)
(In thousands)

 
 
Three Months Ended
 
Six Months Ended
 
 
June 30,
 
June 30,
 
 
2018
 
2017
 
2018
 
2017
 
 
 
 
 
 
 
 
 
Net income (loss)
 
$
(112,296
)
 
$
60,439

 
$
(110,694
)
 
$
67,633

 
 
 
 
 
 
 
 
 
Other comprehensive income (loss), net of tax
 
 

 
 

 
 

 
 

Change in unrealized gains on investments in available-for-sale securities:
 
 
 
 
 
 
 
 
Change in fair value of investments in available-for-sale securities, net of tax
 
—

 
—

 
(578
)
 
—

Adjustment for net gains realized and included in net income, net of tax
 
—

 
—

 
(603
)
 
—

Total change in unrealized gains on investments in available-for-sale securities, net of tax(a)
 
—

 
—

 
(1,181
)
 
—

Total other comprehensive income/(loss), net of tax
 
—

 
—

 
(1,181
)
 
—

Comprehensive income (loss)
 
(112,296
)
 
60,439

 
(111,875
)
 
67,633

Less: Comprehensive loss attributable to noncontrolling interests
 
—

 
—

 
—

 
(47
)
Comprehensive income (loss) attributable to PDL’s shareholders
 
$
(112,296
)
 
$
60,439

 
$
(111,875
)
 
$
67,680

 ______________________________________________
(a) Net of tax of zero and zero for the three months ended June 30, 2018 and 2017, respectively, and $314 and zero for the six months ended June 30, 2018 and 2017, respectively.

See accompanying notes.

4


PDL BIOPHARMA, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share amounts) 
 
June 30,
 
December 31,
 
2018
 
2017
 
(unaudited)
 
(Note 1)
Assets
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
395,653

 
$
527,266

Short-term investments
—

 
4,848

Accounts receivable, net
19,531

 
31,183

Notes receivable
58,058

 
53,613

Inventories
14,801

 
9,147

Prepaid and other current assets
20,628

 
14,386

Total current assets
508,671

 
640,443

Property and equipment, net
9,223

 
7,222

Royalty rights - at fair value
335,163

 
349,223

Notes and other receivables, long-term
12,829

 
17,124

Intangible assets, net
54,472

 
215,823

Other assets
25,637

 
13,288

Total assets
$
945,995

 
$
1,243,123

 
 
 
 
Liabilities and Stockholders’ Equity
 

 
 

Current liabilities:
 

 
 

Accounts payable
$
11,212

 
$
19,785

Accrued liabilities
34,294

 
45,881

Accrued income taxes
217

 
1,377

Convertible notes payable
—

 
126,066

Total current liabilities
45,723

 
193,109

Convertible notes payable
120,945

 
117,415

Contingent consideration
18,900

 
42,000

Other long-term liabilities
47,799

 
44,709

Total liabilities
233,367

 
397,233

 
 
 
 
Commitments and contingencies (Note 12)


 


 
 
 
 
Stockholders’ equity:
 

 
 

Preferred stock, par value $0.01 per share, 10,000 shares authorized; no shares issued and outstanding
—

 
—

Common stock, par value $0.01 per share, 350,000 shares authorized; 145,971 and 153,775 shares issued and outstanding at June 30, 2018 and December 31, 2017, respectively
1,460

 
1,538

Additional paid-in capital
(100,229
)
 
(102,443
)
Accumulated other comprehensive income
—

 
1,181

Retained earnings
811,397

 
945,614

Total stockholders’ equity
712,628

 
845,890

Total liabilities and stockholders’ equity
$
945,995

 
$
1,243,123


See accompanying notes.

5


PDL BIOPHARMA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(In thousands)
 
Six Months Ended June 30,
 
2018
 
2017
Cash flows from operating activities
 
 
 
Net income (loss)
$
(110,694
)
 
$
67,633

Adjustments to reconcile net income to net cash provided by (used in) operating activities:
 

 
 

Amortization of convertible notes and term loan offering costs
3,911

 
5,394

Amortization of intangible assets
12,677

 
12,164

Impairment of intangible assets
152,330

 
—

Change in fair value of royalty rights - at fair value
(23,933
)
 
(96,871
)
Change in fair value of derivative asset
(74
)
 
(136
)
Change in fair value of anniversary payment and contingent consideration
(22,735
)
 
2,649

Other amortization, depreciation and accretion of embedded derivative
2,028

 
591

Gain on sale of available-for-sale securities
(764
)
 
(93
)
Loss on disposal of property and equipment
66

 
—

Inventory obsolescence
(491
)
 
161

Bad debt allowance
43

 
54

Stock-based compensation expense
2,218

 
2,075

Deferred income taxes
(11,276
)
 
29,223

Changes in assets and liabilities, net of effects of business acquired:
 

 
 

Accounts receivable
10,764

 
15,058

Receivables from licensees and other
945

 
6,000

Prepaid and other current assets
(6,816
)
 
(2,700
)
Accrued interest on notes receivable
(150
)
 
15,263

Inventories
(5,343
)
 
(1,823
)
Other assets
(1,531
)
 
8

Accounts payable
(8,679
)
 
993

Accrued liabilities
(5,789
)
 
5,542

Deferred revenue
(5,970
)
 
—

Accrued income taxes
(1,159
)
 
10,278

Other long-term liabilities
666

 
(9,851
)
Net cash provided by (used in) operating activities
(19,756
)
 
61,612

Cash flows from investing activities
 

 
 

Purchase of investments
—

 
(19,860
)
Proceeds from sales of available-for-sale securities
4,116

 
29,045

Proceeds from royalty rights - at fair value
37,993

 
48,062

Sale of royalty rights - at fair value
—

 
108,169

Proceeds from sales of assets held for sale
—

 
8,142

Purchase of property and equipment
(3,915
)
 
(705
)
Net cash provided by investing activities
38,194

 
172,853

Cash flows from financing activities
 

 
 

Repayment of convertible notes
(126,447
)
 
—

Cash paid for purchase of noncontrolling interest
—

 
(2,170
)
Cash dividends paid
—

 
(21
)
Repurchase and retirement of common stock
(23,604
)
 
(30,000
)
Net cash used in financing activities
(150,051
)
 
(32,191
)
Net increase (decrease) in cash and cash equivalents
(131,613
)
 
202,274

Cash and cash equivalents at beginning of the period
527,266

 
147,154

Cash and cash equivalents at end of period
$
395,653

 
$
349,428

 
 
 
 
Supplemental cash flow information
 

 
 

Cash paid for income taxes
$
3,980

 
$
14,205

Cash paid for interest
$
4,591

 
$
4,695

 
 
 
 
Supplemental schedule of non-cash investing and financing activities
 
 
 
Asset held for sale reclassified from notes receivable to other assets
$
—

 
$
10,000

Assets held for sale reclassified from other assets to intangibles
$
1,811

 
$
—

Extinguishment of notes receivable
$
—

 
$
43,909

See accompanying notes.

6


PDL BIOPHARMA, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
June 30, 2018
(Unaudited)

1. Summary of Significant Accounting Policies
 
Basis of Presentation
 
The accompanying unaudited Condensed Consolidated Financial Statements of PDL Biopharma, Inc. and its subsidiaries (collectively, the “Company” or “PDL”) have been prepared in accordance with Generally Accepted Accounting Principles (United States) (“GAAP”) for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments), that management of the Company believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.
 
The accompanying unaudited Condensed Consolidated Financial Statements and related financial information should be read in conjunction with the Company’s audited Consolidated Financial Statements and the related notes thereto for the year ended December 31, 2017, included in its Annual Report on Form 10-K for the fiscal year ended December 31, 2017, filed with the Securities and Exchange Commission (“SEC”) on March 16, 2018. The Condensed Consolidated Balance Sheet at December 31, 2017, has been derived from the audited Consolidated Financial Statements at that date, but does not include all disclosures required by GAAP.

Significant Accounting Policies

The Company’s significant accounting policies are described in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017. Summarized below are the accounting pronouncements adopted subsequent to December 31, 2017.

Adopted Accounting Pronouncements

In August 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-15, Classification of Certain Cash Receipts and Cash Payments. The new standard provides for specific guidance how certain transactions are classified in the statement of cash flows. Effective January 1, 2018, the Company adopted the requirements of ASU No. 2016-15. The adoption did not have an effect on the Consolidated Financial Statements on the adoption date and no adjustment to prior year Consolidated Financial Statements was required.

In October 2016, the FASB issued ASU No. 2016-16, Intra-Entity Transfers of Assets Other Than Inventory, which requires companies to account for the income tax effects of intercompany sales and transfers of assets other than inventory in the period in which the transfer occurs. Effective January 1, 2018, the Company adopted the requirements of ASU No. 2016-16. The adoption did not have an effect on the Consolidated Financial Statements on the adoption date and no adjustment to prior year Consolidated Financial Statements was required.

In November 2016, the FASB issued ASU No. 2016-18, Restricted Cash, which requires entities to show the changes in total of cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. Effective January 1, 2018, the Company adopted the requirements of ASU No. 2016-18. The adoption did not have an effect on the Consolidated Financial Statements on the adoption date and no adjustment to prior year Consolidated Financial Statements was required.

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). Effective January 1, 2018, the Company adopted the requirements of ASU No. 2014-09 using the modified retrospective method as discussed in Note 2 below. All amounts and disclosures set forth in this Quarterly Report on Form 10-Q reflect these changes.

Recently Issued Accounting Pronouncements

In February 2016, the FASB issued ASU No. 2016-02, Leases, which seeks to increase transparency and comparability among organizations by, among other things, recognizing lease assets and lease liabilities on the balance sheet for leases classified as operating leases under previous GAAP and disclosing key information about leasing arrangements. ASU No. 2016-02 becomes effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the provisions of ASU No. 2016-02 and assessing the impact, if any, it may have on the Company’s Condensed Consolidated Financial Statements.

7



In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments. The new guidance amends the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology, which will result in more timely recognition of losses. ASU No. 2016-13 has an effective date of the fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company is currently evaluating ASU No. 2016-13 and assessing the impact, if any, it may have to the Company’s consolidated results of operations, financial position and cash flows.

 2. Revenue from Contracts with Customers

Adoption of New Revenue Standard

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers that supersedes Accounting Standards Codification (“ASC”) Topic 605, Revenue Recognition. Subsequently, the FASB issued several updates to ASU No. 2014-09, which are pending content or otherwise codified in ASC Topic 606 (“ASC 606”). ASC 606 also includes new guidance on costs related to a contract, which is codified in ASC Subtopic 340-40. The Company adopted ASC 606 on January 1, 2018 using the modified retrospective method for all contracts not substantially completed as of the date of adoption. The cumulative impact of the adoption ASC 606 was not material to the Company therefore the Company did not record any adjustments to retained earnings. The reported results for 2018 reflect the application of ASC 606 guidance while the reported results for 2017 were prepared under the guidance of ASC Topic 605, which is also referred to herein as “legacy GAAP” or the “previous guidance”.

Revenue

A. Significant Accounting Policy

In accordance with ASC 606, revenue is recognized when a customer obtains control of promised products and services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these products and services. A five-step model is utilized to achieve the core principle and includes the following steps: (1) identify the customer contract; (2) identify the contract’s performance obligation; (3) determine the transactions price; (4) allocate the transactions price to the performance obligation; and (5) recognize revenue when the performance obligation is satisfied.

B. Practical Expedients

Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from revenue.

Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost and are included in cost of revenues.

Sales commissions and other incremental costs of obtaining contracts are expensed as incurred as the amortization periods are less than one year.

C. Nature of Goods and Services

The following is a description of principal activities - separated by reportable segments - from which the Company generates its revenue. For more detailed information about reportable segments, see Note 20.

i. Pharmaceutical

The pharmaceutical segment of the Company principally generates revenue from products sold to wholesalers and distributors. Customer orders are generally fulfilled within a few days of receipt resulting in minimal order backlog. Contractual performance obligations are usually limited to transfer of the product to the customer. The transfer occurs either upon shipment or upon receipt of the product in certain non-U.S. countries after considering when the customer obtains control of the product. In addition, for some non-U.S. countries, the Company sells product on a consignment basis where control is not transferred until the customer resells the product to an end user. At these points, customers are able to direct the use of and obtain substantially all of the remaining benefits of the product.


8


Sales to customers are initially invoiced at contractual list prices. Payment terms are typically 30 to 90 days based on customary practice in each country. Revenue is reduced from the list price at the time of recognition for expected charge-backs, discounts, rebates, sales allowances and product returns, which are referred to as gross-to-net adjustments. These reductions are attributed to various commercial agreements, managed healthcare organizations and government programs such as Medicare, Medicaid, and the 340B Drug Pricing Program containing various pricing implications such as mandatory discounts, pricing protection below wholesaler list price and other discounts when Medicare Part D beneficiaries are in the coverage gap. These various reductions in the transaction price have been estimated using either a most likely amount or expected value method depending on their nature and have been reflected as liabilities and are settled through cash payments, typically within time periods ranging from a few months to one year. Significant judgment is required in estimating gross-to-net adjustments considering legal interpretations of applicable laws and regulations, historical experience, payer channel mix, current contract prices under applicable programs, unbilled claims, processing time lags and inventory levels in the distribution channel.

ii. Medical Devices

The medical devices segment of the Company principally generates revenue from the sale and lease of the LENSAR® Laser System (“LLS”), related procedure devices and licenses, and service agreements.

For bundled packages, the Company accounts for individual products and services separately if they are distinct - i.e. if a product or service is separately identifiable from other items in the bundled package and if the customer can benefit from it on its own or with other resources that are readily available to the customer. As the Company both sells and leases the LLS, the consideration (including any discounts) is first allocated between lease and non-lease components and then allocated between the separate products and services based on their stand-alone selling prices. The consideration (including any discounts) is allocated between separate products and services in a bundle based on their stand-alone selling prices. The stand-alone selling prices for the Patient Interface Devices (“PIDs”) and procedure licenses are determined based on the prices at which the Company separately sells the PIDs and procedure licenses. The LLS system and warranty stand-alone selling prices are determined using the expected cost plus a margin approach.

The Company sells and leases the LLS to customers. For LSS sales, the Company recognizes revenue in products revenue when a customer takes possession of the system. This usually occurs after the customer signs a contract, LENSAR installs the system, and LENSAR performs the requisite training for use of the system. For LLS leases, the Company recognizes revenue in products revenue over the length of the lease in products revenue in accordance with ASC Topic 840, Leases.

The LLS requires both a consumable, a PID, and a procedure license to perform each procedure. The Company recognizes revenue for PIDs in products revenue when the customer takes possession of the PID. PIDs are sold by the case. The Company recognizes revenue for procedure licenses in products revenue when a customer purchases a procedure license from the web portal. Typically, consideration for PIDs and procedure licenses is considered fixed consideration except as noted below. Certain customer agreements provide for variable consideration through tiered volume discount pricing.

The Company provides an extended warranty that provides additional services beyond the standard warranty. The Company recognizes revenue in products revenue over the warranty period. Customers have the option of renewing the warranty period, which is considered a new and separate contract.

iii. Income Generating Assets

Licenses of intellectual property: If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license.

In January 2018, DFM, LLC, a wholly-owned subsidiary of the Company, granted an exclusive license related to certain Direct Flow Medical assets in exchange for $0.5 million in cash and up to $2.0 million in royalty payments. The $0.5 million payment was accounted for in accordance with ASC 606 under which the full cash payment was recognized as revenue in the first quarter of 2018 as DFM, LLC had fulfilled its performance obligation under the agreement.


9


Royalties: The Company recognizes royalty revenues related to the sale of products by its licensees that incorporate the Company's technologies. Royalties qualify for the sales-and-usage exemption under Topic 606 as (i) royalties are based strictly on the sales-and-usage by the licensee; and (ii) a license of IP is the sole or predominant item to which such royalties relate. Based on this exemption, these royalties are earned under the terms of a license agreement in the period the products are sold by the Company's partner and the Company has a present right to payment.

D. Disaggregation of Revenue

The Company disaggregates its revenue from contracts with customers by segment and geographic location, as the Company believes it best depicts how the nature, amount, timing and uncertainty of its revenue and cash flows are affected by economic factors. In the following table, revenue is disaggregated by segment and primary geographical market for the three and six months ended June 30, 2018:
 
 
Three Months Ended
 
Six Months Ended
 
 
June 30, 2018
 
June 30, 2018
(in thousands)
 
Medical Devices
 
Pharmaceutical
 
Medical Devices
 
Pharmaceutical
 
 
 
 
 
 
 
 
 
Primary geographical markets:
 
 
 
 
 
 
 
 
North America
 
$
615

 
$
10,776

 
$
2,319

 
$
21,707

Europe
 
679

 
6,371

 
1,294

 
12,362

Asia
 
1,643

 
8,732

 
2,757

 
10,152

Other
 
107

 
—

 
220

 
—

Total revenue from contracts with customers1
 
$
3,044

 
$
25,879

 
$
6,590

 
$
44,221

_______________
1 The table above does not include Medical Device lease revenue of $2.8 million and $4.3 million for the three and six months ended June 30, 2018, respectively.

E. Contract Balances

The following table provides information about receivables, contract assets and contract liabilities from contracts with customers:
(in thousands)
 
June 30, 2018
 
January 1, 2018
 
 
 
 
 
Receivables, current and non-current, net
 
$
19,970

 
$
30,771

Contract assets
 
$
3,235

 
$
—

Contract liabilities
 
$
5,114

 
$
10,084


Receivables, Net—Receivables, net, include amounts billed and currently due from customers. The amounts due are stated at their net estimated realizable value. The Company maintains an allowance for doubtful accounts to provide for the estimated amount of receivables that will not be collected. The allowance is based upon an assessment of customer creditworthiness, historical payment experience, the age of outstanding receivables and collateral to the extent applicable.

Contract assets—The Company’s contract assets represent revenue recognized for performance obligations completed before an unconditional right to payment exists, and therefore invoicing or associated reporting from the customer regarding the computation of the net product sales has not yet occurred. The Company classifies contract assets as current based on the timing of when it expects to receive payment and is included in prepaid and other current assets in the Company’s consolidated balance sheets.
(in thousands)
 
Medical Devices
 
Pharmaceutical
 
Total
 
 
 
 
 
 
 
Contract assets at January 1, 2018
 
$
—

 
$
—

 
$
—

Contract assets recognized
 
—

 
3,235

 
3,235

Contract assets at June 30, 2018
 
$
—

 
$
3,235

 
$
3,235



10


Contract Liabilities—The Company’s contract liabilities consist of deferred revenue for products sold to customers for which the performance obligation has not been completed by the Company. The Company classifies deferred revenue as current or noncurrent based on the timing of when it expects to recognize revenue. The noncurrent portion of deferred revenue is included in other long-term liabilities in the Company’s consolidated balance sheets.
(in thousands)
 
Medical Devices
 
Pharmaceutical
 
Total
 
 
 
 
 
 
 
Contract liabilities at January 1, 2018
 
$
1,391

 
$
8,693

 
$
10,084

Additions
 
547

 
3,880

 
4,427

Amounts recognized into revenue
 
(704
)
 
(8,693
)
 
(9,397
)
Contract liabilities at June 30, 2018
 
$
1,234

 
$
3,880

 
$
5,114


F. Transaction Price Allocated to Future Performance Obligations

The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period.
 
 
Six Months Ended
 
 
 
 
(in thousands)
 
December 31, 2018
 
Thereafter
 
Total
 
 
 
 
 
 
 
Pharmaceutical product sales
 
$
1,000

 
$
—

 
$
1,000

Medical device product sales
 
$
1,878

 
$
2,352

 
$
4,230


The Company does not disclose the value of unsatisfied performance obligations for (i) contracts with original expected lengths of one year or less or (ii) contracts for which the Company recognizes revenue at the amount to which it has the right to invoice for the products delivered or services performed.

3. Net Income (loss) per Share
 
 
Three Months Ended
 
Six Months Ended
 
 
June 30,
 
June 30,
Net Income (Loss) per Basic and Diluted Share:
 
2018
 
2017
 
2018
 
2017
 (in thousands except per share amounts)
 
 
 
 
 
 
 
 
Numerator
 
 
 
 
 
 
 
 
Income (loss) attributable to PDL’s shareholders used to compute net income per basic and diluted share
 
$
(112,296
)
 
$
60,439

 
$
(110,694
)
 
$
67,680

 
 
 
 
 
 
 
 
 
Denominator
 
 

 
 

 
 
 
 
Total weighted average shares used to compute net income attributable to PDL’s shareholders, per basic share
 
146,923

 
155,654

 
149,186

 
159,677

Restricted stock outstanding
 
—

 
740

 
—

 
491

Shares used to compute net income (loss) attributable to PDL’s shareholders, per diluted share
 
146,923

 
156,394

 
149,186

 
160,168

 
 
 
 
 
 
 
 
 
Net income (loss) attributable to PDL’s shareholders per share - basic
 
$
(0.76
)
 
$
0.39

 
$
(0.74
)
 
$
0.42

Net income (loss) attributable to PDL’s shareholders per share - diluted
 
$
(0.76
)
 
$
0.39

 
$
(0.74
)
 
$
0.42


The Company computes net income per diluted share using the sum of the weighted-average number of common and common equivalent shares outstanding. Common equivalent shares used in the computation of net income per diluted share include shares that may be issued pursuant to outstanding stock options and restricted stock awards, the 4.0% Convertible Senior Notes due February 1, 2018 (the “February 2018 Notes”) that were repaid on February 1, 2018, and the 2.75% Convertible Senior Notes due December 1, 2021 (the “December 2021 Notes”), in each case, on a weighted average basis for the period that the

11


notes were outstanding, including the effect of adding back interest expense and the underlying shares using the if converted method.

December 2021 Notes Capped Call Potential Dilution

In November 2016, the Company issued $150.0 million in aggregate principal of the December 2021 Notes, which provide in certain situations for the conversion of the outstanding principal amount of the December 2021 Notes into shares of the Company’s common stock at a predefined conversion rate. For additional information on the conversion rates on the Company’s convertible debt, see Note 13. In conjunction with the issuance of the December 2021 Notes, the Company entered into a capped call transaction with a hedge counterparty. The capped call transaction is expected generally to reduce the potential dilution, and/or offset, to an extent, the cash payments the Company may choose to make in excess of the principal amount, upon conversion of the December 2021 Notes. The Company has excluded the capped call transaction from the net income (loss) per diluted share computation as such securities would have an antidilutive effect and those securities should be considered separately rather than in the aggregate in determining whether their effect on net income (loss) per diluted share would be dilutive or antidilutive. For additional information regarding the capped call transaction related to the Company’s December 2021 Notes, see Note 13.

Anti-Dilutive Effect of Restricted Stock Awards and Stock Options

For the three months ended June 30, 2018 and 2017, the Company excluded approximately 1.0 million and 2.2 million shares underlying restricted stock awards, respectively, and for the six months ended June 30, 2018 and 2017, the Company excluded approximately 1.1 million and 2.0 million shares underlying restricted stock awards, respectively, calculated on a weighted average basis, from its net income (loss) per diluted share calculations because their effect was anti-dilutive.

For the three months ended June 30, 2018 and 2017, the Company excluded approximately 4.9 million and zero shares underlying outstanding stock options, respectively, and for the six months ended June 30, 2018 and 2017, the Company excluded approximately 4.9 million and zero shares underlying outstanding stock options, respectively, calculated on a weighted average basis, from its net income (loss) per diluted share calculations because their effect was anti-dilutive.

No 4. Fair Value Measurements

The fair value of the Company’s financial instruments are estimates of the amounts that would be received if the Company were to sell an asset or pay to transfer a liability in an orderly transaction between market participants at the measurement date or exit price. The assets and liabilities are categorized and disclosed in one of the following three categories:

Level 1 – based on quoted market prices in active markets for identical assets and liabilities;
 
Level 2 – based on quoted market prices for similar assets and liabilities, using observable market-based inputs or unobservable market-based inputs corroborated by market data; and
 
Level 3 – based on unobservable inputs using management’s best estimate and assumptions when inputs are unavailable.


12


Assets/Liabilities Measured and Recorded at Fair Value on a Recurring Basis

The following table presents the fair value of the Company’s financial instruments measured at fair value on a recurring basis by level within the valuation hierarchy:
 
 
June 30, 2018
 
December 31, 2017
(in thousands)
 
Level 1
 
Level 2
 
Level 3
 
Total
 
Level 1
 
Level 2
 
Level 3
 
Total
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Financial assets:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Money market funds
 
$
324,105

 
$
—

 
$
—

 
$
324,105

 
$
417,563

 
$
—

 
$
—

 
$
417,563

Corporate securities
 
—

 
—

 
—

 
—

 
4,848

 
—

 
—

 
4,848

Warrants
 
—

 
103

 
—

 
103

 
—

 
29

 
—

 
29

Royalty rights - at fair value
 
—

 
—

 
335,163

 
335,163

 
—

 
—

 
349,223

 
349,223

Total
 
$
324,105

 
$
103

 
$
335,163

 
$
659,371

 
$
422,411

 
$
29

 
$
349,223

 
$
771,663

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Financial liabilities:
 
 

 
 

 
 
 
 

 
 

 
 

 
 
 
 

Contingent consideration, current1
 
$
—

 
$
—

 
$
1,140

 
$
1,140

 
$
—

 
$
—

 
$
—

 
$
—

Contingent consideration, non-current
 
—

 
—

 
18,900

 
18,900

 
—

 
—

 
42,000

 
42,000

Total
 
$
—

 
$
—

 
$
20,040

 
$
20,040

 
$
—

 
$
—

 
$
42,000

 
$
42,000

 ___________________
1 Contingent consideration, current is classified as “Accrued liabilities” on the Condensed Consolidated Balance Sheet. See Note 11 for details.

There have been no transfers between levels during the six month periods ended June 30, 2018 and December 31, 2017. The Company recognizes transfers between levels on the date of the event or change in circumstances that caused the transfer.

Corporate Securities

Corporate securities consisted primarily of U.S. corporate equity holdings. The fair value of corporate securities is estimated using market quoted prices.

Warrants

Warrants consist primarily of purchased call options to buy U.S. corporate equity holdings and derivative assets acquired as part of note receivable investments. The fair value of the warrants is estimated using recently quoted market prices or estimated fair value of the underlying equity security and the Black-Scholes option pricing model.

Royalty Rights - At Fair Value

Depomed Royalty Agreement

On October 18, 2013, the Company entered into the Royalty Purchase and Sale Agreement (the “Depomed Royalty Agreement”) with Depomed, Inc. and Depo DR Sub, LLC (together, “Depomed”), whereby the Company acquired the rights to receive royalties and milestones payable on sales of Type 2 diabetes products licensed by Depomed in exchange for a $240.5 million cash payment. Total consideration was $241.3 million, which was comprised of the $240.5 million cash payment to Depomed and $0.8 million in transaction costs.

The rights acquired include Depomed’s royalty and milestone payments accruing from and after October 1, 2013: (a) from Santarus, Inc. (“Santarus”) (which was subsequently acquired by Salix Pharmaceuticals, Inc. (“Salix”), which itself was acquired by Valeant Pharmaceuticals International, Inc. (which was subsequently acquired by Bausch Health Companies Inc.) (“Bausch Health”)) with respect to sales of Glumetza (metformin HCL extended-release tablets) in the United States; (b) from Merck & Co., Inc. with respect to sales of Janumet® XR (sitagliptin and metformin HCL extended-release tablets); (c) from Janssen Pharmaceutica N.V. with respect to potential future development milestones and sales of its recently approved fixed-dose combination of Invokana® (canagliflozin) and extended-release metformin tablets, marketed as Invokamet XR®; (d) from

13


Boehringer Ingelheim with respect to potential future development milestones and sales of the investigational fixed-dose combinations of drugs and extended-release metformin subject to Depomed’s license agreement with Boehringer Ingelheim, including its recently approved products, Jentadueto XR® and Syngardy XR®; and (e) from LG Life Sciences and Bausch Health for sales of extended-release metformin tablets in Korea and Canada, respectively.

Under the terms of the Depomed Royalty Agreement, the Company receives all royalty and milestone payments due under license agreements between Depomed and its licensees until the Company has received payments equal to two times the cash payment it made to Depomed, after which all net payments received by Depomed will be shared evenly between the Company and Depomed.

The Depomed Royalty Agreement terminates on the third anniversary following the date upon which the later of the following occurs: (a) October 25, 2021, or (b) at such time as no royalty payments remain payable under any license agreement and each of the license agreements has expired by its terms.

As of June 30, 2018 and December 31, 2017, the Company determined that its royalty purchase interest in Depo DR Sub, LLC represented a variable interest in a variable interest entity. However, the Company does not have the power to direct the activities of Depo DR Sub, LLC that most significantly impact Depo DR Sub, LLC’s economic performance and is not the primary beneficiary of Depo DR Sub, LLC; therefore, Depo DR Sub, LLC is not subject to consolidation by the Company.

The financial asset acquired represents a single unit of accounting. The fair value of the financial asset acquired was determined by using a discounted cash flow analysis related to the expected future cash flows to be generated by each licensed product. This financial asset is classified as a Level 3 asset within the fair value hierarchy, as the Company’s valuation utilized significant unobservable inputs, including estimates as to the probability and timing of future commercialization for products not yet approved by regulatory agencies outside of the United States. The discounted cash flows are based upon expected royalties from sales of licensed products over a nine-year period. The discount rates utilized range from 10% to 24%. Significant judgment is required in selecting appropriate discount rates. At June 30, 2018, an evaluation was performed to assess those rates and general market conditions potentially affecting the fair market value, of the financial asset. Should these discount rates increase or decrease by 2.5%, the fair value of the asset could decrease by $12.8 million or increase by $14.7 million, respectively. A third-party expert was engaged to assist management develop its original estimate of the expected future cash flows. The estimated fair value of the asset is subject to variation should those cash flows vary significantly from those estimates. The Company periodically assesses the expected future cash flows and to the extent such payments are greater or less than its initial estimates, or the timing of such payments is materially different than the original estimates, the Company will adjust the estimated fair value of the asset. Should the expected royalties increase or decrease by 2.5%, the fair value of the asset could increase or decrease by $5.4 million, respectively.

When the Company acquired the Depomed royalty rights, Glumetza was marketed by Santarus. In January 2014, Salix acquired Santarus and assumed responsibility for commercializing Glumetza, which was generally perceived to be a positive development because of Salix’s larger sales force and track record in the successful commercialization of therapies. In late 2014, Salix made a number of disclosures relating to an excess of supply at the distribution level of Glumetza and other drugs that it commercialized and the practices leading to this excess of supply which were under review by Salix’s audit committee in relation to the related accounting practices. Because of these disclosures and the Company’s lack of direct access to information as to the levels of inventory of Glumetza in the distribution channels, the Company commenced a review of all public statements by Salix, publicly available historical third-party prescription data, analyst reports and other relevant data sources. The Company also engaged a third-party expert to specifically assess estimated inventory levels of Glumetza in the distribution channel and to ascertain the potential effects those inventory levels may have on expected future cash flows. Salix was acquired by Bausch Health in early April 2015. In mid-2015, Bausch Health implemented two price increases on Glumetza. At year-end 2015, a third-party expert was engaged by the Company to assess the impact of the Glumetza price adjustments and near-term market entrance of generic equivalents to the expected future cash flows. Based on the analysis performed, management revised the underlying assumptions used in the discounted cash flow analysis at year-end 2015. In February and August 2016, a total of three generic equivalents to Glumetza were approved to enter the market. In February 2016, Lupin Pharmaceuticals, Inc. and in August 2017, Teva Pharmaceutical Industries, Ltd., each launched a generic equivalent approved product. To date, the third generic equivalent to Glumetza has not launched.

In May 2017, the Company received notification that a subsidiary of Bausch Health had launched an authorized generic equivalent product in February 2017, and the Company received royalties on such authorized generic equivalent product under the same terms as the branded Glumetza product, retroactive to February 2017.

At December 31, 2017, management re-evaluated, with assistance of a third-party expert, the market share data, the gross-to-net revenue adjustment assumptions and Glumetza demand data, including the delay in launch of additional generic equivalent

14


products and the entry of an authorized generic product by Bausch Health. These data and assumptions are based on available but limited information. At June 30, 2018, management updated the expected future cash flows based on the current period demand and supply data of Glumetza and the authorized generic equivalent product launched by Bausch Health.

As of June 30, 2018, the Company’s discounted cash flow analysis reflects its expectations as to the amount and timing of future cash flows up to the valuation date, including future cash flows for the authorized generic equivalent product. The Company continues to monitor whether the generic competition further affects sales of Glumetza and thus royalties on such sales paid to the Company, and the impact of the launched authorized generic equivalent. Due to the uncertainty around Bausch Health’s marketing and pricing strategy, as well as the recent generic competition and limited historical demand data after generic market entrance, the Company may need to further evaluate future cash flows in the event of more rapid reduction or increase in market share of Glumetza and its authorized generic equivalent product and/or a further erosion in net pricing.

In February 2016, at the Company’s request and pursuant to the Depomed Royalty Agreement, Depomed exercised its audit right with respect to Glumetza royalties. The independent auditor engaged to perform the royalty audit completed it in July 2017, and based upon the results of the audit, Depomed, on behalf of the Company, filed a lawsuit on September 7, 2017, against Bausch Health and one of its subsidiaries, claiming damages for unpaid royalties, fees and interest. Bausch Health, Depomed and the Company entered into a settlement agreement on October 27, 2017 whereby the parties agreed to dismiss the litigation, with prejudice, and Bausch Health agreed to pay to Depomed $13.0 million. The full amount of the settlement payment was transferred to the Company under the terms of the Depomed Royalty Agreement in November 2017.

On May 31, 2016, the Company obtained a notification indicating that the U.S. Food and Drug Administration (“FDA”) approved Jentadueto XR for use in patients with Type 2 diabetes. In June 2016, the Company received a $6.0 million FDA approval milestone pursuant to the terms of the Depomed Royalty Agreement. The product approval was earlier than initially expected. Based on the FDA approval and anticipated timing of the product launch, the Company adjusted the timing of future cash flows and discount rate used in the discounted cash flow model at June 30, 2016. As of December 31, 2017, management re-evaluated, the cash flow assumptions for Jentadueto XR and revised the discounted cash flow model. As of June 30, 2018, the Company’s discounted cash flow analysis reflects its expectations as to the amount and timing of future cash flows up to the valuation date.

On September 21, 2016, the Company obtained a notification indicating that the FDA approved Invokamet XR for use in patients with Type 2 diabetes. The product approval triggered a $5.0 million approval milestone payment to the Company pursuant to the terms of the Depomed Royalty Agreement. Based on the FDA approval and timing of the product launch, the Company adjusted the timing of future cash flows and discount rate used in the discounted cash flow model.

On December 13, 2016, the Company obtained a notification indicating that the FDA approved Synjardy XR for use in patients with Type 2 diabetes. The product approval triggered a $6.0 million approval milestone payment to the Company pursuant to the terms of the Depomed Royalty Agreement. Based on the FDA approval and the April 2017 launch of Synjardy XR by Boehringer Ingelheim, the Company adjusted the timing of future cash flows and discount rate used in the discounted cash flow model.

As of June 30, 2018, the fair value of the asset acquired as reported in the Company’s Condensed Consolidated Balance Sheet was $214.1 million and the maximum loss exposure was $214.1 million.

Viscogliosi Brothers Royalty Agreement

On June 26, 2014, the Company entered into a Royalty Purchase and Sale Agreement (the “VB Royalty Agreement”) with Viscogliosi Brothers, LLC (“VB”), whereby VB conveyed to the Company the right to receive royalties payable on sales of a spinal implant that has received pre-market approval from the FDA held by VB and commercialized by Paradigm Spine, LLC (“Paradigm Spine”), in exchange for a $15.5 million cash payment, less fees.

The royalty rights acquired includes royalties accruing from and after April 1, 2014. Under the terms of the VB Royalty Agreement, the Company receives all royalty payments due to VB pursuant to certain technology transfer agreements between VB and Paradigm Spine until the Company has received payments equal to 2.3 times the cash payment made to VB, after which all rights to receive royalties will be returned to VB. VB’s ability to repurchase the royalty right for as specified amount expired on June 26, 2018.

The fair value of the royalty right at June 30, 2018, was determined by using a discounted cash flow analysis related to the expected future cash flows to be received. This asset is classified as a Level 3 asset, as the Company’s valuation utilized significant unobservable inputs, including estimates as to the probability and timing of future sales of the licensed product. The

15


discounted cash flow was based upon expected royalties from sales of licensed product over a ten-year period. The discount rate utilized was 15.0%. Significant judgment is required in selecting the appropriate discount rate. Should this discount rate increase or decrease by 2.5%, the fair value of this asset could decrease by $1.4 million or increase by $1.6 million, respectively. Should the expected royalties increase or decrease by 2.5%, the fair value of the asset could increase or decrease by $0.4 million, respectively. A third-party expert was engaged to assist management with the development of its estimate of the expected future cash flows, when deemed necessary. The fair value of the asset is subject to variation should those cash flows vary significantly from the Company’s estimates. At each reporting period, an evaluation is performed to assess those estimates, discount rates utilized and general market conditions affecting fair market value.

As of June 30, 2018, the fair value of the asset acquired as reported in the Company’s Condensed Consolidated Balance Sheet was $14.7 million and the maximum loss exposure was $14.7 million.

University of Michigan Royalty Agreement

On November 6, 2014, the Company acquired a portion of all royalty payments of the Regents of the University of Michigan’s (“U-M”) worldwide royalty interest in Cerdelga (eliglustat) for $65.6 million pursuant to the Royalty Purchase and Sale Agreement with U-M (the “U-M Royalty Agreement”). Under the terms of the U-M Royalty Agreement, the Company receives 75% of all royalty payments due under U-M’s license agreement with Genzyme Corporation, a Sanofi company (“Genzyme”) until expiration of the licensed patents, excluding any patent term extension. Cerdelga, an oral therapy for adult patients with Gaucher disease type 1, was developed by Genzyme. Cerdelga was approved in the United States in August 2014, in the European Union in January 2015, and in Japan in March 2015. In addition, marketing applications for Cerdelga are under review by other regulatory authorities. While marketing applications have been approved in the United States, the European Union and Japan, national pricing and reimbursement decisions are delayed in some countries. At December 31, 2017, a third-party expert was engaged by the Company to assess the impact of the delayed pricing and reimbursement decisions to Cerdelga’s expected future cash flows. Based on the analysis performed, management revised the underlying assumptions used in the discounted cash flow analysis at December 31, 2017. As of June 30, 2018, the Company’s discounted cash flow analysis reflects its expectations as to the amount and timing of future cash flows up to the valuation date.

The fair value of the royalty right at June 30, 2018 was determined by using a discounted cash flow analysis related to the expected future cash flows to be received. This asset is classified as a Level 3 asset, as the Company’s valuation utilized significant unobservable inputs, including estimates as to the probability and timing of future sales of the licensed product. The discounted cash flow was based upon expected royalties from sales of licensed product over a four-year period. The discount rate utilized was approximately 12.8%. Significant judgment is required in selecting the appropriate discount rate. Should this discount rate increase or decrease by 2.5%, the fair value of this asset could decrease by $1.2 million or increase by $1.4 million, respectively. Should the expected royalties increase or decrease by 2.5%, the fair value of the asset could increase or decrease by $0.7 million, respectively. A third-party expert is engaged to assist management with the development of its estimate of the expected future cash flows, when deemed necessary. The fair value of the asset is subject to variation should those cash flows vary significantly from the Company’s estimates. An evaluation of those estimates, discount rates utilized and general market conditions affecting fair market value is performed in each reporting period.

As of June 30, 2018, the fair value of the asset acquired as reported in the Company’s Condensed Consolidated Balance Sheet was $26.1 million and the maximum loss exposure was $26.1 million.

AcelRx Royalty Agreement

On September 18, 2015, the Company entered into a royalty interest assignment agreement (the “AcelRx Royalty Agreement”) with ARPI LLC, a wholly owned subsidiary of AcelRx Pharmaceuticals, Inc. (“AcelRx”), whereby the Company acquired the rights to receive a portion of the royalties and certain milestone payments on sales of Zalviso® (sufentanil sublingual tablet system) in the European Union, Switzerland and Australia by AcelRx’s commercial partner, Grünenthal, in exchange for a $65.0 million cash payment. Under the terms of the AcelRx Royalty Agreement, the Company receives 75% of all royalty payments and 80% of the first four commercial milestone payments due under AcelRx’s license agreement with Grünenthal until the earlier to occur of (i) receipt by the Company of payments equal to three times the cash payments made to AcelRx and (ii) the expiration of the licensed patents (expected to be in January of 2032). Zalviso received marketing approval by the European Commission in September 2015. Grünenthal launched Zalviso in the second quarter of 2016 and the Company started to receive royalties in the third quarter of 2016.

As of June 30, 2018, and December 31, 2017, the Company determined that its royalty rights under the AcelRx Royalty Agreement represented a variable interest in a variable interest entity. However, the Company does not have the power to direct

16


the activities of ARPI LLC that most significantly impact ARPI LLC’s economic performance and is not the primary beneficiary of ARPI LLC; therefore, ARPI LLC is not subject to consolidation by the Company.

The fair value of the royalty right at June 30, 2018 was determined by using a discounted cash flow analysis related to the expected future cash flows to be received. This asset is classified as a Level 3 asset, as the Company’s valuation utilized significant unobservable inputs, including estimates as to the probability and timing of future sales of the licensed product. The discounted cash flow was based upon expected royalties from sales of licensed product over a fourteen-year period. The discount rate utilized was approximately 13.4%. Significant judgment is required in selecting the appropriate discount rate. Should this discount rate increase or decrease by 2.5%, the fair value of this asset could decrease by $9.8 million or increase by $12.0 million, respectively. Should the expected royalties increase or decrease by 2.5%, the fair value of the asset could increase or decrease by $1.9 million, respectively. A third-party expert is engaged to assist management with the development of its estimate of the expected future cash flows, when deemed necessary. The fair value of the asset is subject to variation should those cash flows vary significantly from the Company’s estimates. Based on the number of treated patients to date, management adjusted the timing of the expected future cash flows used in the discounted cash flow model at December 31, 2017. At June 30, 2018, management performed an evaluation of those estimates, discount rates utilized and general market conditions to determine the fair market value of the asset, and such an evaluation is performed for each reporting period. As of June 30, 2018, the Company’s discounted cash flow analysis reflects its expectations as to the amount and timing of future cash flows up to the valuation date.

As of June 30, 2018, the fair value of the asset acquired as reported in the Company’s Condensed Consolidated Balance Sheet was $77.4 million and the maximum loss exposure was $77.4 million.

Kybella Royalty Agreement

On July 8, 2016, the Company entered into a royalty purchase and sales agreement with an individual, whereby the Company acquired that individual’s rights to receive certain royalties on sales of KYBELLA® by Allergen plc in exchange for a $9.5 million cash payment and up to $1.0 million in future milestone payments based upon product sales targets. The Company started to receive royalty payments during the third quarter of 2016.

The fair value of the royalty right at June 30, 2018, was determined by using a discounted cash flow analysis related to the expected future cash flows to be received. This asset is classified as a Level 3 asset, as the Company’s valuation utilized significant unobservable inputs, including estimates as to the probability and timing of future sales of the licensed product. The discounted cash flow was based upon expected royalties from sales of a licensed product over a seven-year period. The discount rate utilized was approximately 14.4%. Significant judgment is required in selecting the appropriate discount rate. Should this discount rate increase or decrease by 2.5%, the fair value of this asset could decrease by $0.2 million or increase by $0.3 million, respectively. Should the expected royalties increase or decrease by 2.5%, the fair value of the asset could increase or decrease by $0.1 million, respectively. A third-party expert is engaged to assist management with the development of its estimate of the expected future cash flows, when deemed necessary. The fair value of the asset is subject to variation should those cash flows vary significantly from the Company’s estimates. At each reporting period, an evaluation of those estimates, discount rates utilized and general market conditions affecting fair market value is performed in each reporting period.

As of June 30, 2018, the fair value of the asset acquired as reported in the Company’s Condensed Consolidated Balance Sheet was $2.8 million and the maximum loss exposure was $2.8 million.


17


The following tables summarize the changes in Level 3 assets and the gains and losses included in earnings for the six months ended June 30, 2018:
Fair Value Measurements Using Significant Unobservable Inputs (Level 3) - Royalty Rights Assets
 
 
 
 
 
 
 
(in thousands)
 
Royalty Rights -
At Fair Value
Fair value as of December 31, 2017
 
 
 
$
349,223

 
 
 
 
 
 
 
 
Total net change in fair value for the period
 
 
 
 
 
 
Change in fair value of royalty rights - at fair value
 
$
23,933

 
 
 
 
Proceeds from royalty rights - at fair value
 
$
(37,993
)
 
 
 
 
Total net change in fair value for the period
 
 
 
(14,060
)
 
 
 
 
 
 
 
Fair value as of June 30, 2018
 


 
$
335,163


Fair Value Measurements Using Significant Unobservable Inputs (Level 3) - Royalty Rights Assets
 
 
 
 
 
 
 
 
 
Fair Value as of
 
Royalty Rights -
 
Fair Value as of
(in thousands)
 
December 31, 2017
 
Change in Fair Value
 
June 30, 2018
 
 
 
 
 
 
 
Depomed
 
$
232,038

 
$
(17,967
)
 
$
214,071

VB
 
14,380

 
284

 
14,664

U-M
 
26,769

 
(620
)
 
26,149

AcelRx
 
72,894

 
4,539

 
77,433

Avinger
 
396

 
(396
)
 
—

KYBELLA
 
2,746

 
100

 
2,846

 
 
$
349,223

 
$
(14,060
)
 
$
335,163

Fair Value Measurements Using Significant Unobservable Inputs (Level 3) - Liabilities
 
 
 
(in thousands)
 
Contingent Consideration
Fair value as of December 31, 2017
 
$
(42,000
)
 
 
 
 
 
 
Total net change in fair value for the period
 
22,735

 
Fair value of financial instruments acquired
 
(1,560
)
 
Settlement of financial instrument
 
785

 
 
 
 
 
Fair value as of June 30, 2018
 
$
(20,040
)

The fair value of the contingent consideration was determined using an income approach derived from revenue estimates and a probability assessment with respect to the likelihood of achieving (a) the level of net sales or (b) generic product launch that would trigger the milestone payments. The key assumptions in determining the fair value are the discount rate and the probability assigned to the potential milestones being achieved. The fair value of the contingent consideration is remeasured each reporting period, with changes in fair value recorded in the Condensed Consolidated Statements of Income. The change in fair value of the contingent consideration during the six months ending June 30, 2018 is due primarily to the changes in the probabilities in the generic entry milestones and the additional contingent consideration acquired as part of the assets acquired by LENSAR from Precision Eye Services, as described in note 9.

18



Gains and losses from changes in Level 3 assets included in earnings for each period are presented in “Royalty rights - change in fair value” and gains and losses from changes in Level 3 liabilities included in earnings for each period are presented in “Change in fair value of anniversary payment and contingent consideration” as follows:
 
 
Three Months Ended
 
Six Months Ended
 
 
June 30,
 
June 30,
(in thousands)
 
2018
 
2017
 
2018
 
2017
 
 
 
 
 
 
 
 
 
Total change in fair value for the period included in earnings for royalty right assets held at the end of the reporting period
 
$
12,842

 
$
83,725

 
$
23,933

 
$
96,871

 
 
 
 
 
 
 
 
 
Total change in fair value for the period included in earnings for liabilities held at the end of the reporting period
 
$
22,135

 
$
(1,207
)
 
$
22,735

 
$
(2,649
)

Assets/Liabilities Measured and Recorded at Fair Value on a Nonrecurring Basis

The Company remeasures the fair value of certain assets and liabilities upon the occurrence of certain events. Such assets consist of cost-method equity investments and long-lived assets, including property and equipment and intangible assets. During the three months ended June 30, 2018, the Company recorded an impairment charge of $152.3 million for the Noden intangible asset related to the increased probability of a generic version of aliskiren being launched in the United States. As a result of this impairment charge, which was based on the estimated fair value of the assets, the remaining carrying value of the these intangible assets was determined to be $40.1 million. The fair value calculation included level 3 inputs. For additional information on the impairment charge, see note 10.

Assets/Liabilities Not Subject to Fair Value Recognition

The following tables present the fair value of assets and liabilities not subject to fair value recognition by level within the valuation hierarchy:
 
 
June 30, 2018
 
December 31, 2017
(in thousands)
 
Carrying Value
 
Fair Value
Level 2
 
Fair Value
Level 3
 
Carrying Value
 
Fair Value
Level 2
 
Fair Value
Level 3
 
 
 
 
 
 
 
 
 
 
 
 
 
Assets:
 
 
 
 
 
 
 
 
 
 
 
 
Wellstat Diagnostics note receivable
 
$
50,191

 
$
—

 
$
57,224

 
$
50,191

 
$
—

 
$
51,308

Hyperion note receivable
 
1,200

 
—

 
1,200

 
1,200

 
—

 
1,200

CareView note receivable
 
19,496

 
—

 
19,507

 
19,346

 
—

 
18,750

Total
 
$
70,887

 
$
—

 
$
77,931

 
$
70,737

 
$
—

 
$
71,258

 
 
 
 
 
 
 
 
 
 
 
 
 
Liabilities:
 
 

 
 

 
 

 
 

 
 

 
 

February 2018 Notes
 
$
—

 
$
—

 
$
—

 
$
126,066

 
$
126,131

 
$
—

December 2021 Notes
 
120,945

 
139,052

 
—

 
117,415

 
148,028

 
—

Total
 
$
120,945

 
$
139,052

 
$
—

 
$
243,481

 
$
274,159

 
$
—


As of June 30, 2018 and December 31, 2017, the estimated fair values of the Hyperion Catalysis International, Inc. note receivable, and CareView Communications, Inc. (“CareView”) note receivable were determined using one or more discounted cash flow models, incorporating expected payments and the interest rate extended on the notes receivable, with fixed interest rates and incorporating expected payments for notes receivable with a variable rate of return.

When deemed necessary the Company engages a third-party valuation expert to assist in evaluating its investments and the related inputs needed to estimate the fair value of certain investments. The Company determined its notes receivable assets are Level 3 assets as the Company’s valuations utilized significant unobservable inputs, including estimates of future revenues, discount rates, expectations about settlement, terminal values and required yield. To provide support for the estimated fair value measurements, the Company considered forward-looking performance related to the investment and current measures associated with high yield indices, and reviewed the terms and yields of notes placed by specialty finance and venture firms both across industries and in similar sectors.

19



The CareView note receivable is secured by substantially all assets of, and equity interests in CareView. The Wellstat Diagnostics note receivable is secured by substantially all assets of Wellstat Diagnostics and is supported by a guaranty from the Wellstat Diagnostics Guarantors (as defined in Note 7 below). The estimated fair value of the collateral assets was determined by using an asset approach and discounted cash flow model related to the underlying collateral and was adjusted to consider estimated costs to sell the assets.

On June 30, 2018, the carrying values of several of the Company’s notes receivable differed from their estimated fair value. This is the result of discount rates used when performing a discounted cash flow for fair value valuation purposes.

The fair values of the Company’s convertible notes were determined using quoted market pricing or dealer quotes.

The following table represents significant unobservable inputs used in determining the estimated fair value of impaired notes receivable investments:
Asset
 
Valuation
Technique
 
Unobservable
Input
 
June 30,
2018
 
December 31,
2017
 
 
 
 
 
 
 
 
 
Wellstat Diagnostics
 
 
 
 
 
 
 
 
Wellstat Guarantors Intellectual Property
 
Income Approach
 
 
 
 
 
 
 
 
 
 
Discount rate
 
12%
 
12%
 
 
 
 
Royalty amount
 
$21 million
 
$21 million
Settlement Amount
 
Income Approach
 
 
 
 
 
 
 
 
 
 
Discount rate
 
15%
 
15%
 
 
 
 
Settlement amount
 
$36 million
 
$32 million
 
 
 
 
 
 
 
 
 
Real Estate Property
 
Market Approach
 
 
 
 
 
 
 
 
 
 
Annual appreciation rate
 
4%
 
4%
 
 
 
 
Estimated realtor fee
 
6%
 
6%
 
 
 
 
Estimated disposal date
 
6/30/2019
 
6/30/2019
 
 
 
 
 
 
 
 
 
CareView
 
 
 
 
 
 
 
 
Note receivable cash flows
 
Income Approach
 
 
 
 
 
 
 
 
 
 
Discount rate
 
17.5%
 
17.5%

At June 30, 2018, the Company had three notes receivable investments on non-accrual status with a cumulative investment cost and fair value of approximately $70.9 million and $77.9 million, respectively, compared to three note receivable investments on non-accrual status at December 31, 2017 with a cumulative investment cost and fair value of approximately $70.7 million and $71.3 million, respectively. For the three and six months ended June 30, 2018, the Company recognized $0.8 million and $1.5 million, respectively, of interest revenue for the CareView note receivable investment as a result of cash interest payments made during the period; for the three and six months ended June 30, 2017, the Company did not recognize any interest for note receivable investments on non-accrual status. During the three and six months ended June 30, 2018, the Company recognized losses on extinguishment of notes receivable of zero and zero, respectively, and during the three and six months ended June 30, 2017, the Company recognized losses on extinguishment of notes receivable of $12.2 million and $12.2 million, respectively.

5. Cash, Cash Equivalents and Short-term Investments
 
As of June 30, 2018, and December 31, 2017, the Company had invested its excess cash balances primarily in cash, money market funds and a corporate equity security. The Company’s securities are classified as available-for-sale and are carried at estimated fair value, with unrealized gains and losses reported in “Accumulated other comprehensive income” in stockholders’ equity, net of estimated taxes. See Note 4 for fair value measurement information. The cost of securities sold is based on the specific identification method. To date, the Company has not experienced credit losses on investments in these instruments, and it does not require collateral for its investment activities.


20


The following tables summarize the Company’s cash and available-for-sale securities’ amortized cost, gross unrealized gains and fair value by significant investment category reported as cash and cash equivalents, or short-term investments as of June 30, 2018 and December 31, 2017:
 
 
 
 
 
 
 
 
Reported as:
(in thousands)
 
 Amortized Cost
 
 Unrealized Gains
 
 Estimated Fair Value
 
 Cash and Cash Equivalents
 
Short-Term Investments
 
 
 
 
 
 
 
 
 
 
 
June 30, 2018
 
 
 
 
 
 
 
 
 
 
Cash
 
$
71,548

 
$
—

 
$
71,548

 
$
71,548

 
$
—

Money market funds
 
324,105

 
—

 
324,105

 
324,105

 
—

Total
 
$
395,653

 
$
—

 
$
395,653

 
$
395,653

 
$
—

 
 
 
 
 
 
 
 
 
 
 
December 31, 2017
 
 
 
 
 
 
 
 
 
 
Cash
 
$
109,703

 
$
—

 
$
109,703

 
$
109,703

 
$
—

Money market funds
 
417,563

 
—

 
417,563

 
417,563

 
—

Corporate securities
 
3,353

 
1,495

 
4,848

 
—

 
4,848

Total
 
$
530,619

 
$
1,495

 
$
532,114

 
$
527,266

 
$
4,848


The Company recognized zero and $0.8 million of gains on sales of available-for-sale securities in the three and six months ended June 30, 2018, respectively. The Company did not recognize any gains or losses on sales of available-for-sale securities in the three and six months ended June 30, 2017.

The unrealized gains on investments included in “Other comprehensive income (loss), net of tax” was zero and $1.2 million as of June 30, 2018, and December 31, 2017, respectively.

6. Concentration of Credit Risk

Product Line Concentration

The percentage of total revenue recognized, which individually accounted for 10% or more of the Company’s total revenues, was as follows:
 
 
 
 
Three Months Ended June 30,
 
Six Months Ended June 30,
Licensee
 
Product Name
 
2018
 
2017
 
2018
 
2017
Biogen
 
Tysabri®
 
3%
 
11%
 
5%
 
16%
 
 
 
 
 
 
 
 
 
 
 
Depomed
 
Glumetza, Janumet XR, Jentadueto XR, Synjardy XR and Invokamet XR
 
20%
 
61%
 
20%
 
49%
 
 
 
 
 
 
 
 
 
 
 
N/A
 
Tekturna, Tekturna HCT, Rasilez and Rasilez HCT
 
56%
 
11%
 
52%
 
15%
 
 
 
 
 
 
 
 
 
 
 
LENSAR
 
LENSAR Laser System
 
13%
 
2%
 
13%
 
1%

7. Notes and Other Long-Term Receivables

Notes and other long-term receivables included the following significant agreements:

Wellstat Diagnostics Note Receivable and Credit Agreement and Related Litigation

On November 2, 2012, the Company and Wellstat Diagnostics entered into a $40.0 million credit agreement pursuant to which the Company was to accrue quarterly interest payments at the rate of 5% per annum (payable in cash or in kind). In addition, the Company was to receive quarterly royalty payments based on a low double-digit royalty rate of Wellstat Diagnostics’ net revenues, generated by the sale, distribution or other use of Wellstat Diagnostics’ products, if any, commencing upon the

21


commercialization of its products. A portion of the proceeds of the $40.0 million credit agreement were used to repay certain notes receivable which Wellstat Diagnostics entered into in March 2012.

In January 2013, the Company was informed that, as of December 31, 2012, Wellstat Diagnostics had used funds contrary to the terms of the credit agreement and breached Sections 2.1.2 and 7 of the credit agreement. The Company sent Wellstat Diagnostics a notice of default on January 22, 2013, and accelerated the amounts owed under the credit agreement. In connection with the notice of default, the Company exercised one of its available remedies and transferred approximately $8.1 million of available cash from a bank account of Wellstat Diagnostics to the Company and applied the funds to amounts due under the credit agreement. On February 28, 2013, the parties entered into a forbearance agreement whereby the Company agreed to refrain from exercising additional remedies for 120 days. During such forbearance period, the Company provided approximately $1.3 million to Wellstat Diagnostics to fund ongoing operations of the business. During the year ended December 31, 2013, approximately $8.7 million was advanced pursuant to the forbearance agreement.

On August 15, 2013, the Company entered into an amended and restated credit agreement with Wellstat Diagnostics. The Company determined that the new agreement should be accounted for as a modification of the existing agreement.

Except as otherwise described herein, the material terms of the amended and restated credit agreement are substantially the same as those of the original credit agreement, including quarterly interest payments at the rate of 5% per annum (payable in cash or in kind). In addition, the Company was to continue to receive quarterly royalty payments based on a low double-digit royalty rate of Wellstat Diagnostics’ net revenues. However, pursuant to the amended and restated credit agreement: (i) the principal amount was reset to approximately $44.1 million, which was comprised of approximately $33.7 million original loan principal and interest, $1.3 million term loan principal and interest and $9.1 million forbearance principal and interest; (ii) the specified internal rates of return increased; (iii) the default interest rate was increased; (iv) Wellstat Diagnostics’ obligation to provide certain financial information increased in frequency to monthly; (v) internal financial controls were strengthened by requiring Wellstat Diagnostics to maintain an independent, third-party financial professional with control over fund disbursements; (vi) the Company waived the existing events of default; and (vii) the owners and affiliates of Wellstat Diagnostics were required to contribute additional capital to Wellstat Diagnostics upon the sale of an affiliate entity. The amended and restated credit agreement had an ultimate maturity date of December 31, 2021 (but has subsequently been accelerated as described below).

In June 2014, the Company received information from Wellstat Diagnostics showing that it was generally unable to pay its debts as they became due, constituting an event of default under the amended and restated credit agreement.

On August 5, 2014, the Company delivered a notice of default (the “Wellstat Diagnostics Borrower Notice”) to Wellstat Diagnostics, which accelerated all obligations under the amended and restated credit agreement and demanded immediate payment in full in an amount equal to approximately $53.9 million, (which amount, in accordance with the terms of the amended and restated credit agreement, included an amount that, together with interest and royalty payments already made to the Company, would generate a specified internal rate of return to the Company), plus accruing fees, costs and interest, and demanded that Wellstat Diagnostics protect and preserve all collateral securing its obligations.

On August 7, 2014, the Company delivered a notice (the “Wellstat Diagnostics Guarantor Notice”) to each of the guarantors of Wellstat Diagnostics’ obligations to the Company (collectively, the “Wellstat Diagnostics Guarantors”) under the credit agreement, which included a demand that the guarantors remit payment to the Company in the amount of the outstanding obligations. The guarantors include certain affiliates and related companies of Wellstat Diagnostics, including Wellstat Therapeutics and Wellstat Diagnostics’ stockholders.

On September 24, 2014, the Company filed an ex-parte petition for appointment of receiver with the Circuit Court of Montgomery County, Maryland (the “Wellstat Diagnostics Petition”), which was granted on the same day. Wellstat Diagnostics remained in operation during the period of the receivership with incremental additional funding from the Company. On May 24, 2017, Wellstat Diagnostics transferred substantially all of its assets to the Company pursuant to a credit bid. The credit bid reduced the outstanding balance of the loan by an immaterial amount.

On September 4, 2015, the Company filed in the Supreme Court of New York a motion for summary judgment in lieu of complaint which requested that the court enter judgment against certain of the Wellstat Diagnostics Guarantors for the total amount due on the Wellstat Diagnostics debt, plus all costs and expenses including lawyers’ fees incurred by the Company in enforcement of the related guarantees. On September 23, 2015, the Company filed in the same court an ex parte application for a temporary restraining order and order of attachment of the Wellstat Diagnostics Guarantor defendants’ assets. Although the court denied the Company’s request for a temporary restraining order at a hearing on September 24, 2015, it ordered that assets

22


of the Wellstat Diagnostics Guarantor defendants should be held in status quo ante and only used in the normal course of business.

On July 29, 2016, the Supreme Court of New York granted the Company’s motion for summary judgment and held that the Wellstat Diagnostics Guarantor defendants are liable for all “Obligations” owed by Wellstat Diagnostics to the Company. After appeal by the Wellstat Diagnostics Guarantor defendants, on February 14, 2017, the Appellate Division of the Supreme Court of New York reversed on procedural grounds a portion of the Memorandum of Decision granting the Company summary judgment in lieu of complaint, but affirmed the portion of the Memorandum of Decision denying the Wellstat Diagnostics Guarantor defendants’ motion for summary judgment in which they sought a determination that the guarantees had been released. As a result, the litigation has been remanded to the Supreme Court of New York to proceed on the Company’s claims as a plenary action. On June 21, 2017, the Supreme Court of New York ordered the Company to file a Complaint, which was filed by the Company on July 20, 2017. The Wellstat Diagnostics Guarantors filed their answer on August 9, 2017, including counterclaims against the Company alleging breach of contract, breach of fiduciary duty, and tortious interference with prospective economic advantage. This case is currently pending and in the pre-trial phase.

On October 14, 2016, the Company sent a notice of default and reference to foreclosure proceedings to certain of the Wellstat Diagnostics Guarantors which are not defendants in the New York action, but which are owners of real estate assets over which a deed of trust in favor of the Company securing the guarantee of the loan to Wellstat Diagnostics had been executed. On March 2, 2017, the Company sent a second notice to foreclose on the real estate assets, and noticed the sale for March 29, 2017. The sale was taken off the calendar by the trustee under the deed of trust and has not been re-scheduled yet. On March 6, 2017, the Company sent a letter to the Wellstat Diagnostics Guarantors seeking information in preparation for a UCC Article 9 sale of some or all of the intellectual property-related collateral of the Wellstat Diagnostics Guarantors. The Wellstat Diagnostics Guarantors did not respond to the Company’s letter, but on March 17, 2017, filed an order to show cause with the Supreme Court of New York to enjoin the Company’s sale of the real estate or enforcing its security interests in the Wellstat Diagnostics Guarantors’ intellectual property during the pendency of any action involving the guarantees at issue. In June 2018, the Delaware Supreme Court largely affirmed a September 2017 decision of the Delaware Chancery Court awarding Wellstat Therapeutics $55.8 million in damages, plus interest, against BTG International, Inc. for breach of contract. In October 2017, the Company had filed a motion with the Supreme Court of New York requesting a pre-judgement attachment of the award. On February 6, 2018, the Supreme Court of New York issued an order from the bench which enjoins the Wellstat Diagnostics Guarantors from selling, encumbering, removing, transferring or altering the collateral pending the outcome of the proceedings before it. The Supreme Court of New York also issued an order precluding the Company from foreclosing on certain of the Wellstat Diagnostics Guarantors’ collateral pending the outcome of the proceedings before it.

On October 22, 2015, certain of the Wellstat Diagnostics Guarantors filed a separate complaint against the Company in the Supreme Court of New York seeking a declaratory judgment that certain contractual arrangements entered into between the parties subsequent to Wellstat Diagnostics’ default, and which relate to a split of proceeds in the event that the Wellstat Diagnostics Guarantors voluntarily monetize any assets that are the Company’s collateral, is of no force or effect. This case has been joined for all purposes, including trial, and consolidated with the pending case filed by the Company.

Effective April 1, 2014, and as a result of the event of default, the Company determined the loan to be impaired and it ceased to accrue interest revenue. At that time and as of June 30, 2018, it has been determined that an allowance on the carrying value of the note was not necessary, as the Company believes the value of the collateral securing Wellstat Diagnostics’ obligations exceeds the carrying value of the asset and is sufficient to enable the Company to recover the current carrying value of $50.2 million. The Company continues to closely monitor the timing and expected recovery of amounts due, including litigation and other matters related to Wellstat Diagnostics Guarantors’ assets. There can be no assurance that an allowance on the carrying value of the notes receivable investment will not be necessary in a future period depending on future developments.

Hyperion Agreement

On January 27, 2012, the Company and Hyperion Catalysis International, Inc. (“Hyperion”) (which is also a Wellstat Diagnostics Guarantor) entered into an agreement whereby Hyperion sold to the Company the royalty streams due from Showa Denko K.K. (“SDK”) related to a certain patent license agreement between Hyperion and SDK dated December 31, 2008. The agreement assigned the patent license agreement royalty stream accruing from January 1, 2012 through December 31, 2013, to the Company in exchange for the lump sum payment to Hyperion of $2.3 million. In exchange for the lump sum payment, the Company was to receive two equal payments of $1.2 million on each of March 5, 2013 and 2014. The first payment of $1.2 million was paid on March 5, 2013, but Hyperion has not made the second payment that was due on March 5, 2014. Effective as of such date and as a result of the event of default, the Company ceased to accrue interest revenue. As of June 30, 2018, the estimated fair value of the collateral was determined to be in excess of the carrying value. There can be no assurance that this

23


will be true in the event of the Company’s foreclosure on the collateral, nor can there be any assurance of realizing value from such collateral.

Avinger Credit and Royalty Agreement

On April 18, 2013, the Company entered into a credit agreement with Avinger, Inc. (the “Avinger Credit and Royalty Agreement”). Under the terms of the Avinger Credit and Royalty Agreement, the Company receives a low, single-digit royalty on Avinger’s net revenues until April 2018. Commencing in October 2015, after Avinger repaid $21.4 million pursuant to its note receivable prior to its maturity date, the royalty on Avinger’s net revenues reduced by 50%, subject to certain minimum payments from the prepayment date until April 18, 2018. The Company has accounted for the royalty rights in accordance with the fair value option. As of April 18, 2018, there are no further obligations owed to PDL.

LENSAR Credit Agreement

On October 1, 2013, the Company entered into a credit agreement with LENSAR, Inc. (“LENSAR”), pursuant to which the Company made available to LENSAR up to $60.0 million to be used by LENSAR in connection with the commercialization of its currently marketed LENSAR™ Laser System. Of the $60.0 million available to LENSAR, an initial $40.0 million, net of fees, was funded by the Company at the close of the transaction. The remaining $20.0 million was never funded. Outstanding borrowings under the loans bore interest at the rate of 15.5% per annum, payable quarterly in arrears.

On May 12, 2015, the Company entered into a forbearance agreement with LENSAR, pursuant to which the Company agreed to refrain from exercising certain remedies available to it resulting from the failure of LENSAR to comply with a liquidity covenant and make interest payments due under the credit agreement. Under the forbearance agreement, the Company agreed to provide LENSAR with up to an aggregate of $8.5 million in weekly increments through the period ended September 30, 2015 plus employee retention amounts of approximately $0.5 million in the form of additional loans, subject to LENSAR meeting certain milestones related to LENSAR obtaining additional capital to fund the business or sell the business and repay outstanding amounts under the credit agreement. In exchange for the forbearance, LENSAR agreed to additional reporting covenants, the engagement of a chief restructuring officer and an increase on the interest rate to 18.5%, applicable to all outstanding amounts under the credit agreement.

On September 30, 2015, the Company agreed to extend the forbearance agreement until October 9, 2015 and provide for up to an additional $0.8 million in funding while LENSAR negotiated a potential sale of its assets. On October 9, 2015, the forbearance agreement expired, but the Company agreed to fund LENSAR’s operations while LENSAR continued to negotiate a potential sale of its assets.

On November 15, 2015, LENSAR, LLC (“LENSAR/Alphaeon”), a wholly owned subsidiary of Alphaeon Corporation (“Alphaeon”), and LENSAR entered into the Asset Purchase Agreement whereby LENSAR/Alphaeon agreed to acquire certain assets of LENSAR and assumed certain liabilities of LENSAR. The acquisition was consummated on December 15, 2015.

In connection with the closing of the acquisition, LENSAR/Alphaeon entered into an amended and restated credit agreement with the Company, assuming $42.0 million in loans as part of the borrowings under the Company’s prior credit agreement with LENSAR. In addition, Alphaeon issued 1.7 million shares of its Class A common stock to the Company.

The Company has estimated a fair value of $3.84 per share for the 1.7 million shares of Alphaeon Class A common stock received in connection with the transactions and recognized this investment as a cost-method investment of $6.6 million included in other long-term assets. The Alphaeon Class A common stock is subject to other-than-temporary impairment assessments in future periods. There is no other-than-temporary impairment charge incurred as of June 30, 2018.

In December 2016, LENSAR, re-acquired the assets from LENSAR/Alphaeon and the Company entered into a second amended and restated credit agreement with LENSAR whereby LENSAR assumed all obligations under the amended and restated credit agreement with LENSAR/Alphaeon. Also in December, LENSAR filed for a voluntary petition under Chapter 11 of the U.S. Bankruptcy Code (“Chapter 11 case”) with the support of the Company. In January 2017, the Company agreed to provide debtor-in-possession financing of up to $2.8 million in new advances to LENSAR so that it could continue to operate its business during the Chapter 11 case. LENSAR filed a Chapter 11 plan of reorganization with the Company’s support under which LENSAR would issue 100% of its equity interests to the Company in exchange for the cancellation of the Company’s claims as a secured creditor in the Chapter 11 case, other than with respect to the debtor-in-possession financing, and would thereby become an operating wholly-owned subsidiary of the Company. On April 26, 2017, the bankruptcy court approved the plan of reorganization.


24


Pursuant to the plan of reorganization, LENSAR emerged from bankruptcy on May 11, 2017 as a wholly-owned subsidiary of the Company, and the Company started to consolidate LENSAR’s financial statements under the voting interest model beginning May 11, 2017.

For additional information on LENSAR please refer to Note 10 under “Intangible Assets,” Note 19 under “Business Combinations” and Note 20 under “Segment Information.”

Direct Flow Medical Credit Agreement

On November 5, 2013, the Company entered into a credit agreement with Direct Flow Medical, Inc. (“Direct Flow Medical”) under which the Company agreed to provide up to $50.0 million to Direct Flow Medical. Of the $50.0 million available to Direct Flow Medical, an initial $35.0 million (tranche one), net of fees, was funded by the Company at the close of the transaction.

On November 10, 2014, the Company and Direct Flow Medical agreed to an amendment to the credit agreement to permit Direct Flow Medical to borrow the $15.0 million second tranche upon receipt by Direct Flow Medical of a specified minimum amount of proceeds from an equity offering prior to December 31, 2014. In exchange, the parties amended the credit agreement to provide for additional fees associated with certain liquidity events, such as a change of control or the consummation of an initial public offering, and granted the Company certain board of director observation rights. On November 19, 2014, upon Direct Flow Medical satisfying the amended tranche two milestone, the Company funded the $15.0 million second tranche to Direct Flow Medical, net of fees.

Outstanding borrowings under tranche one bore interest at the rate of 15.5% per annum, payable quarterly in arrears, until the occurrence of the second tranche. Upon occurrence of the borrowing of this second tranche, the interest rate applicable to all loans under the credit agreement was decreased to 13.5% per annum, payable quarterly in arrears.

Under the terms of the credit agreement, Direct Flow Medical’s obligation to repay loan principal commenced on the twelfth interest payment date, September 30, 2016. The principal amount outstanding at commencement of repayment was required to be repaid in equal installments until final maturity of the loans. The loans were to mature on November 5, 2018. The obligations under the credit agreement were secured by a pledge of substantially all of the assets of Direct Flow Medical and any of its subsidiaries.

On December 21, 2015, Direct Flow Medical and the Company entered into a waiver to the credit agreement in anticipation of Direct Flow Medical being unable to comply with the liquidity covenant and make interest payments due under the credit agreement, which was subsequently extended on January 14, 2016, and further delayed the timing of the interest payments through the period ending September 30, 2016 while Direct Flow Medical sought additional financing to operate its business.

On January 28, 2016, the Company funded an additional $5.0 million to Direct Flow Medical in the form of a short-term secured promissory note.

On February 26, 2016, the Company and Direct Flow Medical entered into the fourth amendment to the credit agreement that, among other things, (i) converted the $5.0 million short-term secured promissory note into a loan under the credit agreement with substantially the same interest and payment terms as the existing loans, (ii) added a conversion feature whereby the $5.0 million loan would convert into equity of Direct Flow Medical upon the occurrence of certain events and (iii) provided for a second $5.0 million convertible loan tranche commitment, to be funded at the option of the Company. The commitment for the second tranche was not funded and has since expired. In addition, (i) the Company agreed to waive the liquidity covenant and delay the timing of the unpaid interest payments until September 30, 2016 and (ii) Direct Flow Medical agreed to issue to the Company a specified amount of warrants to purchase shares of convertible preferred stock on the first day of each month for the duration of the waiver period at an exercise price of $0.01 per share.

On July 15, 2016, the Company and Direct Flow Medical entered into the fifth amendment and limited waiver to the credit agreement. The Company funded an additional $1.5 million to Direct Flow Medical in the form of a note with substantially the same interest and payment terms as the existing loans and a conversion feature whereby the $1.5 million loan would convert into equity of Direct Flow Medical upon the occurrence of certain events. In addition, Direct Flow Medical agreed to issue to the Company warrants to purchase shares of convertible preferred stock at an exercise price of $0.01 per share.

On September 12, 2016, the Company and Direct Flow Medical entered into the sixth amendment and limited waiver to the credit agreement under which the Company funded an additional $1.5 million to Direct Flow Medical in the form of a note with substantially the same interest and payment terms as the existing loans. In addition, Direct Flow Medical agreed to issue to

25


the Company a specified amount of warrants to purchase shares of convertible preferred stock at an exercise price of $0.01 per share.

On September 30, 2016, the Company and Direct Flow Medical entered into a waiver to the credit agreement where the parties agreed, among other things, to (i) delay payment on all overdue interest payments until October 31, 2016, (ii) waive the initial principal repayment until October 31, 2016 and (iii) continue to waive the liquidity requirements until October 31, 2016. Further, Direct Flow Medical agreed to issue to the Company a specified amount of warrants to purchase shares of convertible preferred stock at an exercise price of $0.01 per share.

On October 31, 2016, the Company agreed to extend the waivers described above until November 30, 2016 and on November 14, 2016, the Company advanced an additional $1.0 million loan while Direct Flow Medical continued to seek additional financing.

On November 16, 2016, Direct Flow Medical advised the Company that its potential financing source had modified its proposal from an equity investment to a loan with a substantially smaller amount and under less favorable terms. Direct Flow Medical shut down its operations in December 2016 and in January 2017 made an assignment for the benefit of creditors. The Company then initiated foreclosure proceedings, resulting in the Company obtaining ownership of most of the Direct Flow Medical assets through the Company’s wholly-owned subsidiary, DFM, LLC. The assets were held for sale and carried at the lower of carrying amount or fair value, less estimated selling costs, which is primarily based on supporting data from market participant sources, and valid offers from third parties.

At December 31, 2016, the Company completed an impairment analysis and concluded that the situation qualified as a troubled debt restructuring and recognized an impairment loss of $51.1 million.

In January 2017, the Company started to actively market the asset held for sale. On January 23, 2017, the Company and DFM, LLC entered into an Intellectual Property Assignment Agreement with Hong Kong Haisco Pharmaceutical Co., Limited (“Haisco”), a Chinese pharmaceutical company, whereby Haisco acquired former Direct Flow Medical clinical, regulatory and commercial information and intellectual property rights exclusively in China for $7.0 million. The Company, through DFM, LLC also sold Haisco certain manufacturing equipment for $450,000 and collected $692,000 on outstanding Direct Flow Medical accounts receivable during the year ended December 31, 2017.

On January 6, 2018, DFM, LLC and HaisThera Advisors Co., Limited (“HaisThera”) entered into a license agreement whereby DFM, LLC granted HaisThera an exclusive license to develop, manufacture and commercialize percutaneously implanting stentless aortic valve in the European Union. The consideration for the license agreement was $500,000 upfront and up to $2.0 million in royalty payments.

kaléo Note Purchase Agreement

On April 1, 2014, the Company entered into a note purchase agreement with Accel 300, LLC (“Accel 300”), a wholly-owned subsidiary of kaléo, Inc. (“kaléo”), pursuant to which the Company acquired $150.0 million of secured notes due 2029 (the “kaléo Note”). The kaléo Note was issued pursuant to an indenture between Accel 300 and U.S. Bank, National Association, as trustee, and was secured by 20% of net sales of its first approved product, Auvi-Q® (epinephrine auto-injection, USP) (known as Allerject® in Canada) and 10% of net sales of kaléo’s second proprietary auto-injector based product, EVZIO (naloxone hydrochloride injection) (the “kaléo Revenue Interests”), and a pledge of kaléo’s equity ownership in Accel 300.

On September 21, 2017, the Company entered into an agreement (the “kaléo Note Sale Agreement”) with MAM-Kangaroo Lender, LLC, a Delaware limited liability company (the “kaléo Purchaser”), pursuant to which the Company sold its entire interest in the kaléo Note.

Pursuant to the kaléo Note Sale Agreement, the kaléo Purchaser paid to the Company an amount equal to 100% of the then outstanding principal, a premium of 1% of such amount and accrued interest under the kaléo Note, for an aggregate cash purchase price of $141.7 million, subject to an 18-month escrow holdback of $1.4 million against certain potential contingencies. For a further discussion on this topic, see Note 12.

CareView Credit Agreement

On June 26, 2015, the Company entered into a credit agreement with CareView, under which the Company made available to CareView up to $40.0 million in two tranches of $20.0 million each. Under the terms of the credit agreement, the first tranche of $20.0 million, net of fees, was funded by the Company upon CareView’s attainment of a specified milestone relating to the

26


placement of CareView Systems®, on October 7, 2015. On October 7, 2015, the Company and CareView entered into an amendment of the credit agreement to modify certain definitions related to the first and second tranche milestones. The second $20.0 million tranche would be funded upon CareView’s attainment of specified milestones relating to the placement of CareView Systems and consolidated earnings before interest, taxes, depreciation and amortization, to be accomplished no later than June 30, 2017. Such milestones were not achieved, and there is no additional funding obligation due from the Company. Outstanding borrowings under the credit agreement will bear interest at the rate of 13.5% per annum and are payable quarterly in arrears.

As part of the transaction, the Company received a warrant to purchase approximately 4.4 million shares of common stock of CareView at an exercise price of $0.45 per share. The Company has accounted for the warrant as derivative asset with an offsetting credit as debt discount. At each reporting period the warrant is marked to market for changes in fair value.

In connection with the October 2015 amendment of the credit agreement, the Company and CareView also agreed to amend the warrant to purchase common stock agreement by reducing the warrant’s exercise price from $0.45 to $0.40 per share.

In February 2018, the Company entered into a modification agreement with CareView whereby the Company agreed, effective as of December 28, 2017, to modify the credit agreement before remedies could otherwise have become available to the Company under the credit agreement in relation to certain obligations of CareView that would potentially not be met, including the requirement to make principal payments. Under the modification agreement the Company agreed that (i) a lower liquidity covenant would be applicable and (ii) principal repayment would be delayed for a period of up to December 31, 2018. In exchange for agreeing to these modifications, among other things, the exercise price of the Company’s warrants to purchase 4.4 million shares of common stock of CareView was repriced from $0.40 to $0.03 per share and, subject to the occurrence of certain events, CareView agreed to grant the Company additional equity interests. At June 30, 2018, the Company determined an estimated fair value of the warrant to be $0.1 million.

Effective October 1, 2017, the Company determined the loan to be impaired and it ceased to accrue interest revenue. At June 30, 2018, it has been determined that an allowance on the carrying value of the note was not necessary.

8. Inventories

Inventories consisted of the following:
 
 
June 30,
 
December 31,
(in thousands)
 
2018
 
2017
 
 
 
 
 
Raw materials
 
$
1,771

 
$
1,717

Work in process
 
1,677

 
1,119

Finished goods
 
11,353

 
6,311

Total inventory
 
$
14,801

 
$
9,147


As of June 30, 2018 and December 31, 2017, the Company deferred approximately $0.2 million and $1.3 million, respectively, of costs associated with inventory transfers made under the Company’s third party logistic provider service arrangement. These costs have been recorded as other assets on the Company’s Condensed Consolidated Balance Sheet as of June 30, 2018 and December 31, 2017. The Company will recognize the cost of product sold as inventory is transferred from its third-party logistics provider to the Company’s customers.

During the three and six months ended June 30, 2018, the Company recognized a reduction in the inventory provision of $0.6 million and $0.5 million, respectively, and during the three and six months ended June 30, 2017, the Company recognized an inventory write-down of $0.1 million and $0.2 million, respectively, related to Tekturna®, Tekturna HCT®, Rasilez® and Rasilez HCT® (collectively, the “Noden Products” or “Tekturna”) that the Company would not be able to sell prior to their expiration.

9. Asset Acquisition

On January 8, 2018, LENSAR entered into an Asset Purchase Agreement with Precision Eye Services (“PES”) to purchase assets used in PES’ laser-assisted cataract surgery business. The assets purchased include equipment, inventory and PES’ customer contracts. No workforce was transferred as part of the transaction.


27


The Company assessed the acquisition of PES assets under ASC Topic 805, Business Combinations (“ASC 805”). Under ASC 805, the Company determined that the acquired assets did not constitute a business and that the transaction would be accounted for as an asset acquisition.

The following table summarizes the fair values of the identifiable assets acquired and liabilities assumed at the acquisition date (in thousands):
Equipment and inventory
 
$
848

Fixed assets
 
67

Intangible assets (customer relationships)
 
1,845

Total identifiable assets
 
$
2,760

 
 
 
Consideration paid at closing, cash
 
$
1,200

Conversion consideration
 
920

Contingent consideration
 
640

Total fair value of consideration
 
$
2,760


10. Intangible Assets

Intangible Assets, Net

On June 8, 2018, Noden Pharma DAC (“Noden DAC”), a wholly owned subsidiary of the Company, entered into a Settlement Agreement (the “Settlement Agreement”) with Anchen Pharmaceuticals, Inc. and its affiliates (“Anchen”) to resolve the patent litigation relating to infringement of U.S. Patent No. 8,617,595 (the “595 Patent”) based on their submission of an Abbreviated New Drug Application (“ANDA”) seeking authorization from the U.S. FDA to market a generic version of aliskiren, the active ingredient in the Tekturna and Tekturna HCT drug. Under the Settlement Agreement, Anchen, the sole ANDA filer of which the Company is aware, agreed to not commercialize its generic version of aliskiren prior to March 1, 2019. Per the Settlement Agreement, Anchen may commercialize their formulation of aliskiren, but is not permitted to commercialize a copy of Tekturna.

Accordingly, management evaluated the ongoing value of the Noden DAC asset group based upon the probability of Anchen’s market entry of a generic version of aliskiren in the United States and the associated cash flows and conducted a test for impairment. Due to the increased probability of a generic version of aliskiren being launched in the United States the Company revised its estimates of future cash flows and as a result of this analysis determined that the sum of undiscounted cash flows was not greater than the carrying value of the assets. Therefore, the Company performed a discounted cash flow analysis to estimated the fair value of the asset group in accordance with ASC Topic 360, Impairment or Disposal of Long-lived Assets. The cash flows are those expected to be generated by market participants, discounted to reflect an appropriate amount of risk, which was determined to be 21%. The Company concluded that the Noden DAC acquired product rights and customer relationship long-lived assets, with a carrying amount of $192.5 million, were no longer recoverable and wrote them down to their estimated fair value of $40.1 million, resulting in an impairment charge of $152.3 million as of June 30, 2018. This write-down is included in “Impairment of intangible assets” in the Condensed Consolidated Statements of Income and the Condensed Consolidated Statements of Cash Flows. The remaining Noden DAC intangible asset balance, part of the Pharmaceutical reportable segment, of $40.1 million will be amortized straight-line over the remaining useful life of 8 years.

28



The components of intangible assets as of June 30, 2018 and December 31, 2017 were as follows:
 
 
June 30, 2018
 
December 31, 2017
(in thousands)
 
Gross Carrying Amount
 
Accumulated Amortization
 
Net Carrying Amount
 
Gross Carrying Amount
 
Accumulated Amortization
 
Net Carrying Amount
 
 
 
 
 
 
 
 
 
 
 
 
 
Finite-lived intangible assets:
 
 
 
 
 
 
 
 
 
 
 
 
Acquired products rights(1)
 
$
36,143

 
$
—

 
$
36,143

 
$
216,690

 
$
(32,503
)
 
$
184,187

Customer relationships(1) (2)
 
8,028

 
(341
)
 
7,687

 
26,080

 
(3,729
)
 
22,351

Acquired technology(2) (3)
 
11,011

 
(806
)
 
10,205

 
9,200

 
(409
)
 
8,791

Acquired trademarks(2)
 
570

 
(133
)
 
437

 
570

 
(76
)
 
494

 
 
$
55,752

 
$
(1,280
)
 
$
54,472

 
$
252,540

 
$
(36,717
)
 
$
215,823

________________
(1) The Company acquired certain intangible assets as part of the Noden Transaction. They are amortized on a straight-line basis over a weighted average period of 8.0 years.
(2) The Company acquired certain intangible assets as part of the LENSAR transaction, as described further in Note 19. They are amortized over a weighted average period of 15.0 years. The intangible assets for acquired technology and trademarks are being amortized over their estimated useful lives using the straight-line method of amortization. The intangible assets for customer relationships are being amortized using a double-declining method of amortization as such method better represents the economic benefits to be obtained.
(3)
The Company acquired certain intangible assets as part of the foreclosure on certain of Direct Flow Medical assets, as described further in Note 7. They are amortized over a weighted average period of 10.0 years. The intangible assets for acquired technology are being amortized over their estimated useful lives using the straight-line method of amortization.

For the three and six months ended June 30, 2018, amortization expense was $6.4 million and $12.7 million, respectively, and for the three and six months ended June 30, 2017, amortization expense was $6.1 million and $12.2 million, respectively.

Based on the intangible assets recorded at June 30, 2018, and assuming no subsequent additions to or impairment of the underlying assets, the remaining estimated amortization expense is expected to be as follows (in thousands):
Fiscal Year
 
Amount
 
 
 
2018 (Remaining six months)
 
$
3,154

2019
 
6,275

2020
 
6,240

2021
 
6,209

2022
 
6,104

2023
 
6,040

Thereafter
 
20,450

Total remaining estimated amortization expense
 
$
54,472



29


11. Accrued Liabilities

Accrued liabilities consist of the following:
(in thousands)
 
June 30,
2018
 
December 31,
2017
 
 
 
 
 
Compensation
 
$
7,046

 
$
6,043

Interest
 
344

 
2,451

Deferred revenue
 
4,904

 
9,741

Dividend payable
 
77

 
79

Legal
 
1,027

 
595

Accrued rebates, chargebacks and other revenue reserves
 
16,931

 
19,613

Refund to manufacturer
 
—

 
647

Customer advances
 
—

 
3,198

Contingent consideration, current
 
1,140

 
—

Other
 
2,825

 
3,514

Total
 
$
34,294

 
$
45,881


The following table provides a summary of activity with respect to the Company’s sales allowances and accruals for the six months ended June 30, 2018:
(in thousands)
 
Discount and Distribution Fees
 
Government Rebates and Chargebacks
 
Assistance and Other Discounts
 
Product Return
 
Total
 
 
 
 
 
 
 
 
 
 
 
Balance at December 31, 2017:
 
$
3,422

 
$
8,709

 
$
4,178

 
$
3,304

 
$
19,613

Allowances for current period sales
 
4,749

 
7,859

 
4,174

 
1,291

 
18,073

Allowances for prior period sales
 
—

 
24

 
—

 
65

 
89

Credits/payments for current period sales
 
(2,057
)
 
(2,847
)
 
(2,019
)
 
—

 
(6,923
)
Credits/payments for prior period sales
 
(3,724
)
 
(7,629
)
 
(2,178
)
 
(390
)
 
(13,921
)
Balance at June 30, 2018:
 
$
2,390

 
$
6,116

 
$
4,155

 
$
4,270

 
$
16,931


12. Commitments and Contingencies

Wellstat Litigation

On September 4, 2015, the Company filed in the Supreme Court of New York a motion for summary judgment in lieu of complaint which requested that the court enter judgment against Wellstat Diagnostics Guarantors for the total amount due on the Wellstat Diagnostics debt, plus all costs and expenses including lawyers’ fees incurred by the Company in enforcement of the related guarantees. On July 29, 2016, the court issued its Memorandum of Decision granting the Company’s motion for summary judgment and denying the Wellstat Diagnostics Guarantors’ cross-motion for summary judgment seeking a determination that they were no longer liable under the guarantees. The Supreme Court of New York held that the Wellstat Diagnostics Guarantors are liable for all “Obligations” owed by Wellstat Diagnostics to the Company. It did not set a specific dollar amount due, but ordered that a judicial hearing officer or special referee be designated to determine the amount of the Obligations owing, and awarded the Company its attorneys’ fees and costs in an amount to be determined. On July 29, 2016, the Wellstat Diagnostics Guarantors filed a notice of appeal from the Memorandum of Decision to the Appellate Division of the Supreme Court of New York. On February 14, 2017, the Appellate Division reversed the summary judgment decision of the Supreme Court in the Company’s favor, but affirmed the denial of the Wellstat Guarantors’ cross-motion for summary judgment. The Appellate Division determined that the action was inappropriate for summary judgment pursuant to New York Civil Practice Law & Rules section 3213 on procedural grounds, but specifically made no determination regarding whether the Company was entitled to a judgment on the merits. Pursuant to this decision, the action has been remanded to the Supreme Court for further proceedings on the merits. The proceeding is being conducted as a plenary proceeding, with both parties having the opportunity to take discovery and file dispositive motions in accordance with New York civil procedure.


30


Noden Pharma DAC v Anchen Pharmaceuticals, Inc. et al

On June 12, 2017, Noden filed a complaint against Anchen Pharmaceuticals, Inc. (“Anchen”) and Par Pharmaceutical (“Par”) for infringement of the 595 Patent based on their submission of an ANDA seeking authorization from the FDA to market a generic version of aliskiren hemifumarate tablets, 150 mg and 300 mg, in the United States. Noden’s suit triggered a 30-month stay of FDA approval of that application under the Hatch Waxman Act. Par filed a counterclaim seeking a declaratory judgment that their proposed generic version of aliskiren hemifumarate hydrochlorothiazide tablets (150 mg eq. base/12.5 mg HCT, 150 mg eq. base/25 mg HCT, 300 mg eq. base/12.5 mg HCT, and 300 mg eq. base/25 mg HCT), described in a separate ANDA submitted by Par to FDA, alleging noninfringement of U.S. Patent No. 8,618,172 (the “‘172 Patent”), also owned by Noden. This case was filed in the United States District Court for the District of Delaware. In March 2018, each of the parties to the proceeding filed a joint stipulation of dismissal of the defendants’ counterclaim seeking a declaratory judgment of non-infringement of the ‘172 Patent. In the stipulation, Anchen and Par agreed that they will not seek, or otherwise join or assist in, any post-grant review, including inter partes review, of the ‘172 Patent or U.S. Patent No. 9,023,893 (the “893 Patent”). The defendants further stipulated that they will not seek approval of Par’s ANDA or submit any other ANDA seeking approval to market aliskiren hemifumarate hydrochlorothiazide prior to the expiration of the ‘172 Patent in July of 2028. Both the ‘172 Patent and the ‘893 Patent are listed in the Orange Book for Tekturna HCT.

On June 8, 2018, Noden and Anchen entered into the Settlement Agreement. Under the Settlement Agreement, the parties agreed to file a stipulation of dismissal with the court to facilitate dismissal of the litigation in its entirety, with prejudice. In the Settlement Agreement, Noden granted Anchen a non-exclusive, royalty free, fully paid up and non-transferable license to manufacture and commercialize in the United States a generic version of aliskiren which is described in Anchen’s ANDA, and Anchen agreed not to commercialize its generic version of aliskiren prior to March 1, 2019. The license grant excludes certain formulations covered by the ‘595 patent which closely relate to the commercial formulation of Tekturna marketed by Noden. The Settlement Agreement includes a release by each party for liabilities associated with the litigation and an acknowledgement from Anchen that the ‘595 patent claims are valid and enforceable. Anchen’s ANDA has not yet been approved by the FDA and any commercialization by Anchen will be subject to their ability to obtain such approval.

Other Legal Proceedings

From time to time, the Company is involved in lawsuits, arbitrations, claims, investigations and proceedings, consisting of intellectual property, commercial, employment and other matters, which arise in the ordinary course of business. The Company makes provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Such provisions are reviewed at least quarterly and adjusted to reflect the impact of settlement negotiations, judicial and administrative rulings, advice of legal counsel, and other information and events pertaining to a particular case. Litigation is inherently unpredictable. If any unfavorable ruling were to occur in any specific period, there exists the possibility of a material adverse impact on the results of the Company’s operations of that period and on its cash flows and liquidity.

Lease Guarantee

In connection with the spin-off (the “Spin-Off”) by the Company of Facet Biotech Corporation (“Facet”), the Company entered into amendments to the leases for the Company’s former facilities in Redwood City, California, under which Facet was added as a co-tenant, and a Co-Tenancy Agreement, under which Facet agreed to indemnify us for all matters related to the leases attributable to the period after the Spin-Off date. As of June 30, 2018, the total lease payments for the duration of the guarantee, which runs through December 2021, are approximately $39.5 million. In April 2010, Abbott Laboratories acquired Facet and later renamed the entity AbbVie Biotherapeutics, Inc. (“AbbVie”). If AbbVie were to default under its lease obligations, the Company could be held liable by the landlord as a co-tenant and, thus, the Company has in substance guaranteed the payments under the lease agreements for the Redwood City facilities.

The Company prepared a discounted, probability weighted cash flow analysis to calculate the estimated fair value of the lease guarantee as of the Spin-Off. The Company was required to make assumptions regarding the probability of Facet’s default on the lease payment, the likelihood of a sublease being executed and the times at which these events could occur. These assumptions are based on information that the Company received from real estate brokers and the then-current economic conditions, as well as expectations of future economic conditions. The fair value of this lease guarantee was charged to additional paid-in capital upon the Spin-Off and any future adjustments to the carrying value of the obligation will also be recorded in additional paid-in capital.


31


The Company has recorded a liability of $10.7 million on its Condensed Consolidated Balance Sheets as of June 30, 2018 and December 31, 2017, related to this guarantee. In future periods, the Company may adjust this liability for any changes in the ultimate outcome of this matter that are both probable and estimable.

Purchase Obligations

Noden and Novartis entered into a supply agreement pursuant to which Novartis will manufacture and supply to Noden a bulk tableted form of the Noden Products, and for the additional supply of active pharmaceutical ingredient form, for specified periods of time prior to the transfer of manufacturing responsibilities for the Noden Products to another manufacturer. The supply agreement may be terminated by either party for material breach that remains uncured for a specified time period. Noden has placed firm orders for bulk product of $14.4 million, which will be fulfilled within the next twelve months. Under the terms of the supply agreement, Noden is committed to purchase certain minimum quantities of bulk product and active pharmaceutical ingredient that would amount to approximately $114.3 million over the next twenty-four months if fulfilled, of which $61.4 million is committed over the next twelve months. While the supply agreement provides that the parties will agree to reasonable accommodations with respect to changes in firm orders, the Company expects that Noden will meet the requirements of the supply agreement, unless otherwise negotiated. The commitments in the supply agreement terminate upon transfer to another manufacturer.

LENSAR and Coherent, Inc. entered into an Original Equipment Manufacturer agreement pursuant to which Coherent, Inc. will manufacture and supply to LENSAR Staccato Lasers. The supply agreement commits LENSAR to a minimum purchase obligation of approximately $3.5 million over the next twenty-four months, of which $1.2 million is committed over the next twelve months. The Company expects that LENSAR will meet this requirement. For more information about the LENSAR transaction, see Note 19.

Escrow Receivable

On September 21, 2017, the Company entered into the kaléo Note Sale Agreement, pursuant to which the Company sold its entire interest in the kaléo Note.

Pursuant to the kaléo Note Sale Agreement, the purchaser paid to the Company an amount equal to 100% of the then outstanding principal, a premium of 1% of such amount and accrued interest under the kaléo Notes, for an aggregate cash purchase price of $141.7 million.

Pursuant to the terms of the kaléo Note Sale Agreement, $1.4 million of the aggregate purchase price was deposited into an escrow account as a potential payment against certain contingencies, which expires on the 18th month anniversary of the closing date. Upon the expiration of escrow period, the escrow agent is required to release remaining funds to the Company.

The Company does not expect there to be any claims by the purchaser under the escrow agreement. However, in the event that such a claim is made, and if successful, the amount of such a claim up to $1.4 million would be released from the escrow account to the purchaser, which amount would be reduced from the amount released to the Company at the end of the 18-month escrow period. As of June 30, 2018, the Company is not aware of any claims by the purchaser that would reduce the escrow receivable.

13. Convertible Notes
  
 
 
 
 
Principal Balance Outstanding
 
Carrying Value
 
 
 
 
June 30,
 
June 30,
 
December 31,
Description
 
Maturity Date
 
2018
 
2018
 
2017
(In thousands)
 
 
 
 
 
 
 
 
Convertible Notes
 
 
 
 
 
 
 
 
February 2018 Notes
 
February 1, 2018
 
$
—

 
$
—

 
$
126,066

December 2021 Notes
 
December 1, 2021
 
$
150,000

 
120,945

 
117,415

Total
 
 
 
 

 
$
120,945

 
$
243,481



32


February 2018 Notes

On February 12, 2014, the Company issued $300.0 million in aggregate principal amount, at par, of the February 2018 Notes in an underwritten public offering, for net proceeds of $290.2 million. The February 2018 Notes were due February 1, 2018, and the Company paid interest at 4.0% on the February 2018 Notes semiannually in arrears on February 1 and August 1 of each year, beginning August 1, 2014. A portion of the proceeds from the February 2018 Notes, net of amounts used for purchased call option transactions and provided by the warrant transactions described below, were used to redeem $131.7 million of the Company’s 2.975% Convertible Senior Notes due February 17, 2016.

On November 20, 2015, the Company’s agent initiated the repurchase of $53.6 million in aggregate principal amount of its February 2018 Notes for $43.7 million in cash in four open market transactions. The closing of these transactions occurred on November 30, 2015. It was determined that the repurchase of the principal amount shall be accounted for as a partial extinguishment of the February 2018 Notes. As a result, a gain on extinguishment of $6.5 million was recorded at closing of the transaction. The $6.5 million gain on extinguishment included the de-recognition of the original issuance discount of $3.1 million, outstanding deferred issuance costs of $0.9 million and agent fees of $0.1 million. In connection with this repurchase of the February 2018 Notes, the Company unwound a portion of the purchased call options related to the notes. As a result of this unwinding, the Company received $0.3 million in cash. The payments received have been recorded as an increase to additional paid-in-capital. In addition, the Company unwound a portion of the warrants for $0.2 million in cash, payable by the Company. The payments have been recorded as a decrease to additional paid-in-capital.

On November 22, 2016, the Company repurchased $120.0 million in aggregate principal amount of its February 2018 Notes for approximately $121.5 million in cash (including $1.5 million of accrued interest) in open market transactions. It was determined that the repurchase of the principal amount shall be accounted for as an extinguishment. The extinguishment included the de-recognition of the original issuance discount of $4.3 million and outstanding deferred issuance costs of $1.3 million. In connection with the repurchase of the February 2018 Notes, the Company unwound a portion of the purchased call options. The unwind transaction of the purchased call option did not result in any cash payments between the parties. In addition, the Company and the counterparties agreed to unwind a portion of the warrants, which also did not result in any cash payments between the parties.

In accordance with the accounting guidance for convertible debt instruments that may be settled in cash or other assets on conversion, the Company was required to separately account for the liability component of the instrument in a manner that reflects the market interest rate for a similar nonconvertible instrument at the date of issuance. As a result, the Company separated the principal balance of the February 2018 Notes between the fair value of the debt component and the fair value of the common stock conversion feature. Using an assumed borrowing rate of 7.0%, which represents the estimated market interest rate for a similar nonconvertible instrument available to the Company on the date of issuance, the Company recorded a total debt discount of $29.7 million, allocated $19.3 million to additional paid-in capital and allocated $10.4 million to deferred tax liability. The discount was being amortized to interest expense over the term of the February 2018 Notes and increases interest expense during the term of the February 2018 Notes from the 4.0% cash coupon interest rate to an effective interest rate of 6.9%.

On February 1, 2018, upon maturity of the February 2018 Notes, the Company repaid a total cash amount of $129.0 million to the custodian, The Bank of New York Mellon Trust Company, N.A., which was comprised of $126.4 million in principal amount and $2.6 million in accrued interest, to retire the February 2018 Notes.

The carrying value and unamortized discount of the February 2018 Notes were as follows:
(In thousands)
 
June 30, 2018
 
December 31, 2017
 
 
 
 
 
Principal amount of the February 2018 Notes
 
$
—

 
$
126,447

Unamortized discount of liability component
 
—

 
(381
)
Net carrying value of the February 2018 Notes
 
$
—

 
$
126,066



33


Interest expense for the February 2018 Notes on the Company’s Condensed Consolidated Statements of Income was as follows:
 
 
Three Months Ended
 
Six Months Ended
 
 
June 30,
 
June 30,
(In thousands)
 
2018
 
2017
 
2018
 
2017
 
 
 
 
 
 
 
 
 
Contractual coupon interest
 
$
—

 
$
1,264

 
$
421

 
$
2,529

Amortization of debt issuance costs
 
—

 
250

 
88

 
499

Amortization of debt discount
 
—

 
851

 
293

 
1,699

Total
 
$
—

 
$
2,365

 
$
802

 
$
4,727


Purchased Call Options and Warrants

In connection with the issuance of the February 2018 Notes, the Company entered into purchased call option transactions with two hedge counterparties. The Company paid an aggregate amount of $31.0 million for the purchased call options with terms substantially similar to the embedded conversion options in the February 2018 Notes. The purchased call options covered, subject to anti-dilution and certain other customary adjustments substantially similar to those in the February 2018 Notes, approximately 13.8 million shares of the Company’s common stock. The purchased call options expired on February 1, 2018.

In addition, the Company sold to the hedge counterparties warrants exercisable, on a cashless basis, for the sale of rights to receive shares of common stock that will initially underlie the February 2018 Notes at a strike price of $10.3610 per share, which represents a premium of approximately 30% over the last reported sale price of the Company’s common stock of $7.97 on February 6, 2014. The Company received an aggregate amount of $11.4 million for the sale from the two counterparties.

The purchased call options and warrants are considered indexed to the Company stock, require net-share settlement, and met all criteria for equity classification at inception and in subsequent periods. The purchased call options cost of $31.0 million, less deferred taxes of $10.8 million, and the $11.4 million received for the warrants, was recorded as adjustments to additional paid-in capital.

December 2021 Notes

On November 22, 2016, the Company issued $150.0 million in aggregate principal amount, at par, of the December 2021 Notes in an underwritten public offering, for net proceeds of $145.7 million. The December 2021 Notes are due December 1, 2021, and the Company pays interest at 2.75% on the December 2021 Notes semiannually in arrears on June 1 and December 1 of each year, beginning June 1, 2017. A portion of the proceeds from the December 2021 Notes, net of amounts used for the capped call transaction described below, was used to extinguish $120.0 million of the February 2018 Notes.

Upon the occurrence of a fundamental change, as defined in the indenture, holders have the option to require the Company to repurchase their December 2021 Notes at a purchase price equal to 100% of the principal, plus accrued interest.

The December 2021 Notes are convertible under any of the following circumstances:
•
During any fiscal quarter (and only during such fiscal quarter) commencing after the fiscal quarter ended June 30, 2017, if the last reported sale price of Company common stock for at least 20 trading days (whether or not consecutive), in the period of 30 consecutive trading days, ending on, and including, the last trading day of the immediately preceding fiscal quarter, exceeds 130% of the conversion price for the notes on each applicable trading day;
•
During the five business-day period immediately after any five consecutive trading-day period, which the Company refers to as the measurement period, in which the trading price per $1,000 principal amount of notes for each trading day of that measurement period was less than 98% of the product of the last reported sale price of Company common stock and the conversion rate for the notes for each such trading day; or
•
Upon the occurrence of specified corporate events as described in the indenture.

The initial conversion rate for the December 2021 Notes is 262.2951 shares of the Company’s common stock per $1,000 principal amount of December 2021 Notes, which is equivalent to an initial conversion price of approximately $3.81 per share of common stock, subject to adjustments upon the occurrence of certain specified events as set forth in the indenture.


34


In accordance with the accounting guidance for convertible debt instruments that may be settled in cash or other assets on conversion, the Company was required to separately account for the liability component of the instrument in a manner that reflects the market interest rate for a similar nonconvertible instrument at the date of issuance. As a result, the Company separated the principal balance of the December 2021 Notes between the fair value of the debt component and the fair value of the common stock conversion feature. Using an assumed borrowing rate of 9.5%, which represents the estimated market interest rate for a similar nonconvertible instrument available to the Company on the date of issuance, the Company recorded a total debt discount of $4.3 million, allocated $23.8 million to additional paid-in capital and allocated $12.8 million to deferred tax liability. The discount is being amortized to interest expense over the term of the December 2021 Notes and increases interest expense during the term of the December 2021 Notes from the 2.75% cash coupon interest rate to an effective interest rate of 3.4%. As of June 30, 2018, the remaining discount amortization period is 3.4 years.

The carrying value and unamortized discount of the December 2021 Notes were as follows:
(In thousands)
 
June 30, 2018
 
December 31, 2017
 
 
 
 
 
Principal amount of the December 2021 Notes
 
$
150,000

 
$
150,000

Unamortized discount of liability component
 
(29,055
)
 
(32,585
)
Net carrying value of the December 2021 Notes
 
$
120,945

 
$
117,415


Interest expense for the December 2021 Notes on the Company’s Condensed Consolidated Statements of Income was as follows:
 
 
Three Months Ended
 
Six Months Ended
 
 
June 30,
 
June 30,
(In thousands)
 
2018
 
2017
 
2018
 
2017
 
 
 
 
 
 
 
 
 
Contractual coupon interest
 
$
1,031

 
$
1,032

 
$
2,062

 
$
2,063

Amortization of debt issuance costs
 
19

 
18

 
38

 
36

Amortization of debt discount
 
135

 
131

 
269

 
261

Amortization of conversion feature
 
1,626

 
1,469

 
3,225

 
2,899

Total
 
$
2,811

 
$
2,650

 
$
5,594

 
$
5,259


As of June 30, 2018, the December 2021 Notes are not convertible. At June 30, 2018, the if-converted value of the December 2021 Notes did not exceed the principal amount.

Capped Call Transaction

In connection with the offering of the December 2021 Notes, the Company entered into a privately-negotiated capped call transaction with an affiliate of the underwriter of such issuance. The aggregate cost of the capped call transaction was $14.4 million. The capped call transaction is generally expected to reduce the potential dilution upon conversion of the December 2021 Notes and/or partially offset any cash payments the Company is required to make in excess of the principal amount of converted December 2021 Notes in the event that the market price per share of the Company’s common stock, as measured under the terms of the capped call transaction, is greater than the strike price of the capped call transaction. This initially corresponds to the approximate $3.81 per share conversion price of the December 2021 Notes and is subject to anti-dilution adjustments substantially similar to those applicable to the conversion rate of the December 2021 Notes. The cap price of the capped call transaction was initially $4.88 per share, and is subject to certain adjustments under the terms of the capped call transaction. The Company will not be required to make any cash payments to the option counterparty upon the exercise of the options that are a part of the capped call transaction, but the Company will be entitled to receive from it an aggregate amount of cash and/or number of shares of the Company’s common stock, based on the settlement method election chosen for the related convertible notes, with a value equal to the amount by which the market price per share of the Company’s common stock, as measured under the terms of the capped call transaction, is greater than the strike price of the capped call transaction during the relevant valuation period under the capped call transaction, with such number of shares of the Company’s common stock and/or amount of cash subject to the cap price.

The Company evaluated the capped call transaction under authoritative accounting guidance and determined that they should be accounted for as separate transactions and classified as a net reduction to additional paid-in capital within stockholders’ equity with no recurring fair value measurement recorded.

35



14. Other Long-Term Liabilities

Other long-term liabilities consist of the following:
 
 
June 30,
 
December 31,
(in thousands)
 
2018
 
2017
 
 
 
 
 
Accrued lease liability
 
$
10,700

 
$
10,700

Long-term incentive accrual
 
1,978

 
1,729

Uncertain tax positions
 
31,133

 
30,682

Long-term deferred tax liabilities
 
3,538

 
1,208

Dividend payable
 
45

 
47

Other
 
405

 
343

Total
 
$
47,799

 
$
44,709

 

In connection with the Spin-Off, the Company entered into amendments to the leases for the Company’s former facilities in Redwood City, California, by which the Company has in substance guaranteed the payments under the lease agreements for the Redwood City facilities. For further discussion of the Spin-Off and the lease guarantee, see Note 12. The Company has recorded a liability of $10.7 million on the Company’s Condensed Consolidated Balance Sheets as of June 30, 2018, and December 31, 2017, related to this guarantee.

15. Stock-Based Compensation

The Company grants restricted stock awards and stock options pursuant to a stockholder approved stock-based incentive plan. This incentive plan is described in further detail in Note 16, Stock-Based Compensation, of Notes to the Condensed Consolidated Financial Statements in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017.

The following table summarizes the Company’s stock option and restricted stock award activity during the six months ended June 30, 2018:
 
 
Stock Options
 
Restricted Stock Awards
(In thousands except per share amounts)
 
Number of Shares Outstanding
 
Weighted Average Exercise Price
 
Number of Shares Outstanding
 
Weighted Average Grant-date Fair Value Per Share
 
 
 
 
 
 
 
 
 
Balance at December 31, 2017
 
961

 
$
3.21

 
2,305

 
$
2.68

Granted
 
3,894

 
$
2.94

 
481

 
$
2.71

Vested or released
 
—

 
$
—

 
(401
)
 
$
2.50

Forfeited or canceled
 
—

 
$
—

 
(119
)
 
$
2.38

Balance at June 30, 2018
 
4,855

 
$
2.99

 
2,266

 
$
2.73


16. Income Taxes
 
Income tax expense (benefit) for the three months ended June 30, 2018 and 2017, was $(14.3) million and $53.9 million, respectively, and for the six months ended June 30, 2018 and 2017, was $(13.2) million and $60.4 million, respectively, which resulted primarily from applying the federal statutory income tax rate to income before income taxes. The Company’s effective tax rate for the current period differs from the U.S. federal statutory rate of 21% due primarily to the effect of the foreign rate differential related to the impairment of the intangible assets related to the Noden Products.

The uncertain tax positions increased during the three months ended June 30, 2018 and 2017, by zero and $28.9 million, respectively, and for the six months ended June 30, 2018 and 2017, zero and $29.7 million, respectively, resulting from an increase in tax uncertainties and estimated tax liabilities.


36


On December 22, 2017, the SEC issued Staff Accounting Bulletin No. 118 to address the application of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the 2017 Tax Cuts and Job Act. The accounting for all items is expected to be complete during 2018 as additional guidance related to Global Intangible Low-Taxed Income (“GILTI”) is released. Any differences between what was previously recorded and the final amounts or estimates done for subsequent quarters are not expected to be material.

The Company’s income tax returns are subject to examination by U.S. federal, state and local tax authorities for tax years 2000 forward. The Company is currently under income tax examination by the state of California for the tax years 2009 through 2015 and by the Internal Revenue Service for the tax year 2016. Although the timing of the resolution of income tax examinations is highly uncertain, and the amounts ultimately paid, if any, upon resolution of the issues raised by the taxing authorities may differ materially from the amounts accrued for each year, the Company does not anticipate any material change to the amount of its unrecognized tax benefit over the next 12 months.

17. Stockholders’ Equity

Stock Repurchase Program

On March 1, 2017, the Company’s board of directors authorized the repurchase through March 2018 of issued and outstanding shares of the Company’s common stock having an aggregate value of up to $30.0 million pursuant to a share repurchase program. The repurchases under the share repurchase program were made from time to time in the open market or in privately negotiated transactions and were funded from the Company’s working capital. All shares of common stock repurchased under the Company’s share repurchase program were retired and restored to authorized but unissued shares of common stock at June 30, 2017. The Company repurchased 13.3 million shares of its common stock under the share repurchase program during the fiscal year ended December 31, 2017, for an aggregate purchase price of $30.0 million, or an average cost of $2.25 per share, including trading commission.

On September 25, 2017, the Company’s board of directors authorized the repurchase of issued and outstanding shares of the Company’s common stock having an aggregate value of up to $25.0 million pursuant to a new share repurchase program. The repurchases under the new share repurchase program are made from time to time in the open market or in privately negotiated transactions and are funded from the Company’s working capital. The amount and timing of such repurchases are dependent upon the price and availability of shares, general market conditions and the availability of cash. Repurchases may also be made under a trading plan under Rule 10b5-1, which would permit shares to be repurchased when the Company might otherwise be precluded from doing so because of self-imposed trading blackout periods or other regulatory restrictions. All shares of common stock repurchased under the Company’s new share repurchase program are expected to be retired and restored to authorized but unissued shares of common stock. The Company repurchased 6.8 million shares of its common stock under the share repurchase program during the three months ended June 30, 2018, for an aggregate purchase price of $19.4 million, or an average cost of $2.87 per share, including trading commissions, and a total of 8.2 million shares of its common stock during the six months ended June 30, 2018, for an aggregate purchase price of $23.6 million, or an average cost of $2.89 per share, including trading commission. All shares repurchased were retired.

From July 1, 2018 to July 5, 2018, the Company completed the $25.0 million share repurchase program by repurchasing approximately 0.6 million shares of its common stock at a weighted average price of $2.44 per share for a total of $1.4 million. The total amounts repurchased by the Company under the share repurchase program equal approximately 8.7 million shares of its common stock for an aggregate purchase price of $25.0 million, or an average cost of $2.89 per share, including trading commissions.

18. Accumulated Other Comprehensive Income

Comprehensive income is comprised of net income (loss) and other comprehensive income (loss). The Company includes unrealized net gains (losses) on investments held in its available-for-sale securities in other comprehensive income (loss), and present the amounts net of tax. The Company’s other comprehensive income (loss) is included in the Company’s Condensed Consolidated Statements of Comprehensive Income.


37


The balance of accumulated other comprehensive income, net of tax, was as follows:
(in thousands)
 
Unrealized gains (losses) on available-for-sale securities
 
Total Accumulated Other Comprehensive Income (Loss)
 
 
 
 
 
Beginning Balance at December 31, 2017
 
$
1,181

 
$
1,181

Activity for the six months ended June 30, 2018
 
(1,181
)
 
(1,181
)
Ending Balance at June 30, 2018
 
$
—

 
$
—


19. Business Combinations

LENSAR TRANSACTION

Description of the LENSAR Transaction

In December 2016, LENSAR filed the Chapter 11 case with the support of the Company, as its largest senior secured creditor under a credit agreement, as amended, that the Company and LENSAR had entered into in 2013. For more information regarding the credit agreement between the Company and LENSAR, please see Note 7. In January 2017, the Company agreed to provide debtor-in-possession financing of up to $2.8 million in new advances to LENSAR so that it could continue to operate its business during the remainder of the Chapter 11 case. As part of the Chapter 11 case, LENSAR filed a Chapter 11 plan of reorganization, with the Company’s support, under which LENSAR would issue 100% of its equity securities to the Company in exchange for the cancellation of the Company’s claims as a secured creditor in the Chapter 11 case. Following consummation of the Plan, LENSAR would become an operating subsidiary of the Company and the Company provided LENSAR a new, senior-secured, first-priority term loan facility (the “Exit Facility”).

On April 26, 2017, the bankruptcy court approved the plan of reorganization. On May 11, 2017, LENSAR and the Company consummated the plan of reorganization and LENSAR emerged from bankruptcy. Pursuant to the plan of reorganization, the Company obtained control of 100% of the outstanding voting shares of LENSAR. All assets of the LENSAR bankruptcy estate re-vested in reorganized LENSAR free and clear of all liens, claims or charges. The consummation of the plan of reorganization related transactions effect binding and valid transfers to reorganized LENSAR with all rights, title and interest in the acquired assets. Upon consummation of the plan of reorganization, all debt owed to the Company was eliminated other than the Exit Facility. Liabilities to other creditors, including general unsecured creditors, were satisfied through the plan of reorganization. 

The Company concluded that the LENSAR transaction shall be accounted in accordance with ASC 805 that do not involve a transfer of consideration (“combinations by contract”) by applying the acquisition method.

Fair Value of Consideration Transferred

Contemporaneously with the cancellation of the Company’s notes receivable with a carrying value of $43.9 million, the Company acquired 100% equity interests in LENSAR, at fair value, for $31.7 million, resulting in a loss on extinguishment of notes receivable of $10.6 million. The fair value of the equity interest in LENSAR was determined primarily using the “income method,” which starts with a forecast of all expected future cash flows of the acquired business. The acquisition resulted in a gain on bargain purchase because the fair value of assets acquired and liabilities assumed exceeded the total of the fair value of the equity interest in LENSAR by approximately $9.3 million, which was recorded in the Consolidated Statement of Income for the year ended December 31, 2017.


38


Assets Acquired and Liabilities Assumed

The following table summarizes the fair values of the identifiable intangible assets acquired and liabilities assumed at the acquisition date (in thousands):
Cash
 
$
1,983

Tangible assets
 
18,647

Intangible assets (1)
 
11,970

Net deferred tax assets
 
25,723

Total identifiable assets
 
58,323

Current liabilities
 
(6,673
)
Total liabilities assumed
 
(6,673
)
 
 
 
Net loss on derecognition of notes receivables
 
(10,615
)
Gain on bargain purchase, net of loss on extinguishment of notes receivable
 
(9,309
)
Total fair value of consideration
 
$
31,726

______________
(1) As of the effective date of the transaction, identifiable intangible assets are required to be measured at fair value.  The fair value measurement is based on significant inputs that are unobservable in the market and thus represents a Level 3 measurement. The Company used an income approach to estimate the preliminary fair value of the intangibles which includes technology, trademarks and customer relationships. The assumptions used to estimate the cash flows of the business included a discount rate of 16%, estimated gross margins ranging from 37-72%, income tax rate of 35%, and operating expenses consisting of direct costs based on the anticipated level of revenues.  The intangible assets have a weighted-average useful life of approximately 15.0 years. The intangible assets for acquired technology and trademarks are being amortized over their estimated useful lives using the straight-line method of amortization. The intangible assets for customer relationship are being amortized using a double-declining method of amortization as such method better represents the economic benefits to be obtained.

Pro Forma Impact of Business Combination

The following table represents the unaudited consolidated financial information for the Company on a pro forma basis for the three and six months ended June 30, 2018 and 2017, assuming that the LENSAR transaction had closed on January 1, 2016. The historical financial information has been adjusted to give effect to pro forma items that are directly attributable to the acquisitions and are expected to have a continuing impact on the consolidated results. Additionally, the following table sets forth unaudited financial information and has been compiled from historical financial statements and other information, but is not necessarily indicative of the results that actually would have been achieved had the transactions occurred on the dates indicated or that may be achieved in the future.
 
 
Three Months Ended
 
Six Months Ended
 
 
June 30,
 
June 30,
(in thousands)
 
2018
 
2017
 
2018
 
2017
 
 
 
 
 
 
 
 
 
Pro forma revenues
 
$
46,575

 
$
145,554

 
$
85,093

 
$
194,820

Pro forma net income (loss)
 
$
(112,296
)
 
$
59,351

 
$
(110,694
)
 
$
64,124

Pro forma net income (loss) per share - basic
 
$
(0.76
)
 
$
0.38

 
$
(0.74
)
 
$
0.40

Pro forma net income (loss) per share - diluted
 
$
(0.76
)
 
$
0.38

 
$
(0.74
)
 
$
0.40


The unaudited pro forma consolidated results include historical revenues and expenses of assets acquired in the LENSAR Transaction with the following adjustments:
•
Adjustment to recognize incremental amortization expense based on the fair value of intangibles acquired;
•
Elimination of non-recurring charges directly related to the acquisition that were included in the historical results of operations for the Company; and
•
Adjustment to recognize pro forma income tax based on income tax benefit on the amortization of intangible asset at the statutory tax rate of the United States, at such time (35.0%), and the income tax benefit on the interest expense at the statutory tax rate of the United States, at such time (35.0%).

39



20. Segment Information

In connection with acquiring 100% of the equity interests of LENSAR in May 2017, the Company added a third reportable segment, “Medical Devices” and renamed the previous product sales segment “Pharmaceutical”.

Information regarding the Company’s segments for the three and six months ended June 30, 2018 and 2017 is as follows:
Revenues by segment
 
Three Months Ended
 
Six Months Ended
 
 
June 30,
 
June 30,
(in thousands)
 
2018
 
2017
 
2018
 
2017
 
 
 
 
 
 
 
 
 
Pharmaceutical
 
$
25,879

 
$
16,212

 
44,221

 
28,794

Medical devices
 
5,882

 
2,617

 
10,864

 
2,617

Income generating assets
 
14,814

 
125,006

 
30,008

 
157,864

Total revenues
 
$
46,575

 
$
143,835

 
$
85,093

 
$
189,275


Income (loss) by segment
 
Three Months Ended
 
Six Months Ended
 
 
June 30,
 
June 30,
(in thousands)
 
2018
 
2017
 
2018
 
2017
 
 
 
 
 
 
 
 
 
Pharmaceutical
 
$
(111,335
)
 
$
(891
)
 
(113,048
)
 
(4,624
)
Medical devices
 
(1,904
)
 
(1,195
)
 
(2,491
)
 
(1,195
)
Income generating assets
 
943

 
62,525

 
4,845

 
73,499

Total net income (loss)
 
$
(112,296
)
 
$
60,439

 
$
(110,694
)
 
$
67,680


Information regarding the Company’s segments as of June 30, 2018 and December 31, 2017 is as follows:
Long-lived assets by segment
 
 
 
 
(in thousands)
 
June 30,
2018
 
December 31,
2017
 
 
 
 
 
Pharmaceutical
 
$
3,474

 
$
822

Medical devices
 
5,606

 
6,263

Income generating assets
 
143

 
137

Total long-lived assets
 
$
9,223

 
$
7,222


The operations for the Company’s Pharmaceutical and Medical Devices segments are primarily located in Ireland and the United Stated, respectively.

21. Subsequent Events

Share Repurchase Program

From July 1, 2018 to July 5, 2018, the Company completed the $25.0 million share repurchase program by repurchasing approximately 0.6 million shares of its common stock at a weighted average price of $2.44 per share for a total of $1.4 million. The total amounts repurchased by the Company under the share repurchase program equal approximately 8.7 million shares of its common stock for an aggregate purchase price of $25.0 million, or an average cost of $2.89 per share, including trading commissions.

Depomed Reversionary Interest Purchase

On August 2, 2018, PDL Investment Holding, LLC (“PDLIH”), a subsidiary of the Company, entered into an amendment of the Depomed Royalty Agreement, pursuant to which PDLIH, as an assignee of the Company, acquired all of Depomed’s remaining rights to royalties and milestones payable on sales of type 2 diabetes products licensed by Depomed for up to $20.0 million.

40


Prior to this amendment of the Depomed Royalty Agreement, the Company would have shared future royalties equally with Depomed after total cash received by the Company reached $481.0 million, or two times the Company’s original investment, which the Company expects to occur by October 2020.

On August 2, 2018, under the terms of the amendment, the Company made an initial payment of $10.0 million to Depomed. On August 7, 2018, an additional $10.0 million payment was made to Depomed, as certain conditions specified in the amendment were met.

41


ITEM 2.             MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
 
This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts are “forward-looking statements” for purposes of these provisions, including any projections of earnings, revenues or other financial items, any statements of the plans and objectives of management for future operations, including any statements concerning new licensing, any statements regarding future economic conditions or performance, and any statement of assumptions underlying any of the foregoing. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, forward-looking statements can be identified by the use of terminology such as “may,” “will,” “intends,” “plans,” “believes,” “anticipates,” “expects,” “estimates,” “predicts,” “potential,” “continue” or “opportunity,” or the negative thereof or other comparable terminology. The forward-looking statements in this quarterly report are only predictions. Although we believe that the expectations presented in the forward-looking statements contained herein are reasonable at the time they were made, there can be no assurance that such expectations or any of the forward-looking statements will prove to be correct. These forward-looking statements, including with regards to our future financial condition and results of operations, are subject to inherent risks and uncertainties, including but not limited to the risk factors set forth below or incorporated by reference herein, and for the reasons described elsewhere in this Quarterly Report on Form 10-Q. All forward-looking statements and reasons why results may differ included in this Quarterly Report on Form 10-Q are made as of the date hereof. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

OVERVIEW

We seek to provide a significant return for our stockholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotechnology, pharmaceutical and medical device industries. In 2012, we began providing alternative sources of capital through royalty monetizations and debt facilities, and in 2016, we began acquiring commercial-stage products and launching specialized companies dedicated to the commercialization of these products. To date, we have consummated seventeen of such transactions, of which nine are active and outstanding. We have one debt transaction outstanding, representing deployed and committed capital of $20.0 million: CareView; we have one hybrid royalty/debt transaction outstanding, representing deployed and committed capital of $44.0 million: Wellstat Diagnostics; and we have five royalty transactions outstanding, representing deployed and committed capital of $416.1 million and $417.1 million, respectively: KYBELLA®, AcelRx, University of Michigan, Viscogliosi Brothers and Depomed. Our equity and loan investments in Noden represent deployed and committed capital of $179.0 million and $202.0 million, respectively, and our converted equity and loan investment in LENSAR represents deployed capital of $40.0 million.

We operate in three segments designated as Pharmaceutical, Medical Devices and Income Generating Assets.

Our Pharmaceutical segment consists of revenue derived from Tekturna®, Tekturna HCT®, Rasilez® and Rasilez HCT® (collectively, the “Noden Products” or “Tekturna”) sales. Our Medical Devices segment consists of revenue derived from the LENSAR® Laser System sales. Our Income Generating Assets segment consists of revenue derived from (i) notes and other long-term receivables, (ii) royalty rights - at fair value, (iii) equity investments and (iv) royalties from issued patents in the United States and elsewhere, covering the humanization of antibodies, which we refer to as the Queen et al. patents. Prospectively, we expect to focus on the acquisition of additional products and devices and expect to transact fewer royalty transactions and still fewer debt transactions. We anticipate that over time more of our revenues will come from our Pharmaceutical and Medical Devices segments and less of our revenues will come from our Income Generating Assets segment.

Pharmaceutical

In 2016 we began acquiring, and plan to continue to acquire, commercial-stage products and companies who own or are acquiring pharmaceutical products. Our objective with respect to these transactions is to maximize our portfolio’s total return by generating current income from product sales. We consummated our first transaction of this type with the acquisition of the Noden Products in July 2016.

42



Noden/Tekturna

On July 1, 2016, our subsidiary, Noden Pharma DAC, entered into an asset purchase agreement (“Noden Purchase Agreement”) whereby it purchased from Novartis Pharma AG (“Novartis”) the exclusive worldwide rights to manufacture, market, and sell the Noden Products and certain related assets and assumed certain related liabilities (the “Noden Transaction”). Upon the consummation of the Noden Transaction, a noncontrolling interest holder acquired 6% equity interests in Noden. We purchased the equity interest of the noncontrolling interest holder in May 2017.

Tekturna (or Rasilez outside the United States) contains aliskiren, a direct renin inhibitor, for the treatment of hypertension. While indicated as a first line treatment, it is more commonly used as a third line treatment in those patients who are intolerant of angiotensin converting enzyme inhibitors (“ACEIs”) and angiotensin II receptor blockers (“ARBs”). It is not indicated for use with ACEIs and ARBs in patients with diabetes or renal impairment. Tekturna HCT (or Rasilez HCT outside the United States) is a combination of aliskiren and hydrochlorothiazide, a diuretic, for the treatment of hypertension in patients not adequately controlled by monotherapy and as an initial therapy in patients likely to need multiple drugs to achieve their blood pressure goals. It is not indicated for use with ACEIs and ARBs in patient with diabetes or renal impairment and not for use in patients with known anuria or hypersensitivity to sulfonamide derived drugs. Studies indicate that approximately 12% of hypertension patients are ACEI/ARB inhibitor-intolerant. Tekturna/Rasilez and Tekturna/Rasilez HCT are contraindicated for use by pregnant women.

The Noden Purchase Agreement provides for various transition periods for development and commercialization activities relating to the Noden Products. Initially, Novartis distributed the Noden Products on behalf of Noden worldwide and Noden received a profit transfer on such sales. In the United States, the duration of the profit transfer ran from July 1, 2016 through October 4, 2016. Outside the United States, the profit transfer ended in the first quarter of 2018. On the transfer of the marketing authorization from Novartis to Noden in each country the profit transfer arrangement terminates. Generally, the profit transfer to Noden is defined as gross revenues less product cost and a low single digit percentage fee to Novartis. Prior to the transfer of the marketing authorization, revenue will be presented on a “net” basis; after the transfer of the marketing authorization, revenue will be presented on a “gross” basis, meaning product costs will be reported separately and there will be no fee to Novartis.

Because Novartis has not actively commercialized the Noden Products for many years, and sales of the Noden Products have been declining annually since that time, the ability of Noden to promote these Noden Products successfully and efficiently will determine whether revenues can be stabilized.

Medical Devices

LENSAR

In December 2016, LENSAR filed a voluntary petition under Chapter 11 of the U.S. Bankruptcy Code (the “Chapter 11 case”). With our support, LENSAR filed a Chapter 11 plan of reorganization under which LENSAR would issue 100% of its equity interests to us in exchange for the cancellation of our claims as a secured creditor in the Chapter 11 case. On May 11, 2017, pursuant to the plan of reorganization and the Chapter 11 plan of reorganization, most of LENSAR’s outstanding debt owed to us was converted to equity and LENSAR became our wholly-owned operating subsidiary.

LENSAR is a medical device company focused on the next generation femtosecond cataract laser technology for refractive cataract surgery. Cataract surgery is the highest volume surgical procedure performed worldwide with over 26.2 million surgeries performed in 2017. The LENSAR® Laser System offers cataract surgeons automation and customization for their astigmatism treatment planning and other essential steps of the refractive cataract surgery procedure with the highest levels of precision, accuracy, and efficiency. These features assist surgeons in managing their astigmatism treatment plans for optimal overall visual outcomes.

The LENSAR® Laser System has been approved by the FDA for anterior capsulotomy, lens fragmentation, and corneal and arcuate incisions. The LENSAR Laser with Augmented Reality™ provides an accurate 3-D model of the relevant anatomical features of each patient’s anterior segment, allowing precise laser delivery and to enhance the surgical confidence in performing accurate corneal incisions, precise size, shape and location of free-floating capsulotomies, and efficient lens fragmentation for all grades. The LENSAR® Laser System - fs 3D (LLS-fs 3D) with Streamline™ includes the integration with various pre-op diagnostic devices, automated Iris Registration with automatic cyclorotation adjustment, IntelliAxis-C™ (corneal) and IntelliAxis-L™ (Lens) markers for simple alignment without errors associated with manually marking the eye, of Toric IOLs as well as treatment planning tools for precision guided laser treatments. The corneal incision–only mode, expanded

43


remote diagnostics capabilities, additional pre-programmable preferences, thoughtful ergonomics, and up to 20 seconds faster laser treatment times with Streamline allow for seamless integration and maximum surgical efficiency.

For details regarding LENSAR, the LENSAR transaction and Chapter 11 case, see Note 19 to the Condensed Consolidated Financial Statements included in Item 1 of this Quarterly Report on Form 10-Q.

Income Generating Assets

We acquire income generating assets when such assets can be acquired on terms that we believe allow us to increase return to our stockholders. The income generating assets typically consist of (i) notes and other long-term receivables, (ii) royalty rights and hybrid notes/royalty receivables, (iii) equity investments acquired in connection with note receivable transactions and (iv) royalties from issued patents in the United States and elsewhere. We primarily focus our income generating asset acquisition strategy on commercial-stage therapies and medical devices having strong economic fundamentals. However, our acquired income generating assets will not, in the near term, replace completely the revenues we generated from our license agreements related to our Queen et al. patents. In the second quarter of 2016, our revenues materially decreased after we stopped receiving payments from certain Queen et al. patent licenses and legal settlements, which accounted for 11%, 68% and 82% of our 2017, 2016 and 2015 revenues, respectively.

Royalty Rights - At Fair Value

We have entered into various royalty purchase agreements with counterparties, whereby the counterparty conveys to us the right to receive royalties that are typically payable on sales revenue generated by the sale, distribution or other use of the counterparties’ products. Certain of our royalty agreements provide the counterparty with the right to repurchase the royalty rights at any time for a specified amount.

We record the royalty rights at fair value using discounted cash flows related to the expected future cash flows to be received. We use significant judgment in determining our valuation inputs, including estimates as to the probability and timing of future sales of the licensed product. A third-party expert is generally engaged to assist us with the development of our estimate of the expected future cash flows. The estimated fair value of the asset is subject to variation should those cash flows vary significantly from our estimates. At each reporting period, an evaluation is performed to assess those estimates, discount rates utilized and general market conditions affecting fair market value.

While we currently maintain this portfolio of royalty rights, our intention is to pursue fewer of these transactions while we focus on acquiring additional pharmaceutical products or companies. At June 30, 2018, we had a total of five royalty rights transactions outstanding.

Notes and Other Long-Term Receivables

We have entered, and may continue to enter, into credit agreements with borrowers across the healthcare industry, under which we make available cash loans to be used by the borrower. Obligations under these credit agreements are typically secured by a pledge of substantially all the assets of the borrower and any of its subsidiaries. While we currently maintain this portfolio of notes receivable, our intention is to pursue fewer debt transactions, and focus on acquiring additional pharmaceutical products or companies. At June 30, 2018, we had a total of two notes receivable transaction outstanding.

Equity Investments

In connection with credit and royalty agreements, from time to time we may make equity investments in healthcare companies. Our investment objective with respect to potential equity investments is to maximize our portfolio total return by generating current income from capital appreciation, and our primary business objectives are to increase our net income, net operating income and asset value by investing in companies with the potential for equity appreciation and realized gains.

Royalties from Queen et al. patents

While the Queen et al. patents have expired and the resulting royalty revenue has dropped substantially since the first quarter of 2016, we continue to receive royalty revenue from one product under the Queen et al. patent licenses, Tysabri®, as a result of sales of licensed product that was manufactured prior to patent expiry. In November 2017, we were notified by Biogen Inc. (“Biogen”) that product supply for Tysabri® that was manufactured prior to patent expiry, and for which we would receive royalties on, had been extinguished in the United States and was rapidly being reduced in other countries. As a result, we

44


anticipate royalties from product sales of Tysabri to be substantially lower in 2018 and are expected to cease after the first quarter of 2019.

Intellectual Property

Patents

Tekturna is protected by multiple patents worldwide, which specifically cover the composition of matter, the pharmaceutical formulations and methods of production. In the United States, the FDA Orange Book lists one patent, U.S. patent No. 5,559,111 (the “’111 Patent”), which covers compositions of matter comprising aliskiren. The ‘111 Patent expires on January 21, 2019, which was previously extended through a pediatric extension. In addition, the FDA Orange Book for Tekturna lists U.S. Patent No. 8,617,595, which covers certain compositions comprising aliskiren, together with other formulation components, and will expire on February 19, 2026. The FDA Orange Book for Tekturna HCT lists U.S. patent No. 8,618,172, which covers certain compositions comprising aliskiren, together with other formulation components, and will expire on July 13, 2028. In Europe, European patent No. 678 503B (the “’503B Patent”) expired in 2015. However, numerous SPCs have been granted which are based on the ‘503B Patent and which will provide for extended protection. These SPCs generally expire in April of 2020.
 
LENSAR has developed the LENSAR® Laser System (the “LENSAR Technology”). The LENSAR Technology is the only femtosecond cataract laser built specifically for refractive cataract surgery. The LENSAR Technology is protected by over 60 patents in the United States and the rest of the world and over 45 pending patents in the United States and rest of the world.

We have been issued patents in the United States and elsewhere, covering the humanization of antibodies, which we refer to as our Queen et al. patents. Our Queen et al. patents, for which final patent expiry was in December 2014, covered, among other things, humanized antibodies, methods for humanizing antibodies, polynucleotide encoding in humanized antibodies and methods of producing humanized antibodies.

Our U.S. patent No. 5,693,761 (the “761 Patent”), which expired on December 2, 2014, covered methods and materials used in the manufacture of humanized antibodies. In addition to covering methods and materials used in the manufacture of humanized antibodies, coverage under our 761 Patent typically extended to the use or sale of compositions made with those methods and/or materials. Our European patent no. 0 451 216B (the “216B Patent”) expired in Europe in December 2009. We have been granted Supplementary Protection Certificates (“SPCs”) for the Avastin®, Herceptin®, Lucentis®, Xolair® and Tysabri® products in many of the jurisdictions in the European Union in connection with the 216B Patent. The SPCs effectively extended our patent protection with respect to Avastin, Herceptin, Lucentis, Xolair and Tysabri generally until December 2014, except that the SPCs for Herceptin expired in July 2014. Because SPCs are granted on a jurisdiction-by-jurisdiction basis, the duration of the extension varies slightly in certain jurisdictions.

Licensing Agreements
 
We previously entered into licensing agreements under our Queen et al. patents with numerous entities that are independently developing or have developed humanized antibodies. Although the Queen et al. patents and related rights have expired, we are entitled under our license agreements to continue to receive royalties in certain instances based on net sales of products that were made prior to but sold after patent expiry. In addition, we are entitled to royalties based on know-how provided to a licensee. In general, these agreements cover antibodies targeting antigens specified in the license agreements. Under our licensing agreements, we are entitled to receive a flat-rate royalty based upon our licensees’ net sales of covered antibodies.

Our total revenues from licensees under our Queen et al. patents were $1.2 million and $16.3 million, net of rebates and foreign exchange hedge adjustments, for the three months ended June 30, 2018 and 2017, respectively, and $4.0 million and $30.4 million, net of rebates and foreign exchange hedge adjustments, for the six months ended June 30, 2018 and 2017, respectively.

Licensing Agreements for Marketed Products

In the three and six months ended June 30, 2018 and 2017, we received royalties on sales of Tysabri from Biogen.

Biogen

We entered into a patent license agreement, effective April 24, 1998, under which we granted to Elan Corporation, plc (“Elan”) a license under our Queen et al. patents to make, use and sell antibodies that bind to the cellular adhesion molecule α4 in patients with multiple sclerosis. Under the agreement, we are entitled to receive a flat royalty rate in the low, single digits based on Elan’s net sales of the Tysabri product. This license agreement entitles us to royalties following the expiration of our patents

45


with respect to sales of licensed product manufactured prior to patent expiry in jurisdictions providing patent protection. In April 2013, Biogen, Inc. (“Biogen”) completed its purchase of Elan’s interest in Tysabri, and in connection with such purchase all obligations under our patent license agreement with Elan were assumed by Biogen.

In November 2017, we were notified by Biogen that product supply that was manufactured prior to patent expiry, and for which we would receive royalties on, had been extinguished in the United States and was rapidly being reduced in other countries. This will result in a reduction in royalties from product sales of Tysabri, and we expect royalties to be substantially lower in 2018 and are expected to cease in the first quarter of 2019.

Economic and Industry-wide Factors
 
Various economic and industry-wide factors are relevant to our business, including changes to laws and interpretation of those laws that protect our intellectual property rights, our licensees’ ability to obtain or retain regulatory approval for products licensed under our patents, fluctuations in foreign currency exchange rates, the ability to attract, retain and integrate qualified personnel, as well as overall global economic conditions. We actively monitor economic, industry and market factors affecting our business; however, we cannot predict the impact such factors may have on our future results of operations, liquidity and cash flows. See also the risk factors included in “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017 for additional factors that may impact our business and results of operations.

Critical Accounting Policies and Use of Estimates

Our management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which we have prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on our limited historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

During the six months ended June 30, 2018, there have been no significant changes to our critical accounting policies and estimates from those presented in Part II, Item 7 of our Annual Report on Form 10-K for the fiscal year ended December 31, 2017, that are of significance, or potential significance, to us.

Operating Results

Three and six months ended June 30, 2018, compared to three and six months ended June 30, 2017

Revenues

 
 
Three Months Ended
 
Change from Prior
 
Six Months Ended
 
Change from Prior
 
 
June 30,
 
 
June 30,
 
(dollars in thousands)
 
2018
 
2017
 
Year %
 
2018
 
2017
 
Year %
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenues
 
 
 
 
 
 
 
 
 
 
 
 
Royalties from Queen et al. patents
 
$
1,218

 
$
16,285

 
(93%)
 
$
4,001

 
$
30,441

 
(87%)
Royalty rights - change in fair value
 
12,842

 
83,725

 
(85%)
 
23,933

 
96,871

 
(75%)
Interest revenue
 
751

 
5,460

 
(86%)
 
1,500

 
10,917

 
(86%)
Product revenue, net
 
31,761

 
18,829

 
69%
 
55,085

 
31,410

 
75%
License and other
 
3

 
19,536

 
(100%)
 
574

 
19,636

 
(97%)
Total revenues
 
$
46,575

 
$
143,835

 
(68%)
 
$
85,093

 
$
189,275

 
(55%)

Total revenues were $46.6 million for the three months ended June 30, 2018, compared with $143.8 million for the three months ended June 30, 2017. Our total revenues decreased by 68%, or $97.3 million, for the three months ended June 30, 2018, when compared to the same period of 2017. Our revenues decreased 55%, or $104.2 million, for the six months ended June 30, 2018, when compared to the same period of 2017. The decrease was primarily due to a higher prior year royalty rights - change in fair value as a result of the increase in fair value of the Depomed, Inc. royalty asset based upon revised future cash flows and

46


a prior year payment from Merck as part of the previously announced settlement agreement to resolve the patent infringement lawsuits related to Keytruda®, as well as due to the decreased 2018 sales of Tysabri that was manufactured prior to the patent expiry date, decreased interest revenues due to the sale of the kaléo note receivable asset, partially offset by an increase in product revenues derived from sales of the LENSAR Laser System, which we did not begin to recognize until May 2017 and revenue from our Pharmaceutical segment related to Noden.

Revenue from our Pharmaceutical segment for the three and six months ended June 30, 2018 was $25.9 million and $44.2 million, respectively, an increase of 60% and 54%, respectively, compared to the same periods last year. All pharmaceutical revenues were derived from sales of the Noden Products. While we acquired the exclusive worldwide rights to manufacture, market, and sell the Noden Products from Novartis on July 1, 2016, Novartis was still the primary obligor during the first through third quarters of 2017 for ex-U.S. sales, therefore revenue is presented on a “net” basis for those periods for all ex-U.S. sales. Our revenue recognition policies require estimated product returns, pricing discounts including rebates offered pursuant to mandatory federal and state government programs and chargebacks, prompt pay discounts and distribution fees and co-pay assistance for product sales at each period.

The following table provides a summary of activity with respect to our sales allowances and accruals for the six months ended June 30, 2018:
(in thousands)
 
Discount and Distribution Fees
 
Government Rebates and Chargebacks
 
Assistance and Other Discounts
 
Product Return
 
Total
 
 
 
 
 
 
 
 
 
 
 
Balance at December 31, 2017:
 
$
3,422

 
$
8,709

 
$
4,178

 
$
3,304

 
$
19,613

Allowances for current period sales
 
4,749

 
7,859

 
4,174

 
1,291

 
18,073

Allowances for prior period sales
 
—

 
24

 
—

 
65

 
89

Credits/payments for current period sales
 
(2,057
)
 
(2,847
)
 
(2,019
)
 
—

 
(6,923
)
Credits/payments for prior period sales
 
(3,724
)
 
(7,629
)
 
(2,178
)
 
(390
)
 
(13,921
)
Balance at June 30, 2018
 
$
2,390

 
$
6,116

 
$
4,155

 
$
4,270

 
$
16,931


Revenue from our Medical Devices segment for the three and six months ended June 30, 2018 was $5.9 million and $10.9 million, respectively. All revenues from our Medical Devices segment were derived from LENSAR laser system revenue, procedures and consumables and service revenue which we began to recognize on May 11, 2017.

Revenue from our Income Generating Assets segment for the three and six months ended June 30, 2018 were $14.8 million and $30.0 million, respectively, a decrease of 88% and 81%, respectively.

The following tables provides a summary of activity with respect to our royalty rights - change in fair value for the three and six months ended June 30, 2018:
 
 
Three Months Ended
 
 
June 30, 2018
 
 
 
 
 
 
 
 
 
 
 
Change in
 
Royalty Rights -
(in thousands)
 
Cash Royalties
 
Fair Value
 
Change in Fair Value
 
 
 
 
 
 
 
Depomed
 
$
17,689

 
$
(8,535
)
 
$
9,154

VB
 
263

 
147

 
$
410

U-M
 
1,289

 
(434
)
 
$
855

AcelRx
 
68

 
2,301

 
$
2,369

Avinger
 
61

 
(101
)
 
$
(40
)
KYBELLA
 
—

 
94

 
$
94

 
 
$
19,370

 
$
(6,528
)
 
$
12,842


47



 
 
Six Months Ended
 
 
June 30, 2018
 
 
 
 
 
 
 
 
 
 
 
Change in
 
Royalty Rights -
(in thousands)
 
Cash Royalties
 
Fair Value
 
Change in Fair Value
 
 
 
 
 
 
 
Depomed
 
$
34,597

 
$
(17,967
)
 
$
16,630

VB
 
543

 
284

 
827

U-M
 
2,284

 
(620
)
 
1,664

AcelRx
 
120

 
4,539

 
4,659

Avinger
 
366

 
(396
)
 
(30
)
KYBELLA
 
83

 
100

 
183

 
 
$
37,993

 
$
(14,060
)
 
$
23,933


The following table summarizes the percentage of our total revenues that individually accounted for 10% or more of our total revenues for the three and six months ended June 30, 2018 and 2017:
 
 
 
 
Three Months Ended
 
Six Months Ended
 
 
 
 
June 30,
 
June 30,
Licensee
 
Product Name
 
2018
 
2017
 
2018
 
2017
 
 
 
 
 
 
 
 
 
 
 
Biogen
 
Tysabri
 
3%
 
11%
 
5%
 
16%
 
 
 
 
 
 
 
 
 
 
 
Depomed
 
Glumetza, Janumet XR, Jentadueto XR, Synjardy XR and Invokamet XR
 
20%
 
61%
 
20%
 
49%
 
 
 
 
 
 
 
 
 
 
 
N/M
 
Tekturna, Tekturna HCT, Rasilez and Rasilez HCT
 
56%
 
11%
 
52%
 
15%
 
 
 
 
 
 
 
 
 
 
 
LENSAR
 
LENSAR Laser System
 
13%
 
2%
 
13%
 
1%

Operating Expenses

 
 
Three Months Ended
 
Change from Prior
 
Six Months Ended
 
Change from Prior
 
 
June 30,
 
 
June 30,
 
(In thousands)
 
2018
 
2017
 
Year %
 
2018
 
2017
 
Year %
 
 
 
 
 
 
 
 
 
 
 
 
 
Cost of product revenue, (excluding intangible amortization)
 
$
14,524

 
$
4,515

 
222%
 
$
25,090

 
$
7,067

 
255%
Amortization of intangible assets
 
6,384

 
6,148

 
4%
 
12,677

 
12,163

 
4%
General and administrative
 
14,529

 
11,288

 
29%
 
26,190

 
23,864

 
10%
Sales and marketing
 
5,385

 
3,616

 
49%
 
10,898

 
6,200

 
76%
Research and development
 
684

 
4,281

 
(84)%
 
1,477

 
6,047

 
(76)%
Impairment of intangible assets
 
152,330

 
—

 
N/M
 
152,330

 
—

 
N/M
Change in fair value of acquisition-related contingent consideration
 
(22,135
)
 
1,207

 
N/M
 
(22,735
)
 
2,649

 
N/M
Total operating expenses
 
$
171,701

 
$
31,055

 
453%
 
$
205,927

 
$
57,990

 
255%
Percentage of total revenues
 
369
%
 
22
%
 
 
 
242
%
 
31
%
 
 
_____________________
N/M = Not meaningful

The increase in operating expenses for the three months ended June 30, 2018, as compared to the same period in 2017, was a result of an impairment of intangible assets related to the Noden Products due to the increased probability of a generic version

48


of aliskiren being launched in the United States, partially offset by a decrease in fair value of the contingent liability related to changes in the probabilities in the generic entry milestones. Further events, such as FDA approval of a generic version of aliskiren or publicly announced plans of a launch of a generic version of aliskiren, may be indicators of impairment which may require the Company to perform additional impairment tests including testing for recoverability by estimating the undiscounted future cash flows with respect to the asset against its carrying value. The Pharmaceutical and Medical Devices segments contributed additional cost of product revenue of $8.4 million and $1.6 million, respectively, which was due to increased revenue in the Pharmaceutical segment and recognition of costs of goods for ex-U.S. revenue and increased revenue from the Medical Devices segment which PDL did not begin to recognized until May 2017. General and administrative expenses increased $3.2 million due to a full quarter of expenses from LENSAR in 2018 versus a partial quarter as a result of its acquisition in May 2017, operation growth for our Pharmaceutical segment and due to business development expenses for the Income Generating Asset segment. Sales and marketing expense increased $1.8 million due to an increase in marketing efforts in the pharmaceutical and medical device segments.

The increase in operating expenses for the six months ended June 30, 2018, as compared to the same period in 2017, was primarily a result of the impairment of intangible assets related to the Noden Products due to the increased probability of a generic version of aliskiren being launched in the United States, partially offset by a decrease in fair value of the contingent liability related to changes in the probabilities in the generic entry milestones. The Pharmaceutical and Medical Devices segments contributed additional cost of product revenue of $14.0 million and $4.0 million, respectively, which was due to increased revenue in the Pharmaceutical segment and recognition of costs of goods for ex-U.S. revenue and increased revenue from the Medical Devices segment, which we did not begin to recognize until May 2017.

Non-operating Income (Expense), Net

Non-operating income (expense), net, for the three and six months ended June 30, 2018 decreased, as compared to the same period in 2017, primarily due to the repayment of the February 2018 Notes in February 2018, partially offset by an increase in interest income from investments. The decrease in interest expense for the three and six months ended June 30, 2018, as compared to the same period in 2017, consisted primarily of non-cash interest expense as we are required to compute interest expense using the interest rate for similar nonconvertible instruments in accordance with the accounting guidance for convertible debt instruments that may be settled in cash or other assets on conversion.

Income Taxes

Income tax expense for the three months ended June 30, 2018 and 2017, was $(14.3) million and $53.9 million, respectively, and for the six months ended June 30, 2018 and 2017, was $(13.2) million and $60.4 million, respectively, which resulted primarily from applying the federal statutory income tax rate to income before income taxes. Our effective tax rate for the current period differs from the U.S. federal statutory rate of 21% due primarily to the foreign rate differential related to the impairment of intangible assets related to the Noden Products.

The uncertain tax positions increased during the three months ended June 30, 2018 and 2017, by zero and $28.9 million, respectively, and for the six months ended June 30, 2018 and 2017, zero and $29.7 million, respectively, resulting from an increase in tax uncertainties and estimated tax liabilities.

On December 22, 2017, the SEC issued Staff Accounting Bulletin No. 118 to address the application of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the 2017 Tax Cuts and Job Act. The accounting for all items is expected to be complete during 2018 as additional guidance related to GILTI is released. Any differences between what was previously recorded and the final amounts or estimates done for subsequent quarters are not expected to be material.

The Company’s income tax returns are subject to examination by U.S. federal, state and local tax authorities for tax years 2000 forward. The Company is currently under income tax examination by the state of California for the tax years 2009 through 2015 and by the Internal Revenue Service for the tax year 2016. Although the timing of the resolution of income tax examinations is highly uncertain, and the amounts ultimately paid, if any, upon resolution of the issues raised by the taxing authorities may differ materially from the amounts accrued for each year, the Company does not anticipate any material change to the amount of its unrecognized tax benefit over the next 12 months.


49


Net Income (Loss) Per Share
 
Net income (loss) per share for the three and six months ended June 30, 2018 and 2017, is presented below:
 
Three Months Ended
 
Six Months Ended
 
June 30,
 
June 30,
 
2018
 
2017
 
2018
 
2017
 
 
 
 
 
 
 
 
Net income (loss) per share - basic
$
(0.76
)
 
$
0.39

 
$
(0.74
)
 
$
0.42

Net income (loss) per share - diluted
$
(0.76
)
 
$
0.39

 
$
(0.74
)
 
$
0.42


Liquidity and Capital Resources

We finance our operations primarily through royalty and other license-related revenues, public and private placements of debt and equity securities, interest income on invested capital and revenues from product sales. We currently have 19 full-time employees managing our intellectual property, our asset acquisitions, operations and other corporate activities as well as providing for certain essential reporting and management functions of a public company. In addition, we have 15 full-time employees at our operating subsidiary, Noden, who manage Noden’s business and operations, and 58 full time employees at our operating subsidiary, LENSAR, who manage the medical device business and operations.

Our future capital requirements are difficult to forecast and will depend upon many factors, including our ability to identify and acquire pharmaceutical products, the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, the resources we devote to developing and supporting our products and other factors. Additionally, we will continue to evaluate possible acquisitions of new products, devices, royalty revenues or other income generating assets, which may require the use of cash or additional financing.

The general cash needs of our Pharmaceutical, Medical Device and Income Generating Assets segments can vary significantly. In our Pharmaceutical segment, cash needs tend to be driven primarily by material purchases and anticipated near-term capital expenditures. In our Medical Device segment, the primary factors determining cash needs tend to be the funding of our operations. The cash needs of our Income Generating Assets segment tend to be driven by legal and professional service fees. On a consolidated basis, cash needs tend to be driven by funding of potential repurchases of our common stock and additional acquisition transactions.

We had cash, cash equivalents and short-term investments in the aggregate of $395.7 million and $532.1 million at June 30, 2018 and December 31, 2017, respectively. The decrease was primarily attributable to the repayment of the February 2018 Notes of $126.4 million, the repurchase of common stock for $23.6 million, the purchase of fixed assets of $3.9 million and cash used in operating activities of $19.8 million, partially offset by proceeds from royalty right payments of $38.0 million and proceeds from the sale of available for sale securities of $4.1 million.

On September 25, 2017, we announced that our board of directors authorized the repurchase of issued and outstanding shares of our common stock having an aggregate value of up to $25.0 million pursuant to a share repurchase program. Due to trading restrictions, we did not implement the share repurchase plan until March 2018. The repurchases under the share repurchase program are made from time to time in the open market or in privately negotiated transactions and are funded from our working capital. The amount and timing of such repurchases are dependent upon the price and availability of shares, general market conditions and the availability of cash. Repurchases may also be made under a trading plan under Rue 10b5-1, which would permit shares to be repurchased when we might otherwise be precluded from doing so because of self-imposed trading blackout periods or other regulatory restrictions. All shares of common stock repurchased under the share repurchase program are expected to be retired and restored to authorized but unissued shares of common stock. The total amounts repurchased by us under the share repurchase program equal approximately 8.7 million shares of common stock for an aggregate purchase price of $25.0 million, or an average cost of $2.89 per share, including trading commissions.

We believe that cash from future revenues from acquired income generating assets and products, net of operating expenses, debt service and income taxes, plus cash on hand, will be sufficient to fund our operations over the next several years. Our continued success is dependent on our ability to acquire new income generating assets and products, and the timing of these transactions, in order to provide recurring cash flows going forward and to support our business model, and to pay amounts due on our debt as they become due.


50


We continuously evaluate alternatives to increase return for our stockholders, including, for example, purchasing income generating assets, selling discreet assets, buying back our convertible notes, repurchasing our common stock and selling our company.

We may consider additional debt or equity financings to support the growth of our business if cash flows from existing investments are not sufficient to fund future potential investment opportunities and acquisitions.

Off-Balance Sheet Arrangements

As of June 30, 2018, we did not have any off-balance sheet arrangements, as defined under SEC Regulation S-K Item 303(a)(4)(ii).

Contractual Obligations

Convertible Notes

As of June 30, 2018, our convertible note obligation consisted of our December 2021 Notes, which in the aggregate totaled $150.0 million in principal.

We expect that our debt service obligations over the next several years will consist of interest payments and repayment of our December 2021 Notes. We may further seek to exchange, repurchase or otherwise acquire the convertible notes in the open market in the future, which could adversely affect the amount or timing of any distributions to our stockholders. We would make such exchanges or repurchases only if we deemed it to be in our stockholders’ best interest. We may finance such repurchases with cash on hand and/or with public or private equity or debt financings if we deem such financings to be available on favorable terms.

Noden Purchase Agreement

Pursuant to the Noden Purchase Agreement, Noden is required to pay up to $95.0 million in milestone payments, subject to the occurrence of such milestones. If the milestones are achieved, we expect to fund at least $38.0 million in the form of additional equity contributions to Noden.

LENSAR Asset Purchase Agreement

Pursuant to the LENSAR Asset Purchase Agreement with Precision Eye Services (“PES”), LENSAR is required to pay up to $1.6 million in milestone payments, subject to the occurrence of such milestones. As of June 30, 2018, there have been $0.8 million in milestone payments.

Kybella Royalty Agreement

On July 8, 2016, we entered into a royalty purchase and sales agreement with an individual, whereby we acquired that individual’s rights to receive certain royalties on sales of KYBELLA by Allergan plc, in exchange for a $9.5 million cash payment and up to $1.0 million in future milestone payments based upon product sales targets.

Guarantees

Redwood City Lease Guarantee

In connection with the Spin-Off of Facet, we entered into amendments to the leases for our former facilities in Redwood City, California, under which Facet was added as a co-tenant, and a Co-Tenancy Agreement, under which Facet agreed to indemnify us for all matters related to the leases attributable to the period after the Spin-Off date.

Purchase Obligation

Noden and Novartis entered into a supply agreement pursuant to which Novartis will manufacture and supply to Noden a and bulk tableted form of the Noden Products, and for the additional supply of active pharmaceutical ingredient form, for specified periods of time prior to the transfer of manufacturing responsibilities for the Noden Products to another manufacturer. The supply agreement may be terminated by either party for material breach that remains uncured for a specified time period. Noden has placed firm orders for bulk product of $14.4 million, which will be fulfilled within the next twelve months. Under

51


the terms of the supply agreement, Noden is committed to purchase certain minimum quantities of bulk product and active pharmaceutical ingredient that would amount to approximately $114.3 million over the next twenty-four months, of which $61.4 million is committed over the next twelve months. While the supply agreement provides that the parties will agree to reasonable accommodations with respect to changes in firm orders, the Company expects that Noden will meet the requirements of the supply agreement, unless otherwise negotiated. The commitments in the supply agreement terminate upon transfer to another manufacturer.

LENSAR and Coherent, Inc. entered into an Original Equipment Manufacturer agreement pursuant to which Coherent, Inc. will manufacture and supply to LENSAR Staccato Lasers. The supply agreement commits LENSAR to a minimum purchase obligation of approximately $3.5 million over the next twenty-four months, of which $1.2 million is committed over over the next twelve months. The Company expects that LENSAR will meet this requirement.

Escrow Receivable

On September 21, 2017, we entered into an agreement (the “kaléo Note Sale Agreement”) with MAM-Kangaroo Lender, LLC, a Delaware limited liability company (the “Purchaser”), pursuant to which we sold our entire interest in the notes issued by Accel 300, LLC (“Accel 300”) pursuant to that certain Indenture, dated as of April 1, 2014, by and between Accel 300 and U.S. Bank National Association, as the current trustee of the notes described therein (the “kaléo Note”).

Pursuant to the kaléo Note Sale Agreement, the Purchaser paid to us an amount equal to 100% of the then outstanding principal, a premium of 1% of such amount and accrued interest under the kaléo Notes, for an aggregate cash purchase price of $141.7 million.

Pursuant to the terms of the kaléo Note Sale Agreement, $1.4 million of the aggregate purchase price was deposited into an escrow account as a potential payment against certain contingencies, which expires on the 18th month anniversary of the closing date. Upon the expiration of the escrow period, the escrow agent is required to release remaining funds to us.

We do not expect there to be any claims by the Purchaser under the escrow agreement. However, in the event that such a claim is made, and if successful, the amount of such a claim up to $1.4 million would be released from the escrow to the Purchaser, which amount would be reduced from the amount released to us at the end of the 18 month escrow period. As of June 30, 2018, we are not aware of any claims by the Purchaser that would reduce the escrow receivable.

52


ITEM 3.      QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
 
As of June 30, 2018, there have been no material changes in our market risk from that described in “Item 7A. Quantitative and Qualitative Disclosures About Market Risk” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017.


53


ITEM 4.        CONTROLS AND PROCEDURES
 
Evaluation of Disclosure Controls and Procedures
 
Under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended) as of June 30, 2018. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of June 30, 2018, our disclosure controls and procedures were effective.
 
Changes in Internal Control Over Financial Reporting

There have been no changes in our internal control over financial reporting that occurred during the quarter ended June 30, 2018, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. However, on May 11, 2017, we acquired LENSAR. In accordance with the SEC’s published guidance, our Annual Report on Form 10-K for the year ending December 31, 2017 did not include consideration of the internal controls of LENSAR within management’s assessment of the effectiveness of internal control over financial reporting as of December 31, 2017. We are in the process of integrating LENSAR into our overall internal control over financial reporting process and will incorporate LENSAR into our annual assessment of internal control over financial reporting as of December 31, 2018.

Beginning January 1, 2018, we implemented ASC 606, Revenue from Contracts with Customers. Although the new revenue standard is expected to have an immaterial impact on our ongoing net income (loss), we did implement changes to our processes related to revenue recognition and the control activities with them. These included the development of new policies based on the five-step model provided in the new revenue standard, new training, ongoing contract review requirements, and gathering of information provided for disclosures.
 
Limitations on the Effectiveness of Controls
 
A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of inherent limitations in all control systems, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may not be prevented or detected on a timely basis, and no evaluation of controls can provide absolute assurance that all control issues, if any, within an organization have been detected. We continue to improve and refine our internal controls and our compliance with existing controls is an ongoing process.


54


PART II. OTHER INFORMATION

ITEM 1.           LEGAL PROCEEDINGS

The information set forth in Note 12 “Commitments and Contingencies” to our Notes to Condensed Consolidated Financial Statements included in Part I, Item 1, of this Quarterly Report on Form 10-Q is incorporated by reference herein.

ITEM 1A.        RISK FACTORS

There have been no material changes to the risk factors included in “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

There were no unregistered sales of equity securities during the period covered by this report.

Issuer Purchases of Equity Securities

The following table contains information relating to the repurchases of our common stock made by us in the three months ended June 30, 2018 (in thousands):
Fiscal Period
 
Total Number of Shares Repurchased
 
Average Price Paid Per Share
 
Total Number of Shares Purchased As Part of a Publicly Announced Program
 
Approximate Dollar Amount of Shares That May Yet be Purchased Under the Program(1)
April 1, 2018
to
April 30, 2018
 
1,652

 
3.03

 
1,652

 
15,841

May 1, 2018
to
May 31, 2018
 
2,861

 
2.93

 
2,861

 
7,469

June 1, 2018
to
June 30, 2018
 
2,252

 
2.70

 
2,252

 
1,392

Total during three months ended June 30, 2018
 
6,765

 
$
2.87

 
6,765

 
$
1,392

____________________
(1) On September 25, 2017, our board of directors authorized the repurchase of issued and outstanding shares of our common stock having an aggregate value of up to $25.0 million pursuant to a new share repurchase program. The repurchase program may be suspended or discontinue at any time without notice.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

None.

ITEM 5. OTHER INFORMATION

None.

ITEM 6.    EXHIBITS

The exhibits listed in the exhibit index preceding the signature page are filed or furnished as part of this report.


55


EXHIBIT INDEX
Exhibit Number
Exhibit Title
 
 
3.1
Restated Certificate of Incorporation effective March 23, 1993 (incorporated by reference to Exhibit 3.1 to Annual Report on Form 10-K filed March 31, 1993)
 
 
3.2
 
 
3.3
 
 
3.4
 
 
3.5
 
 
3.6
 
 
10.1*#
 
 
10.2#
 
 
12.1#
 
 
31.1#
 
 
31.2#
 
 
32.1**#
 
 
101.INS
XBRL Instance Document
101.SCH
XBRL Taxonomy Extension Schema
101.CAL
XBRL Taxonomy Extension Calculation Linkbase
101.DEF
XBRL Taxonomy Extension Definition Linkbase
101.LAB
XBRL Taxonomy Extension Label Linkbase
101.PRE
XBRL Taxonomy Extension Presentation Linkbase
 
 
#
Filed herewith.
*
Management contract or compensation plan or arrangement
**
This certification accompanies the Quarterly Report on Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Quarterly Report on Form 10-Q), irrespective of any general incorporation language contained in such filing.


56


SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
Dated:
August 9, 2018
 
PDL BIOPHARMA, INC. (REGISTRANT)
 
 
 
 
 
 
 
/s/    John P. McLaughlin
 
John P. McLaughlin
 
Chief Executive Officer
(Principal Executive Officer)
 


/s/    Peter S. Garcia
 
Peter S. Garcia
 
Vice President and Chief Financial Officer (Principal Financial Officer and
Principal Accounting Officer)
 


57
 EX-10.1 2 pdli-2018063010qex101.htm 2018 ANNUAL BONUS PLAN Exhibit


Exhibit 10.1


PDL BIOPHARMA, INC.

2018 Annual Bonus Plan

This 2018 Annual Bonus Plan (the “Plan”) is intended to enhance stockholder value by promoting a connection between the performance of PDL BioPharma, Inc. (the “Company”) and the compensation of personnel of the Company and to promote retention of high performing personnel. The Plan is being implemented under the Company’s Amended and Restated 2005 Equity Incentive Plan (as amended, the “2005 Equity Plan”), which was approved by the Company’s stockholders. The annual bonuses will be granted as a Cash-Based Award pursuant to the 2005 Equity Plan.
 
1.All employees of the Company working 30 hours per week or more (each, a “Participant”) are eligible to receive annual bonuses for 2018 according to this Plan. The Plan will be administered by the Compensation Committee of the Board of Directors of the Company (the “Committee”). The Committee shall have all powers and discretion necessary to administer the Plan, determine awards and to control its operation and may delegate responsibilities to Company officers as it deems appropriate. A Participant who does not demonstrate satisfactory individual performance (50% or higher), however, will not be eligible for any portion of his or her bonus, including the portion based on Company performance.
2.The determination of the amount of payments under the plan shall be based on the performance of the 2018 Corporate Goals and the 2018 Individual Goals as well as the other factors set forth in this Section 3. Company performance shall be determined by the Committee based on the Company’s ability to accomplish corporate goals (“2018 Corporate Goals”) as approved by the Committee and the Board of Directors and set forth in Exhibit A(i). The Committee may adjust or modify the 2018 Corporate Goals to reflect changed Company objectives. Individual performance of the Company’s officers shall be reviewed and recommended to the Committee by the Chief Executive Officer, except for the performance of the Chief Executive Officer, which shall be determined by the Committee based on the Company’s achievement of established Corporate Goals. Individual performance of employees shall be reviewed by the appropriate manager and approved by the Chief Executive Officer. In all cases, individual performance shall be based on the 2018 Individual Goals that have been approved by the Chief Executive Officer and set forth as Exhibit B, which may be adjusted or modified to reflect changed employee objectives (the “2018 Individual Goals”).
The Committee shall have the sole discretion on the basis of individual or corporate performance metrics to determine that the actual amount paid with respect to a Participant’s award will be equal to or less than (but not greater than) the maximum payout calculated. For clarification, the Committee may determine, in its sole discretion on the basis of individual or corporate performance metrics that a reduced bonus, or no bonus, shall be paid to individual, regardless of achievement of the 2018 Corporate Goals or the 2018 Individual Goals.
3.To be eligible for a bonus, a Participant must be on payroll prior to October 1, 2018, and must be employed by the Company as of the date of payment of the bonus. A Participant hired after April 1, 2018, shall be eligible for a pro-rated bonus.
4.A Participant who has taken an approved leave of absence pursuant to the Company’s policies during 2018 shall receive a pro-rated bonus, at the Compensation Committee's discretion. The amount of a Participant’s bonus is based on a target percentage of such Participant’s annual base salary for the 2018 calendar year. The target percentage for executives has been determined by the Committee and for employees has been determined by the manager at the beginning of the Plan Year. The target percentage shall then be adjusted based on the level of attainment of 2018 Corporate Goals and 2018 Individual Goals over the course of the Plan Year to arrive at a final performance percentage. For each person, the target percentage and ratio of attainment of 2018 Corporate Goals and 2018 Individual Goals is set forth as Exhibit C.
5.The Company performance percentage and/or the individual performance percentage may exceed 100% in the event the Company or the individual Participant exceeds expected goals, provided that neither percentage may exceed 200%; provided, that, for the avoidance of doubt, the stretch goals set forth in Exhibit A(ii) shall be calculated exclusive of such percentages. For example, assuming the Company has met 100% of its 2018 Corporate Goals, a Participant, who has met 150% of his or her 2018 Individual Goals, has a target percentage of 25%, has a corporate-to-individual goal ratio of 50%/50% and a base pay rate of $100,000 will receive a bonus of $31,250 (100% x 0.5 + 150% x 0.5 = 125%; and 125% x 25% = 31.25%; and 31.25% of Participant’s base pay rate of $100,000 = $31,250). All determinations and decisions made by the Committee shall be final, conclusive and binding on all persons and shall be given the maximum deference permitted by law.




6.This Plan is effective for the Company’s 2018 calendar year beginning January 1, 2018, through December 31, 2018 (the “Plan Year”), and will expire automatically on December 31, 2018. Bonus payments will be made no later than February 15th, 2019.
7.The Company shall withhold all applicable taxes from any bonus payment, including any federal, state and local taxes.
8.Nothing in this Plan shall interfere with or limit in any way the right of the Company to terminate any Participant’s employment or service at any time, with or without cause. Nothing in these guidelines should be construed as an employment agreement or an entitlement to any Participant for any incentive payment hereunder.
9.This Plan and all awards shall be construed in accordance with and governed by the laws of the State of Nevada, without regard to its conflict of law provisions.
10.Payments under this Plan shall be unsecured, unfunded obligations of the Company. To the extent a Participant has any rights under this Plan, the Participant’s rights shall be those of a general unsecured creditor of the Company.



EX-10.2 3 pdli-2018063010qex102.htm AMENDMENT NO. 1 TO ROYALTY PURCHASE AND SALE AGREEMENT Exhibit


Exhibit 10.2


    

AMENDMENT NO. 1
TO ROYALTY PURCHASE AND SALE AGREEMENT
AND BILL OF SALE
AMENDMENT NO. 1 TO ROYALTY PURCHASE AND SALE AGREEMENT AND BILL OF SALE dated as of August 2, 2018 (the “Amendment”) among DEPOMED, INC., a California corporation (“Depomed”), DEPO DR SUB, LLC, a Delaware limited liability company (the “Seller”, and together with Depomed, the “Selling Parties”), and PDL Investment Holdings, LLC, a Delaware limited liability company (as assignee of PDL BIOPHARMA, INC., the “Purchaser”)
PRELIMINARY STATEMENTS
A.The Purchaser, Depomed and the Seller have entered into that certain Royalty Purchase and Sale Agreement dated as of October 18, 2013 (as amended, restated, amended and restated, supplemented or otherwise modified prior to the date hereof, the “Existing Royalty Purchase Agreement” and as amended, restated, supplemented or otherwise modified from time to time including pursuant hereto, the “Royalty Purchase Agreement”).
B.Pursuant to Section 5.8 of the Existing Royalty Purchase Agreement, upon the Reversionary Interest Commencement Date, Depomed shall be entitled to receive the Reversionary Interest.
C.In exchange for a payment of up to $20,000,000 from the Purchaser, the Selling Parties are willing to (1) amend the Existing Royalty Purchase Agreement and the other Transaction Documents to, among other changes, remove the right of Depomed to receive the Reversionary Interest, and (2) transfer the equity interest in the Seller from Depomed to the Purchaser or its designee, in each case upon the terms and conditions set forth herein.
NOW, THEREFORE, in consideration of the premises and for other good and valuable consideration, the sufficiency and receipt of all of which is hereby acknowledged, the parties hereto hereby agree as follows:
SECTION 1. Definitions. Capitalized terms not otherwise defined in this Amendment have the same meanings as specified in the Royalty Purchase Agreement.
SECTION 2. Amendments to Existing Royalty Purchase Agreement and Bill of Sale. Subject to the terms and conditions set forth herein, effective on the Amendment Effective Date (as defined below):
(a)Section 1.1 of the Existing Royalty Purchase Agreement shall be amended by:
(i)adding the following definition in appropriate alphabetical order: “DM Portfolio Intellectual Property Transferee” has the meaning set forth in Section 5.5(b).”;
(ii)adding the following definition in appropriate alphabetical order: ““First Amendment” means the Amendment No. 1 to Royalty Purchase and Sale Agreement, dated as of the Amendment Effective Date (as defined therein), among Depomed, the Seller and the Purchaser.”;
(iii)deleting the definitions of “Reversionary Interest”, “Reversionary Interest Commencement Date” and “Reversionary Interest Threshold”, and any reference to any such defined terms in the Royalty Purchase Agreement or any other Transaction Document shall be deemed deleted and of no further force and effect; and
(iv)deleting the phrase “, subject to the Reversionary Interest” in the definition of “Subject Assets”.
(b)Section 2.5(a) of the Existing Royalty Purchase Agreement shall be amended by deleting the phrase “, subject to the Reversionary Interest”.
(c)Section 5.5(b) of the Existing Royalty Purchase Agreement shall be amended and restated in its entirety as follows:
“(b)    The Selling Parties shall not, without the prior written consent of the Purchaser and subject in all respects to Section 5.5(a), withhold any consent, grant any consent, exercise or waive any right or option, fail to exercise or waive any right or option or take or fail to take any action in respect of, affecting or relating to the Subject




Assets, any DM Portfolio Product or the License Agreements, insofar as they relate to any DM Portfolio Product or DM Portfolio Intellectual Property Rights, until and unless all of the membership interests in Seller have been transferred to the Purchaser, and thereafter only if doing so could not reasonably be expected to, in any case, (i) result in an Adverse Change or (ii) conflict with or cause a default under, or breach or termination of any Transaction Document or the License Agreements. In addition, Depomed shall in no event directly or indirectly sell, assign, convey, transfer or otherwise dispose of any DM Portfolio Intellectual Property Rights to a Person (a “DM Portfolio Intellectual Property Transferee”) unless any applicable License Agreement has been concurrently assigned to such DM Portfolio Intellectual Property Transferee.”
(d)Section 5.8 of the Existing Royalty Purchase Agreement shall be amended by deleting it in its entirety and replacing it with: “[Intentionally Omitted].”
(e)Section 5.9 of the Existing Royalty Purchase Agreement shall be amended by:
(i)
revising the first two sentences of Section 5.9(a) to read as follows: “Notwithstanding the accounting treatment thereof, for United States federal, state, local and foreign tax purposes, the Selling Parties and the Purchaser shall (i) treat the transactions contemplated by the Transaction Documents as a sale as of the Closing Date and (ii) treat the transactions contemplated by the First Amendment as a sale as of the Amendment Effective Date (as defined in the First Amendment). Accordingly, any and all Royalty Payments made pursuant to the License Agreements after the Closing Date (including any Royalty Payments in respect of the interest treated as sold to Purchaser pursuant to the transactions contemplated by the First Amendment) shall be treated as made to the Purchaser for United States federal, state, local and foreign tax purposes.”
(ii)
changing the references to Section 5.8 in Section 5.9(b) to Section 5.9.
(f)A new Section 5.17 is hereby added to the Existing Royalty Purchase Agreement as follows:
“Section 5.17    Power of Attorney.
(a)    Appointment and Powers of PDL Subsidiary. Depomed, in its capacity as Member of Seller, hereby irrevocably constitutes and appoints the PDL Subsidiary and any officer or agent thereof, with full power of substitution, as its true and lawful attorney-in-fact with full irrevocable power and authority in the place and stead of Depomed, in its capacity as Member of Seller, and in the name of Depomed, Seller, or in PDL Subsidiary’s own name, for the purpose of carrying out the terms of the LLC Agreement, to take any and all appropriate action and to execute any and all documents and instruments which may be necessary or desirable to accomplish the purposes of the LLC Agreement, without notice to or assent by Depomed or Seller. To the extent permitted by law, Depomed and Seller each hereby ratifies all that PDL Subsidiary shall lawfully do or cause to be done by virtue of this Power of Attorney. This Power of Attorney is a power coupled with an interest and is irrevocable.
(b)    Ratification by Seller. To the extent permitted by law, each Grantor hereby ratifies all that said attorneys shall lawfully do or cause to be done by virtue of this Section 5.17. This power of attorney is a power coupled with an interest and is irrevocable.
(c)    No Duty on the PDL Subsidiary. The powers conferred on the PDL Subsidiary, its directors, officers and agents pursuant to this Section 5.17 are solely to protect the PDL Subsidiary’s and the Purchaser’s interests under the Transaction Documents and shall not impose any duty (fiduciary or otherwise) upon any of them to exercise any such powers.
(g)Section 7.1 of the Existing Royalty Purchase Agreement shall be amended by adding the following clauses (C) and (D) to the proviso thereof:
“(C) from and after the Amendment Effective Date (as defined in the First Amendment), to the extent resulting from acts or omissions of the Seller directed by the Purchaser or its Affiliates pursuant to the power of attorney granted under Section 5.17 or (D) from and after the Consent Effective Date (as defined in the First Amendment), to the extent resulting from acts or omissions of the Seller directed by the Purchaser or its Affiliates acting in the capacity as the Manager of the Seller or a Member of the Seller.”




(h)Section 7 of the Bill of Sale shall be amended by deleting the phrase “, subject to the Reversionary Interest” in the definition of “Subject Assets”.
(i)As of the Amendment Effective Date, all rights granted to Depomed with respect to the Reversionary Interest by the Existing Royalty Purchase Agreement shall terminate, have no further force and effect and, if necessary, are hereby reconveyed to the Purchaser.
(j)Notwithstanding anything herein or any of the Transaction Documents, on and after the Amendment Effective Date, none of Depomed, or any of its unit holders, shareholders, managers, officers, directors, heirs, successors and assigns, shall have any duty, liability or obligation of any nature with respect to the actions or inactions of Seller that are solely the result of the exercise by PDL Subsidiary of its rights, obligations or control under the LLC Agreement. Further, from and after the transfer of the Seller to the Purchaser as contemplated by Section 6(c) of this Amendment, none of Depomed, or any of its unit holders, shareholders, managers, officers, directors, heirs, successors and assigns, shall have not have any duty, liability or obligation of any nature with respect to the actions or inactions of Seller.
SECTION 3. Conditions to Effectiveness of Amendment. This Amendment shall become effective on the date (the “Amendment Effective Date”) when:
(a)the Purchaser shall have received a copy of this Amendment, duly executed and delivered by each of the Selling Parties;
(b)the Purchaser shall have received, in form and substance satisfactory to the Purchaser, an executed release with respect to any lien granted on the Reversionary Interest and the equity interests of the Seller in favor of Deerfield Private Design Fund III, L.P., as collateral agent (in such capacity, the “Deerfield Collateral Agent”) for the purchasers party to the Note Purchase Agreement dated as of April 2, 2015 among Depomed, such purchasers and the Deerfield Collateral Agent; and
(c)the Purchaser shall pay (or cause to be paid) to Depomed $10,000,000 in immediately available funds by wire transfer to the Seller Account.
SECTION 4. Conditions Precedent to Final Payment. The Purchaser shall pay (or cause to be paid) to Depomed $10,000,000 in immediately available funds by wire transfer to the Seller Account when (the date on which the conditions below have been satisfied or waived by the Purchaser, the “Consent Effective Date”):
(a)the Purchaser shall have received an executed copy of an amended and restated limited liability company agreement of the Seller in the form attached hereto as Exhibit A (the “LLC Agreement”) and Depomed, as the sole member of the Seller, shall have taken action by written consent of the sole member in the form attached hereto as Exhibit B to appoint the PDL Subsidiary as the sole manager of the Seller; and
(b)the Purchaser shall have received a Required Consent (as defined in Section 6(b) herein) with respect to the Santarus Agreement.
SECTION 5. Representations and Warranties. Each party hereto represents and warrants to the others that:
(a)Such party has taken all necessary organizational action to authorize the execution, delivery and performance of this Amendment.
(b)This Amendment has been duly executed and delivered by each party and constitutes a legal, valid and binding obligation of such party, enforceable against such party in accordance with its terms, subject to the applicable bankruptcy, insolvency, reorganization, moratorium or other laws affecting creditors’ rights generally and subject to general principles of equity, regardless of whether considered in a proceeding in equity or at law.
SECTION 6. Further Assurances.
(a)Each Seller Party agrees, at the Purchaser’s sole cost and expense, to consent to or take any action reasonably requested by the Purchaser to further evidence, give effect to or carry out the terms of this Amendment.
(b)Depomed shall use its commercially reasonable efforts to obtain the Required Consents with respect to each License Agreement within 90 days of the Amendment Effective Date (or such later date as agreed to in writing by the Purchaser in its sole discretion). “Required Consents” means the written consent of each Licensee to the transfer of the equity interests in the Seller or rights under the License Agreement from Depomed or the Seller, as applicable, to a Subsidiary of the Purchaser (the “PDL Subsidiary”) and, in the case of the Santarus Agreement, the appointment of the PDL Subsidiary to serve as the sole manager of the Seller, in form and substance reasonably satisfactory to the Purchaser.




(c)Promptly after receipt of the Required Consents, Depomed shall transfer its membership interests in Seller to the PDL Subsidiary.
SECTION 7. Reference to and Effect on the Existing Royalty Purchase Agreement and the Transaction Documents.
(a)On and after the Amendment Effective Date, each reference in the Existing Royalty Purchase Agreement to “this Agreement”, “hereunder”, “hereof” or words of like import referring to the Existing Royalty Purchase Agreement shall mean and be a reference to the Existing Royalty Purchase Agreement as amended by this Amendment on the Amendment Effective Date.
(b)The Existing Royalty Purchase Agreement and each of the other Transaction Documents, as specifically amended by this Amendment, are and shall continue to be in full force and effect and are hereby in all respects ratified and confirmed.
(c)The execution, delivery and effectiveness of this Amendment shall not, except as expressly provided herein, operate as a waiver of any right, power or remedy of any of the Purchaser or the Selling Parties under any of the Transaction Documents, nor constitute a modification, acceptance or waiver of any other provision of any of the Transaction Documents.
SECTION 8. Counterparts. This Amendment may be signed in any number of counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. Any counterparty may be executed by facsimile or other electronic transmission (including .pdf) and such facsimile or other electronic transmission shall be deemed an original.
SECTION 9. Miscellaneous. THIS AMENDMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE INTERNAL SUBSTANTIVE LAWS OF THE STATE OF NEW YORK WITHOUT REFERENCE TO THE RULES THEREOF RELATING TO CONFLICTS OF LAW OTHER THAN SECTION 5-1401 OF THE GENERAL OBLIGATIONS LAW OF THE STATE OF NEW YORK, AND THE OBLIGATIONS, RIGHTS AND REMEDIES OF THE PARTIES HEREUNDER SHALL BE DETERMINED IN ACCORDANCE WITH SUCH LAWS. Sections 9.2, 9.3, 9.4, 9.7(b)-(d), 9.8, 9.9, 9.11, 9.12, 9.13 and 9.14 of the Existing Royalty Purchase Agreement are hereby incorporated by reference into this Amendment, mutatis mutandis, and the parties hereto hereby agree that such provisions shall apply to this Amendment with the same force and effect as if set forth herein in their entirety.
IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed by their respective officers thereunto duly authorized, as of the date first above written.
DEPOMED, INC.
By: /S/    ARTHUR HIGGINS
Name: Arthur Higgins
Title: Chief Executive Officer


DEPO DR SUB, LLC
By: /S/ ARTHUR HIGGINS
Name: Arthur Higgins
Title: Chief Executive Officer


PDL Investment Holdings, LLC
By: /S/    CHRISTOPHER STONE
Name: Christopher Stone
Title: Chief Executive Officer and Treasurer



 EX-12.1 4 pdli-2018063010qex121.htm RATIO OF EARNINGS TO FIXED CHARGES Exhibit


Exhibit 12.1

PDL BIOPHARMA, INC.
COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES
(Unaudited)
(Amount in thousands, except for ratios)



 
 
 
 
 
 
 
 
 
 
 
 
For the Six Months Ended June 30, 2018
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2013
 
2014
 
2015
 
2016
 
2017
 
Earnings:
 
 
 
 
 
 
 
 
 
 
 
 
Income (loss) before income taxes
 
$
401,876

 
$
501,272

 
$
530,138

 
$
109,370

 
$
184,527

 
$
(123,940
)
Add: fixed charges
 
24,931

 
39,274

 
27,123

 
18,330

 
20,507

 
6,604

Earnings
 
$
426,807

 
$
540,546

 
$
557,261

 
$
127,700

 
$
205,034

 
$
(117,336
)
Fixed Charges:
 
 
 
 
 
 
 
 
 
 
 
 
Interest expense1
 
$
24,871

 
$
39,211

 
$
27,059

 
$
18,267

 
$
20,221

 
$
6,396

Estimated interest portion of rent expense2
 
60

 
63

 
64

 
63

 
286

 
208

Fixed charges
 
$
24,931

 
$
39,274

 
$
27,123

 
$
18,330

 
$
20,507

 
$
6,604

Ratio of earnings to fixed charges
 
17.12

 
13.76

 
20.55

 
6.97

 
10.00

 
(17.77
)
_____________________________________
1 Interest expense includes amortization of debt discount and expenses.
2 Represents the estimated portion of operating lease rental expense that is considered by us to be representative of interest and amortization of discount related to indebtedness.



 EX-31.1 5 pdli-2018063010qex311.htm CERTIFICATION Exhibit
Exhibit 31.1

CERTIFICATIONS
 
I, John P. McLaughlin, Chief Executive Officer, of PDL BioPharma, Inc., certify that:

(1) I have reviewed this Quarterly Report on Form 10-Q of PDL BioPharma, Inc.;

(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(4) The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

(5) The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:
August 9, 2018
 
 
 
 
/s/ John P. McLaughlin
 
John P. McLaughlin
Chief Executive Officer
(Principal Executive Officer)
 


 EX-31.2 6 pdli-2018063010qex312.htm CERTIFICATION Exhibit


Exhibit 31.2

CERTIFICATIONS
 
I, Peter S. Garcia, Vice President and Chief Financial Officer, of PDL BioPharma, Inc., certify that:

(1) I have reviewed this Quarterly Report on Form 10-Q of PDL BioPharma, Inc.;

(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(4) The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

(5) The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:
August 9, 2018
 
 
 
 
/s/ Peter S. Garcia
 
Peter S. Garcia
Vice President and Chief Financial Officer
(Principal Financial Officer)
 



 EX-32.1 7 pdli-2018063010qex321.htm CERTIFICATION Exhibit
Exhibit 32.1

CERTIFICATION

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. Section 1350), John P. McLaughlin, Chief Executive Officer of PDL BioPharma, Inc. (the “Company”), and Peter S. Garcia, Vice President and Chief Financial Officer of the Company, each hereby certifies that, to the best of their knowledge:

(1) The Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2018, to which this Certification is attached as Exhibit 32.1 (the “Periodic Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, and

(2) The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Dated: August 9, 2018
 
By:
 
 
 
/s/ JOHN P. MCLAUGHLIN
 
 
John P. McLaughlin
 
 
Chief Executive Officer
 
 
(Principal Executive Officer)
 
 
 
 
 
 
 
By:
 
 
 
/s/ PETER S. GARCIA
 
 
Peter S. Garcia
 
 
Vice President and Chief Financial Officer
 
 
(Principal Financial Officer)
_________________________________________
(1)
This certification accompanies the Quarterly Report on Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of PDL BioPharma, Inc. under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing. A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to PDL BioPharma, Inc. and will be retained by PDL BioPharma, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.




 EX-101.INS 8 pdli-20180630.xml XBRL INSTANCE DOCUMENT 0000882104 2018-01-01 2018-06-30 0000882104 2018-07-30 0000882104 2017-04-01 2017-06-30 0000882104 pdli:Queenetal.patentsMember 2018-04-01 2018-06-30 0000882104 2017-01-01 2017-06-30 0000882104 2018-04-01 2018-06-30 0000882104 pdli:AcquiredrightsMember 2018-04-01 2018-06-30 0000882104 pdli:Queenetal.patentsMember 2017-01-01 2017-06-30 0000882104 pdli:AcquiredrightsMember 2017-01-01 2017-06-30 0000882104 pdli:Queenetal.patentsMember 2017-04-01 2017-06-30 0000882104 pdli:AcquiredrightsMember 2018-01-01 2018-06-30 0000882104 pdli:Queenetal.patentsMember 2018-01-01 2018-06-30 0000882104 pdli:AcquiredrightsMember 2017-04-01 2017-06-30 0000882104 2018-06-30 0000882104 2017-12-31 0000882104 2017-03-31 0000882104 2016-12-31 0000882104 pdli:MedicaldevicesMember 2018-06-30 0000882104 pdli:GreaterthanoneyearMember pdli:MedicaldevicesMember 2018-06-30 0000882104 pdli:GreaterthanoneyearMember pdli:PharmaceuticalMember 2018-06-30 0000882104 pdli:LessthanoneyearMember pdli:MedicaldevicesMember 2018-06-30 0000882104 pdli:PharmaceuticalMember 2018-06-30 0000882104 pdli:LessthanoneyearMember pdli:PharmaceuticalMember 2018-06-30 0000882104 2018-01-01 0000882104 pdli:MedicaldevicesMember us-gaap:NonUsMember 2018-01-01 2018-06-30 0000882104 pdli:PharmaceuticalMember us-gaap:EuropeMember 2017-01-01 2017-06-30 0000882104 pdli:MedicaldevicesMember us-gaap:NorthAmericaMember 2018-01-01 2018-06-30 0000882104 pdli:PharmaceuticalMember us-gaap:AsiaMember 2018-04-01 2018-06-30 0000882104 pdli:MedicaldevicesMember 2017-01-01 2017-06-30 0000882104 pdli:MedicaldevicesMember 2018-04-01 2018-06-30 0000882104 pdli:MedicaldevicesMember 2018-01-01 2018-06-30 0000882104 pdli:PharmaceuticalMember us-gaap:EuropeMember 2018-04-01 2018-06-30 0000882104 pdli:PharmaceuticalMember us-gaap:AsiaMember 2017-01-01 2017-06-30 0000882104 pdli:MedicaldevicesMember us-gaap:EuropeMember 2018-01-01 2018-06-30 0000882104 pdli:PharmaceuticalMember us-gaap:NorthAmericaMember 2017-01-01 2017-06-30 0000882104 pdli:PharmaceuticalMember us-gaap:NonUsMember 2018-04-01 2018-06-30 0000882104 pdli:MedicaldevicesMember us-gaap:EuropeMember 2018-04-01 2018-06-30 0000882104 pdli:PharmaceuticalMember 2018-04-01 2018-06-30 0000882104 pdli:MedicaldevicesMember us-gaap:NonUsMember 2018-04-01 2018-06-30 0000882104 pdli:PharmaceuticalMember us-gaap:NorthAmericaMember 2018-04-01 2018-06-30 0000882104 pdli:MedicaldevicesMember us-gaap:NonUsMember 2017-01-01 2017-06-30 0000882104 pdli:MedicaldevicesMember us-gaap:AsiaMember 2018-04-01 2018-06-30 0000882104 pdli:MedicaldevicesMember us-gaap:AsiaMember 2018-01-01 2018-06-30 0000882104 pdli:MedicaldevicesMember us-gaap:NorthAmericaMember 2018-04-01 2018-06-30 0000882104 pdli:PharmaceuticalMember 2018-01-01 2018-06-30 0000882104 pdli:PharmaceuticalMember 2017-12-31 0000882104 pdli:MedicaldevicesMember 2017-12-31 0000882104 us-gaap:RestrictedStockMember 2018-04-01 2018-06-30 0000882104 us-gaap:RestrictedStockMember 2017-01-01 2017-06-30 0000882104 us-gaap:RestrictedStockMember 2017-04-01 2017-06-30 0000882104 us-gaap:RestrictedStockMember 2018-01-01 2018-06-30 0000882104 us-gaap:RestrictedStockMember 2017-01-01 2017-06-30 0000882104 us-gaap:RestrictedStockMember 2018-04-01 2018-06-30 0000882104 us-gaap:OptionOnSecuritiesMember 2018-01-01 2018-06-30 0000882104 us-gaap:OptionOnSecuritiesMember 2017-04-01 2017-06-30 0000882104 us-gaap:RestrictedStockMember 2018-01-01 2018-06-30 0000882104 us-gaap:OptionOnSecuritiesMember 2017-01-01 2017-06-30 0000882104 pdli:December2021NotesMember 2015-11-20 0000882104 us-gaap:OptionOnSecuritiesMember 2018-04-01 2018-06-30 0000882104 us-gaap:RestrictedStockMember 2017-04-01 2017-06-30 0000882104 pdli:RoyaltyrightMember 2018-06-30 0000882104 pdli:RoyaltyrightMember 2018-01-01 2018-06-30 0000882104 pdli:RoyaltyrightMember 2017-12-31 0000882104 2017-10-27 2017-10-28 0000882104 2016-12-12 2016-12-13 0000882104 pdli:VBMember 2018-06-30 0000882104 pdli:CareViewMember 2018-01-01 2018-06-30 0000882104 pdli:KybellaMember 2018-06-30 0000882104 2014-11-06 0000882104 2016-09-21 2016-09-21 0000882104 pdli:KybellaMember 2018-04-01 2018-06-30 0000882104 pdli:AcelRxMember 2018-06-30 0000882104 pdli:DepomedMember 2018-06-30 0000882104 pdli:DepomedMember 2013-10-18 0000882104 pdli:VBMember 2014-06-26 0000882104 pdli:UniversityofMichiganMember 2018-06-30 0000882104 pdli:DepomedMember 2018-01-01 2018-06-30 0000882104 pdli:AcelRxMember 2018-04-01 2018-06-30 0000882104 pdli:VBMember 2018-04-01 2018-06-30 0000882104 pdli:VBMember 2018-01-01 2018-06-30 0000882104 pdli:UniversityofMichiganMember 2018-04-01 2018-06-30 0000882104 pdli:NodenMember 2018-06-30 0000882104 pdli:KybellaMember 2016-07-09 0000882104 pdli:CareViewMember 2018-04-01 2018-06-30 0000882104 pdli:AcelRxMember 2015-09-18 0000882104 2016-06-01 2016-06-02 0000882104 pdli:KybellaMember 2016-07-07 2016-07-08 0000882104 pdli:December2021NotesMember 2018-06-30 0000882104 pdli:HyperionMember us-gaap:FairValueInputsLevel3Member 2017-12-31 0000882104 pdli:HyperionMember 2017-12-31 0000882104 pdli:CareViewMember us-gaap:FairValueInputsLevel2Member 2017-12-31 0000882104 pdli:CareViewMember us-gaap:FairValueInputsLevel3Member 2017-12-31 0000882104 us-gaap:FairValueInputsLevel3Member 2017-12-31 0000882104 pdli:WellstatNoteReceivableMember 2017-12-31 0000882104 pdli:December2021NotesMember us-gaap:FairValueInputsLevel2Member 2017-12-31 0000882104 us-gaap:FairValueInputsLevel2Member 2017-12-31 0000882104 pdli:CareViewMember us-gaap:FairValueInputsLevel3Member 2018-06-30 0000882104 pdli:December2021NotesMember 2017-12-31 0000882104 pdli:CareViewMember 2018-06-30 0000882104 pdli:WellstatNoteReceivableMember us-gaap:FairValueInputsLevel3Member 2017-12-31 0000882104 pdli:WellstatNoteReceivableMember 2018-06-30 0000882104 us-gaap:FairValueInputsLevel3Member 2018-06-30 0000882104 pdli:February2018NotesMember us-gaap:FairValueInputsLevel2Member 2017-12-31 0000882104 pdli:December2021NotesMember us-gaap:FairValueInputsLevel2Member 2018-06-30 0000882104 pdli:HyperionMember us-gaap:FairValueInputsLevel2Member 2017-12-31 0000882104 pdli:WellstatNoteReceivableMember us-gaap:FairValueInputsLevel3Member 2018-06-30 0000882104 pdli:CareViewMember 2017-12-31 0000882104 pdli:HyperionMember us-gaap:FairValueInputsLevel2Member 2018-06-30 0000882104 pdli:HyperionMember us-gaap:FairValueInputsLevel3Member 2018-06-30 0000882104 pdli:CareViewMember us-gaap:FairValueInputsLevel2Member 2018-06-30 0000882104 pdli:HyperionMember 2018-06-30 0000882104 us-gaap:FairValueInputsLevel2Member 2018-06-30 0000882104 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2018-06-30 0000882104 us-gaap:EquitySecuritiesMember 2017-12-31 0000882104 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2018-06-30 0000882104 us-gaap:MoneyMarketFundsMember 2018-06-30 0000882104 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2017-12-31 0000882104 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel1Member 2018-06-30 0000882104 us-gaap:FairValueInputsLevel1Member 2017-12-31 0000882104 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel2Member 2017-12-31 0000882104 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2017-12-31 0000882104 us-gaap:FairValueInputsLevel1Member 2018-06-30 0000882104 us-gaap:MoneyMarketFundsMember 2017-12-31 0000882104 us-gaap:EquitySecuritiesMember 2018-06-30 0000882104 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel2Member 2018-06-30 0000882104 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel1Member 2017-12-31 0000882104 pdli:RoyaltyrightMember pdli:AvingerMember 2017-12-31 0000882104 pdli:RoyaltyrightMember pdli:AcelRxMember 2018-06-30 0000882104 pdli:RoyaltyrightMember pdli:DepomedMember 2017-12-31 0000882104 pdli:RoyaltyrightMember pdli:UniversityofMichiganMember 2018-01-01 2018-06-30 0000882104 pdli:RoyaltyrightMember pdli:VBMember 2017-12-31 0000882104 pdli:RoyaltyrightMember pdli:AvingerMember 2018-06-30 0000882104 pdli:RoyaltyrightMember pdli:KybellaMember 2017-12-31 0000882104 pdli:RoyaltyrightMember pdli:UniversityofMichiganMember 2017-12-31 0000882104 pdli:RoyaltyrightMember pdli:KybellaMember 2018-01-01 2018-06-30 0000882104 pdli:RoyaltyrightMember pdli:KybellaMember 2018-06-30 0000882104 pdli:RoyaltyrightMember pdli:DepomedMember 2018-06-30 0000882104 pdli:RoyaltyrightMember pdli:AvingerMember 2018-01-01 2018-06-30 0000882104 pdli:RoyaltyrightMember pdli:VBMember 2018-06-30 0000882104 pdli:RoyaltyrightMember pdli:VBMember 2018-01-01 2018-06-30 0000882104 pdli:RoyaltyrightMember pdli:UniversityofMichiganMember 2018-06-30 0000882104 pdli:RoyaltyrightMember pdli:DepomedMember 2018-01-01 2018-06-30 0000882104 pdli:RoyaltyrightMember pdli:AcelRxMember 2018-01-01 2018-06-30 0000882104 pdli:RoyaltyrightMember pdli:AcelRxMember 2017-12-31 0000882104 pdli:ContingentConsiderationMember 2018-06-30 0000882104 pdli:ContingentConsiderationMember 2018-01-01 2018-06-30 0000882104 pdli:ContingentConsiderationMember 2017-12-31 0000882104 us-gaap:MoneyMarketFundsMember 2017-12-31 0000882104 us-gaap:EquitySecuritiesMember 2017-12-31 0000882104 us-gaap:CashAndCashEquivalentsMember 2018-06-30 0000882104 us-gaap:MoneyMarketFundsMember 2018-06-30 0000882104 us-gaap:CashAndCashEquivalentsMember 2017-12-31 0000882104 pdli:DepomedMember 2017-01-01 2017-06-30 0000882104 pdli:LENSARMember pdli:InterestrevenuesMember 2018-04-01 2018-06-30 0000882104 pdli:NodenMember 2017-01-01 2017-06-30 0000882104 pdli:NodenMember 2018-04-01 2018-06-30 0000882104 pdli:ElanMember pdli:TysabriMember 2017-01-01 2017-06-30 0000882104 pdli:ElanMember pdli:TysabriMember 2017-04-01 2017-06-30 0000882104 pdli:DepomedMember 2018-01-01 2018-06-30 0000882104 pdli:DepomedMember 2017-04-01 2017-06-30 0000882104 pdli:LENSARMember pdli:InterestrevenuesMember 2017-04-01 2017-06-30 0000882104 pdli:LENSARMember pdli:InterestrevenuesMember 2018-01-01 2018-06-30 0000882104 pdli:ElanMember pdli:TysabriMember 2018-01-01 2018-06-30 0000882104 pdli:NodenMember pdli:TysabriMember 2017-04-01 2017-06-30 0000882104 pdli:NodenMember pdli:TysabriMember 2018-01-01 2018-06-30 0000882104 pdli:DepomedMember 2018-04-01 2018-06-30 0000882104 pdli:LENSARMember pdli:InterestrevenuesMember 2017-01-01 2017-06-30 0000882104 pdli:ElanMember pdli:TysabriMember 2018-04-01 2018-06-30 0000882104 pdli:DirectFlowMember 2016-07-15 0000882104 pdli:DirectFlowMember 2017-02-05 2017-02-06 0000882104 pdli:CareViewMember 2015-06-26 0000882104 pdli:WellstatDiagnosticsMember 2013-08-15 0000882104 pdli:HyperionMember 2012-01-27 0000882104 pdli:AdditionalLoanMember 2015-09-29 0000882104 pdli:TranchethreeMember pdli:DirectFlowMember 2015-12-15 0000882104 pdli:CareViewMember 2015-10-07 0000882104 pdli:LENSARMember 2013-10-03 0000882104 pdli:DirectFlowMember 2013-11-06 0000882104 pdli:InitialLoanMember pdli:WellstatDiagnosticsMember 2013-08-13 2013-08-15 0000882104 pdli:CreditAgreementMember pdli:WellstatDiagnosticsMember 2012-11-02 0000882104 2017-09-20 2017-09-21 0000882104 2015-12-15 0000882104 pdli:AlphaeonMember 2015-12-31 0000882104 pdli:DirectFlowMember 2016-09-12 0000882104 pdli:LENSARMember 2015-05-12 0000882104 pdli:KaleoNoteReceivableMember 2017-09-20 2017-09-21 0000882104 pdli:TermloanandinterestMember pdli:WellstatDiagnosticsMember 2013-08-13 2013-08-15 0000882104 2016-07-15 2016-07-16 0000882104 pdli:CareViewMember 2018-06-30 0000882104 pdli:CreditAgreementMember pdli:WellstatDiagnosticsMember 2013-08-13 2013-08-15 0000882104 pdli:LENSARMember 2013-10-02 2013-10-03 0000882104 pdli:AdditionalLoanMember pdli:WellstatDiagnosticsMember 2013-06-28 0000882104 pdli:LENSARMember 2015-12-15 0000882104 pdli:CareViewMember 2015-06-26 2015-06-26 0000882104 pdli:HyperionMember 2013-03-05 0000882104 pdli:WellstatDiagnosticsMember 2018-06-30 0000882104 pdli:CreditAgreementMember pdli:WellstatDiagnosticsMember 2013-01-01 2013-12-31 0000882104 pdli:DirectFlowMember 2016-11-14 0000882104 pdli:DirectFlowMember 2014-11-10 2014-11-10 0000882104 pdli:DirectFlowMember 2013-11-04 2013-11-05 0000882104 pdli:WellstatDiagnosticsMember 2014-09-30 0000882104 pdli:DirectFlowMember 2017-02-08 2017-02-09 0000882104 pdli:DirectFlowMember 2016-12-29 2016-12-30 0000882104 pdli:AvingerMember 2015-09-22 2015-09-22 0000882104 pdli:AdditionalLoanMember pdli:LENSARMember 2013-10-02 2013-10-03 0000882104 pdli:KaleoNoteReceivableMember 2014-04-01 0000882104 2015-12-31 0000882104 2018-02-02 0000882104 pdli:DirectFlowMember 2017-02-13 2017-02-14 0000882104 pdli:CreditAgreementMember pdli:WellstatDiagnosticsMember 2013-01-01 2013-01-31 0000882104 pdli:CreditAgreementMember pdli:LENSARMember 2017-02-05 2017-02-06 0000882104 pdli:CareViewMember 2018-02-02 0000882104 pdli:ForbearanceprincipalandinterestMember pdli:WellstatDiagnosticsMember 2013-08-13 2013-08-15 0000882104 pdli:RoyaltyAgreementMember pdli:AvingerMember 2013-07-01 2018-04-30 0000882104 2015-05-12 0000882104 pdli:DirectFlowMember 2016-09-29 0000882104 2017-10-01 2017-12-31 0000882104 2018-01-06 0000882104 2018-01-07 2018-01-08 0000882104 us-gaap:PatentedTechnologyMember 2018-06-30 0000882104 us-gaap:TrademarksMember 2017-12-31 0000882104 us-gaap:CustomerRelationshipsMember 2018-06-30 0000882104 us-gaap:PatentedTechnologyMember 2017-12-31 0000882104 us-gaap:TrademarksMember 2018-06-30 0000882104 us-gaap:ContractualRightsMember 2017-12-31 0000882104 us-gaap:ContractualRightsMember 2018-06-30 0000882104 us-gaap:CustomerRelationshipsMember 2017-12-31 0000882104 2018-06-29 0000882104 pdli:NexttwelvemonthsMember pdli:LENSARMember 2018-06-30 0000882104 pdli:NexttwentyfourmonthsMemberMember pdli:LENSARMember 2018-06-30 0000882104 pdli:NextthirtysixmonthsMember pdli:NodenMember 2018-06-30 0000882104 pdli:NexttwelvemonthsMember pdli:NodenMember 2018-06-30 0000882104 pdli:February2018NotesMember 2017-01-01 2017-06-30 0000882104 pdli:February2018NotesMember 2018-01-01 2018-06-30 0000882104 pdli:February2018NotesMember 2017-04-01 2017-06-30 0000882104 pdli:February2018NotesMember 2018-04-01 2018-06-30 0000882104 pdli:December2021NotesMember 2018-01-01 2018-06-30 0000882104 pdli:February2018NotesMember 2014-02-12 0000882104 pdli:December2021NotesMember 2016-11-22 0000882104 pdli:December2021NotesMember 2016-11-20 2016-11-21 0000882104 pdli:PurchasedCallOptionsMember 2018-06-30 0000882104 pdli:February2018NoteWarrantMember 2014-02-04 2014-02-05 0000882104 pdli:February2018NotesMember 2015-11-19 2015-11-20 0000882104 2018-02-01 2018-02-02 0000882104 pdli:February2018NotesMember 2016-11-22 0000882104 pdli:February2018NotesMember 2015-11-20 0000882104 pdli:February2018NotePurchaseCallOptionMember 2014-02-10 2014-02-11 0000882104 pdli:February2018NotesMember 2016-11-20 2016-11-21 0000882104 pdli:February2018NotesMember 2014-02-10 2014-02-11 0000882104 pdli:Series2012NotesMember 2014-02-06 0000882104 pdli:February2018NotePurchaseCallOptionMember 2018-06-30 0000882104 2014-02-06 0000882104 pdli:February2018NoteWarrantMember 2018-06-30 0000882104 pdli:December2021NotesMember 2018-04-01 2018-06-30 0000882104 pdli:December2021NotesMember 2017-04-01 2017-06-30 0000882104 pdli:December2021NotesMember 2017-01-01 2017-06-30 0000882104 pdli:February2018NotesMember 2018-06-30 0000882104 pdli:February2018NotesMember 2017-12-31 0000882104 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-06-30 0000882104 us-gaap:RestrictedStockMember 2017-12-31 0000882104 us-gaap:EmployeeStockOptionMember 2017-12-31 0000882104 us-gaap:EmployeeStockOptionMember 2018-06-30 0000882104 us-gaap:RestrictedStockMember 2018-06-30 0000882104 2018-03-01 2018-07-05 0000882104 2017-03-02 0000882104 2017-09-25 0000882104 2017-01-01 2017-12-31 0000882104 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-12-31 0000882104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000882104 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-06-30 0000882104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0000882104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-06-30 0000882104 pdli:LENSARMember 2017-05-11 0000882104 pdli:LENSARMember 2017-05-12 2017-05-13 0000882104 2017-05-12 2017-05-13 0000882104 2017-05-10 2017-05-11 0000882104 pdli:LENSARMember 2017-01-20 0000882104 pdli:LENSARMember 2017-05-10 2017-05-11 0000882104 pdli:IncomegeneratingassetsMember 2018-04-01 2018-06-30 0000882104 pdli:MedicaldevicesMember 2017-04-01 2017-06-30 0000882104 pdli:IncomegeneratingassetsMember 2017-04-01 2017-06-30 0000882104 pdli:PharmaceuticalMember 2017-04-01 2017-06-30 0000882104 pdli:PharmaceuticalMember 2017-01-01 2017-06-30 0000882104 pdli:IncomegeneratingassetsMember 2017-01-01 2017-06-30 0000882104 pdli:IncomegeneratingassetsMember 2018-01-01 2018-06-30 0000882104 pdli:IncomegeneratingassetsMember 2018-06-30 0000882104 pdli:IncomegeneratingassetsMember 2017-12-31 0000882104 2018-08-01 2018-08-02 0000882104 us-gaap:SubsequentEventMember 2018-08-01 2018-08-02 0000882104 us-gaap:SubsequentEventMember 2018-08-02 0000882104 us-gaap:SubsequentEventMember 2018-07-01 2018-07-05 0000882104 us-gaap:SubsequentEventMember 2018-06-30 0000882104 2018-05-08 iso4217:USD iso4217:USD xbrli:shares xbrli:pure xbrli:shares false --12-31 Q2 2018 2018-06-30 10-Q 0000882104 145400381 Yes Accelerated Filer PDL BIOPHARMA, INC. No Yes 0.01 19613000 16931000 18000 250000 36000 499000 19000 0 38000 88000 10000000 0 0 1811000 4178000 4155000 532114000 109703000 4848000 417563000 395653000 71548000 324105000 2170000 0 240500000 65600000 -1207000 -2649000 22135000 22735000 -96871000 -23933000 83725000 96871000 12842000 23933000 23933000 1207000 2649000 -22135000 -22735000 50000000 20000000 60000000 15000000 40000000 2800000 8700000 30 0 0.05 0.98 1.30 19300000 23800000 10400000 12800000 43700000 121500000 10800000 900000 1300000 3422000 2390000 4400000 0.070 0.095 0.21 8709000 6116000 0.155 0.05 0.155 0.135 0.185 5460000 10917000 751000 800000 1500000 1500000 3.84 1000000 2800000 4300000 13800000 2 0.75 0.75 1200000 1000 8100000 3304000 4270000 270000 31000000 241300000 15500000 65000000 9500000 0.50 800000 349223000 349223000 335163000 335163000 77400000 214100000 2800000 26100000 14700000 481000000 20000000 20000000 170000 70700000 70900000 43900000 31183000 19531000 19785000 11212000 1400000 1729000 1978000 1377000 217000 45881000 34294000 595000 1027000 10700000 10700000 1181000 1181000 1181000 0 0 0 20000000 -102443000 -100229000 12164000 12677000 131000 851000 261000 1699000 135000 0 269000 293000 5394000 3911000 6148000 12163000 6384000 12677000 0 2200000 0 2000000 4900000 1000000 4900000 1100000 1243123000 945995000 640443000 508671000 771663000 422411000 29000 349223000 659371000 324105000 103000 335163000 1495000 0 1495000 0 0 0 0 4848000 4848000 0 0 0 0 530619000 109703000 3353000 417563000 395653000 71548000 324105000 4848000 0 4848000 0 0 0 0 0 0 0 764000 0.38 -0.76 0.38 -0.76 59351000 -112296000 145554000 46575000 -9309000 6271000 6271000 0 0 31726000 1200000 2649000 -22735000 0 1140000 1140000 920000 10000000 42000000 42000000 18900000 18900000 640000 58323000 2760000 1983000 67000 11970000 1845000 848000 -6673000 25723000 18647000 -10615000 31700000 147154000 349428000 527266000 109703000 0 417563000 395653000 71548000 324105000 417563000 417563000 0 324105000 324105000 0 202274000 -131613000 0.45 0.40 0.01 0.01 0.03 4400000 500000 8500000 800000 0.01 0.01 350000000 350000000 153775000 145971000 153775000 145971000 1538000 1460000 60439000 67680000 -112296000 -111875000 60439000 67633000 -112296000 -111875000 0.61 0.11 0.02 0.11 0.49 0.16 0.01 0.15 0.20 0.03 0.13 0.56 0.20 0.05 0.13 0.52 19970000 30771000 10084000 1391000 8693000 5114000 1234000 3880000 10084000 4427000 547000 3880000 -9397000 -704000 -8693000 2800000 117415000 126066000 120945000 0 300000000 131700000 150000000 150000000 117415000 120945000 126066000 0 4515000 7067000 14524000 25090000 3198000 0 647000 0 1469000 2899000 1626000 3225000 10.3610 4.88 3.81 262.2951 P3Y5M5D 150000000 126447000 150000000 0 0.069 0.034 0.040 0.028 2021-12-01 2018-02-01 2600000 126400000 53600000 120000000 32585000 381000 29055000 0 29700000 3100000 4300000 4300000 1300000 200000 29223000 -11276000 9741000 4904000 1208000 3538000 591000 2028000 79000 77000 47000 45000 0.39 0.42 -0.76 -0.74 0.39 0.42 -0.76 -0.74 6043000 7046000 43909000 0 0 0 0 0 0.150 0.21 -14060000 4539000 -396000 -17967000 100000 -620000 284000 349223000 72894000 396000 232038000 2746000 26769000 14380000 335163000 77433000 0 214071000 2846000 26149000 14664000 22735000 -1560000 785000 -42000000 -20040000 Should this discount rate increase or decrease by 2.5%, the fair value of this asset could decrease by $9.8 million or increase by $12.0 million, respectively. Should the expected royalties increase or decrease by 2.5%, the fair value of the asset could increase or decrease by $1.9 million, respectively Should this discount rate increase or decrease by 2.5%, the fair value of this asset could decrease by $0.2 million or increase by $0.3 million, respectively. Should the expected royalties increase or decrease by 2.5%, the fair value of the asset could increase or decrease by $0.1 million, respectively Should this discount rate increase or decrease by 2.5%, the fair value of this asset could decrease by $1.2 million or increase by $1.4 million, respectively. Should the expected royalties increase or decrease by 2.5%, the fair value of the asset could increase or decrease by $0.7 million, respectively. Should these discount rates increase or decrease by 2.5%, the fair value of the asset could decrease by $12.8 million or increase by $14.7 million, respectively. A third-party expert was engaged to assist management develop its original estimate of the expected future cash flows. The estimated fair value of the asset is subject to variation should those cash flows vary significantly from those estimates. The Company periodically assesses the expected future cash flows and to the extent such payments are greater or less than its initial estimates, or the timing of such payments is materially different than the original estimates, the Company will adjust the estimated fair value of the asset. Should the expected royalties increase or decrease by 2.5%, the fair value of the asset could increase or decrease by $5.4 million, respectively. Should this discount rate increase or decrease by 2.5%, the fair value of this asset could decrease by $1.4 million or increase by $1.6 million, respectively. Should the expected royalties increase or decrease by 2.5%, the fair value of the asset could increase or decrease by $0.4 million, respectively. 136000 74000 100000 100000 44100000 9100000 33700000 1300000 51100000 P8Y 36717000 32503000 3729000 409000 76000 1280000 0 341000 806000 133000 20450000 6275000 3154000 6040000 6104000 6209000 6240000 252540000 216690000 26080000 9200000 570000 55752000 40100000 36143000 8028000 11011000 570000 192500000 215823000 184187000 22351000 8791000 494000 54472000 36143000 7687000 10205000 437000 55800000 9300000 10600000 93000 764000 0 -66000 6500000 12200000 12200000 0 0 11288000 23864000 14529000 26190000 152300000 39500000 0 0 152330000 152330000 114312000 128058000 -126561000 -123940000 53873000 60400000 60425000 -14265000 -13246000 -13200000 14205000 3980000 -6000000 -945000 993000 -8679000 -15058000 -10764000 10278000 -1159000 5542000 -5789000 0 -5970000 1823000 5343000 -15263000 150000 -9851000 666000 -8000 1531000 2700000 6816000 740000 491000 0 0 215823000 54472000 5015000 9986000 2811000 6396000 2650000 2365000 5259000 4727000 2811000 0 5594000 802000 1032000 1264000 2063000 2529000 1031000 0 2062000 421000 1500000 4695000 4591000 2451000 344000 6311000 11353000 9147000 14801000 1717000 1771000 1119000 1677000 100000 161000 200000 -500000 -600000 -491000 276000 488000 1376000 3290000 6600000 1700000 397233000 233367000 1243123000 945995000 193109000 45723000 0 0 42000000 0 0 20040000 42000000 20040000 343000 405000 30682000 31133000 19536000 19636000 3000 574000 13000000 0.134 0.10 0.144 0.128 148028000 126131000 274159000 139052000 139052000 -32191000 -150051000 172853000 38194000 61612000 -19756000 60439000 62525000 -1195000 -891000 67680000 73499000 -1195000 -4624000 -112296000 943000 -1904000 -111335000 -110694000 4845000 -2491000 -113048000 0 -47000 0 0 60439000 67680000 -112296000 -110694000 7222000 137000 6263000 822000 9223000 143000 5606000 3474000 1532000 -3227000 -1435000 -3106000 70737000 19346000 1200000 50191000 70887000 19496000 1200000 50191000 53613000 58058000 17124000 12829000 243481000 117415000 126066000 120945000 120945000 71300000 0 18750000 0 1200000 51308000 71258000 77900000 0 19507000 0 1200000 57224000 77931000 53900000 2300000 40000000 1300000 40000000 35000000 150000000 5000000 42000000 1500000 1500000 1000000 50200000 31055000 57990000 171701000 205927000 112780000 131285000 -125126000 -120834000 3514000 2825000 13288000 25637000 0 0 0 -1181000 0 0 0 -1181000 -1181000 0 -47000 0 0 0 0 0 603000 0 0 0 -578000 0 0 0 -314000 44709000 47799000 -48062000 -37993000 -37993000 30000000 23604000 21000 0 19860000 0 10000000 705000 3915000 0.01 0.01 10000000 10000000 0 0 0 0 0 0 0.01 14386000 20628000 21400000 141700000 8142000 0 290200000 145700000 11400000 14400000 29045000 4116000 500000 700000 7000000 108169000 0 60439000 67633000 -112296000 -110694000 7222000 9223000 54000 43000 61400000 3500000 114300000 1200000 129000000 0 126447000 4281000 6047000 684000 1477000 945614000 811397000 44221000 0 10152000 12362000 21707000 3044000 1643000 679000 107000 615000 25879000 8732000 6371000 0 10776000 6590000 2757000 1294000 220000 2319000 6000000 5000000 6000000 2352000 0 1878000 1000000 4230000 1000000 143835000 125006000 2617000 16212000 189275000 157864000 2617000 28794000 46575000 14814000 5882000 25879000 85093000 30008000 10864000 44221000 83725000 16285000 96871000 30441000 12842000 1218000 23933000 4001000 18829000 31410000 31761000 55085000 3616000 6200000 5385000 10898000 2075000 2218000 2.38 481000 2.94 2.71 2305000 2266000 2.68 2.73 401000 2.50 -119000 3894000 961000 4855000 3.21 2.99 7.97 30000000 25000000 25000000 8700000 600000 13300000 6800000 8200000 25000000 1400000 30000000 19400000 23600000 845890000 712628000 2.89 2.44 2.25 2.87 2.89 0 29700000 0 28900000 77400000 214100000 2800000 26100000 14700000 29000 29000 103000 103000 0 156394000 160168000 146923000 149186000 155654000 159677000 146923000 149186000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides a summary of activity with respect to the Company&#8217;s sales allowances and accruals for the </font><font style="font-family:inherit;font-size:10pt;">six months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Discount and Distribution Fees</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Government Rebates and Chargebacks</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Assistance and Other Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Product Return</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2017:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,422</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,709</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,178</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,304</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,613</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allowances for current period sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,749</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,859</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,174</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,291</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,073</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allowances for prior period sales</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Credits/payments for current period sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,057</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,847</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,019</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,923</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Credits/payments for prior period sales</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,724</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,629</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,178</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(390</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,921</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at June 30, 2018:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,390</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,116</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,155</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,270</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,931</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ollows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:677px;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:341px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total change in fair value for the period included in earnings for royalty right assets held at the end of the reporting period</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,842</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83,725</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,933</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">96,871</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total change in fair value for the period included in earnings for liabilities held at the end of the reporting period</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,135</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,207</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,735</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,649</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Assets/Liabilities Measured and Recorded at Fair Value on a Nonrecurring Basis</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company remeasures the fair value of certain assets and liabilities upon the occurrence of certain events. Such assets consist of cost-method equity investments and long-lived assets, including property and equipment and intangible assets. During the three months ended June 30, 2018, the Company recorded an impairment charge of </font><font style="font-family:inherit;font-size:10pt;">$152.3 million</font><font style="font-family:inherit;font-size:10pt;"> for the Noden intangible asset related to the increased probability of a generic version of aliskiren being launched in the United States. As a result of this impairment charge, which was based on the estimated fair value of the assets, the remaining carrying value of the these intangible assets was determined to be </font><font style="font-family:inherit;font-size:10pt;">$40.1 million</font><font style="font-family:inherit;font-size:10pt;">. The fair value calculation included level 3 inputs. For additional information on the impairment charge, see note 10.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Assets/Liabilities Not Subject to Fair Value Recognition</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following tables present the fair value of assets and liabilities not subject to fair value recognition by level within the valuation h</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The carrying value and unamortized discount of the December 2021 Notes were as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(In thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June&#160;30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal amount of the December 2021 Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">150,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">150,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unamortized discount of liability component</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,055</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32,585</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net carrying value of the December 2021 Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120,945</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">117,415</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The carrying value and unamortized discount of the February 2018 Notes were as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(In thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June&#160;30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal amount of the February 2018 Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">126,447</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unamortized discount of liability component</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(381</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net carrying value of the February 2018 Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">126,066</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense for the December 2021 Notes on the Company&#8217;s Condensed Consolidated Statements of Income was as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:start;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(In thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contractual coupon interest</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,031</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,032</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,062</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,063</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of debt issuance costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of debt discount</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">135</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">131</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">269</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">261</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of conversion feature</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,626</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,469</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,225</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,899</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,811</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,650</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,594</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,259</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense for the February 2018 Notes on the Company&#8217;s Condensed Consolidated Statements of Income was as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:start;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(In thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:start;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contractual coupon interest</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,264</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">421</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,529</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:start;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of debt issuance costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">250</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">499</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:start;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of debt discount</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">851</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">293</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,699</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,365</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">802</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,727</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">. Accrued Liabilities</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued liabilities consist of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June&#160;30, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,046</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,043</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">344</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,451</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,904</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,741</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Legal</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,027</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">595</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued rebates, chargebacks and other revenue reserves</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,931</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,613</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Refund to manufacturer</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">647</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer advances</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,198</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent consideration, current</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,140</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,825</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,514</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,294</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,881</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides a summary of activity with respect to the Company&#8217;s sales allowances and accruals for the </font><font style="font-family:inherit;font-size:10pt;">six months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Discount and Distribution Fees</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Government Rebates and Chargebacks</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Assistance and Other Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Product Return</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2017:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,422</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,709</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,178</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,304</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,613</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allowances for current period sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,749</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,859</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,174</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,291</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,073</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allowances for prior period sales</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Credits/payments for current period sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,057</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,847</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,019</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,923</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Credits/payments for prior period sales</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,724</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,629</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,178</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(390</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,921</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at June 30, 2018:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,390</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,116</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,155</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,270</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,931</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited Condensed Consolidated Financial Statements of PDL Biopharma, Inc. and its subsidiaries (collectively, the &#8220;Company&#8221; or &#8220;PDL&#8221;) have been prepared in accordance with Generally Accepted Accounting Principles (United States) (&#8220;GAAP&#8221;) for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments), that management of the Company believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited Condensed Consolidated Financial Statements and related financial information should be read in conjunction with the Company&#8217;s audited Consolidated Financial Statements and the related notes thereto for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, included in its Annual Report on Form 10-K for the fiscal year ended December 31, 2017, filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on March 16, 2018. The Condensed Consolidated Balance Sheet at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, has been derived from the audited Consolidated Financial Statements at that date, but does not include all disclosures required by GAAP.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Significant Accounting Policies</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s significant accounting policies are described in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended&#160;December&#160;31, 2017. Summarized below are the accounting pronouncements adopted subsequent to December 31, 2017.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pro forma revenues</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,575</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">145,554</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85,093</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">194,820</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pro forma net income (loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(112,296</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59,351</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(110,694</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,124</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pro forma net income (loss) per share - basic</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.38</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.74</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.40</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pro forma net income (loss) per share - diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.76</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.38</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.74</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.40</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">19. Business Combinations</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">LENSAR TRANSACTION</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Description of the LENSAR Transaction</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2016, LENSAR filed the Chapter 11 case with the support of the Company, as its largest senior secured creditor under a credit agreement, as amended, that the Company and LENSAR had entered into in 2013. For more information regarding the credit agreement between the Company and LENSAR, please see Note 7. In January 2017, the Company agreed to provide debtor-in-possession financing of up to </font><font style="font-family:inherit;font-size:10pt;">$2.8 million</font><font style="font-family:inherit;font-size:10pt;"> in new advances to LENSAR so that it could continue to operate its business during the remainder of the Chapter 11 case. As part of the Chapter 11 case, LENSAR filed a Chapter 11 plan of reorganization, with the Company&#8217;s support, under which LENSAR would issue 100% of its equity securities to the Company in exchange for the cancellation of the Company&#8217;s claims as a secured creditor in the Chapter 11 case. Following consummation of the Plan, LENSAR would become an operating subsidiary of the Company and the Company provided LENSAR a new, senior-secured, first-priority term loan facility (the &#8220;Exit Facility&#8221;).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 26, 2017, the bankruptcy court approved the plan of reorganization. On May 11, 2017, LENSAR and the Company consummated the plan of reorganization and LENSAR emerged from bankruptcy. Pursuant to the plan of reorganization, the Company obtained control of 100% of the outstanding voting shares of LENSAR. All assets of the LENSAR bankruptcy estate re-vested in reorganized LENSAR free and clear of all liens, claims or charges.&#160;The consummation of the plan of reorganization related transactions effect binding and valid transfers to reorganized LENSAR with all rights, title and interest in the acquired assets. Upon consummation of the plan of reorganization, all debt owed to the Company was eliminated other than the Exit Facility. Liabilities to other creditors, including general unsecured creditors, were satisfied through the plan of reorganization.&#160; </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company concluded that the LENSAR transaction shall be accounted in accordance with ASC 805 that do not involve a transfer of consideration (&#8220;combinations by contract&#8221;) by applying the acquisition method.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value of Consideration Transferred</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contemporaneously with the cancellation of the Company&#8217;s notes receivable with a carrying value of </font><font style="font-family:inherit;font-size:10pt;">$43.9 million</font><font style="font-family:inherit;font-size:10pt;">, the Company acquired 100% equity interests in LENSAR, at fair value, for </font><font style="font-family:inherit;font-size:10pt;">$31.7 million</font><font style="font-family:inherit;font-size:10pt;">, resulting in a loss on extinguishment of notes receivable of </font><font style="font-family:inherit;font-size:10pt;">$10.6 million</font><font style="font-family:inherit;font-size:10pt;">. The fair value of the equity interest in LENSAR was determined primarily using the &#8220;income method,&#8221; which starts with a forecast of all expected future cash flows of the acquired business. The acquisition resulted in a gain on&#160;bargain purchase&#160;because the fair value of assets acquired and liabilities assumed exceeded the total of the fair value of the equity interest in LENSAR by approximately </font><font style="font-family:inherit;font-size:10pt;">$9.3 million</font><font style="font-family:inherit;font-size:10pt;">, which was recorded in the Consolidated Statement of Income for the year ended December 31, 2017.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Assets Acquired and Liabilities Assumed</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the fair values of the identifiable intangible assets acquired and liabilities assumed at the acquisition date (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:88%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,983</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,647</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,970</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net deferred tax assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,723</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total identifiable assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58,323</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,673</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities assumed</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,673</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss on derecognition of notes receivables</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,615</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gain on bargain purchase, net of loss on extinguishment of notes receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,309</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total fair value of consideration</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,726</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">______________</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font><font style="font-family:inherit;font-size:10pt;"> As of the effective date of the transaction, identifiable intangible assets are required to be measured at fair value.&#160; The fair value measurement is based on significant inputs that are unobservable in the market and thus represents a Level 3 measurement. The Company used an income approach to estimate the preliminary fair value of the intangibles which includes technology, trademarks and customer relationships. The assumptions used to estimate the cash flows of the business included a discount rate of 16%, estimated gross margins ranging from 37-72%, income tax rate of 35%, and operating expenses consisting of direct costs based on the anticipated level of revenues.&#160;&#160;The intangible assets have a weighted-average useful life of approximately 15.0 years.&#160;The intangible assets for acquired technology and trademarks are being amortized over their estimated useful lives using the straight-line method of amortization. The intangible assets for customer relationship are being amortized using a double-declining method of amortization as such method better represents the economic benefits to be obtained.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Pro Forma Impact of Business Combination</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table represents the unaudited consolidated financial information for the Company on a pro forma basis for the three and </font><font style="font-family:inherit;font-size:10pt;">six months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, assuming that the LENSAR transaction had closed on January 1, 2016. The historical financial information has been adjusted to give effect to pro forma items that are directly attributable to the acquisitions and are expected to have a continuing impact on the consolidated results. Additionally, the following table sets forth unaudited financial information and has been compiled from historical financial statements and other information, but is not necessarily indicative of the results that actually would have been achieved had the transactions occurred on the dates indicated or that may be achieved in the future.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pro forma revenues</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,575</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">145,554</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85,093</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">194,820</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pro forma net income (loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(112,296</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59,351</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(110,694</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,124</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pro forma net income (loss) per share - basic</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.38</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.74</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.40</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pro forma net income (loss) per share - diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.76</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.38</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.74</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.40</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The unaudited pro forma consolidated results include historical revenues and expenses of assets acquired in the LENSAR Transaction with the following adjustments:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adjustment to recognize incremental amortization expense based on the fair value of intangibles acquired;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Elimination of non-recurring charges directly related to the acquisition that were included in the historical results of operations for the Company; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adjustment to recognize pro forma income tax based on income tax benefit on the amortization of intangible asset at the statutory tax rate of the United States, at such time (35.0%), and the income tax benefit on the interest expense at the statutory tax rate of the United States, at such time (35.0%).</font></div></td></tr></table></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5. Cash, Cash Equivalents and Short-term Investments</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company had invested its excess cash balances primarily in cash, money market funds and a corporate equity security. The Company&#8217;s securities are classified as available-for-sale and are carried at estimated fair value, with unrealized gains and losses reported in &#8220;Accumulated other comprehensive income&#8221; in stockholders&#8217; equity, net of estimated taxes. See Note 4 for fair value measurement information. The cost of securities sold is based on the specific identification method. To date, the Company has not experienced credit losses on investments in these instruments, and it does not require collateral for its investment activities.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following tables summarize the Company&#8217;s cash and available-for-sale securities&#8217; amortized cost, gross unrealized gains and fair value by significant investment category reported as cash and cash equivalents, or short-term investments as of&#160;</font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and&#160;December&#160;31, 2017:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21" rowspan="1"></td></tr><tr><td style="width:46%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Reported as:</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;Unrealized Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;Estimated Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;Cash and Cash Equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Short-Term Investments</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,548</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,548</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,548</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">324,105</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">324,105</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">324,105</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">395,653</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">395,653</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">395,653</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109,703</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109,703</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109,703</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">417,563</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">417,563</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">417,563</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,353</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,495</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,848</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,848</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">530,619</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,495</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">532,114</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">527,266</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,848</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognized </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;"> of gains on sales of available-for-sale securities in the three and six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, respectively. The Company did not recognize any gains or losses on sales of available-for-sale securities in the three and six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The unrealized gains on investments included in &#8220;Other comprehensive income (loss), net of tax&#8221; was </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, and December 31, 2017, respectively.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">12. Commitments and Contingencies</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Wellstat Litigation</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 4, 2015, the Company filed in the Supreme Court of New York a motion for summary judgment in lieu of complaint which requested that the court enter judgment against Wellstat Diagnostics Guarantors for the total amount due on the Wellstat Diagnostics debt, plus all costs and expenses including lawyers&#8217; fees incurred by the Company in enforcement of the related guarantees. On July 29, 2016, the court issued its Memorandum of Decision granting the Company&#8217;s motion for summary judgment and denying the Wellstat Diagnostics Guarantors&#8217; cross-motion for summary judgment seeking a determination that they were no longer liable under the guarantees. The Supreme Court of New York held that the Wellstat Diagnostics Guarantors are liable for all &#8220;Obligations&#8221; owed by Wellstat Diagnostics to the Company. It did not set a specific dollar amount due, but ordered that a judicial hearing officer or special referee be designated to determine the amount of the Obligations owing, and awarded the Company its attorneys&#8217; fees and costs in an amount to be determined. On July 29, 2016, the Wellstat Diagnostics Guarantors filed a notice of appeal from the Memorandum of Decision to the Appellate Division of the Supreme Court of New York. On February 14, 2017, the Appellate Division reversed the summary judgment decision of the Supreme Court in the Company&#8217;s favor, but affirmed the denial of the Wellstat Guarantors&#8217; cross-motion for summary judgment. The Appellate Division determined that the action was inappropriate for summary judgment pursuant to New York Civil Practice Law &amp; Rules section 3213 on procedural grounds, but specifically made no determination regarding whether the Company was entitled to a judgment on the merits. Pursuant to this decision, the action has been remanded to the Supreme Court for further proceedings on the merits. The proceeding is being conducted as a plenary proceeding, with both parties having the opportunity to take discovery and file dispositive motions in accordance with New York civil procedure.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Noden Pharma DAC v Anchen Pharmaceuticals, Inc. et al</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 12, 2017, Noden filed a complaint against Anchen Pharmaceuticals, Inc. (&#8220;Anchen&#8221;) and Par Pharmaceutical (&#8220;Par&#8221;) for infringement of the 595 Patent based on their submission of an ANDA seeking authorization from the FDA to market a generic version of aliskiren hemifumarate tablets, 150 mg and 300 mg, in the United States. Noden&#8217;s suit triggered a 30-month stay of FDA approval of that application under the Hatch Waxman Act. Par filed a counterclaim seeking a declaratory judgment that their proposed generic version of aliskiren hemifumarate hydrochlorothiazide tablets (150 mg eq. base/12.5 mg HCT, 150 mg eq. base/25 mg HCT, 300 mg eq. base/12.5 mg HCT, and 300 mg eq. base/25 mg HCT), described in a separate ANDA submitted by Par to FDA, alleging noninfringement of U.S. Patent No. 8,618,172 (the &#8220;&#8216;172 Patent&#8221;), also owned by Noden. This case was filed in the United States District Court for the District of Delaware. In March 2018, each of the parties to the proceeding filed a joint stipulation of dismissal of the defendants&#8217; counterclaim seeking a declaratory judgment of non-infringement of the &#8216;172 Patent. In the stipulation, Anchen and Par agreed that they will not seek, or otherwise join or assist in, any post-grant review, including </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">inter partes</font><font style="font-family:inherit;font-size:10pt;"> review, of the &#8216;172 Patent or U.S. Patent No. 9,023,893 (the &#8220;893 Patent&#8221;). The defendants further stipulated that they will not seek approval of Par&#8217;s ANDA or submit any other ANDA seeking approval to market aliskiren hemifumarate hydrochlorothiazide prior to the expiration of the &#8216;172 Patent in July of 2028. Both the &#8216;172 Patent and the &#8216;893 Patent are listed in the Orange Book for Tekturna HCT.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 8, 2018, Noden and Anchen entered into the Settlement Agreement. Under the Settlement Agreement, the parties agreed to file a stipulation of dismissal with the court to facilitate dismissal of the litigation in its entirety, with prejudice. In the Settlement Agreement, Noden granted Anchen a non-exclusive, royalty free, fully paid up and non-transferable license to manufacture and commercialize in the United States a generic version of aliskiren which is described in Anchen&#8217;s ANDA, and Anchen agreed not to commercialize its generic version of aliskiren prior to March 1, 2019. The license grant excludes certain formulations covered by the &#8216;595 patent which closely relate to the commercial formulation of Tekturna marketed by Noden. The Settlement Agreement includes a release by each party for liabilities associated with the litigation and an acknowledgement from Anchen that the &#8216;595 patent claims are valid and enforceable. Anchen&#8217;s ANDA has not yet been approved by the FDA and any commercialization by Anchen will be subject to their ability to obtain such approval.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Legal Proceedings</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, the Company is involved in lawsuits, arbitrations, claims, investigations and proceedings, consisting of intellectual property, commercial, employment and other matters, which arise in the ordinary course of business. The Company makes provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Such provisions are reviewed at least quarterly and adjusted to reflect the impact of settlement negotiations, judicial and administrative rulings, advice of legal counsel, and other information and events pertaining to a particular case. Litigation is inherently unpredictable. If any unfavorable ruling were to occur in any specific period, there exists the possibility of a material adverse impact on the results of the Company&#8217;s operations of that period and on its cash flows and liquidity.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Lease Guarantee</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the spin-off (the &#8220;Spin-Off&#8221;) by the Company of Facet Biotech Corporation (&#8220;Facet&#8221;), the Company entered into amendments to the leases for the Company&#8217;s former facilities in Redwood City, California, under which Facet was added as a co-tenant, and a Co-Tenancy Agreement, under which Facet agreed to indemnify us for all matters related to the leases attributable to the period after the Spin-Off date. As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the total lease payments for the duration of the guarantee, which runs through December 2021, are approximately </font><font style="font-family:inherit;font-size:10pt;">$39.5 million</font><font style="font-family:inherit;font-size:10pt;">. In April 2010, Abbott Laboratories acquired Facet and later renamed the entity AbbVie Biotherapeutics, Inc. (&#8220;AbbVie&#8221;). If AbbVie were to default under its lease obligations, the Company could be held liable by the landlord as a co-tenant and, thus, the Company has in substance guaranteed the payments under the lease agreements for the Redwood City facilities.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company prepared a discounted, probability weighted cash flow analysis to calculate the estimated fair value of the lease guarantee as of the Spin-Off. The Company was required to make assumptions regarding the probability of Facet&#8217;s default on the lease payment, the likelihood of a sublease being executed and the times at which these events could occur. These assumptions are based on information that the Company received from real estate brokers and the then-current economic conditions, as well as expectations of future economic conditions. The fair value of this lease guarantee was charged to additional paid-in capital upon the Spin-Off and any future adjustments to the carrying value of the obligation will also be recorded in additional paid-in capital.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has recorded a liability of </font><font style="font-family:inherit;font-size:10pt;">$10.7 million</font><font style="font-family:inherit;font-size:10pt;"> on its Condensed Consolidated Balance Sheets as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, related to this guarantee. In future periods, the Company may adjust this liability for any changes in the ultimate outcome of this matter that are both probable and estimable.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Purchase Obligations</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Noden and Novartis entered into a supply agreement pursuant to which Novartis will manufacture and supply to Noden a bulk tableted form of the Noden Products, and for the additional supply of active pharmaceutical ingredient form, for specified periods of time prior to the transfer of manufacturing responsibilities for the Noden Products to another manufacturer. The supply agreement may be terminated by either party for material breach that remains uncured for a specified time period. Noden has placed firm orders for bulk product of $14.4 million, which will be fulfilled within the next twelve months. Under the terms of the supply agreement, Noden is committed to purchase certain minimum quantities of bulk product and active pharmaceutical ingredient that would amount to approximately </font><font style="font-family:inherit;font-size:10pt;">$114.3 million</font><font style="font-family:inherit;font-size:10pt;"> over the next twenty-four months if fulfilled, of which </font><font style="font-family:inherit;font-size:10pt;">$61.4 million</font><font style="font-family:inherit;font-size:10pt;"> is committed over the next twelve months. While the supply agreement provides that the parties will agree to reasonable accommodations with respect to changes in firm orders, the Company expects that Noden will meet the requirements of the supply agreement, unless otherwise negotiated. The commitments in the supply agreement terminate upon transfer to another manufacturer.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">LENSAR and Coherent, Inc. entered into an Original Equipment Manufacturer agreement pursuant to which Coherent, Inc. will manufacture and supply to LENSAR Staccato Lasers. The supply agreement commits LENSAR to a minimum purchase obligation of approximately </font><font style="font-family:inherit;font-size:10pt;">$3.5 million</font><font style="font-family:inherit;font-size:10pt;"> over the next twenty-four months, of which </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;"> is committed over the next twelve months. The Company expects that LENSAR will meet this requirement. For more information about the LENSAR transaction, see Note 19.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Escrow Receivable</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 21, 2017, the Company entered into the kal&#233;o Note Sale Agreement, pursuant to which the Company sold its entire interest in the kal&#233;o Note.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the kal&#233;o Note Sale Agreement, the purchaser paid to the Company an amount equal to 100% of the then outstanding principal, a premium of </font><font style="font-family:inherit;font-size:10pt;">1%</font><font style="font-family:inherit;font-size:10pt;"> of such amount and accrued interest under the kal&#233;o Notes, for an aggregate cash purchase price of </font><font style="font-family:inherit;font-size:10pt;">$141.7 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the terms of the kal&#233;o Note Sale Agreement, </font><font style="font-family:inherit;font-size:10pt;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;"> of the aggregate purchase price was deposited into an escrow account as a potential payment against certain contingencies, which expires on the 18th month anniversary of the closing date. Upon the expiration of escrow period, the escrow agent is required to release remaining funds to the Company.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company does not expect there to be any claims by the purchaser under the escrow agreement. However, in the event that such a claim is made, and if successful, the amount of such a claim up to </font><font style="font-family:inherit;font-size:10pt;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;"> would be released from the escrow account to the purchaser, which amount would be reduced from the amount released to the Company at the end of the 18-month escrow period. As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company is not aware of any claims by the purchaser that would reduce the escrow receivable.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">18. Accumulated Other Comprehensive Income</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Comprehensive income is comprised of net income (loss) and other comprehensive income (loss). The Company includes unrealized net gains (losses) on investments held in its available-for-sale securities in other comprehensive income (loss), and present the amounts net of tax. The Company&#8217;s other comprehensive income (loss) is included in the Company&#8217;s Condensed Consolidated Statements of Comprehensive Income.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The balance of accumulated other comprehensive income, net of tax, was as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized gains (losses) on available-for-sale securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Accumulated Other Comprehensive Income (Loss)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,181</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,181</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Activity for the six months ended June 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,181</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,181</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ending Balance at June 30, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6. Concentration of Credit Risk</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Product Line Concentration</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The percentage of total revenue recognized, which individually accounted for 10% or more of the Company&#8217;s total revenues, was as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:48%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Licensee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Product Name</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Biogen</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Tysabri</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depomed</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Glumetza, Janumet XR, Jentadueto XR, Synjardy XR and Invokamet XR</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">N/A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Tekturna, Tekturna HCT, Rasilez and Rasilez HCT</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">LENSAR</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">LENSAR Laser System</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1%</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides information about receivables, contract assets and contract liabilities from contracts with customers:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:66%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">January 1, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Receivables, current and non-current, net</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,970</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,771</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,235</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,114</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,084</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Receivables, Net</font><font style="font-family:inherit;font-size:10pt;">&#8212;Receivables, net, include amounts billed and currently due from customers. The amounts due are stated at their net estimated realizable value. The Company maintains an allowance for doubtful accounts to provide for the estimated amount of receivables that will not be collected. The allowance is based upon an assessment of customer creditworthiness, historical payment experience, the age of outstanding receivables and collateral to the extent applicable.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contract assets</font><font style="font-family:inherit;font-size:10pt;">&#8212;The Company&#8217;s contract assets represent revenue recognized for performance obligations completed before an unconditional right to payment exists, and therefore invoicing or associated reporting from the customer regarding the computation of the net product sales has not yet occurred. The Company classifies contract assets as current based on the timing of when it expects to receive payment and is included in prepaid and other current assets in the Company&#8217;s consolidated balance sheets.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:52%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Medical Devices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pharmaceutical</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract assets at January 1, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract assets recognized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,235</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,235</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract assets at June 30, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,235</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,235</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contract Liabilities</font><font style="font-family:inherit;font-size:10pt;">&#8212;The Company&#8217;s contract liabilities consist of deferred revenue for products sold to customers for which the performance obligation has not been completed by the Company. The Company classifies deferred revenue as current or noncurrent based on the timing of when it expects to recognize revenue. The noncurrent portion of deferred revenue is included in other long-term liabilities in the Company&#8217;s consolidated balance sheets.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Medical Devices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pharmaceutical</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liabilities at January 1, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,391</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,693</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,084</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">547</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,880</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,427</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amounts recognized into revenue</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(704</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,693</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,397</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liabilities at June 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,234</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,880</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,114</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> disaggregates its revenue from contracts with customers by segment and geographic location, as the Company believes it best depicts how the nature, amount, timing and uncertainty of its revenue and cash flows are affected by economic factors. In the following table, revenue is disaggregated by segment and primary geographical market for the three and six months ended June 30, 2018:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Medical Devices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pharmaceutical</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Medical Devices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pharmaceutical</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Primary geographical markets:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">North America</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">615</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,776</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,319</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,707</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Europe</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">679</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,371</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,294</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,362</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Asia</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,643</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,732</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,757</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,152</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">107</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">220</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenue from contracts with customers</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">1</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,044</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,879</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,590</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,221</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">_______________</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">1</sup></font><font style="font-family:inherit;font-size:10pt;"> The table above does not include Medical Device lease revenue of </font><font style="font-family:inherit;font-size:10pt;">$2.8 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$4.3 million</font><font style="font-family:inherit;font-size:10pt;"> for the three and six months ended June 30, 2018, respectively.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">15. Stock-Based Compensation</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company grants restricted stock awards and stock options pursuant to a stockholder approved stock-based incentive plan. This incentive plan is described in further detail in Note 16, Stock-Based Compensation, of Notes to the Condensed Consolidated Financial Statements in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the Company&#8217;s stock option and restricted stock award activity during the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">six months ended June 30, 2018</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="15" rowspan="1"></td></tr><tr><td style="width:50%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restricted Stock Awards</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(In thousands except per share amounts)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of Shares Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of Shares Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Grant-date Fair Value Per Share</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">961</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,305</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.68</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,894</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.94</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">481</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.71</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested or released</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(401</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited or canceled</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(119</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.38</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at June 30, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,855</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.99</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,266</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.73</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">. Net Income (loss) per Share</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Income (Loss) per Basic and Diluted Share:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="vertical-align:top;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;vertical-align:top;">&#160;</font><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;vertical-align:top;">(in thousands except per share amounts)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Numerator</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) attributable to PDL&#8217;s shareholders used to compute net income per basic and diluted share</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(112,296</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,439</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(110,694</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,680</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Denominator</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total weighted average shares used to compute net income attributable to PDL&#8217;s shareholders, per basic share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">146,923</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">155,654</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">149,186</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">159,677</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock outstanding</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">740</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">491</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares used to compute net income (loss) attributable to PDL&#8217;s shareholders, per diluted share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">146,923</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">156,394</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">149,186</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">160,168</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net income (loss) attributable to PDL&#8217;s shareholders per share - basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.76</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.39</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.74</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.42</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net income (loss) attributable to PDL&#8217;s shareholders per share - diluted</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.39</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.74</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company computes net income per diluted share using the sum of the weighted-average number of common and common equivalent shares outstanding. Common equivalent shares used in the computation of net income per diluted share include shares that may be issued pursuant to outstanding stock options and restricted stock awards, the 4.0% Convertible Senior Notes due February 1, 2018 (the &#8220;February 2018 Notes&#8221;) that were repaid on February 1, 2018, and the 2.75% Convertible Senior Notes due December 1, 2021 (the &#8220;December 2021 Notes&#8221;), in each case, on a weighted average basis for the period that the notes were outstanding, including the effect of adding back interest expense and the underlying shares using the if converted method.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">December 2021 Notes Capped Call Potential Dilution</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2016, the Company issued </font><font style="font-family:inherit;font-size:10pt;">$150.0 million</font><font style="font-family:inherit;font-size:10pt;"> in aggregate principal of the December 2021 Notes, which provide in certain situations for the conversion of the outstanding principal amount of the December 2021 Notes into shares of the Company&#8217;s common stock at a predefined conversion rate. For additional information on the conversion rates on the Company&#8217;s convertible debt, see Note 13. In conjunction with the issuance of the December 2021 Notes, the Company entered into a capped call transaction with a hedge counterparty. The capped call transaction is expected generally to reduce the potential dilution, and/or offset, to an extent, the cash payments the Company may choose to make in excess of the principal amount, upon conversion of the December 2021 Notes. The Company has excluded the capped call transaction from the net income (loss) per diluted share computation as such securities would have an antidilutive effect and those securities should be considered separately rather than in the aggregate in determining whether their effect on net income (loss) per diluted share would be dilutive or antidilutive. For additional information regarding the capped call transaction related to the Company&#8217;s December 2021 Notes, see Note 13.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Anti-Dilutive Effect of Restricted Stock Awards and Stock Options</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the three months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, the Company excluded approximately </font><font style="font-family:inherit;font-size:10pt;">1.0 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2.2 million</font><font style="font-family:inherit;font-size:10pt;"> shares underlying restricted stock awards, respectively, and for the </font><font style="font-family:inherit;font-size:10pt;">six months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, the Company excluded approximately </font><font style="font-family:inherit;font-size:10pt;">1.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2.0 million</font><font style="font-family:inherit;font-size:10pt;"> shares underlying restricted stock awards, respectively, calculated on a weighted average basis, from its net income (loss) per diluted share calculations because their effect was anti-dilutive.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the three months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, the Company excluded approximately </font><font style="font-family:inherit;font-size:10pt;">4.9 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;"> shares underlying outstanding stock options, respectively, and for the </font><font style="font-family:inherit;font-size:10pt;">six months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, the Company excluded approximately </font><font style="font-family:inherit;font-size:10pt;">4.9 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;"> shares underlying outstanding stock options, respectively, calculated on a weighted average basis, from its net income (loss) per diluted share calculations because their effect was anti-dilutive.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following tables summarize the changes in Level 3 assets and the gains and losses included in earnings for the </font><font style="font-family:inherit;font-size:10pt;">six months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:10px;" rowspan="1" colspan="1"></td><td style="width:505px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:62px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:62px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurements Using Significant Unobservable Inputs (Level 3) - Royalty Rights Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Royalty Rights - </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">At Fair Value</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Fair value as of December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">349,223</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total net change in fair value for the period</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Change in fair value of royalty rights - at fair value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">23,933</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Proceeds from royalty rights - at fair value</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(37,993</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total net change in fair value for the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(14,060</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Fair value as of June 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">335,163</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:332px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:95px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:106px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:99px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurements Using Significant Unobservable Inputs (Level 3) - Royalty Rights Assets</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value as of</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Royalty Rights -</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value as of</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Change in Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">June 30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Depomed</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">232,038</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(17,967</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">214,071</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">VB</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14,380</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">284</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14,664</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">U-M</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">26,769</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(620</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">26,149</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">AcelRx</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">72,894</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,539</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">77,433</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Avinger</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">396</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(396</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">KYBELLA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,746</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">100</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,846</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">349,223</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(14,060</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">335,163</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:684px;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:10px;" rowspan="1" colspan="1"></td><td style="width:286px;" rowspan="1" colspan="1"></td><td style="width:286px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:82px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurements Using Significant Unobservable Inputs (Level 3) - Liabilities</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Contingent Consideration</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Fair value as of December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(42,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total net change in fair value for the period</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">22,735</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Fair value of financial instruments acquired</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,560</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Settlement of financial instrument</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">785</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Fair value as of June 30, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(20,040</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4. Fair Value Measurements</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the Company&#8217;s financial instruments are estimates of the amounts that would be received if the Company were to sell an asset or pay to transfer a liability in an orderly transaction between market participants at the measurement date or exit price. The assets and liabilities are categorized and disclosed in one of the following three categories:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1 &#8211; based on quoted market prices in active markets for identical assets and liabilities;</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2 &#8211; based on quoted market prices for similar assets and liabilities, using observable market-based inputs or unobservable market-based inputs corroborated by market data; and</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3 &#8211; based on unobservable inputs using management&#8217;s best estimate and assumptions when inputs are unavailable.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Assets/Liabilities Measured and Recorded at Fair Value on a Recurring Basis</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the fair value of the Company&#8217;s financial instruments measured at fair value on a recurring basis by level within the valuation hierarchy:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="33" rowspan="1"></td></tr><tr><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June&#160;30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial assets:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">324,105</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">324,105</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">417,563</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">417,563</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,848</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,848</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">103</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">103</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Royalty rights - at fair value</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">335,163</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">335,163</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">349,223</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">349,223</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">324,105</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">103</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">335,163</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">659,371</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">422,411</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">349,223</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">771,663</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial liabilities:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent consideration, current</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">1</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,140</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,140</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent consideration, non-current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,900</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,900</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,040</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,040</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;___________________</font></div><div style="line-height:120%;text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">1</sup></font><font style="font-family:inherit;font-size:10pt;"> Contingent consideration, current is classified as &#8220;Accrued liabilities&#8221; on the Condensed Consolidated Balance Sheet. See Note 11 for details.</font></div><div style="line-height:120%;text-align:left;padding-left:60px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There have been </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> transfers between levels during the six month periods ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and December 31, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">. The Company recognizes transfers between levels on the date of the event or change in circumstances that caused the transfer.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Corporate Securities</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate securities consisted primarily of U.S. corporate equity holdings. The fair value of corporate securities is estimated using market quoted prices.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Warrants</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants consist primarily of purchased call options to buy U.S. corporate equity holdings and derivative assets acquired as part of note receivable investments. The fair value of the warrants is estimated using recently quoted market prices or estimated fair value of the underlying equity security and the Black-Scholes option pricing model.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Royalty Rights - At Fair Value</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Depomed Royalty Agreement</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October&#160;18, 2013, the Company entered into the Royalty Purchase and Sale Agreement (the &#8220;Depomed Royalty Agreement&#8221;) with Depomed, Inc. and Depo DR Sub, LLC (together, &#8220;Depomed&#8221;), whereby the Company acquired the rights to receive royalties and milestones payable on sales of Type 2 diabetes products licensed by Depomed in exchange for a </font><font style="font-family:inherit;font-size:10pt;">$240.5 million</font><font style="font-family:inherit;font-size:10pt;"> cash payment. Total consideration was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$241.3 million</font><font style="font-family:inherit;font-size:10pt;">, which was comprised of the </font><font style="font-family:inherit;font-size:10pt;">$240.5 million</font><font style="font-family:inherit;font-size:10pt;"> cash payment to Depomed and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;"> in transaction costs.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The rights acquired include Depomed&#8217;s royalty and milestone payments accruing from and after October 1, 2013: (a) from Santarus, Inc. (&#8220;Santarus&#8221;) (which was subsequently acquired by Salix Pharmaceuticals, Inc. (&#8220;Salix&#8221;), which itself was acquired by Valeant Pharmaceuticals International, Inc. (which was subsequently acquired by Bausch Health Companies Inc.) (&#8220;Bausch Health&#8221;)) with respect to sales of Glumetza (metformin HCL extended-release tablets) in the United States; (b) from Merck &amp; Co., Inc. with respect to sales of Janumet</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> XR (sitagliptin and metformin HCL extended-release tablets); (c) from Janssen Pharmaceutica N.V. with respect to potential future development milestones and sales of its recently approved fixed-dose combination of Invokana</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> (canagliflozin) and extended-release metformin tablets, marketed as Invokamet XR</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">; (d) from Boehringer Ingelheim with respect to potential future development milestones and sales of the investigational fixed-dose combinations of drugs and extended-release metformin subject to Depomed&#8217;s license agreement with Boehringer Ingelheim, including its recently approved products, Jentadueto XR</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> and Syngardy XR</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">; and (e) from LG Life Sciences and Bausch Health for sales of extended-release metformin tablets in Korea and Canada, respectively.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the Depomed Royalty Agreement, the Company receives all royalty and milestone payments due under license agreements between Depomed and its licensees until the Company has received payments equal to two times the cash payment it made to Depomed, after which all net payments received by Depomed will be shared evenly between the Company and Depomed.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Depomed Royalty Agreement terminates on the third anniversary following the date upon which the later of the following occurs: (a) October 25, 2021, or (b) at such time as no royalty payments remain payable under any license agreement and each of the license agreements has expired by its terms.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, the Company determined that its royalty purchase interest in Depo DR Sub, LLC represented a variable interest in a variable interest entity. However, the Company does not have the power to direct the activities of Depo DR Sub, LLC that most significantly impact Depo DR Sub, LLC&#8217;s economic performance and is not the primary beneficiary of Depo DR Sub, LLC; therefore, Depo DR Sub, LLC is not subject to consolidation by the Company.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The financial asset acquired represents a single unit of accounting. The fair value of the financial asset acquired was determined by using a discounted cash flow analysis related to the expected future cash flows to be generated by each licensed product. This financial asset is classified as a Level 3 asset within the fair value hierarchy, as the Company&#8217;s valuation utilized significant unobservable inputs, including estimates as to the probability and timing of future commercialization for products not yet approved by regulatory agencies outside of the United States. The discounted cash flows are based upon expected royalties from sales of licensed products over a nine-year period. The discount rates utilized range from </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">24%</font><font style="font-family:inherit;font-size:10pt;">. Significant judgment is required in selecting appropriate discount rates. At </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, an evaluation was performed to assess those rates and general market conditions potentially affecting the fair market value, of the financial asset. </font><font style="font-family:inherit;font-size:10pt;">Should these discount rates increase or decrease by 2.5%, the fair value of the asset could decrease by $12.8 million or increase by $14.7 million, respectively. A third-party expert was engaged to assist management develop its original estimate of the expected future cash flows. The estimated fair value of the asset is subject to variation should those cash flows vary significantly from those estimates. The Company periodically assesses the expected future cash flows and to the extent such payments are greater or less than its initial estimates, or the timing of such payments is materially different than the original estimates, the Company will adjust the estimated fair value of the asset. Should the expected royalties increase or decrease by 2.5%, the fair value of the asset could increase or decrease by $5.4 million, respectively.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">When the Company acquired the Depomed royalty rights, Glumetza was marketed by Santarus. In January 2014, Salix acquired Santarus and assumed responsibility for commercializing Glumetza, which was generally perceived to be a positive development because of Salix&#8217;s larger sales force and track record in the successful commercialization of therapies. In late 2014, Salix made a number of disclosures relating to an excess of supply at the distribution level of Glumetza and other drugs that it commercialized and the practices leading to this excess of supply which were under review by Salix&#8217;s audit committee in relation to the related accounting practices. Because of these disclosures and the Company&#8217;s lack of direct access to information as to the levels of inventory of Glumetza in the distribution channels, the Company commenced a review of all public statements by Salix, publicly available historical third-party prescription data, analyst reports and other relevant data sources. The Company also engaged a third-party expert to specifically assess estimated inventory levels of Glumetza in the distribution channel and to ascertain the potential effects those inventory levels may have on expected future cash flows. Salix was acquired by Bausch Health in early April 2015. In mid-2015, Bausch Health implemented two price increases on Glumetza. At year-end 2015, a third-party expert was engaged by the Company to assess the impact of the Glumetza price adjustments and near-term market entrance of generic equivalents to the expected future cash flows. Based on the analysis performed, management revised the underlying assumptions used in the discounted cash flow analysis at year-end 2015. In February and August 2016, a total of three generic equivalents to Glumetza were approved to enter the market. In February 2016, Lupin Pharmaceuticals, Inc. and in August 2017, Teva Pharmaceutical Industries, Ltd., each launched a generic equivalent approved product. To date, the third generic equivalent to Glumetza has not launched.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2017, the Company received notification that a subsidiary of Bausch Health had launched an authorized generic equivalent product in February 2017, and the Company received royalties on such authorized generic equivalent product under the same terms as the branded Glumetza product, retroactive to February 2017. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At December 31, 2017, management re-evaluated, with assistance of a third-party expert, the market share data, the gross-to-net revenue adjustment assumptions and Glumetza demand data, including the delay in launch of additional generic equivalent products and the entry of an authorized generic product by Bausch Health. These data and assumptions are based on available but limited information. At </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, management updated the expected future cash flows based on the current period demand and supply data of Glumetza and the authorized generic equivalent product launched by Bausch Health.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company&#8217;s discounted cash flow analysis reflects its expectations as to the amount and timing of future cash flows up to the valuation date, including future cash flows for the authorized generic equivalent product. The Company continues to monitor whether the generic competition further affects sales of Glumetza and thus royalties on such sales paid to the Company, and the impact of the launched authorized generic equivalent. Due to the uncertainty around Bausch Health&#8217;s marketing and pricing strategy, as well as the recent generic competition and limited historical demand data after generic market entrance, the Company may need to further evaluate future cash flows in the event of more rapid reduction or increase in market share of Glumetza and its authorized generic equivalent product and/or a further erosion in net pricing. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, at the Company&#8217;s request and pursuant to the Depomed Royalty Agreement, Depomed exercised its audit right with respect to Glumetza royalties. The independent auditor engaged to perform the royalty audit completed it in July 2017, and based upon the results of the audit, Depomed, on behalf of the Company, filed a lawsuit on September 7, 2017, against Bausch Health and one of its subsidiaries, claiming damages for unpaid royalties, fees and interest.&#160;Bausch Health, Depomed and the Company entered into a settlement agreement on October 27, 2017 whereby the parties agreed to dismiss the litigation, with prejudice, and Bausch Health agreed to pay to Depomed </font><font style="font-family:inherit;font-size:10pt;">$13.0 million</font><font style="font-family:inherit;font-size:10pt;">.&#160;The full amount of the settlement payment was transferred to the Company under the terms of the Depomed Royalty Agreement in November 2017.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 31, 2016, the Company obtained a notification indicating that the U.S. Food and Drug Administration (&#8220;FDA&#8221;) approved Jentadueto XR for use in patients with Type 2 diabetes. In June 2016, the Company received a </font><font style="font-family:inherit;font-size:10pt;">$6.0 million</font><font style="font-family:inherit;font-size:10pt;"> FDA approval milestone pursuant to the terms of the Depomed Royalty Agreement. The product approval was earlier than initially expected. Based on the FDA approval and anticipated timing of the product launch, the Company adjusted the timing of future cash flows and discount rate used in the discounted cash flow model at June 30, 2016. As of December 31, 2017, management re-evaluated, the cash flow assumptions for Jentadueto XR and revised the discounted cash flow model. As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company&#8217;s discounted cash flow analysis reflects its expectations as to the amount and timing of future cash flows up to the valuation date.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 21, 2016, the Company obtained a notification indicating that the FDA approved Invokamet XR for use in patients with Type 2 diabetes. The product approval triggered a </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;"> approval milestone payment to the Company pursuant to the terms of the Depomed Royalty Agreement. Based on the FDA approval and timing of the product launch, the Company adjusted the timing of future cash flows and discount rate used in the discounted cash flow model.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 13, 2016, the Company obtained a notification indicating that the FDA approved Synjardy XR for use in patients with Type 2 diabetes. The product approval triggered a </font><font style="font-family:inherit;font-size:10pt;">$6.0 million</font><font style="font-family:inherit;font-size:10pt;"> approval milestone payment to the Company pursuant to the terms of the Depomed Royalty Agreement. Based on the FDA approval and the April 2017 launch of Synjardy XR by Boehringer Ingelheim, the Company adjusted the timing of future cash flows and discount rate used in the discounted cash flow model.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the fair value of the asset acquired as reported in the Company&#8217;s Condensed Consolidated Balance Sheet was </font><font style="font-family:inherit;font-size:10pt;">$214.1 million</font><font style="font-family:inherit;font-size:10pt;"> and the maximum loss exposure was </font><font style="font-family:inherit;font-size:10pt;">$214.1 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Viscogliosi Brothers Royalty Agreement</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 26, 2014, the Company entered into a Royalty Purchase and Sale Agreement (the &#8220;VB Royalty Agreement&#8221;) with Viscogliosi Brothers, LLC (&#8220;VB&#8221;), whereby VB conveyed to the Company the right to receive royalties payable on sales of a spinal implant that has received pre-market approval from the FDA held by VB and commercialized by Paradigm Spine, LLC (&#8220;Paradigm Spine&#8221;), in exchange for a </font><font style="font-family:inherit;font-size:10pt;">$15.5 million</font><font style="font-family:inherit;font-size:10pt;"> cash payment, less fees.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The royalty rights acquired includes royalties accruing from and after April 1, 2014. Under the terms of the VB Royalty Agreement, the Company receives all royalty payments due to VB pursuant to certain technology transfer agreements between VB and Paradigm Spine until the Company has received payments equal to 2.3 times the cash payment made to VB, after which all rights to receive royalties will be returned to VB. VB&#8217;s ability to repurchase the royalty right for as specified amount expired on June 26, 2018.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the royalty right at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, was determined by using a discounted cash flow analysis related to the expected future cash flows to be received. This asset is classified as a Level 3 asset, as the Company&#8217;s valuation utilized significant unobservable inputs, including estimates as to the probability and timing of future sales of the licensed product. The discounted cash flow was based upon expected royalties from sales of licensed product over a ten-year period. The discount rate utilized was </font><font style="font-family:inherit;font-size:10pt;">15.0%</font><font style="font-family:inherit;font-size:10pt;">. Significant judgment is required in selecting the appropriate discount rate. </font><font style="font-family:inherit;font-size:10pt;">Should this discount rate increase or decrease by 2.5%, the fair value of this asset could decrease by $1.4 million or increase by $1.6 million, respectively. Should the expected royalties increase or decrease by 2.5%, the fair value of the asset could increase or decrease by $0.4 million, respectively.</font><font style="font-family:inherit;font-size:10pt;"> A third-party expert was engaged to assist management with the development of its estimate of the expected future cash flows, when deemed necessary. The fair value of the asset is subject to variation should those cash flows vary significantly from the Company&#8217;s estimates. At each reporting period, an evaluation is performed to assess those estimates, discount rates utilized and general market conditions affecting fair market value. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the fair value of the asset acquired as reported in the Company&#8217;s Condensed Consolidated Balance Sheet was </font><font style="font-family:inherit;font-size:10pt;">$14.7 million</font><font style="font-family:inherit;font-size:10pt;"> and the maximum loss exposure was </font><font style="font-family:inherit;font-size:10pt;">$14.7 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">University of Michigan Royalty Agreement</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 6, 2014, the Company acquired a portion of all royalty payments of the Regents of the University of Michigan&#8217;s (&#8220;U-M&#8221;) worldwide royalty interest in Cerdelga (eliglustat) for </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$65.6 million</font><font style="font-family:inherit;font-size:10pt;"> pursuant to the Royalty Purchase and Sale Agreement with U-M (the &#8220;U-M Royalty Agreement&#8221;). Under the terms of the U-M Royalty Agreement, the Company receives </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">75%</font><font style="font-family:inherit;font-size:10pt;"> of all royalty payments due under U-M&#8217;s license agreement with Genzyme Corporation, a Sanofi company (&#8220;Genzyme&#8221;) until expiration of the licensed patents, excluding any patent term extension. Cerdelga, an oral therapy for adult patients with Gaucher disease type 1, was developed by Genzyme. Cerdelga was approved in the United States in August 2014, in the European Union in January 2015, and in Japan in March 2015. In addition, marketing applications for Cerdelga are under review by other regulatory authorities. While marketing applications have been approved in the United States, the European Union and Japan, national pricing and reimbursement decisions are delayed in some countries. At December 31, 2017, a third-party expert was engaged by the Company to assess the impact of the delayed pricing and reimbursement decisions to Cerdelga&#8217;s expected future cash flows. Based on the analysis performed, management revised the underlying assumptions used in the discounted cash flow analysis at December 31, 2017. As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company&#8217;s discounted cash flow analysis reflects its expectations as to the amount and timing of future cash flows up to the valuation date.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the royalty right at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> was determined by using a discounted cash flow analysis related to the expected future cash flows to be received. This asset is classified as a Level 3 asset, as the Company&#8217;s valuation utilized significant unobservable inputs, including estimates as to the probability and timing of future sales of the licensed product. The discounted cash flow was based upon expected royalties from sales of licensed product over a four-year period. The discount rate utilized was approximately </font><font style="font-family:inherit;font-size:10pt;">12.8%</font><font style="font-family:inherit;font-size:10pt;">. Significant judgment is required in selecting the appropriate discount rate. </font><font style="font-family:inherit;font-size:10pt;">Should this discount rate increase or decrease by 2.5%, the fair value of this asset could decrease by $1.2 million or increase by $1.4 million, respectively. Should the expected royalties increase or decrease by 2.5%, the fair value of the asset could increase or decrease by $0.7 million, respectively.</font><font style="font-family:inherit;font-size:10pt;"> A third-party expert is engaged to assist management with the development of its estimate of the expected future cash flows, when deemed necessary. The fair value of the asset is subject to variation should those cash flows vary significantly from the Company&#8217;s estimates. An evaluation of those estimates, discount rates utilized and general market conditions affecting fair market value is performed in each reporting period.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the fair value of the asset acquired as reported in the Company&#8217;s Condensed Consolidated Balance Sheet was </font><font style="font-family:inherit;font-size:10pt;">$26.1 million</font><font style="font-family:inherit;font-size:10pt;"> and the maximum loss exposure was </font><font style="font-family:inherit;font-size:10pt;">$26.1 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">AcelRx Royalty Agreement</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 18, 2015, the Company entered into a royalty interest assignment agreement (the &#8220;AcelRx Royalty Agreement&#8221;) with ARPI LLC, a wholly owned subsidiary of AcelRx Pharmaceuticals, Inc. (&#8220;AcelRx&#8221;), whereby the Company acquired the rights to receive a portion of the royalties and certain milestone payments on sales of Zalviso</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> (sufentanil sublingual tablet system) in the European Union, Switzerland and Australia by AcelRx&#8217;s commercial partner, Gr&#252;nenthal, in exchange for a </font><font style="font-family:inherit;font-size:10pt;">$65.0 million</font><font style="font-family:inherit;font-size:10pt;"> cash payment. Under the terms of the AcelRx Royalty Agreement, the Company receives </font><font style="font-family:inherit;font-size:10pt;">75%</font><font style="font-family:inherit;font-size:10pt;"> of all royalty payments and 80% of the first four commercial milestone payments due under AcelRx&#8217;s license agreement with Gr&#252;nenthal until the earlier to occur of (i) receipt by the Company of payments equal to three times the cash payments made to AcelRx and (ii) the expiration of the licensed patents (expected to be in January of 2032). Zalviso received marketing approval by the European Commission in September 2015. Gr&#252;nenthal launched Zalviso in the second quarter of 2016 and the Company started to receive royalties in the third quarter of 2016.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, and December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, the Company determined that its royalty rights under the AcelRx Royalty Agreement represented a variable interest in a variable interest entity. However, the Company does not have the power to direct the activities of ARPI LLC that most significantly impact ARPI LLC&#8217;s economic performance and is not the primary beneficiary of ARPI LLC; therefore, ARPI LLC is not subject to consolidation by the Company.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the royalty right at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> was determined by using a discounted cash flow analysis related to the expected future cash flows to be received. This asset is classified as a Level 3 asset, as the Company&#8217;s valuation utilized significant unobservable inputs, including estimates as to the probability and timing of future sales of the licensed product. The discounted cash flow was based upon expected royalties from sales of licensed product over a fourteen-year period. The discount rate utilized was approximately </font><font style="font-family:inherit;font-size:10pt;">13.4%</font><font style="font-family:inherit;font-size:10pt;">. Significant judgment is required in selecting the appropriate discount rate. </font><font style="font-family:inherit;font-size:10pt;">Should this discount rate increase or decrease by 2.5%, the fair value of this asset could decrease by $9.8 million or increase by $12.0 million, respectively. Should the expected royalties increase or decrease by 2.5%, the fair value of the asset could increase or decrease by $1.9 million, respectively</font><font style="font-family:inherit;font-size:10pt;">. A third-party expert is engaged to assist management with the development of its estimate of the expected future cash flows, when deemed necessary. The fair value of the asset is subject to variation should those cash flows vary significantly from the Company&#8217;s estimates. Based on the number of treated patients to date, management adjusted the timing of the expected future cash flows used in the discounted cash flow model at December 31, 2017. At June 30, 2018, management performed an evaluation of those estimates, discount rates utilized and general market conditions to determine the fair market value of the asset, and such an evaluation is performed for each reporting period. As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company&#8217;s discounted cash flow analysis reflects its expectations as to the amount and timing of future cash flows up to the valuation date.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the fair value of the asset acquired as reported in the Company&#8217;s Condensed Consolidated Balance Sheet was </font><font style="font-family:inherit;font-size:10pt;">$77.4 million</font><font style="font-family:inherit;font-size:10pt;"> and the maximum loss exposure was </font><font style="font-family:inherit;font-size:10pt;">$77.4 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Kybella Royalty Agreement</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On July 8, 2016, the Company entered into a royalty purchase and sales agreement with an individual, whereby the Company acquired that individual&#8217;s rights to receive certain royalties on sales of KYBELLA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> by Allergen plc in exchange for a </font><font style="font-family:inherit;font-size:10pt;">$9.5 million</font><font style="font-family:inherit;font-size:10pt;"> cash payment and up to </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> in future milestone payments based upon product sales targets. The Company started to receive royalty payments during the third quarter of 2016.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the royalty right at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, was determined by using a discounted cash flow analysis related to the expected future cash flows to be received. This asset is classified as a Level 3 asset, as the Company&#8217;s valuation utilized significant unobservable inputs, including estimates as to the probability and timing of future sales of the licensed product. The discounted cash flow was based upon expected royalties from sales of a licensed product over a seven-year period. The discount rate utilized was approximately </font><font style="font-family:inherit;font-size:10pt;">14.4%</font><font style="font-family:inherit;font-size:10pt;">. Significant judgment is required in selecting the appropriate discount rate. </font><font style="font-family:inherit;font-size:10pt;">Should this discount rate increase or decrease by 2.5%, the fair value of this asset could decrease by $0.2 million or increase by $0.3 million, respectively. Should the expected royalties increase or decrease by 2.5%, the fair value of the asset could increase or decrease by $0.1 million, respectively</font><font style="font-family:inherit;font-size:10pt;">. A third-party expert is engaged to assist management with the development of its estimate of the expected future cash flows, when deemed necessary. The fair value of the asset is subject to variation should those cash flows vary significantly from the Company&#8217;s estimates. At each reporting period, an evaluation of those estimates, discount rates utilized and general market conditions affecting fair market value is performed in each reporting period.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the fair value of the asset acquired as reported in the Company&#8217;s Condensed Consolidated Balance Sheet was </font><font style="font-family:inherit;font-size:10pt;">$2.8 million</font><font style="font-family:inherit;font-size:10pt;"> and the maximum loss exposure was </font><font style="font-family:inherit;font-size:10pt;">$2.8 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following tables summarize the changes in Level 3 assets and the gains and losses included in earnings for the </font><font style="font-family:inherit;font-size:10pt;">six months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:10px;" rowspan="1" colspan="1"></td><td style="width:505px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:62px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:62px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurements Using Significant Unobservable Inputs (Level 3) - Royalty Rights Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Royalty Rights - </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">At Fair Value</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Fair value as of December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">349,223</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total net change in fair value for the period</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Change in fair value of royalty rights - at fair value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">23,933</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Proceeds from royalty rights - at fair value</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(37,993</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total net change in fair value for the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(14,060</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Fair value as of June 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">335,163</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:332px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:95px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:106px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:99px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurements Using Significant Unobservable Inputs (Level 3) - Royalty Rights Assets</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value as of</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Royalty Rights -</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value as of</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Change in Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">June 30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Depomed</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">232,038</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(17,967</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">214,071</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">VB</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14,380</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">284</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14,664</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">U-M</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">26,769</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(620</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">26,149</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">AcelRx</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">72,894</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,539</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">77,433</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Avinger</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">396</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(396</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">KYBELLA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,746</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">100</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,846</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">349,223</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(14,060</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">335,163</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:684px;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:10px;" rowspan="1" colspan="1"></td><td style="width:286px;" rowspan="1" colspan="1"></td><td style="width:286px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:82px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurements Using Significant Unobservable Inputs (Level 3) - Liabilities</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Contingent Consideration</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Fair value as of December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(42,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total net change in fair value for the period</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">22,735</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Fair value of financial instruments acquired</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,560</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Settlement of financial instrument</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">785</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Fair value as of June 30, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(20,040</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the contingent consideration was determined using an income approach derived from revenue estimates and a probability assessment with respect to the likelihood of achieving (a) the level of net sales or (b) generic product launch that would trigger the milestone payments. The key assumptions in determining the fair value are the discount rate and the probability assigned to the potential milestones being achieved. The fair value of the contingent consideration is remeasured each reporting period, with changes in fair value recorded in the Condensed Consolidated Statements of Income. The change in fair value of the contingent consideration during the six months ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> is due primarily to the changes in the probabilities in the generic entry milestones and the additional contingent consideration acquired as part of the assets acquired by LENSAR from Precision Eye Services, as described in note 9.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gains and losses from changes in Level 3 assets included in earnings for each period are presented in &#8220;Royalty rights - change in fair value&#8221; and gains and losses from changes in Level 3 liabilities included in earnings for each period are presented in &#8220;Change in fair value of anniversary payment and contingent consideration&#8221; as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:677px;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:341px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:66px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total change in fair value for the period included in earnings for royalty right assets held at the end of the reporting period</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,842</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83,725</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,933</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">96,871</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total change in fair value for the period included in earnings for liabilities held at the end of the reporting period</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,135</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,207</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,735</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,649</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Assets/Liabilities Measured and Recorded at Fair Value on a Nonrecurring Basis</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company remeasures the fair value of certain assets and liabilities upon the occurrence of certain events. Such assets consist of cost-method equity investments and long-lived assets, including property and equipment and intangible assets. During the three months ended June 30, 2018, the Company recorded an impairment charge of </font><font style="font-family:inherit;font-size:10pt;">$152.3 million</font><font style="font-family:inherit;font-size:10pt;"> for the Noden intangible asset related to the increased probability of a generic version of aliskiren being launched in the United States. As a result of this impairment charge, which was based on the estimated fair value of the assets, the remaining carrying value of the these intangible assets was determined to be </font><font style="font-family:inherit;font-size:10pt;">$40.1 million</font><font style="font-family:inherit;font-size:10pt;">. The fair value calculation included level 3 inputs. For additional information on the impairment charge, see note 10.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Assets/Liabilities Not Subject to Fair Value Recognition</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following tables present the fair value of assets and liabilities not subject to fair value recognition by level within the valuation hierarchy:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="25" rowspan="1"></td></tr><tr><td style="width:34%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June&#160;30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Carrying Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Carrying Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Wellstat Diagnostics note receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,191</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,224</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,191</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,308</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Hyperion note receivable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CareView note receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,496</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,507</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,346</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,750</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,887</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77,931</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,737</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,258</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liabilities:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 2018 Notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">126,066</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">126,131</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 2021 Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120,945</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">139,052</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">117,415</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">148,028</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120,945</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">139,052</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">243,481</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">274,159</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and December 31, 2017, the estimated fair values of the Hyperion Catalysis International, Inc. note receivable, and CareView Communications, Inc. (&#8220;CareView&#8221;) note receivable were determined using one or more discounted cash flow models, incorporating expected payments and the interest rate extended on the notes receivable, with fixed interest rates and incorporating expected payments for notes receivable with a variable rate of return.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">When deemed necessary the Company engages a third-party valuation expert to assist in evaluating its investments and the related inputs needed to estimate the fair value of certain investments. The Company determined its notes receivable assets are Level 3 assets as the Company&#8217;s valuations utilized significant unobservable inputs, including estimates of future revenues, discount rates, expectations about settlement, terminal values and required yield. To provide support for the estimated fair value measurements, the Company considered forward-looking performance related to the investment and current measures associated with high yield indices, and reviewed the terms and yields of notes placed by specialty finance and venture firms both across industries and in similar sectors.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The CareView note receivable is secured by substantially all assets of, and equity interests in CareView. The Wellstat Diagnostics note receivable is secured by substantially all assets of Wellstat Diagnostics and is supported by a guaranty from the Wellstat Diagnostics Guarantors (as defined in Note 7 below). The estimated fair value of the collateral assets was determined by using an asset approach and discounted cash flow model related to the underlying collateral and was adjusted to consider estimated costs to sell the assets.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the carrying values of several of the Company&#8217;s notes receivable differed from their estimated fair value. This is the result of discount rates used when performing a discounted cash flow for fair value valuation purposes.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair values of the Company&#8217;s convertible notes were determined using quoted market pricing or dealer quotes.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table represents significant unobservable inputs used in determining the estimated fair value of impaired notes receivable investments:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:29%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Asset</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Valuation</font></div><div style="padding-bottom:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Technique</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unobservable</font></div><div style="padding-bottom:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Input</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:2px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div><div style="padding-bottom:2px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Wellstat Diagnostics</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Wellstat Guarantors Intellectual Property</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Approach</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discount rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Royalty amount</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$21 million</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$21 million</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Settlement Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Approach</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discount rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Settlement amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$36 million</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$32 million</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Real Estate Property</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Market Approach</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Annual appreciation rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated realtor fee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated disposal date</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6/30/2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6/30/2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">CareView</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Note receivable cash flows</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Approach</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discount rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17.5%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17.5%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company had three notes receivable investments on non-accrual status with a cumulative investment cost and fair value of approximately </font><font style="font-family:inherit;font-size:10pt;">$70.9 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$77.9 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, compared to three note receivable investments on non-accrual status at December&#160;31, 2017 with a cumulative investment cost and fair value of approximately </font><font style="font-family:inherit;font-size:10pt;">$70.7 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$71.3 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. For the three and six months ended June 30, 2018, the Company recognized </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, of interest revenue for the CareView note receivable investment as a result of cash interest payments made during the period; for the three and six months ended June 30, 2017, the Company did not recognize any interest for note receivable investments on non-accrual status. During the three and </font><font style="font-family:inherit;font-size:10pt;">six months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized losses on extinguishment of notes receivable of </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;">, respectively, and during the three and six months ended June 30, 2017, the Company recognized losses on extinguishment of notes receivable of </font><font style="font-family:inherit;font-size:10pt;">$12.2 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$12.2 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table represents significant unobservable inputs used in determining the estimated fair value of impaired notes receivable investments:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:29%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Asset</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Valuation</font></div><div style="padding-bottom:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Technique</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unobservable</font></div><div style="padding-bottom:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Input</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:2px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div><div style="padding-bottom:2px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Wellstat Diagnostics</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Wellstat Guarantors Intellectual Property</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Approach</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discount rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Royalty amount</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$21 million</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$21 million</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Settlement Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Approach</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discount rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Settlement amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$36 million</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$32 million</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Real Estate Property</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Market Approach</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Annual appreciation rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated realtor fee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated disposal date</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6/30/2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6/30/2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">CareView</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Note receivable cash flows</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Approach</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discount rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17.5%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17.5%</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">. Intangible Assets</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Intangible Assets, Net</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 8, 2018, Noden Pharma DAC (&#8220;Noden DAC&#8221;), a wholly owned subsidiary of the Company, entered into a Settlement Agreement (the &#8220;Settlement Agreement&#8221;) with Anchen Pharmaceuticals, Inc. and its affiliates (&#8220;Anchen&#8221;) to resolve the patent litigation relating to infringement of U.S. Patent No. 8,617,595 (the &#8220;595 Patent&#8221;) based on their submission of an Abbreviated New Drug Application (&#8220;ANDA&#8221;) seeking authorization from the U.S. FDA to market a generic version of aliskiren, the active ingredient in the Tekturna and Tekturna HCT drug. Under the Settlement Agreement, Anchen, the sole ANDA filer of which the Company is aware, agreed to not commercialize its generic version of aliskiren prior to March 1, 2019. Per the Settlement Agreement, Anchen may commercialize their formulation of aliskiren, but is not permitted to commercialize a copy of Tekturna.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accordingly, management evaluated the ongoing value of the Noden DAC asset group based upon the probability of Anchen&#8217;s market entry of a generic version of aliskiren in the United States and the associated cash flows and conducted a test for impairment.&#160;Due to the increased probability of a generic version of aliskiren being launched in the United States the Company revised its estimates of future cash flows and as a result of this analysis determined that the sum of undiscounted cash flows was not greater than the carrying value of the assets. Therefore, the Company performed a discounted cash flow analysis to estimated the fair value of the asset group in accordance with ASC Topic 360, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Impairment or Disposal of Long-lived Assets</font><font style="font-family:inherit;font-size:10pt;">. The cash flows are those expected to be generated by market participants, discounted to reflect an appropriate amount of risk, which was determined to be </font><font style="font-family:inherit;font-size:10pt;">21%</font><font style="font-family:inherit;font-size:10pt;">. The Company concluded that the Noden DAC acquired product rights and customer relationship long-lived assets, with a carrying amount of </font><font style="font-family:inherit;font-size:10pt;">$192.5 million</font><font style="font-family:inherit;font-size:10pt;">, were no longer recoverable and wrote them down to their estimated fair value of </font><font style="font-family:inherit;font-size:10pt;">$40.1 million</font><font style="font-family:inherit;font-size:10pt;">, resulting in an impairment charge of </font><font style="font-family:inherit;font-size:10pt;">$152.3 million</font><font style="font-family:inherit;font-size:10pt;"> as of June 30, 2018. This write-down is included in &#8220;Impairment of intangible assets&#8221; in the Condensed Consolidated Statements of Income and the Condensed Consolidated Statements of Cash Flows. The remaining Noden DAC intangible asset balance, part of the Pharmaceutical reportable segment, of </font><font style="font-family:inherit;font-size:10pt;">$40.1 million</font><font style="font-family:inherit;font-size:10pt;"> will be amortized straight-line over the remaining useful life of </font><font style="font-family:inherit;font-size:10pt;">8 years</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The components of intangible assets as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> were as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.60975609756098%;border-collapse:collapse;text-align:left;"><tr><td colspan="25" rowspan="1"></td></tr><tr><td style="width:28%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross Carrying Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Carrying Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross Carrying Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Carrying Amount</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finite-lived intangible assets:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquired products rights</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,143</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,143</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">216,690</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32,503</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">184,187</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer relationships</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1) (2)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,028</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(341</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,687</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,080</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,729</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,351</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquired technology</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2) (3)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,011</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(806</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,205</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,200</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(409</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,791</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquired trademarks</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">570</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(133</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">437</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">570</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">494</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,752</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,280</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,472</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">252,540</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(36,717</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">215,823</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">________________</font></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:18px;text-indent:-18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1)&#160;The Company acquired certain intangible assets as part of the Noden Transaction. They are amortized on a straight-line basis over a weighted average period of </font><font style="font-family:inherit;font-size:10pt;">8.0 years</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:18px;text-indent:-18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2) The Company acquired certain intangible assets as part of the LENSAR transaction, as described further in Note 19. They are amortized over a weighted average period of 15.0 years. The intangible assets for acquired technology and trademarks are being amortized over their estimated useful lives using the straight-line method of amortization. The intangible assets for customer relationships are being amortized using a double-declining method of amortization as such method better represents the economic benefits to be obtained.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company acquired certain intangible assets as part of the foreclosure on certain of Direct Flow Medical assets, as described further in Note 7. They are amortized over a weighted average period of 10.0 years. The intangible assets for acquired technology are being amortized over their estimated useful lives using the straight-line method of amortization.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the three and </font><font style="font-family:inherit;font-size:10pt;">six months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, amortization expense was </font><font style="font-family:inherit;font-size:10pt;">$6.4 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$12.7 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, and for the three and </font><font style="font-family:inherit;font-size:10pt;">six months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, amortization expense was </font><font style="font-family:inherit;font-size:10pt;">$6.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$12.2 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on the intangible assets recorded at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, and assuming no subsequent additions to or impairment of the underlying assets, the remaining estimated amortization expense is expected to be as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:83%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fiscal Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018 (Remaining six months)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,154</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,275</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,240</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,209</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,104</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,040</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,450</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total remaining estimated amortization expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,472</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">16. Income Taxes</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax expense (benefit) for the three months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, was </font><font style="font-family:inherit;font-size:10pt;">$(14.3) million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$53.9 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, and for the six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, was </font><font style="font-family:inherit;font-size:10pt;">$(13.2) million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$60.4 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, which resulted primarily from applying the federal statutory income tax rate to income before income taxes. The Company&#8217;s effective tax rate for the current period differs from the U.S. federal statutory rate of </font><font style="font-family:inherit;font-size:10pt;">21%</font><font style="font-family:inherit;font-size:10pt;"> due primarily to the effect of the foreign rate differential related to the impairment of the intangible assets related to the Noden Products.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The uncertain tax positions increased during the three months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, by </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$28.9 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, and for the six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$29.7 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, resulting from an increase in tax uncertainties and estimated tax liabilities.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 22, 2017, the SEC issued Staff Accounting Bulletin No. 118 to address the application of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the 2017 Tax Cuts and Job Act. The accounting for all items is expected to be complete during 2018 as additional guidance related to Global Intangible Low-Taxed Income (&#8220;GILTI&#8221;) is released. Any differences between what was previously recorded and the final amounts or estimates done for subsequent quarters are not expected to be material.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s income tax returns are subject to examination by U.S. federal, state and local tax authorities for tax years 2000 forward. The Company is currently under income tax examination by the state of California for the tax years 2009 through 2015 and by the Internal Revenue Service for the tax year 2016. Although the timing of the resolution of income tax examinations is highly uncertain, and the amounts ultimately paid, if any, upon resolution of the issues raised by the taxing authorities may differ materially from the amounts accrued for each year, the Company does not anticipate any material change to the amount of its unrecognized tax benefit over the next 12 months.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8. Inventories</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories consisted of the following:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,771</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,717</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work in process</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,677</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,119</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finished goods</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,353</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,311</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,801</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,147</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company deferred approximately </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, of costs associated with inventory transfers made under the Company&#8217;s third party logistic provider service arrangement. These costs have been recorded as other assets on the Company&#8217;s Condensed Consolidated Balance Sheet as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and December 31, 2017. The Company will recognize the cost of product sold as inventory is transferred from its third-party logistics provider to the Company&#8217;s customers.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the three and six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized a reduction in the inventory provision of </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, and during the three and six months ended June 30, 2017, the Company recognized an inventory write-down of </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, related to Tekturna</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, Tekturna HCT</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, Rasilez</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> and Rasilez HCT</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> (collectively, the &#8220;Noden Products&#8221; or &#8220;Tekturna&#8221;) that the Company would not be able to sell prior to their expiration.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">. Notes and Other Long-Term Receivables</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notes and other long-term receivables included the following significant agreements:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Wellstat Diagnostics Note Receivable and Credit Agreement and Related Litigation</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 2, 2012, the Company and Wellstat Diagnostics entered into a </font><font style="font-family:inherit;font-size:10pt;">$40.0 million</font><font style="font-family:inherit;font-size:10pt;"> credit agreement pursuant to which the Company was to accrue quarterly interest payments at the rate of </font><font style="font-family:inherit;font-size:10pt;">5%</font><font style="font-family:inherit;font-size:10pt;"> per annum (payable in cash or in kind). In addition, the Company was to receive quarterly royalty payments based on a low double-digit royalty rate of Wellstat Diagnostics&#8217; net revenues, generated by the sale, distribution or other use of Wellstat Diagnostics&#8217; products, if any, commencing upon the commercialization of its products. A portion of the proceeds of the $40.0 million credit agreement were used to repay certain notes receivable which Wellstat Diagnostics entered into in March 2012.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2013, the Company was informed that, as of December 31, 2012, Wellstat Diagnostics had used funds contrary to the terms of the credit agreement and breached Sections 2.1.2 and 7 of the credit agreement. The Company sent Wellstat Diagnostics a notice of default on January 22, 2013, and accelerated the amounts owed under the credit agreement. In connection with the notice of default, the Company exercised one of its available remedies and transferred approximately </font><font style="font-family:inherit;font-size:10pt;">$8.1 million</font><font style="font-family:inherit;font-size:10pt;"> of available cash from a bank account of Wellstat Diagnostics to the Company and applied the funds to amounts due under the credit agreement. On February 28, 2013, the parties entered into a forbearance agreement whereby the Company agreed to refrain from exercising additional remedies for 120 days. During such forbearance period, the Company provided approximately </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;"> to Wellstat Diagnostics to fund ongoing operations of the business. During the year ended December 31, 2013, approximately </font><font style="font-family:inherit;font-size:10pt;">$8.7 million</font><font style="font-family:inherit;font-size:10pt;"> was advanced pursuant to the forbearance agreement.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On August 15, 2013, the Company entered into an amended and restated credit agreement with Wellstat Diagnostics. The Company determined that the new agreement should be accounted for as a modification of the existing agreement. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Except as otherwise described herein, the material terms of the amended and restated credit agreement are substantially the same as those of the original credit agreement, including quarterly interest payments at the rate of </font><font style="font-family:inherit;font-size:10pt;">5%</font><font style="font-family:inherit;font-size:10pt;"> per annum (payable in cash or in kind). In addition, the Company was to continue to receive quarterly royalty payments based on a low double-digit royalty rate of Wellstat Diagnostics&#8217; net revenues. However, pursuant to the amended and restated credit agreement: (i) the principal amount was reset to approximately </font><font style="font-family:inherit;font-size:10pt;">$44.1 million</font><font style="font-family:inherit;font-size:10pt;">, which was comprised of approximately </font><font style="font-family:inherit;font-size:10pt;">$33.7 million</font><font style="font-family:inherit;font-size:10pt;"> original loan principal and interest, </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;"> term loan principal and interest and </font><font style="font-family:inherit;font-size:10pt;">$9.1 million</font><font style="font-family:inherit;font-size:10pt;"> forbearance principal and interest; (ii) the specified internal rates of return increased; (iii) the default interest rate was increased; (iv) Wellstat Diagnostics&#8217; obligation to provide certain financial information increased in frequency to monthly; (v) internal financial controls were strengthened by requiring Wellstat Diagnostics to maintain an independent, third-party financial professional with control over fund disbursements; (vi) the Company waived the existing events of default; and (vii) the owners and affiliates of Wellstat Diagnostics were required to contribute additional capital to Wellstat Diagnostics upon the sale of an affiliate entity. The amended and restated credit agreement had an ultimate maturity date of December 31, 2021 (but has subsequently been accelerated as described below).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2014, the Company received information from Wellstat Diagnostics showing that it was generally unable to pay its debts as they became due, constituting an event of default under the amended and restated credit agreement.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On August 5, 2014, the Company delivered a notice of default (the &#8220;Wellstat Diagnostics Borrower Notice&#8221;) to Wellstat Diagnostics, which accelerated all obligations under the amended and restated credit agreement and demanded immediate payment in full in an amount equal to approximately </font><font style="font-family:inherit;font-size:10pt;">$53.9 million</font><font style="font-family:inherit;font-size:10pt;">, (which amount, in accordance with the terms of the amended and restated credit agreement, included an amount that, together with interest and royalty payments already made to the Company, would generate a specified internal rate of return to the Company), plus accruing fees, costs and interest, and demanded that Wellstat Diagnostics protect and preserve all collateral securing its obligations.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On August 7, 2014, the Company delivered a notice (the &#8220;Wellstat Diagnostics Guarantor Notice&#8221;) to each of the guarantors of Wellstat Diagnostics&#8217; obligations to the Company (collectively, the &#8220;Wellstat Diagnostics Guarantors&#8221;) under the credit agreement, which included a demand that the guarantors remit payment to the Company in the amount of the outstanding obligations. The guarantors include certain affiliates and related companies of Wellstat Diagnostics, including Wellstat Therapeutics and Wellstat Diagnostics&#8217; stockholders.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 24, 2014, the Company filed an ex-parte petition for appointment of receiver with the Circuit Court of Montgomery County, Maryland (the &#8220;Wellstat Diagnostics Petition&#8221;), which was granted on the same day. Wellstat Diagnostics remained in operation during the period of the receivership with incremental additional funding from the Company. On May 24, 2017, Wellstat Diagnostics transferred substantially all of its assets to the Company pursuant to a credit bid. The credit bid reduced the outstanding balance of the loan by an immaterial amount.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 4, 2015, the Company filed in the Supreme Court of New York a motion for summary judgment in lieu of complaint which requested that the court enter judgment against certain of the Wellstat Diagnostics Guarantors for the total amount due on the Wellstat Diagnostics debt, plus all costs and expenses including lawyers&#8217; fees incurred by the Company in enforcement of the related guarantees. On September 23, 2015, the Company filed in the same court an ex parte application for a temporary restraining order and order of attachment of the Wellstat Diagnostics Guarantor defendants&#8217; assets. Although the court denied the Company&#8217;s request for a temporary restraining order at a hearing on September 24, 2015, it ordered that assets of the Wellstat Diagnostics Guarantor defendants should be held in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">status quo ante</font><font style="font-family:inherit;font-size:10pt;"> and only used in the normal course of business.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On July 29, 2016, the Supreme Court of New York granted the Company&#8217;s motion for summary judgment and held that the Wellstat Diagnostics Guarantor defendants are liable for all &#8220;Obligations&#8221; owed by Wellstat Diagnostics to the Company.&#160;After appeal by the Wellstat Diagnostics Guarantor defendants, on February 14, 2017, the Appellate Division of the Supreme Court of New York reversed on procedural grounds a portion of the Memorandum of Decision granting the Company summary judgment in lieu of complaint, but affirmed the portion of the Memorandum of Decision denying the Wellstat Diagnostics Guarantor defendants&#8217; motion for summary judgment in which they sought a determination that the guarantees had been released. As a result, the litigation has been remanded to the Supreme Court of New York to proceed on the Company&#8217;s claims as a plenary action. On June 21, 2017, the Supreme Court of New York ordered the Company to file a Complaint, which was filed by the Company on July 20, 2017. The Wellstat Diagnostics Guarantors filed their answer on August 9, 2017, including counterclaims against the Company alleging breach of contract, breach of fiduciary duty, and tortious interference with prospective economic advantage. This case is currently pending and in the pre-trial phase.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 14, 2016, the Company sent a notice of default and reference to foreclosure proceedings to certain of the Wellstat Diagnostics Guarantors which are not defendants in the New York action, but which are owners of real estate assets over which a deed of trust in favor of the Company securing the guarantee of the loan to Wellstat Diagnostics had been executed. On March 2, 2017, the Company sent a second notice to foreclose on the real estate assets, and noticed the sale for March 29, 2017. The sale was taken off the calendar by the trustee under the deed of trust and has not been re-scheduled yet. On March 6, 2017, the Company sent a letter to the Wellstat Diagnostics Guarantors seeking information in preparation for a UCC Article 9 sale of some or all of the intellectual property-related collateral of the Wellstat Diagnostics Guarantors. The Wellstat Diagnostics Guarantors did not respond to the Company&#8217;s letter, but on March 17, 2017, filed an order to show cause with the Supreme Court of New York to enjoin the Company&#8217;s sale of the real estate or enforcing its security interests in the Wellstat Diagnostics Guarantors&#8217; intellectual property during the pendency of any action involving the guarantees at issue. In June 2018, the Delaware Supreme Court largely affirmed a September 2017 decision of the Delaware Chancery Court awarding Wellstat Therapeutics </font><font style="font-family:inherit;font-size:10pt;">$55.8 million</font><font style="font-family:inherit;font-size:10pt;"> in damages, plus interest, against BTG International, Inc. for breach of contract. In October 2017, the Company had filed a motion with the Supreme Court of New York requesting a pre-judgement attachment of the award. On February 6, 2018, the Supreme Court of New York issued an order from the bench which enjoins the Wellstat Diagnostics Guarantors from selling, encumbering, removing, transferring or altering the collateral pending the outcome of the proceedings before it. The Supreme Court of New York also issued an order precluding the Company from foreclosing on certain of the Wellstat Diagnostics Guarantors&#8217; collateral pending the outcome of the proceedings before it.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 22, 2015, certain of the Wellstat Diagnostics Guarantors filed a separate complaint against the Company in the Supreme Court of New York seeking a declaratory judgment that certain contractual arrangements entered into between the parties subsequent to Wellstat Diagnostics&#8217; default, and which relate to a split of proceeds in the event that the Wellstat Diagnostics Guarantors voluntarily monetize any assets that are the Company&#8217;s collateral, is of no force or effect. This case has been joined for all purposes, including trial, and consolidated with the pending case filed by the Company.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective April 1, 2014, and as a result of the event of default, the Company determined the loan to be impaired and it ceased to accrue interest revenue. At that time and as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, it has been determined that an allowance on the carrying value of the note was not necessary, as the Company believes the value of the collateral securing Wellstat Diagnostics&#8217; obligations exceeds the carrying value of the asset and is sufficient to enable the Company to recover the current carrying value of </font><font style="font-family:inherit;font-size:10pt;">$50.2 million</font><font style="font-family:inherit;font-size:10pt;">. The Company continues to closely monitor the timing and expected recovery of amounts due, including litigation and other matters related to Wellstat Diagnostics Guarantors&#8217; assets. There can be no assurance that an allowance on the carrying value of the notes receivable investment will not be necessary in a future period depending on future developments.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hyperion Agreement</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 27, 2012, the Company and Hyperion Catalysis International, Inc. (&#8220;Hyperion&#8221;) (which is also a Wellstat Diagnostics Guarantor) entered into an agreement whereby Hyperion sold to the Company the royalty streams due from Showa Denko K.K. (&#8220;SDK&#8221;) related to a certain patent license agreement between Hyperion and SDK dated December 31, 2008. The agreement assigned the patent license agreement royalty stream accruing from January 1, 2012 through December 31, 2013, to the Company in exchange for the lump sum payment to Hyperion of </font><font style="font-family:inherit;font-size:10pt;">$2.3 million</font><font style="font-family:inherit;font-size:10pt;">. In exchange for the lump sum payment, the Company was to receive </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> equal payments of </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;"> on each of March 5, 2013 and 2014. The first payment of </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;"> was paid on March 5, 2013, but Hyperion has not made the second payment that was due on March 5, 2014. Effective as of such date and as a result of the event of default, the Company ceased to accrue interest revenue. As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the estimated fair value of the collateral was determined to be in excess of the carrying value. There can be no assurance that this will be true in the event of the Company&#8217;s foreclosure on the collateral, nor can there be any assurance of realizing value from such collateral.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Avinger Credit and Royalty Agreement</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 18, 2013, the Company entered into a credit agreement with Avinger, Inc. (the &#8220;Avinger Credit and Royalty Agreement&#8221;). Under the terms of the Avinger Credit and Royalty Agreement, the Company receives a low, single-digit royalty on Avinger&#8217;s net revenues until April 2018. Commencing in October 2015, after Avinger repaid </font><font style="font-family:inherit;font-size:10pt;">$21.4 million</font><font style="font-family:inherit;font-size:10pt;"> pursuant to its note receivable prior to its maturity date, the royalty on Avinger&#8217;s net revenues reduced by </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;">, subject to certain minimum payments from the prepayment date until April 18, 2018. The Company has accounted for the royalty rights in accordance with the fair value option. As of April 18, 2018, there are no further obligations owed to PDL.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">LENSAR Credit Agreement</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 1, 2013, the Company entered into a credit agreement with LENSAR, Inc. (&#8220;LENSAR&#8221;), pursuant to which the Company made available to LENSAR up to </font><font style="font-family:inherit;font-size:10pt;">$60.0 million</font><font style="font-family:inherit;font-size:10pt;"> to be used by LENSAR in connection with the commercialization of its currently marketed LENSAR&#8482; Laser System. Of the </font><font style="font-family:inherit;font-size:10pt;">$60.0 million</font><font style="font-family:inherit;font-size:10pt;"> available to LENSAR, an initial </font><font style="font-family:inherit;font-size:10pt;">$40.0 million</font><font style="font-family:inherit;font-size:10pt;">, net of fees, was funded by the Company at the close of the transaction. The remaining </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;"> was never funded. Outstanding borrowings under the loans bore interest at the rate of </font><font style="font-family:inherit;font-size:10pt;">15.5%</font><font style="font-family:inherit;font-size:10pt;"> per annum, payable quarterly in arrears.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 12, 2015, the Company entered into a forbearance agreement with LENSAR, pursuant to which the Company agreed to refrain from exercising certain remedies available to it resulting from the failure of LENSAR to comply with a liquidity covenant and make interest payments due under the credit agreement. Under the forbearance agreement, the Company agreed to provide LENSAR with up to an aggregate of </font><font style="font-family:inherit;font-size:10pt;">$8.5 million</font><font style="font-family:inherit;font-size:10pt;"> in weekly increments through the period ended September 30, 2015 plus employee retention amounts of approximately </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> in the form of additional loans, subject to LENSAR meeting certain milestones related to LENSAR obtaining additional capital to fund the business or sell the business and repay outstanding amounts under the credit agreement. In exchange for the forbearance, LENSAR agreed to additional reporting covenants, the engagement of a chief restructuring officer and an increase on the interest rate to </font><font style="font-family:inherit;font-size:10pt;">18.5%</font><font style="font-family:inherit;font-size:10pt;">, applicable to all outstanding amounts under the credit agreement.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 30, 2015, the Company agreed to extend the forbearance agreement until October 9, 2015 and provide for up to an additional </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;"> in funding while LENSAR negotiated a potential sale of its assets. On October 9, 2015, the forbearance agreement expired, but the Company agreed to fund LENSAR&#8217;s operations while LENSAR continued to negotiate a potential sale of its assets.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 15, 2015, LENSAR, LLC (&#8220;LENSAR/Alphaeon&#8221;), a wholly owned subsidiary of Alphaeon Corporation (&#8220;Alphaeon&#8221;), and LENSAR entered into the Asset Purchase Agreement whereby LENSAR/Alphaeon agreed to acquire certain assets of LENSAR and assumed certain liabilities of LENSAR. The acquisition was consummated on December 15, 2015.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the closing of the acquisition, LENSAR/Alphaeon entered into an amended and restated credit agreement with the Company, assuming </font><font style="font-family:inherit;font-size:10pt;">$42.0 million</font><font style="font-family:inherit;font-size:10pt;"> in loans as part of the borrowings under the Company&#8217;s prior credit agreement with LENSAR. In addition, Alphaeon issued </font><font style="font-family:inherit;font-size:10pt;">1.7 million</font><font style="font-family:inherit;font-size:10pt;"> shares of its Class A common stock to the Company.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has estimated a fair value of </font><font style="font-family:inherit;font-size:10pt;">$3.84</font><font style="font-family:inherit;font-size:10pt;"> per share for the </font><font style="font-family:inherit;font-size:10pt;">1.7 million</font><font style="font-family:inherit;font-size:10pt;"> shares of Alphaeon Class A common stock received in connection with the transactions and recognized this investment as a cost-method investment of </font><font style="font-family:inherit;font-size:10pt;">$6.6 million</font><font style="font-family:inherit;font-size:10pt;"> included in other long-term assets. The Alphaeon Class A common stock is subject to other-than-temporary impairment assessments in future periods. There is no other-than-temporary impairment charge incurred as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2016, LENSAR, re-acquired the assets from LENSAR/Alphaeon and the Company entered into a second amended and restated credit agreement with LENSAR whereby LENSAR assumed all obligations under the amended and restated credit agreement with LENSAR/Alphaeon. Also in December, LENSAR filed for a voluntary petition under Chapter 11 of the U.S. Bankruptcy Code (&#8220;Chapter 11 case&#8221;) with the support of the Company. In January 2017, the Company agreed to provide debtor-in-possession financing of up to </font><font style="font-family:inherit;font-size:10pt;">$2.8 million</font><font style="font-family:inherit;font-size:10pt;"> in new advances to LENSAR so that it could continue to operate its business during the Chapter 11 case. LENSAR filed a Chapter 11 plan of reorganization with the Company&#8217;s support under which LENSAR would issue 100% of its equity interests to the Company in exchange for the cancellation of the Company&#8217;s claims as a secured creditor in the Chapter 11 case, other than with respect to the debtor-in-possession financing, and would thereby become an operating wholly-owned subsidiary of the Company. On April 26, 2017, the bankruptcy court approved the plan of reorganization.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the plan of reorganization, LENSAR emerged from bankruptcy on May 11, 2017 as a wholly-owned subsidiary of the Company, and the Company started to consolidate LENSAR&#8217;s financial statements under the voting interest model beginning May 11, 2017. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For additional information on LENSAR please refer to Note 10 under &#8220;Intangible Assets,&#8221; Note 19 under &#8220;Business Combinations&#8221; and Note 20 under &#8220;Segment Information.&#8221;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Direct Flow Medical Credit Agreement</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 5, 2013, the Company entered into a credit agreement with Direct Flow Medical, Inc. (&#8220;Direct Flow Medical&#8221;) under which the Company agreed to provide up to </font><font style="font-family:inherit;font-size:10pt;">$50.0 million</font><font style="font-family:inherit;font-size:10pt;"> to Direct Flow Medical. Of the </font><font style="font-family:inherit;font-size:10pt;">$50.0 million</font><font style="font-family:inherit;font-size:10pt;"> available to Direct Flow Medical, an initial </font><font style="font-family:inherit;font-size:10pt;">$35.0 million</font><font style="font-family:inherit;font-size:10pt;"> (tranche one), net of fees, was funded by the Company at the close of the transaction.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 10, 2014, the Company and Direct Flow Medical agreed to an amendment to the credit agreement to permit Direct Flow Medical to borrow the </font><font style="font-family:inherit;font-size:10pt;">$15.0 million</font><font style="font-family:inherit;font-size:10pt;"> second tranche upon receipt by Direct Flow Medical of a specified minimum amount of proceeds from an equity offering prior to December 31, 2014. In exchange, the parties amended the credit agreement to provide for additional fees associated with certain liquidity events, such as a change of control or the consummation of an initial public offering, and granted the Company certain board of director observation rights. On November 19, 2014, upon Direct Flow Medical satisfying the amended tranche two milestone, the Company funded the </font><font style="font-family:inherit;font-size:10pt;">$15.0 million</font><font style="font-family:inherit;font-size:10pt;"> second tranche to Direct Flow Medical, net of fees. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding borrowings under tranche one bore interest at the rate of </font><font style="font-family:inherit;font-size:10pt;">15.5%</font><font style="font-family:inherit;font-size:10pt;"> per annum, payable quarterly in arrears, until the occurrence of the second tranche. Upon occurrence of the borrowing of this second tranche, the interest rate applicable to all loans under the credit agreement was decreased to </font><font style="font-family:inherit;font-size:10pt;">13.5%</font><font style="font-family:inherit;font-size:10pt;"> per annum, payable quarterly in arrears.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the credit agreement, Direct Flow Medical&#8217;s obligation to repay loan principal commenced on the twelfth interest payment date, September 30, 2016. The principal amount outstanding at commencement of repayment was required to be repaid in equal installments until final maturity of the loans. The loans were to mature on November 5, 2018. The obligations under the credit agreement were secured by a pledge of substantially all of the assets of Direct Flow Medical and any of its subsidiaries.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 21, 2015, Direct Flow Medical and the Company entered into a waiver to the credit agreement in anticipation of Direct Flow Medical being unable to comply with the liquidity covenant and make interest payments due under the credit agreement, which was subsequently extended on January 14, 2016, and further delayed the timing of the interest payments through the period ending September 30, 2016 while Direct Flow Medical sought additional financing to operate its business.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 28, 2016, the Company funded an additional </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;"> to Direct Flow Medical in the form of a short-term secured promissory note. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 26, 2016, the Company and Direct Flow Medical entered into the fourth amendment to the credit agreement that, among other things, (i) converted the </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;"> short-term secured promissory note into a loan under the credit agreement with substantially the same interest and payment terms as the existing loans, (ii) added a conversion feature whereby the </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;"> loan would convert into equity of Direct Flow Medical upon the occurrence of certain events and (iii) provided for a second </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;"> convertible loan tranche commitment, to be funded at the option of the Company. The commitment for the second tranche was not funded and has since expired. In addition, (i) the Company agreed to waive the liquidity covenant and delay the timing of the unpaid interest payments until September 30, 2016 and (ii) Direct Flow Medical agreed to issue to the Company a specified amount of warrants to purchase shares of convertible preferred stock on the first day of each month for the duration of the waiver period at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$0.01</font><font style="font-family:inherit;font-size:10pt;"> per share. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On July 15, 2016, the Company and Direct Flow Medical entered into the fifth amendment and limited waiver to the credit agreement. The Company funded an additional </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;"> to Direct Flow Medical in the form of a note with substantially the same interest and payment terms as the existing loans and a conversion feature whereby the </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;"> loan would convert into equity of Direct Flow Medical upon the occurrence of certain events. In addition, Direct Flow Medical agreed to issue to the Company warrants to purchase shares of convertible preferred stock at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$0.01</font><font style="font-family:inherit;font-size:10pt;"> per share.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 12, 2016, the Company and Direct Flow Medical entered into the sixth amendment and limited waiver to the credit agreement under which the Company funded an additional </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;"> to Direct Flow Medical in the form of a note with substantially the same interest and payment terms as the existing loans. In addition, Direct Flow Medical agreed to issue to the Company a specified amount of warrants to purchase shares of convertible preferred stock at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$0.01</font><font style="font-family:inherit;font-size:10pt;"> per share.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 30, 2016, the Company and Direct Flow Medical entered into a waiver to the credit agreement where the parties agreed, among other things, to (i) delay payment on all overdue interest payments until October 31, 2016, (ii) waive the initial principal repayment until October 31, 2016 and (iii) continue to waive the liquidity requirements until October 31, 2016. Further, Direct Flow Medical agreed to issue to the Company a specified amount of warrants to purchase shares of convertible preferred stock at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$0.01</font><font style="font-family:inherit;font-size:10pt;"> per share.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 31, 2016, the Company agreed to extend the waivers described above until November 30, 2016 and on November 14, 2016, the Company advanced an additional </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> loan while Direct Flow Medical continued to seek additional financing.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 16, 2016, Direct Flow Medical advised the Company that its potential financing source had modified its proposal from an equity investment to a loan with a substantially smaller amount and under less favorable terms. Direct Flow Medical shut down its operations in December 2016 and in January 2017 made an assignment for the benefit of creditors. The Company then initiated foreclosure proceedings, resulting in the Company obtaining ownership of most of the Direct Flow Medical assets through the Company&#8217;s wholly-owned subsidiary, DFM, LLC. The assets were held for sale and carried at the lower of carrying amount or fair value, less estimated selling costs, which is primarily based on supporting data from market participant sources, and valid offers from third parties.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At December 31, 2016, the Company completed an impairment analysis and concluded that the situation qualified as a troubled debt restructuring and recognized an impairment loss of </font><font style="font-family:inherit;font-size:10pt;">$51.1 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, the Company started to actively market the asset held for sale. On January 23, 2017, the Company and DFM, LLC entered into an Intellectual Property Assignment Agreement with Hong Kong Haisco Pharmaceutical Co., Limited (&#8220;Haisco&#8221;), a Chinese pharmaceutical company, whereby Haisco acquired former Direct Flow Medical clinical, regulatory and commercial information and intellectual property rights exclusively in China for </font><font style="font-family:inherit;font-size:10pt;">$7.0 million</font><font style="font-family:inherit;font-size:10pt;">. The Company, through DFM, LLC also sold Haisco certain manufacturing equipment for </font><font style="font-family:inherit;font-size:10pt;">$450,000</font><font style="font-family:inherit;font-size:10pt;"> and collected </font><font style="font-family:inherit;font-size:10pt;">$692,000</font><font style="font-family:inherit;font-size:10pt;"> on outstanding Direct Flow Medical accounts receivable during the year ended December 31, 2017.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 6, 2018, DFM, LLC and HaisThera Advisors Co., Limited (&#8220;HaisThera&#8221;) entered into a license agreement whereby DFM, LLC granted HaisThera an exclusive license to develop, manufacture and commercialize percutaneously implanting stentless aortic valve in the European Union. The consideration for the license agreement was $500,000 upfront and up to $2.0 million in royalty payments.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">kal&#233;o Note Purchase Agreement</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 1, 2014, the Company entered into a note purchase agreement with Accel 300, LLC (&#8220;Accel 300&#8221;), a wholly-owned subsidiary of kal&#233;o, Inc. (&#8220;kal&#233;o&#8221;), pursuant to which the Company acquired </font><font style="font-family:inherit;font-size:10pt;">$150.0 million</font><font style="font-family:inherit;font-size:10pt;"> of secured notes due 2029 (the &#8220;kal&#233;o Note&#8221;). The kal&#233;o Note was issued pursuant to an indenture between Accel 300 and U.S. Bank, National Association, as trustee, and was secured by 20% of net sales of its first approved product, Auvi-Q</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> (epinephrine auto-injection, USP) (known as Allerject</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:inherit;font-size:10pt;">in Canada) and 10% of net sales of kal&#233;o&#8217;s second proprietary auto-injector based product, EVZIO (naloxone hydrochloride injection) (the &#8220;kal&#233;o Revenue Interests&#8221;), and a pledge of kal&#233;o&#8217;s equity ownership in Accel 300. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 21, 2017, the Company entered into an agreement (the &#8220;kal&#233;o Note Sale Agreement&#8221;) with MAM-Kangaroo Lender, LLC, a Delaware limited liability company (the &#8220;kal&#233;o Purchaser&#8221;), pursuant to which the Company sold its entire interest in the kal&#233;o Note.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the kal&#233;o Note Sale Agreement, the kal&#233;o Purchaser paid to the Company an amount equal to 100% of the then outstanding principal, a premium of </font><font style="font-family:inherit;font-size:10pt;">1%</font><font style="font-family:inherit;font-size:10pt;"> of such amount and accrued interest under the kal&#233;o Note, for an aggregate cash purchase price of </font><font style="font-family:inherit;font-size:10pt;">$141.7 million</font><font style="font-family:inherit;font-size:10pt;">, subject to an 18-month escrow holdback of </font><font style="font-family:inherit;font-size:10pt;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;"> against certain potential contingencies. For a further discussion on this topic, see Note 12.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">CareView Credit Agreement</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 26, 2015, the Company entered into a credit agreement with CareView, under which the Company made available to CareView up to </font><font style="font-family:inherit;font-size:10pt;">$40.0 million</font><font style="font-family:inherit;font-size:10pt;"> in two tranches of </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;"> each. Under the terms of the credit agreement, the first tranche of </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;">, net of fees, was funded by the Company upon CareView&#8217;s attainment of a specified milestone relating to the placement of CareView Systems</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, on October 7, 2015. On October 7, 2015, the Company and CareView entered into an amendment of the credit agreement to modify certain definitions related to the first and second tranche milestones. The second </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;"> tranche would be funded upon CareView&#8217;s attainment of specified milestones relating to the placement of CareView Systems and consolidated earnings before interest, taxes, depreciation and amortization, to be accomplished no later than June 30, 2017. Such milestones were not achieved, and there is no additional funding obligation due from the Company. Outstanding borrowings under the credit agreement will bear interest at the rate of </font><font style="font-family:inherit;font-size:10pt;">13.5%</font><font style="font-family:inherit;font-size:10pt;"> per annum and are payable quarterly in arrears.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As part of the transaction, the Company received a warrant to purchase approximately </font><font style="font-family:inherit;font-size:10pt;">4.4 million</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock of CareView at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$0.45</font><font style="font-family:inherit;font-size:10pt;"> per share. The Company has accounted for the warrant as derivative asset with an offsetting credit as debt discount. At each reporting period the warrant is marked to market for changes in fair value.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the October 2015 amendment of the credit agreement, the Company and CareView also agreed to amend the warrant to purchase common stock agreement by reducing the warrant&#8217;s exercise price from </font><font style="font-family:inherit;font-size:10pt;">$0.45</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">$0.40</font><font style="font-family:inherit;font-size:10pt;"> per share. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2018, the Company entered into a modification agreement with CareView whereby the Company agreed, effective as of December 28, 2017, to modify the credit agreement before remedies could otherwise have become available to the Company under the credit agreement in relation to certain obligations of CareView that would potentially not be met, including the requirement to make principal payments. Under the modification agreement the Company agreed that (i) a lower liquidity covenant would be applicable and (ii) principal repayment would be delayed for a period of up to December 31, 2018. In exchange for agreeing to these modifications, among other things, the exercise price of the Company&#8217;s warrants to purchase </font><font style="font-family:inherit;font-size:10pt;">4.4 million</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock of CareView was repriced from </font><font style="font-family:inherit;font-size:10pt;">$0.40</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">$0.03</font><font style="font-family:inherit;font-size:10pt;"> per share and, subject to the occurrence of certain events, CareView agreed to grant the Company additional equity interests. At </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company determined an estimated fair value of the warrant to be </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective October 1, 2017, the Company determined the loan to be impaired and it ceased to accrue interest revenue. At </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, it has been determined that an allowance on the carrying value of the note was not necessary.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">. Convertible Notes</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15" rowspan="1"></td></tr><tr><td style="width:30%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:27%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Principal Balance Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Carrying Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Maturity Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(In thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 2018 Notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 1, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">126,066</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 2021 Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 1, 2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">150,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120,945</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">117,415</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120,945</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">243,481</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">February 2018 Notes</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 12, 2014, the Company issued </font><font style="font-family:inherit;font-size:10pt;">$300.0 million</font><font style="font-family:inherit;font-size:10pt;"> in aggregate principal amount, at par, of the February 2018 Notes in an underwritten public offering, for net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$290.2 million</font><font style="font-family:inherit;font-size:10pt;">. The February 2018 Notes were due February 1, 2018, and the Company paid interest at </font><font style="font-family:inherit;font-size:10pt;">4.0%</font><font style="font-family:inherit;font-size:10pt;"> on the February 2018 Notes semiannually in arrears on February 1 and August 1 of each year, beginning August 1, 2014. A portion of the proceeds from the February 2018 Notes, net of amounts used for purchased call option transactions and provided by the warrant transactions described below, were used to redeem </font><font style="font-family:inherit;font-size:10pt;">$131.7 million</font><font style="font-family:inherit;font-size:10pt;"> of the Company&#8217;s 2.975% Convertible Senior Notes due February 17, 2016.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 20, 2015, the Company&#8217;s agent initiated the repurchase of </font><font style="font-family:inherit;font-size:10pt;">$53.6 million</font><font style="font-family:inherit;font-size:10pt;"> in aggregate principal amount of its February 2018 Notes for </font><font style="font-family:inherit;font-size:10pt;">$43.7 million</font><font style="font-family:inherit;font-size:10pt;"> in cash in four open market transactions.&#160;The closing of these transactions occurred on November 30, 2015. It was determined that the repurchase of the principal amount shall be accounted for as a partial extinguishment of the February 2018 Notes. As a result, a gain on extinguishment of </font><font style="font-family:inherit;font-size:10pt;">$6.5 million</font><font style="font-family:inherit;font-size:10pt;"> was recorded at closing of the transaction. The </font><font style="font-family:inherit;font-size:10pt;">$6.5 million</font><font style="font-family:inherit;font-size:10pt;"> gain on extinguishment included the de-recognition of the original issuance discount of </font><font style="font-family:inherit;font-size:10pt;">$3.1 million</font><font style="font-family:inherit;font-size:10pt;">, outstanding deferred issuance costs of </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;"> and agent fees of </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">. In connection with this repurchase of the February 2018 Notes, the Company unwound a portion of the purchased call options related to the notes. As a result of this unwinding, the Company received </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> in cash. The payments received have been recorded as an increase to additional paid-in-capital. In addition, the Company unwound a portion of the warrants for </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> in cash, payable by the Company. The payments have been recorded as a decrease to additional paid-in-capital. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 22, 2016, the Company repurchased </font><font style="font-family:inherit;font-size:10pt;">$120.0 million</font><font style="font-family:inherit;font-size:10pt;"> in aggregate principal amount of its February 2018 Notes for approximately </font><font style="font-family:inherit;font-size:10pt;">$121.5 million</font><font style="font-family:inherit;font-size:10pt;"> in cash (including </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;"> of accrued interest) in open market transactions. It was determined that the repurchase of the principal amount shall be accounted for as an extinguishment. The extinguishment included the de-recognition of the original issuance discount of </font><font style="font-family:inherit;font-size:10pt;">$4.3 million</font><font style="font-family:inherit;font-size:10pt;"> and outstanding deferred issuance costs of </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;">. In connection with the repurchase of the February 2018 Notes, the Company unwound a portion of the purchased call options. The unwind transaction of the purchased call option did not result in any cash payments between the parties. In addition, the Company and the counterparties agreed to unwind a portion of the warrants, which also did not result in any cash payments between the parties.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with the accounting guidance for convertible debt instruments that may be settled in cash or other assets on conversion, the Company was required to separately account for the liability component of the instrument in a manner that reflects the market interest rate for a similar nonconvertible instrument at the date of issuance. As a result, the Company separated the principal balance of the February 2018 Notes between the fair value of the debt component and the fair value of the common stock conversion feature. Using an assumed borrowing rate of </font><font style="font-family:inherit;font-size:10pt;">7.0%</font><font style="font-family:inherit;font-size:10pt;">, which represents the estimated market interest rate for a similar nonconvertible instrument available to the Company on the date of issuance, the Company recorded a total debt discount of </font><font style="font-family:inherit;font-size:10pt;">$29.7 million</font><font style="font-family:inherit;font-size:10pt;">, allocated </font><font style="font-family:inherit;font-size:10pt;">$19.3 million</font><font style="font-family:inherit;font-size:10pt;"> to additional paid-in capital and allocated </font><font style="font-family:inherit;font-size:10pt;">$10.4 million</font><font style="font-family:inherit;font-size:10pt;"> to deferred tax liability. The discount was being amortized to interest expense over the term of the February 2018 Notes and increases interest expense during the term of the February 2018 Notes from the </font><font style="font-family:inherit;font-size:10pt;">4.0%</font><font style="font-family:inherit;font-size:10pt;"> cash coupon interest rate to an effective interest rate of </font><font style="font-family:inherit;font-size:10pt;">6.9%</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 1, 2018, upon maturity of the February 2018 Notes, the Company repaid a total cash amount of </font><font style="font-family:inherit;font-size:10pt;">$129.0 million</font><font style="font-family:inherit;font-size:10pt;"> to the custodian, The Bank of New York Mellon Trust Company, N.A., which was comprised of </font><font style="font-family:inherit;font-size:10pt;">$126.4 million</font><font style="font-family:inherit;font-size:10pt;"> in principal amount and </font><font style="font-family:inherit;font-size:10pt;">$2.6 million</font><font style="font-family:inherit;font-size:10pt;"> in accrued interest, to retire the February 2018 Notes.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The carrying value and unamortized discount of the February 2018 Notes were as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(In thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June&#160;30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal amount of the February 2018 Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">126,447</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unamortized discount of liability component</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(381</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net carrying value of the February 2018 Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">126,066</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense for the February 2018 Notes on the Company&#8217;s Condensed Consolidated Statements of Income was as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:start;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(In thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:start;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contractual coupon interest</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,264</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">421</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,529</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:start;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of debt issuance costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">250</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">499</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:start;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of debt discount</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">851</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">293</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,699</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,365</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">802</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,727</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Purchased Call Options and Warrants</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the issuance of the February 2018 Notes, the Company entered into purchased call option transactions with two hedge counterparties. The Company paid an aggregate amount of </font><font style="font-family:inherit;font-size:10pt;">$31.0 million</font><font style="font-family:inherit;font-size:10pt;"> for the purchased call options with terms substantially similar to the embedded conversion options in the February 2018 Notes. The purchased call options covered, subject to anti-dilution and certain other customary adjustments substantially similar to those in the February 2018 Notes, approximately </font><font style="font-family:inherit;font-size:10pt;">13.8 million</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company&#8217;s common stock. The purchased call options expired on February 1, 2018.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, the Company sold to the hedge counterparties warrants exercisable, on a cashless basis, for the sale of rights to receive shares of common stock that will initially underlie the February 2018 Notes at a strike price of </font><font style="font-family:inherit;font-size:10pt;">$10.3610</font><font style="font-family:inherit;font-size:10pt;"> per share, which represents a premium of approximately 30% over the last reported sale price of the Company&#8217;s common stock of </font><font style="font-family:inherit;font-size:10pt;">$7.97</font><font style="font-family:inherit;font-size:10pt;"> on February 6, 2014. The Company received an aggregate amount of </font><font style="font-family:inherit;font-size:10pt;">$11.4 million</font><font style="font-family:inherit;font-size:10pt;"> for the sale from the two counterparties. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The purchased call options and warrants are considered indexed to the Company stock, require net-share settlement, and met all criteria for equity classification at inception and in subsequent periods. The purchased call options cost of </font><font style="font-family:inherit;font-size:10pt;">$31.0 million</font><font style="font-family:inherit;font-size:10pt;">, less deferred taxes of </font><font style="font-family:inherit;font-size:10pt;">$10.8 million</font><font style="font-family:inherit;font-size:10pt;">, and the </font><font style="font-family:inherit;font-size:10pt;">$11.4 million</font><font style="font-family:inherit;font-size:10pt;"> received for the warrants, was recorded as adjustments to additional paid-in capital. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">December 2021 Notes</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 22, 2016, the Company issued </font><font style="font-family:inherit;font-size:10pt;">$150.0 million</font><font style="font-family:inherit;font-size:10pt;"> in aggregate principal amount, at par, of the December 2021 Notes in an underwritten public offering, for net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$145.7 million</font><font style="font-family:inherit;font-size:10pt;">. The December 2021 Notes are due December 1, 2021, and the Company pays interest at </font><font style="font-family:inherit;font-size:10pt;">2.75%</font><font style="font-family:inherit;font-size:10pt;"> on the December 2021 Notes semiannually in arrears on June 1 and December 1 of each year, beginning June 1, 2017. A portion of the proceeds from the December 2021 Notes, net of amounts used for the capped call transaction described below, was used to extinguish </font><font style="font-family:inherit;font-size:10pt;">$120.0 million</font><font style="font-family:inherit;font-size:10pt;"> of the February 2018 Notes.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon the occurrence of a fundamental change, as defined in the indenture, holders have the option to require the Company to repurchase their December 2021 Notes at a purchase price equal to 100% of the principal, plus accrued interest.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The December 2021 Notes are convertible under any of the following circumstances:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During any fiscal quarter (and only during such fiscal quarter) commencing after the fiscal quarter ended June 30, 2017, if the last reported sale price of Company common stock for at least </font><font style="font-family:inherit;font-size:10pt;">20</font><font style="font-family:inherit;font-size:10pt;"> trading days (whether or not consecutive), in the period of </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;"> consecutive trading days, ending on, and including, the last trading day of the immediately preceding fiscal quarter, exceeds </font><font style="font-family:inherit;font-size:10pt;">130%</font><font style="font-family:inherit;font-size:10pt;"> of the conversion price for the notes on each applicable trading day;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the five business-day period immediately after any five consecutive trading-day period, which the Company refers to as the measurement period, in which the trading price per </font><font style="font-family:inherit;font-size:10pt;">$1,000</font><font style="font-family:inherit;font-size:10pt;"> principal amount of notes for each trading day of that measurement period was less than </font><font style="font-family:inherit;font-size:10pt;">98%</font><font style="font-family:inherit;font-size:10pt;"> of the product of the last reported sale price of Company common stock and the conversion rate for the notes for each such trading day; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon the occurrence of specified corporate events as described in the indenture.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The initial conversion rate for the December 2021 Notes is </font><font style="font-family:inherit;font-size:10pt;">262.2951</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company&#8217;s common stock per </font><font style="font-family:inherit;font-size:10pt;">$1,000</font><font style="font-family:inherit;font-size:10pt;"> principal amount of December 2021 Notes, which is equivalent to an initial conversion price of approximately </font><font style="font-family:inherit;font-size:10pt;">$3.81</font><font style="font-family:inherit;font-size:10pt;"> per share of common stock, subject to adjustments upon the occurrence of certain specified events as set forth in the indenture.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with the accounting guidance for convertible debt instruments that may be settled in cash or other assets on conversion, the Company was required to separately account for the liability component of the instrument in a manner that reflects the market interest rate for a similar nonconvertible instrument at the date of issuance. As a result, the Company separated the principal balance of the December 2021 Notes between the fair value of the debt component and the fair value of the common stock conversion feature. Using an assumed borrowing rate of </font><font style="font-family:inherit;font-size:10pt;">9.5%</font><font style="font-family:inherit;font-size:10pt;">, which represents the estimated market interest rate for a similar nonconvertible instrument available to the Company on the date of issuance, the Company recorded a total debt discount of </font><font style="font-family:inherit;font-size:10pt;">$4.3 million</font><font style="font-family:inherit;font-size:10pt;">, allocated </font><font style="font-family:inherit;font-size:10pt;">$23.8 million</font><font style="font-family:inherit;font-size:10pt;"> to additional paid-in capital and allocated </font><font style="font-family:inherit;font-size:10pt;">$12.8 million</font><font style="font-family:inherit;font-size:10pt;"> to deferred tax liability. The discount is being amortized to interest expense over the term of the December 2021 Notes and increases interest expense during the term of the December 2021 Notes from the </font><font style="font-family:inherit;font-size:10pt;">2.75%</font><font style="font-family:inherit;font-size:10pt;"> cash coupon interest rate to an effective interest rate of </font><font style="font-family:inherit;font-size:10pt;">3.4%</font><font style="font-family:inherit;font-size:10pt;">. As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the remaining discount amortization period is </font><font style="font-family:inherit;font-size:10pt;">3.4 years</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The carrying value and unamortized discount of the December 2021 Notes were as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(In thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June&#160;30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal amount of the December 2021 Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">150,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">150,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unamortized discount of liability component</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,055</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32,585</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net carrying value of the December 2021 Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120,945</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">117,415</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense for the December 2021 Notes on the Company&#8217;s Condensed Consolidated Statements of Income was as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:start;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(In thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contractual coupon interest</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,031</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,032</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,062</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,063</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of debt issuance costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of debt discount</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">135</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">131</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">269</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">261</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of conversion feature</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,626</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,469</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,225</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,899</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,811</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,650</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,594</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,259</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the December 2021 Notes are not convertible. At </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the if-converted value of the December 2021 Notes did not exceed the principal amount.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Capped Call Transaction</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#333333;">In connection with the offering of the December 2021 Notes, the Company entered into a privately-negotiated capped call transaction with an affiliate of the underwriter of such issuance.&#160;The aggregate cost of the&#160;capped call&#160;transaction was&#160;</font><font style="font-family:inherit;font-size:10pt;">$14.4 million</font><font style="font-family:inherit;font-size:10pt;">. The&#160;capped call&#160;transaction is generally expected to reduce the potential dilution upon conversion of the December 2021 Notes and/or partially offset any cash payments the Company is required to make in excess of the principal amount of converted December 2021 Notes in the event that the market price per share of the Company&#8217;s common stock, as measured under the terms of the&#160;capped call&#160;transaction, is greater than the strike price of the&#160;capped call&#160;transaction. This initially corresponds to the approximate&#160;</font><font style="font-family:inherit;font-size:10pt;">$3.81</font><font style="font-family:inherit;font-size:10pt;"> per share conversion price of the December 2021 Notes and is subject to anti-dilution adjustments substantially similar to those applicable to the conversion rate of the December 2021 Notes. The cap price of the&#160;capped call&#160;transaction was initially&#160;</font><font style="font-family:inherit;font-size:10pt;">$4.88</font><font style="font-family:inherit;font-size:10pt;"> per share, and is subject to certain adjustments under the terms of the&#160;capped call&#160;transaction. The Company will not be required to make any cash payments to the option counterparty upon the exercise of the options that are a part of the capped call transaction, but the Company will be entitled to receive from it an aggregate amount of cash and/or number of shares of the Company&#8217;s common stock, based on the settlement method election chosen for the related convertible notes, with a value equal to the amount by which the market price per share of the Company&#8217;s common stock, as measured under the terms of the capped call transaction, is greater than the strike price of the capped call transaction during the relevant valuation period under the capped call transaction, with such number of shares of the Company&#8217;s common stock and/or amount of cash subject to the cap price.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluated the&#160;capped call&#160;transaction under authoritative accounting guidance and determined that they should be accounted for as separate transactions and classified as a net reduction to additional paid-in capital within stockholders&#8217; equity with no recurring fair value measurement recorded.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">9. Asset Acquisition</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 8, 2018, LENSAR entered into an Asset Purchase Agreement with Precision Eye Services (&#8220;PES&#8221;) to purchase assets used in PES&#8217; laser-assisted cataract surgery business. The assets purchased include equipment, inventory and PES&#8217; customer contracts. No workforce was transferred as part of the transaction.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company assessed the acquisition of PES assets under ASC Topic 805, Business Combinations (&#8220;ASC 805&#8221;). Under ASC 805, the Company determined that the acquired assets did not constitute a business and that the transaction would be accounted for as an asset acquisition.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the fair values of the identifiable assets acquired and liabilities assumed at the acquisition date (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:89%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equipment and inventory</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">848</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fixed assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets (customer relationships)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,845</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total identifiable assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,760</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consideration paid at closing, cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,200</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Conversion consideration</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">920</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent consideration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">640</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total fair value of consideration</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,760</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Adopted Accounting Pronouncements</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-15, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Classification of Certain Cash Receipts and Cash Payments</font><font style="font-family:inherit;font-size:10pt;">. The new standard provides for specific guidance how certain transactions are classified in the statement of cash flows. Effective January 1, 2018, the Company adopted the requirements of ASU No. 2016-15. The adoption did not have an effect on the Consolidated Financial Statements on the adoption date and no adjustment to prior year Consolidated Financial Statements was required.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2016, the FASB issued ASU No. 2016-16, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Intra-Entity Transfers of Assets Other Than Inventory</font><font style="font-family:inherit;font-size:10pt;">, which requires companies to account for the income tax effects of intercompany sales and transfers of assets other than inventory in the period in which the transfer occurs. Effective January 1, 2018, the Company adopted the requirements of ASU No. 2016-16. The adoption did not have an effect on the Consolidated Financial Statements on the adoption date and no adjustment to prior year Consolidated Financial Statements was required.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2016, the FASB issued ASU No. 2016-18, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cash</font><font style="font-family:inherit;font-size:10pt;">, which requires entities to show the changes in total of cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. Effective January 1, 2018, the Company adopted the requirements of ASU No. 2016-18. The adoption did not have an effect on the Consolidated Financial Statements on the adoption date and no adjustment to prior year Consolidated Financial Statements was required.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU No. 2014-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;"> (Topic 606). Effective January 1, 2018, the Company adopted the requirements of ASU No. 2014-09 using the modified retrospective method as discussed in Note 2 below. All amounts and disclosures set forth in this Quarterly Report on Form 10-Q reflect these changes.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Issued Accounting Pronouncements</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;">, which seeks to increase transparency and comparability among organizations by, among other things, recognizing lease assets and lease liabilities on the balance sheet for leases classified as operating leases under previous GAAP and disclosing key information about leasing arrangements. ASU No. 2016-02 becomes effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the provisions of ASU No. 2016-02 and assessing the impact, if any, it may have on the Company&#8217;s Condensed Consolidated Financial Statements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU No. 2016-13,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments</font><font style="font-family:inherit;font-size:10pt;">. The new guidance amends the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology, which will result in more timely recognition of losses. ASU No. 2016-13 has an effective date of the fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company is currently evaluating ASU No. 2016-13 and assessing the impact, if any, it may have to the Company&#8217;s consolidated results of operations, financial position and cash flows.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">14. Other Long-Term Liabilities</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other long-term liabilities consist of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued lease liability</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term incentive accrual</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,978</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,729</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Uncertain tax positions</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,133</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,682</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term deferred tax liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,538</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,208</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend payable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">405</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">343</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,799</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,709</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Spin-Off, the Company entered into amendments to the leases for the Company&#8217;s former facilities in Redwood City, California, by which the Company has in substance guaranteed the payments under the lease agreements for the Redwood City facilities. For further discussion of the Spin-Off and the lease guarantee, see Note 12. The Company has recorded a liability of </font><font style="font-family:inherit;font-size:10pt;">$10.7 million</font><font style="font-family:inherit;font-size:10pt;"> on the Company&#8217;s Condensed Consolidated Balance Sheets as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, related to this guarantee.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2. Revenue from Contracts with Customers</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Adoption of New Revenue Standard</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU No. 2014-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;"> that supersedes Accounting Standards Codification (&#8220;ASC&#8221;) Topic 605, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition</font><font style="font-family:inherit;font-size:10pt;">. Subsequently, the FASB issued several updates to ASU No. 2014-09, which are pending content or otherwise codified in ASC Topic 606 (&#8220;ASC 606&#8221;). ASC 606 also includes new guidance on costs related to a contract, which is codified in ASC Subtopic 340-40. The Company adopted ASC 606 on January 1, 2018 using the modified retrospective method for all contracts not substantially completed as of the date of adoption. The cumulative impact of the adoption ASC 606 was not material to the Company therefore the Company did not record any adjustments to retained earnings. The reported results for 2018 reflect the application of ASC 606 guidance while the reported results for 2017 were prepared under the guidance of ASC Topic 605, which is also referred to herein as &#8220;legacy GAAP&#8221; or the &#8220;previous guidance&#8221;. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">A. Significant Accounting Policy</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with ASC 606, revenue is recognized when a customer obtains control of promised products and services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these products and services. A five-step model is utilized to achieve the core principle and includes the following steps: (1) identify the customer contract; (2) identify the contract&#8217;s performance obligation; (3) determine the transactions price; (4) allocate the transactions price to the performance obligation; and (5) recognize revenue when the performance obligation is satisfied.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">B. Practical Expedients</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from revenue.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost and are included in cost of revenues.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sales commissions and other incremental costs of obtaining contracts are expensed as incurred as the amortization periods are less than one year.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">C. Nature of Goods and Services</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a description of principal activities - separated by reportable segments - from which the Company generates its revenue. For more detailed information about reportable segments, see Note 20.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">i. Pharmaceutical</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The pharmaceutical segment of the Company principally generates revenue from products sold to wholesalers and distributors. Customer orders are generally fulfilled within a few days of receipt resulting in minimal order backlog. Contractual performance obligations are usually limited to transfer of the product to the customer. The transfer occurs either upon shipment or upon receipt of the product in certain non-U.S. countries after considering when the customer obtains control of the product. In addition, for some non-U.S. countries, the Company sells product on a consignment basis where control is not transferred until the customer resells the product to an end user. At these points, customers are able to direct the use of and obtain substantially all of the remaining benefits of the product.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sales to customers are initially invoiced at contractual list prices. Payment terms are typically 30 to 90 days based on customary practice in each country. Revenue is reduced from the list price at the time of recognition for expected charge-backs, discounts, rebates, sales allowances and product returns, which are referred to as gross-to-net adjustments. These reductions are attributed to various commercial agreements, managed healthcare organizations and government programs such as Medicare, Medicaid, and the 340B Drug Pricing Program containing various pricing implications such as mandatory discounts, pricing protection below wholesaler list price and other discounts when Medicare Part D beneficiaries are in the coverage gap. These various reductions in the transaction price have been estimated using either a most likely amount or expected value method depending on their nature and have been reflected as liabilities and are settled through cash payments, typically within time periods ranging from a few months to one year. Significant judgment is required in estimating gross-to-net adjustments considering legal interpretations of applicable laws and regulations, historical experience, payer channel mix, current contract prices under applicable programs, unbilled claims, processing time lags and inventory levels in the distribution channel.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">ii. Medical Devices</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The medical devices segment of the Company principally generates revenue from the sale and lease of the LENSAR</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:inherit;font-size:10pt;">Laser System (&#8220;LLS&#8221;), related procedure devices and licenses, and service agreements. </font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For bundled packages, the Company accounts for individual products and services separately if they are distinct - i.e. if a product or service is separately identifiable from other items in the bundled package and if the customer can benefit from it on its own or with other resources that are readily available to the customer. As the Company both sells and leases the LLS, the consideration (including any discounts) is first allocated between lease and non-lease components and then allocated between the separate products and services based on their stand-alone selling prices. The consideration (including any discounts) is allocated between separate products and services in a bundle based on their stand-alone selling prices. The stand-alone selling prices for the Patient Interface Devices (&#8220;PIDs&#8221;) and procedure licenses are determined based on the prices at which the Company separately sells the PIDs and procedure licenses. The LLS system and warranty stand-alone selling prices are determined using the expected cost plus a margin approach. </font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company sells and leases the LLS to customers. For LSS sales, the Company recognizes revenue in products revenue when a customer takes possession of the system. This usually occurs after the customer signs a contract, LENSAR installs the system, and LENSAR performs the requisite training for use of the system. For LLS leases, the Company recognizes revenue in products revenue over the length of the lease in products revenue in accordance with ASC Topic 840, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The LLS requires both a consumable, a PID, and a procedure license to perform each procedure. The Company recognizes revenue for PIDs in products revenue when the customer takes possession of the PID. PIDs are sold by the case. The Company recognizes revenue for procedure licenses in products revenue when a customer purchases a procedure license from the web portal. Typically, consideration for PIDs and procedure licenses is considered fixed consideration except as noted below. Certain customer agreements provide for variable consideration through tiered volume discount pricing.</font></div><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company provides an extended warranty that provides additional services beyond the standard warranty. The Company recognizes revenue in products revenue over the warranty period. Customers have the option of renewing the warranty period, which is considered a new and separate contract.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">iii. Income Generating Assets</font></div><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Licenses of intellectual property:&#160;If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license.</font></div><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2018, DFM, LLC, a wholly-owned subsidiary of the Company, granted an exclusive license related to certain Direct Flow Medical assets in exchange for </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> in cash and up to </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;"> in royalty payments. The </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> payment was accounted for in accordance with ASC 606 under which the full cash payment was recognized as revenue in the first quarter of 2018 as DFM, LLC had fulfilled its performance obligation under the agreement.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Royalties:&#160;The Company recognizes royalty revenues related to the sale of products by its licensees that incorporate the Company's technologies. Royalties qualify for the sales-and-usage exemption under Topic 606 as (i) royalties are based strictly on the sales-and-usage by the licensee; and (ii) a license of IP is the sole or predominant item to which such royalties relate. Based on this exemption, these royalties are earned under the terms of a license agreement in the period the products are sold by the Company's partner and the Company has a present right to payment.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">D. Disaggregation of Revenue</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company disaggregates its revenue from contracts with customers by segment and geographic location, as the Company believes it best depicts how the nature, amount, timing and uncertainty of its revenue and cash flows are affected by economic factors. In the following table, revenue is disaggregated by segment and primary geographical market for the three and six months ended June 30, 2018:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Medical Devices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pharmaceutical</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Medical Devices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pharmaceutical</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Primary geographical markets:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">North America</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">615</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,776</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,319</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,707</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Europe</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">679</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,371</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,294</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,362</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Asia</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,643</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,732</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,757</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,152</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">107</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">220</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenue from contracts with customers</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">1</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,044</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,879</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,590</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,221</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">_______________</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">1</sup></font><font style="font-family:inherit;font-size:10pt;"> The table above does not include Medical Device lease revenue of </font><font style="font-family:inherit;font-size:10pt;">$2.8 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$4.3 million</font><font style="font-family:inherit;font-size:10pt;"> for the three and six months ended June 30, 2018, respectively.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">E. Contract Balances</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides information about receivables, contract assets and contract liabilities from contracts with customers:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:66%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">January 1, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Receivables, current and non-current, net</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,970</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,771</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,235</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,114</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,084</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Receivables, Net</font><font style="font-family:inherit;font-size:10pt;">&#8212;Receivables, net, include amounts billed and currently due from customers. The amounts due are stated at their net estimated realizable value. The Company maintains an allowance for doubtful accounts to provide for the estimated amount of receivables that will not be collected. The allowance is based upon an assessment of customer creditworthiness, historical payment experience, the age of outstanding receivables and collateral to the extent applicable.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contract assets</font><font style="font-family:inherit;font-size:10pt;">&#8212;The Company&#8217;s contract assets represent revenue recognized for performance obligations completed before an unconditional right to payment exists, and therefore invoicing or associated reporting from the customer regarding the computation of the net product sales has not yet occurred. The Company classifies contract assets as current based on the timing of when it expects to receive payment and is included in prepaid and other current assets in the Company&#8217;s consolidated balance sheets.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:52%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Medical Devices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pharmaceutical</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract assets at January 1, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract assets recognized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,235</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,235</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract assets at June 30, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,235</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,235</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contract Liabilities</font><font style="font-family:inherit;font-size:10pt;">&#8212;The Company&#8217;s contract liabilities consist of deferred revenue for products sold to customers for which the performance obligation has not been completed by the Company. The Company classifies deferred revenue as current or noncurrent based on the timing of when it expects to recognize revenue. The noncurrent portion of deferred revenue is included in other long-term liabilities in the Company&#8217;s consolidated balance sheets.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Medical Devices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pharmaceutical</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liabilities at January 1, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,391</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,693</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,084</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">547</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,880</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,427</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amounts recognized into revenue</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(704</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,693</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,397</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liabilities at June 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,234</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,880</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,114</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">F. Transaction Price Allocated to Future Performance Obligations</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period.</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:54%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Thereafter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pharmaceutical product sales</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medical device product sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,878</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,352</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,230</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company does not disclose the value of unsatisfied performance obligations for (i) contracts with original expected lengths of one year or less or (ii) contracts for which the Company recognizes revenue at the amount to which it has the right to invoice for the products delivered or services performed.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period.</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:54%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Thereafter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pharmaceutical product sales</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medical device product sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,878</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,352</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,230</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The components of intangible assets as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> were as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.60975609756098%;border-collapse:collapse;text-align:left;"><tr><td colspan="25" rowspan="1"></td></tr><tr><td style="width:28%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross Carrying Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Carrying Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross Carrying Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Carrying Amount</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finite-lived intangible assets:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquired products rights</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,143</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,143</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">216,690</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32,503</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">184,187</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer relationships</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1) (2)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,028</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(341</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,687</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,080</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,729</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,351</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquired technology</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2) (3)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,011</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(806</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,205</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,200</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(409</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,791</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquired trademarks</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">570</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(133</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">437</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">570</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">494</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,752</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,280</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,472</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">252,540</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(36,717</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">215,823</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">________________</font></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:18px;text-indent:-18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1)&#160;The Company acquired certain intangible assets as part of the Noden Transaction. They are amortized on a straight-line basis over a weighted average period of </font><font style="font-family:inherit;font-size:10pt;">8.0 years</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:18px;text-indent:-18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2) The Company acquired certain intangible assets as part of the LENSAR transaction, as described further in Note 19. They are amortized over a weighted average period of 15.0 years. The intangible assets for acquired technology and trademarks are being amortized over their estimated useful lives using the straight-line method of amortization. The intangible assets for customer relationships are being amortized using a double-declining method of amortization as such method better represents the economic benefits to be obtained.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company acquired certain intangible assets as part of the foreclosure on certain of Direct Flow Medical assets, as described further in Note 7. They are amortized over a weighted average period of 10.0 years. The intangible assets for acquired technology are being amortized over their estimated useful lives using the straight-line method of amortization.</font></div></td></tr></table></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21" rowspan="1"></td></tr><tr><td style="width:46%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Reported as:</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;Unrealized Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;Estimated Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;Cash and Cash Equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Short-Term Investments</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,548</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,548</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,548</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">324,105</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">324,105</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">324,105</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">395,653</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">395,653</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">395,653</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109,703</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109,703</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109,703</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">417,563</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">417,563</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">417,563</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,353</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,495</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,848</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,848</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">530,619</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,495</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">532,114</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">527,266</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,848</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the fair values of the identifiable assets acquired and liabilities assumed at the acquisition date (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:89%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equipment and inventory</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">848</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fixed assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets (customer relationships)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,845</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total identifiable assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,760</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consideration paid at closing, cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,200</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Conversion consideration</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">920</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent consideration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">640</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total fair value of consideration</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,760</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the fair values of the identifiable intangible assets acquired and liabilities assumed at the acquisition date (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:88%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,983</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,647</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,970</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net deferred tax assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,723</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total identifiable assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58,323</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,673</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities assumed</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,673</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss on derecognition of notes receivables</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,615</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gain on bargain purchase, net of loss on extinguishment of notes receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,309</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total fair value of consideration</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,726</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">______________</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font><font style="font-family:inherit;font-size:10pt;"> As of the effective date of the transaction, identifiable intangible assets are required to be measured at fair value.&#160; The fair value measurement is based on significant inputs that are unobservable in the market and thus represents a Level 3 measurement. The Company used an income approach to estimate the preliminary fair value of the intangibles which includes technology, trademarks and customer relationships. The assumptions used to estimate the cash flows of the business included a discount rate of 16%, estimated gross margins ranging from 37-72%, income tax rate of 35%, and operating expenses consisting of direct costs based on the anticipated level of revenues.&#160;&#160;The intangible assets have a weighted-average useful life of approximately 15.0 years.&#160;The intangible assets for acquired technology and trademarks are being amortized over their estimated useful lives using the straight-line method of amortization. The intangible assets for customer relationship are being amortized using a double-declining method of amortization as such method better represents the economic benefits to be obtained.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15" rowspan="1"></td></tr><tr><td style="width:30%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:27%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Principal Balance Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Carrying Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Maturity Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(In thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 2018 Notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 1, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">126,066</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 2021 Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 1, 2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">150,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120,945</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">117,415</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120,945</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">243,481</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Income (Loss) per Basic and Diluted Share:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="vertical-align:top;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;vertical-align:top;">&#160;</font><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;vertical-align:top;">(in thousands except per share amounts)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Numerator</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) attributable to PDL&#8217;s shareholders used to compute net income per basic and diluted share</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(112,296</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,439</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(110,694</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,680</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Denominator</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total weighted average shares used to compute net income attributable to PDL&#8217;s shareholders, per basic share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">146,923</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">155,654</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">149,186</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">159,677</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock outstanding</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">740</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">491</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares used to compute net income (loss) attributable to PDL&#8217;s shareholders, per diluted share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">146,923</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">156,394</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">149,186</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">160,168</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net income (loss) attributable to PDL&#8217;s shareholders per share - basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.76</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.39</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.74</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.42</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net income (loss) attributable to PDL&#8217;s shareholders per share - diluted</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.39</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.74</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="33" rowspan="1"></td></tr><tr><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June&#160;30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial assets:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">324,105</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">324,105</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">417,563</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">417,563</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,848</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,848</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">103</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">103</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Royalty rights - at fair value</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">335,163</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">335,163</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">349,223</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">349,223</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">324,105</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">103</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">335,163</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">659,371</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">422,411</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">349,223</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">771,663</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial liabilities:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent consideration, current</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">1</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,140</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,140</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent consideration, non-current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,900</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,900</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,040</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,040</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories consisted of the following:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,771</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,717</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work in process</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,677</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,119</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finished goods</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,353</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,311</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,801</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,147</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued lease liability</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term incentive accrual</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,978</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,729</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Uncertain tax positions</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,133</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,682</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term deferred tax liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,538</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,208</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend payable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">405</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">343</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,799</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,709</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The percentage of total revenue recognized, which individually accounted for 10% or more of the Company&#8217;s total revenues, was as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:48%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Licensee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Product Name</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Biogen</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Tysabri</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depomed</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Glumetza, Janumet XR, Jentadueto XR, Synjardy XR and Invokamet XR</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">N/A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Tekturna, Tekturna HCT, Rasilez and Rasilez HCT</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">LENSAR</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">LENSAR Laser System</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1%</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Information regarding the Company&#8217;s segments for the three and </font><font style="font-family:inherit;font-size:10pt;">six months ended</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">&#160;and&#160;</font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#160;is as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenues by segment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pharmaceutical</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,879</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,212</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,221</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,794</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medical devices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,882</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,617</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,864</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,617</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income generating assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,814</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">125,006</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,008</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">157,864</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,575</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">143,835</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85,093</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">189,275</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income (loss) by segment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pharmaceutical</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(111,335</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(891</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(113,048</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,624</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medical devices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,904</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,195</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,491</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,195</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income generating assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">943</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,525</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,845</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73,499</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total net income (loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(112,296</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,439</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(110,694</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,680</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Information regarding the Company&#8217;s segments as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> is as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Long-lived assets by segment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June&#160;30, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pharmaceutical</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,474</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">822</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medical devices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,606</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,263</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income generating assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">143</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">137</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total long-lived assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,223</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,222</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on the intangible assets recorded at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, and assuming no subsequent additions to or impairment of the underlying assets, the remaining estimated amortization expense is expected to be as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:83%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fiscal Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018 (Remaining six months)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,154</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,275</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,240</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,209</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,104</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,040</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,450</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total remaining estimated amortization expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,472</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">20. Segment Information</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with acquiring 100% of the equity interests of LENSAR in May 2017, the Company added a third reportable segment, &#8220;Medical Devices&#8221; and renamed the previous product sales segment &#8220;Pharmaceutical&#8221;.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Information regarding the Company&#8217;s segments for the three and </font><font style="font-family:inherit;font-size:10pt;">six months ended</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">&#160;and&#160;</font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#160;is as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenues by segment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pharmaceutical</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,879</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,212</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,221</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,794</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medical devices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,882</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,617</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,864</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,617</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income generating assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,814</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">125,006</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,008</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">157,864</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,575</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">143,835</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85,093</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">189,275</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income (loss) by segment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pharmaceutical</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(111,335</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(891</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(113,048</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,624</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medical devices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,904</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,195</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,491</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,195</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income generating assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">943</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,525</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,845</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73,499</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total net income (loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(112,296</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,439</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(110,694</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,680</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Information regarding the Company&#8217;s segments as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> is as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Long-lived assets by segment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June&#160;30, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pharmaceutical</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,474</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">822</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medical devices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,606</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,263</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income generating assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">143</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">137</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total long-lived assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,223</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,222</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The operations for the Company&#8217;s Pharmaceutical and Medical Devices segments are primarily located in Ireland and the United Stated, respectively.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1. Summary of Significant Accounting Policies</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited Condensed Consolidated Financial Statements of PDL Biopharma, Inc. and its subsidiaries (collectively, the &#8220;Company&#8221; or &#8220;PDL&#8221;) have been prepared in accordance with Generally Accepted Accounting Principles (United States) (&#8220;GAAP&#8221;) for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments), that management of the Company believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited Condensed Consolidated Financial Statements and related financial information should be read in conjunction with the Company&#8217;s audited Consolidated Financial Statements and the related notes thereto for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, included in its Annual Report on Form 10-K for the fiscal year ended December 31, 2017, filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on March 16, 2018. The Condensed Consolidated Balance Sheet at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, has been derived from the audited Consolidated Financial Statements at that date, but does not include all disclosures required by GAAP.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Significant Accounting Policies</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s significant accounting policies are described in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended&#160;December&#160;31, 2017. Summarized below are the accounting pronouncements adopted subsequent to December 31, 2017.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Adopted Accounting Pronouncements</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-15, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Classification of Certain Cash Receipts and Cash Payments</font><font style="font-family:inherit;font-size:10pt;">. The new standard provides for specific guidance how certain transactions are classified in the statement of cash flows. Effective January 1, 2018, the Company adopted the requirements of ASU No. 2016-15. The adoption did not have an effect on the Consolidated Financial Statements on the adoption date and no adjustment to prior year Consolidated Financial Statements was required.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2016, the FASB issued ASU No. 2016-16, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Intra-Entity Transfers of Assets Other Than Inventory</font><font style="font-family:inherit;font-size:10pt;">, which requires companies to account for the income tax effects of intercompany sales and transfers of assets other than inventory in the period in which the transfer occurs. Effective January 1, 2018, the Company adopted the requirements of ASU No. 2016-16. The adoption did not have an effect on the Consolidated Financial Statements on the adoption date and no adjustment to prior year Consolidated Financial Statements was required.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2016, the FASB issued ASU No. 2016-18, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cash</font><font style="font-family:inherit;font-size:10pt;">, which requires entities to show the changes in total of cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. Effective January 1, 2018, the Company adopted the requirements of ASU No. 2016-18. The adoption did not have an effect on the Consolidated Financial Statements on the adoption date and no adjustment to prior year Consolidated Financial Statements was required.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU No. 2014-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;"> (Topic 606). Effective January 1, 2018, the Company adopted the requirements of ASU No. 2014-09 using the modified retrospective method as discussed in Note 2 below. All amounts and disclosures set forth in this Quarterly Report on Form 10-Q reflect these changes.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Issued Accounting Pronouncements</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;">, which seeks to increase transparency and comparability among organizations by, among other things, recognizing lease assets and lease liabilities on the balance sheet for leases classified as operating leases under previous GAAP and disclosing key information about leasing arrangements. ASU No. 2016-02 becomes effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the provisions of ASU No. 2016-02 and assessing the impact, if any, it may have on the Company&#8217;s Condensed Consolidated Financial Statements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU No. 2016-13,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments</font><font style="font-family:inherit;font-size:10pt;">. The new guidance amends the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology, which will result in more timely recognition of losses. ASU No. 2016-13 has an effective date of the fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company is currently evaluating ASU No. 2016-13 and assessing the impact, if any, it may have to the Company&#8217;s consolidated results of operations, financial position and cash flows.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">17. Stockholders&#8217; Equity</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock Repurchase Program</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 1, 2017, the Company&#8217;s board of directors authorized the repurchase through March 2018 of issued and outstanding shares of the Company&#8217;s common stock having an aggregate value of up to </font><font style="font-family:inherit;font-size:10pt;">$30.0 million</font><font style="font-family:inherit;font-size:10pt;"> pursuant to a&#160;share repurchase program. The repurchases under the&#160;share repurchase&#160;program were made from time to time in the open market or in privately negotiated transactions and were funded from the Company&#8217;s working capital. All shares of common stock repurchased under the Company&#8217;s&#160;share repurchase&#160;program were retired and restored to authorized but unissued shares of common stock at June 30, 2017. The Company repurchased </font><font style="font-family:inherit;font-size:10pt;">13.3 million</font><font style="font-family:inherit;font-size:10pt;"> shares of its common stock under the&#160;share repurchase&#160;program during the fiscal year ended December 31, 2017, for an aggregate purchase price of </font><font style="font-family:inherit;font-size:10pt;">$30.0 million</font><font style="font-family:inherit;font-size:10pt;">, or an average cost of </font><font style="font-family:inherit;font-size:10pt;">$2.25</font><font style="font-family:inherit;font-size:10pt;"> per share, including trading commission.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 25, 2017, the Company&#8217;s board of directors authorized the repurchase of issued and outstanding shares of the Company&#8217;s common stock having an aggregate value of up to </font><font style="font-family:inherit;font-size:10pt;">$25.0 million</font><font style="font-family:inherit;font-size:10pt;"> pursuant to a new share repurchase program. The repurchases under the&#160;new share repurchase&#160;program are made from time to time in the open market or in privately negotiated transactions and are funded from the Company&#8217;s working capital. The amount and timing of such repurchases are dependent upon the price and availability of shares, general market conditions and the availability of cash. Repurchases may also be made under a trading plan under Rule 10b5-1, which would permit shares to be repurchased when the Company might otherwise be precluded from doing so because of self-imposed trading blackout periods or other regulatory restrictions. All shares of common stock repurchased under the Company&#8217;s&#160;new share repurchase&#160;program are expected to be retired and restored to authorized but unissued shares of common stock. The Company repurchased </font><font style="font-family:inherit;font-size:10pt;">6.8 million</font><font style="font-family:inherit;font-size:10pt;"> shares of its common stock under the share repurchase program during the three months ended June 30, 2018, for an aggregate purchase price of </font><font style="font-family:inherit;font-size:10pt;">$19.4 million</font><font style="font-family:inherit;font-size:10pt;">, or an average cost of </font><font style="font-family:inherit;font-size:10pt;">$2.87</font><font style="font-family:inherit;font-size:10pt;"> per share, including trading commissions, and a total of </font><font style="font-family:inherit;font-size:10pt;">8.2 million</font><font style="font-family:inherit;font-size:10pt;"> shares of its common stock during the six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, for an aggregate purchase price of </font><font style="font-family:inherit;font-size:10pt;">$23.6 million</font><font style="font-family:inherit;font-size:10pt;">, or an average cost of </font><font style="font-family:inherit;font-size:10pt;">$2.89</font><font style="font-family:inherit;font-size:10pt;"> per share, including trading commission. All shares repurchased were retired.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From July 1, 2018 to July 5, 2018, the Company completed the </font><font style="font-family:inherit;font-size:10pt;">$25.0 million</font><font style="font-family:inherit;font-size:10pt;"> share repurchase program by repurchasing approximately </font><font style="font-family:inherit;font-size:10pt;">0.6 million</font><font style="font-family:inherit;font-size:10pt;"> shares of its common stock at a weighted average price of </font><font style="font-family:inherit;font-size:10pt;">$2.44</font><font style="font-family:inherit;font-size:10pt;"> per share for a total of </font><font style="font-family:inherit;font-size:10pt;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;">. The total amounts repurchased by the Company under the share repurchase program equal approximately </font><font style="font-family:inherit;font-size:10pt;">8.7 million</font><font style="font-family:inherit;font-size:10pt;"> shares of its common stock for an aggregate purchase price of </font><font style="font-family:inherit;font-size:10pt;">$25.0 million</font><font style="font-family:inherit;font-size:10pt;">, or an average cost of </font><font style="font-family:inherit;font-size:10pt;">$2.89</font><font style="font-family:inherit;font-size:10pt;"> per share, including trading commissions.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">21. Subsequent Events</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Share Repurchase Program </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From July 1, 2018 to July 5, 2018, the Company completed the </font><font style="font-family:inherit;font-size:10pt;">$25.0 million</font><font style="font-family:inherit;font-size:10pt;"> share repurchase program by repurchasing approximately </font><font style="font-family:inherit;font-size:10pt;">0.6 million</font><font style="font-family:inherit;font-size:10pt;"> shares of its common stock at a weighted average price of </font><font style="font-family:inherit;font-size:10pt;">$2.44</font><font style="font-family:inherit;font-size:10pt;"> per share for a total of </font><font style="font-family:inherit;font-size:10pt;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;">. The total amounts repurchased by the Company under the share repurchase program equal approximately </font><font style="font-family:inherit;font-size:10pt;">8.7 million</font><font style="font-family:inherit;font-size:10pt;"> shares of its common stock for an aggregate purchase price of </font><font style="font-family:inherit;font-size:10pt;">$25.0 million</font><font style="font-family:inherit;font-size:10pt;">, or an average cost of </font><font style="font-family:inherit;font-size:10pt;">$2.89</font><font style="font-family:inherit;font-size:10pt;"> per share, including trading commissions.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Depomed Reversionary Interest Purchase</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On August 2, 2018, PDL Investment Holding, LLC (&#8220;PDLIH&#8221;), a subsidiary of the Company, entered into an amendment of the Depomed Royalty Agreement, pursuant to which PDLIH, as an assignee of the Company, acquired all of Depomed&#8217;s remaining rights to royalties and milestones payable on sales of type 2 diabetes products licensed by Depomed for up to </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;">. Prior to this amendment of the Depomed Royalty Agreement, the Company would have shared future royalties equally with Depomed after total cash received by the Company reached </font><font style="font-family:inherit;font-size:10pt;">$481.0 million</font><font style="font-family:inherit;font-size:10pt;">, or two times the Company&#8217;s original investment, which the Company expects to occur by October 2020.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On August 2, 2018, under the terms of the amendment, the Company made an initial payment of </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> to Depomed. On August 7, 2018, an additional </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> payment was made to Depomed, as certain conditions specified in the amendment were met.</font></div></div> unaudited Net of tax of zero and zero for the three months ended June 30, 2018 and 2017, respectively Note 1 (1) As of the effective date of the transaction, identifiable intangible assets are required to be measured at fair value. The fair value measurement is based on significant inputs that are unobservable in the market and thus represents a Level 3 measurement. The Company used an income approach to estimate the preliminary fair value of the intangibles which includes technology, trademarks and customer relationships. The assumptions used to estimate the cash flows of the business included a discount rate of 16%, estimated gross margins ranging from 37-72%, income tax rate of 35%, and operating expenses consisting of direct costs based on the anticipated level of revenues. The intangible assets have a weighted-average useful life of approximately 15.0 years. The intangible assets for acquired technology and trademarks are being amortized over their estimated useful lives using the straight-line method of amortization. The intangible assets for customer relationship are being amortized using a double-declining method of amortization as such method better represents the economic benefits to be obtained. unaudited EX-101.SCH 9 pdli-20180630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2111100 - Disclosure - Accrued Liabilities link:presentationLink link:calculationLink link:definitionLink 2311302 - Disclosure - Accrued Liabilities Accrued Liabilities, Current (Tables) link:presentationLink link:calculationLink link:definitionLink 2411404 - Disclosure - Accrued Liabilities (Accrued Liabilities) (Detail) link:presentationLink link:calculationLink link:definitionLink 2411403 - Disclosure - Accrued Liabilities (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2311301 - Disclosure - Accrued Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 2120100 - Disclosure - Accumulated Other Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 2420402 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2420403 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Schedule of Balances of Accumulated Other Comprehensive Income (Loss)) (Detail) link:presentationLink link:calculationLink link:definitionLink 2320301 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables) link:presentationLink link:calculationLink link:definitionLink 2431403 - Disclosure - Asset Acquisitions Asset Acquisition Details (Details) link:presentationLink link:calculationLink link:definitionLink 2431402 - Disclosure - Asset Acquisitions (Details) link:presentationLink link:calculationLink link:definitionLink 2131100 - Disclosure - Asset Acquisitions (Notes) link:presentationLink link:calculationLink link:definitionLink 2331301 - Disclosure - Asset Acquisitions (Tables) link:presentationLink link:calculationLink link:definitionLink 2425405 - Disclosure - Business Combinations Asset and Liabilities Acquired (Details) link:presentationLink link:calculationLink link:definitionLink 2425403 - Disclosure - Business Combinations (Details) link:presentationLink link:calculationLink link:definitionLink 2325302 - Disclosure - Business Combinations Fair Value of Intangible Assets Acquired and Liabilities Assumed (Tables) link:presentationLink link:calculationLink link:definitionLink 2125100 - Disclosure - Business Combinations (Notes) link:presentationLink link:calculationLink link:definitionLink 2425404 - Disclosure - Business Combinations Proforma (Details) link:presentationLink link:calculationLink link:definitionLink 2325301 - Disclosure - Business Combinations (Tables) link:presentationLink link:calculationLink link:definitionLink 2117100 - Disclosure - Cash Dividends link:presentationLink link:calculationLink link:definitionLink 2417402 - Disclosure - Cash Dividends (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2417403 - Disclosure - Cash Dividends (Summary of Conversion Rates for Convertible Notes) (Detail) link:presentationLink link:calculationLink link:definitionLink 2317301 - Disclosure - Cash Dividends (Tables) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Cash Equivalents and Investments link:presentationLink link:calculationLink link:definitionLink 2405404 - Disclosure - Cash Equivalents and Investments (Available-For-Sale Securities Balance Sheet Classification) (Detail) link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Cash Equivalents and Investments (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2405403 - Disclosure - Cash Equivalents and Investments (Summary of Cash and Available-For-Sale Securities) (Detail) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Cash Equivalents and Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2412403 - Disclosure - Commitments and Contingencies (Future Minimum Operating Lease Payments) (Detail) link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - Commitments and Contingencies (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2312301 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1003501 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1002501 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parentheticals) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) link:presentationLink link:calculationLink link:definitionLink 2414400 - Disclosure - Convertible and Non-Recourse Notes (Future Minimum Principal Payments) (Detail) link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - Convertible Notes link:presentationLink link:calculationLink link:definitionLink 2413411 - Disclosure - Convertible Notes Convertible Notes (Interest Expense for December 2021 Notes) (Details) link:presentationLink link:calculationLink link:definitionLink 2413409 - Disclosure - Convertible Notes Convertible Notes (Interest Expense for February 2018 Notes) (Detail) (Details) link:presentationLink link:calculationLink link:definitionLink 2413410 - Disclosure - Convertible Notes Convertible Notes (Summary of December 2021 Notes) (Details) link:presentationLink link:calculationLink link:definitionLink 2413408 - Disclosure - Convertible Notes Convertible Notes (Summary of February 2018 Notes) (Detail) (Details) link:presentationLink link:calculationLink link:definitionLink 2413407 - Disclosure - Convertible Notes (Interest Expense for the May 2015 Notes) (Detail) link:presentationLink link:calculationLink link:definitionLink 2413405 - Disclosure - Convertible Notes (Interest Expense for the Series 2012 Notes) (Detail) link:presentationLink link:calculationLink link:definitionLink 2413402 - Disclosure - Convertible Notes (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2413403 - Disclosure - Convertible Notes (Summary of Convertible Notes) (Detail) link:presentationLink link:calculationLink link:definitionLink 2413406 - Disclosure - Convertible Notes (Summary of May 2015 Notes) (Detail) link:presentationLink link:calculationLink link:definitionLink 2413404 - Disclosure - Convertible Notes (Summary of Series 2012 Notes) (Detail) link:presentationLink link:calculationLink link:definitionLink 2313301 - Disclosure - Convertible Notes (Tables) link:presentationLink link:calculationLink link:definitionLink 2118100 - Disclosure - Customer Concentration link:presentationLink link:calculationLink link:definitionLink 2418402 - Disclosure - Customer Concentration (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2418403 - Disclosure - Customer Concentration (Percentage of Total Revenue From Licenses Over 10% of Revenue) (Detail) link:presentationLink link:calculationLink link:definitionLink 2318301 - Disclosure - Customer Concentration (Tables) link:presentationLink link:calculationLink link:definitionLink 2418404 - Disclosure - Customer Concentration (Total Revenues by Geographic Area) (Detail) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2404403 - Disclosure - Fair Value Measurements (Financial Instruments Measured at Fair Value on a Recurring Basis) (Detail) link:presentationLink link:calculationLink link:definitionLink 2404405 - Disclosure - Fair Value Measurements Level 3 Unobservable Input Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - Fair Value Measurements (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2404404 - Disclosure - Fair Value Measurements (Schedule of Fair Value of Assets and Liabilities not Subject to Fair Value Recognition) (Detail) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Foreign Currency Hedging link:presentationLink link:calculationLink link:definitionLink 2406404 - Disclosure - Foreign Currency Hedging (Fair Value of Foreign Currency Exchange Contracts on Condensed Consolidated Balance Sheet) (Detail) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Foreign Currency Hedging (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2406405 - Disclosure - Foreign Currency Hedging (Schedule of Effect of Derivative Instruments in Consolidated Statements of Income and Consolidated Statements of Comprehensive Income) (Detail) link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - Foreign Currency Hedging (Schedule of Foreign Currency Exchange Contracts Designated as Cash Flow Hedges) (Detail) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Foreign Currency Hedging (Tables) link:presentationLink link:calculationLink link:definitionLink 2119100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2419402 - Disclosure - Income Taxes (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2419403 - Disclosure - Income Taxes (Provision for Income Taxes) (Detail) link:presentationLink link:calculationLink link:definitionLink 2419404 - Disclosure - Income Taxes (Reconciliation of the Income Tax Provision Computed Using the U.S. Statutory Federal Income Tax Rate) (Detail) link:presentationLink link:calculationLink link:definitionLink 2419406 - Disclosure - Income Taxes (Reconciliation of Unrecognized Tax Benefits) (Detail) link:presentationLink link:calculationLink link:definitionLink 2419405 - Disclosure - Income Taxes (Significant Components of Deferred Tax Assets and Liabilities) (Detail) link:presentationLink link:calculationLink link:definitionLink 2319301 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 2426403 - Disclosure - Intangibles and Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 2126100 - Disclosure - Intangibles and Goodwill (Notes) link:presentationLink link:calculationLink link:definitionLink 2326302 - Disclosure - Intangibles and Goodwill Remaining Amortization Expense (Tables) link:presentationLink link:calculationLink link:definitionLink 2426404 - Disclosure - Intangibles and Goodwill Schedule of Finite-Lived Intangible Asset Amortization Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2326301 - Disclosure - Intangibles and Goodwill (Tables) link:presentationLink link:calculationLink link:definitionLink 2428402 - Disclosure - Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 2128100 - Disclosure - Inventory (Notes) link:presentationLink link:calculationLink link:definitionLink 2328301 - Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 2121100 - Disclosure - Legal Proceedings link:presentationLink link:calculationLink link:definitionLink 2421401 - Disclosure - Legal Proceedings (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - Net Income per Share link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - Net Income per Share (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2403403 - Disclosure - Net Income per Share (Net Income Per Basic and Diluted Share) (Detail) link:presentationLink link:calculationLink link:definitionLink 2403404 - Disclosure - Net Income per Share (Net Income Per Basic and Diluted Share) (Details) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - Net Income per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Notes Receivable and Other Long-term Receivables link:presentationLink link:calculationLink link:definitionLink 2407401 - Disclosure - Notes Receivable and Other Long-term Receivables (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Organization and Business link:presentationLink link:calculationLink link:definitionLink 2401401 - Disclosure - Organization and Business (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2124100 - Disclosure - Other Assets link:presentationLink link:calculationLink link:definitionLink 2424402 - Disclosure - Other Assets (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2424403 - Disclosure - Other Assets (Other Assets) (Detail) link:presentationLink link:calculationLink link:definitionLink 2324301 - Disclosure - Other Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - Other Long-Term Liabilities link:presentationLink link:calculationLink link:definitionLink 2415402 - Disclosure - Other Long-Term Liabilities (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2415403 - Disclosure - Other Long-Term Liabilities (Other Long-Term Liabilities) (Detail) link:presentationLink link:calculationLink link:definitionLink 2315301 - Disclosure - Other Long-Term Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Prepaid and Other Current Assets link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - Prepaid and Other Current Assets (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - Prepaid and Other Current Assets (Prepaid and Other Current Assets) (Detail) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Prepaid and Other Current Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - Property and Equipment (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - Property and Equipment (Property and Equipment) (Detail) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 2123100 - Disclosure - Quarterly Financial Data (Unaudited) link:presentationLink link:calculationLink link:definitionLink 2423402 - Disclosure - Quarterly Financial Data (Unaudited) (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2423403 - Disclosure - Quarterly Financial Data (Unaudited) (Quarterly Financial Data (Unaudited)) (Detail) link:presentationLink link:calculationLink link:definitionLink 2323301 - Disclosure - Quarterly Financial Data (Unaudited) (Tables) link:presentationLink link:calculationLink link:definitionLink 2430403 - Disclosure - Revenue from Contracts with Customers Contract Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2430402 - Disclosure - Revenue from Contracts with Customers (Details) link:presentationLink link:calculationLink link:definitionLink 2130100 - Disclosure - Revenue from Contracts with Customers (Notes) link:presentationLink link:calculationLink link:definitionLink 2330301 - Disclosure - Revenue from Contracts with Customers (Tables) link:presentationLink link:calculationLink link:definitionLink 2430404 - Disclosure - Revenue from Contracts with Customers Transaction Price Allocated to the Remaining Performance Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 2427402 - Disclosure - Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink 2127100 - Disclosure - Segment Information (Notes) link:presentationLink link:calculationLink link:definitionLink 2327301 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 2416406 - Disclosure - Stock-Based Compensation (Additional Information Regarding Our Options Exercised) (Detail) link:presentationLink link:calculationLink link:definitionLink 2416402 - Disclosure - Stock-Based Compensation (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2416407 - Disclosure - Stock-Based Compensation (Restricted Stock Activity) (Detail) link:presentationLink link:calculationLink link:definitionLink 2416404 - Disclosure - Stock-Based Compensation (Shares of Company Common Stock Available Under Share-Based Plans) (Detail) link:presentationLink link:calculationLink link:definitionLink 2416403 - Disclosure - Stock-Based Compensation (Stock-Based Compensation Expense for Employees and Directors and Non-Employees) (Detail) link:presentationLink link:calculationLink link:definitionLink 2416405 - Disclosure - Stock-Based Compensation (Summary of Stock Option and Restricted Stock Award Activity) (Detail) link:presentationLink link:calculationLink link:definitionLink 2316301 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2429402 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 2129100 - Disclosure - Stockholders' Equity (Notes) link:presentationLink link:calculationLink link:definitionLink 2329301 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 2122100 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 2422401 - Disclosure - Subsequent Events (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2402406 - Disclosure - Summary of Significant Accounting Policies Correction of immaterial error table (Details) link:presentationLink link:calculationLink link:definitionLink 2402403 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2402404 - Disclosure - Summary of Significant Accounting Policies (Schedule of Property and Equipment of Estimated Useful Lives) (Detail) link:presentationLink link:calculationLink link:definitionLink 2402405 - Disclosure - Summary of Significant Accounting Policies (Schedule of Revenue by Major Customers) (Details) link:presentationLink link:calculationLink link:definitionLink 2302302 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 10 pdli-20180630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 11 pdli-20180630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 12 pdli-20180630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Accumulated Other Comprehensive Income (Loss) [Abstract] Accumulated Other Comprehensive Income (Loss) [Abstract] Comprehensive Income (Loss) Note [Text Block] Comprehensive Income (Loss) Note [Text Block] Customer Concentration [Abstract] Customer Concentration [Abstract] Schedule of Revenue by Major Customers, by Reporting Segment [Table] Schedule of Revenue by Major Customers, by Reporting Segments [Table] Major Customers [Axis] Customer [Axis] Name of Major Customer [Domain] Customer [Domain] Elan [Member] Elan [Member] Licensee which is under contractual arrangment related to product lines. Depomed [Member] Depomed [Member] Depomed [Member] Noden [Member] Noden [Member] Noden [Member] LENSAR [Member] LENSAR [Member] LENSAR [Member] Segments [Axis] Segments [Axis] Segments [Domain] Segments [Domain] Interest revenues [Member] Interest revenues [Member] Interest revenues [Member] Tysabri [Member] Tysabri [Member] Tysabri [Member] Revenue, Major Customer [Line Items] Revenue, Major Customer [Line Items] Concentration Risk, Percentage Concentration Risk, Percentage Asset Acquisitions [Abstract] Asset Acquisitions [Abstract] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Ownership [Axis] Ownership [Axis] Ownership [Domain] Ownership [Domain] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Business Acquisition [Line Items] Business Acquisition [Line Items] Schedule of Business Acquisitions, by Acquisition [Table Text Block] Schedule of Business Acquisitions, by Acquisition [Table Text Block] Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative [Table] Derivative [Table] Derivative, by Nature [Axis] Derivative Instrument [Axis] Derivative Contract Type [Domain] Derivative Contract [Domain] Derivative [Line Items] Derivative [Line Items] Debt Disclosure [Abstract] Debt Instrument [Table] Schedule of Long-term Debt Instruments [Table] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument [Domain] Debt Instrument, Name [Domain] February 2018 Notes [Member] February 2018 Notes [Member] February 2018 Notes [Member] February 2018 Note Warrant [Member] February 2018 Note Warrant [Member] February 2018 Note Warrant [Member] December 2021 Notes [Member] December 2021 Notes [Member] December 2021 Notes [Member] February 2018 Note Purchase Call Option [Member] February 2018 Note Purchase Call Option [Member] February 2018 Note Purchase Call Option [Member] Purchased Call Options [Member] Purchased Call Options [Member] Purchased Call Options [Member] Series 2012 Notes [Member] Series 2012 Notes [Member] Series 2012 Notes [Member] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Debt Instrument [Line Items] Debt Instrument [Line Items] Convertible notes Convertible Debt Principal amount a $5 incentive cash payment per each to convert debt Principal amount a $5 incentive cash payment per each to convert debt The amount of principal tendered which a $5.00 cash payment is made per each to convert the Series 2012 notes to February 2015 notes. Debt instrument, interest rate (in Percent) Debt Instrument, Interest Rate, Stated Percentage Unamortized discount of liability component Debt Instrument, Unamortized Discount Deferred issuance costs Deferred issuance costs Deferred issuance costs Purchase call option unwind Purchase call option unwind Purchase call option unwind Warrant unwind Warrant unwind Warrant unwind Convertible note rate conversion trading days (in days) Convertible note rate conversion trading days (in days) Convertible note rate conversion trading days (in days) Convertible Notes rate conversion consecutive trading days (in days) Convertible Notes rate conversion consecutive trading days (in days) Convertible Notes rate conversion consecutive trading days (in days) Fees and Commissions, Transfer Agent Fees and Commissions, Transfer Agent Debt discount recorded to additional paid in capital Debt discount recorded to additional paid in capital Debt discount recorded to additional paid in capital Debt discount recorded to deferred tax liability Debt discount recorded to deferred tax liability Debt discount recorded to deferred tax liability Minimum conversion price percent for note conversion (in Percent) Minimum conversion price percent for note conversion (in Percent) The minimum conversion price of convertible notes in order for holders to convert their notes. Maximum percent of common stock closing price and conversion rate to convert note (in Percent) Maximum percent of common stock closing price and conversion rate to convert note (in Percent) Maximum percent of common stock closing price and conversion rate to convert note. Debt Instrument, Interest Rate, Effective Percentage Debt Instrument, Interest Rate, Effective Percentage Convertible notes, conversion price (in Dollars per Share) Debt Instrument, Convertible, Conversion Price Estimated market interest rate for similar nonconvertible instrument Estimated market interest rate for similar nonconvertible instrument Estimated market interest rate for similar nonconvertible instrument Debt instrument, convertible, remaining amortization period (in Duration) Debt Instrument, Convertible, Remaining Discount Amortization Period Net proceeds from the issuance of convertible notes Proceeds from Convertible Debt Debt Instrument, Repurchase Amount Debt Instrument, Repurchase Amount Debt instrument, repurchase amount paid Debt instrument, repurchase amount paid Debt instrument, repurchase amount paid Interest Paid Interest Paid Debt Instrument, Face Amount Debt Instrument, Face Amount Conversion Rate per $1,000 Principal Amount (in Ratio) Debt Instrument, Convertible, Conversion Ratio Purchased call options cost Purchased call options cost Cost of the purchased call options. Number of shares of common stock covered by the purchased call options purchased (in Shares) Number of shares of common stock covered by the purchased call options purchased (in Shares) The number of shares of common stock covered by the purchased call option. Proceeds from Issuance of Warrants Proceeds from Issuance of Warrants Deferred taxes included in purchased call options cost Deferred taxes included in purchased call options cost The deferred taxes on purchased call options cost. Gain on conversion of convertible notes Gain (Loss) on Extinguishment of Debt Share Price Share Price Repayments of Debt Repayments of Debt Debt Instrument, Periodic Payment, Principal Debt Instrument, Periodic Payment, Principal Debt Instrument, Periodic Payment, Interest Debt Instrument, Periodic Payment, Interest Summary of Significant Accounting Policies (Narrative) [Abstract] Summary of Significant Accounting Policies (Narrative) [Abstract] Statement [Table] Statement [Table] Products and Services [Axis] Products and Services [Axis] Products and Services [Domain] Products and Services [Domain] Scenario [Axis] Scenario [Axis] Scenario, Unspecified [Domain] Scenario, Unspecified [Domain] Statement [Line Items] Statement [Line Items] Earnings Per Share [Abstract] Schedule of calculation of numerator and denominator in earnings per share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Inventory [Abstract] Inventory [Abstract] Inventory Disclosure [Text Block] Inventory Disclosure [Text Block] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Variable Rate [Axis] Variable Rate [Axis] Variable Rate [Domain] Variable Rate [Domain] Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Debt Instrument, Unamortized Discount Fair Value Disclosures [Abstract] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] VB [Member] VB [Member] VB [Member] University of Michigan [Member] University of Michigan [Member] University of Michigan [Member] AcelRx [Member] AcelRx [Member] AcelRx [Member] Avinger [Member] Avinger [Member] Avinger [Member] Kybella [Member] Kybella [Member] Kybella [Member] Level 3 Rollforward Disclosure Classification [Axis] Level 3 Rollforward Disclosure Classification [Axis] Level 3 Rollforward Disclosure Classification [Axis] Level 3 Rollforward Disclosure Classification [Domain] Level 3 Rollforward Disclosure Classification [Domain] [Domain] for Level 3 Rollforward Disclosure Classification [Axis] Contingent Consideration [Member] Contingent Consideration [Member] Contingent Consideration [Member] Royalty right [Member] Royalty right [Member] Royalty right [Member] Fair Value by Asset Class [Axis] Asset Class [Axis] Asset Class [Domain] Asset Class [Domain] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value Change in fair value of acquired royalty rights Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Sales Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Sales Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Beginning balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value Change in fair value of acquired royalty rights, Level 3 Rollforward Change in fair value of acquired royalty rights, Level 3 Rollforward Change in fair value of acquired royalty rights, Level 3 Rollforward Ending balance Payments for (Proceeds from) Productive Assets Payments for (Proceeds from) Productive Assets Change in fair value included in earnings for liabilities Change in fair value included in earnings for liabilities Change in fair value included in earnings for liabilities Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings Statement of Financial Position [Abstract] Assets Assets [Abstract] Current assets: Assets, Current [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Short-term investments Available-for-sale Securities, Debt Securities, Current Accounts receivable, net Accounts and Other Receivables, Net, Current Notes receivable Notes, Loans and Financing Receivable, Net, Current Prepaid and other current assets Prepaid Expense and Other Assets, Current Total current assets Assets, Current Property and equipment, net Property, Plant and Equipment, Net Inventory, Net Inventory, Net Royalty rights Royalty rights Royalty rights Notes and other receivables, long-term Notes, Loans and Financing Receivable, Net, Noncurrent Intangible Assets, Net (Excluding Goodwill) Intangible Assets, Net (Excluding Goodwill) Other assets Other Assets, Noncurrent Total assets Assets Liabilities and Stockholders' Deficit Liabilities and Equity [Abstract] Current liabilities: Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Accrued liabilities Accrued Liabilities, Current Accrued Income Taxes, Current Accrued Income Taxes, Current Convertible Notes Payable, Current Convertible Notes Payable, Current Total current liabilities Liabilities, Current Convertible notes payable Convertible Notes Payable, Noncurrent Business Combination, Contingent Consideration, Liability, Noncurrent Business Combination, Contingent Consideration, Liability, Noncurrent Other long-term liabilities Other Liabilities, Noncurrent Total liabilities Liabilities Commitments and contingencies (Note 12) Commitments and Contingencies Stockholders' deficit: Stockholders' Equity Attributable to Parent [Abstract] Preferred stock, par value $0.01 per share, 10,000 shares authorized; no shares issued and outstanding Preferred Stock, Value, Issued Common stock, par value $0.01 per share, 350,000 shares authorized; 145,971 and 153,775 shares issued and outstanding at June 30, 2018 and December 31, 2017, respectively Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Retained earnings Retained Earnings (Accumulated Deficit) Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Total liabilities and stockholders’ equity Liabilities and Equity Sales Allowances and Accruals [Abstract] Sales Allowances and Accruals [Abstract] Discount and Distribution Fees Discount and Distribution Fees Discount and Distribution Fees Government rebates and chargebacks Government rebates and chargebacks Government rebates and chargebacks Assistance and Other Discounts Assistance and Other Discounts Assistance and Other Discounts Product return Product return Product return Accrued liabilities, amounts received in advance of revenue recognition Accrued liabilities, amounts received in advance of revenue recognition Accrued liabilities, amounts received in advance of revenue recognition Subsequent Events [Abstract] Subsequent Event [Table] Subsequent Event [Table] Legal Entity [Axis] Legal Entity [Axis] Entity [Domain] Entity [Domain] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event [Member] Subsequent Event [Member] Receivable Type [Axis] Receivable Type [Axis] Receivable Type [Domain] Receivable [Domain] Subsequent Event [Line Items] Subsequent Event [Line Items] Stock Repurchased During Period, Shares Stock Repurchased During Period, Shares Treasury Stock Acquired, Average Cost Per Share Treasury Stock Acquired, Average Cost Per Share Stock Repurchased During Period, Value Stock Repurchased During Period, Value Stock Repurchase Program, Remaining Authorized Repurchase Amount Stock Repurchase Program, Remaining Authorized Repurchase Amount Acquisition Costs, Period Cost Acquisition Costs, Period Cost Royalty trigger amount Royalty trigger amount Royalty trigger amount Payments to Acquire Productive Assets Payments to Acquire Productive Assets Business Combination, Contingent Consideration, Liability, Current Business Combination, Contingent Consideration, Liability, Current Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Business Combination, Consideration Transferred Business Combination, Consideration Transferred Fair Value Inputs, Assets, Quantitative Information [Table Text Block] Fair Value Inputs, Assets, Quantitative Information [Table Text Block] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Schedule of fair value of financial instruments measured on recurring basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule of fair value of assets and liabilities not subject to fair value recognition by level within the valuation hierarchy Schedule of fair value of assets and liabilities not subject to fair value recognition by level within the valuation hierarchy Schedule of fair value of assets and liabilities not subject to fair value recognition by level within the valuation hierarchy Contractual coupon interest Interest Expense, Debt, Excluding Amortization Amortization of debt issuance costs Amortization of debt issuance costs Amortization of debt issuance costs Amortization of debt discount Amortization of Debt Discount (Premium) Total Interest Expense, Debt Cash and Cash Equivalents [Abstract] Schedule of Available-For-Sale Securities [Table] Schedule of Available-for-sale Securities [Table] Major Types of Debt and Equity Securities [Axis] Major Types of Debt and Equity Securities [Axis] Major Types of Debt and Equity Securities [Domain] Major Types of Debt and Equity Securities [Domain] Cash [Member] Cash and Cash Equivalents [Member] Money Market Funds [Member] Money Market Funds [Member] Equity Securities [Member] Equity Securities [Member] Schedule of Available-For-Sale Securities [Line Items] Schedule of Available-for-sale Securities [Line Items] Adjusted Cost Available-for-sale Securities, Amortized Cost Basis Cash, Cash Equivalents and Available-for-Sale Securities, Fair Value Cash, Cash Equivalents and Available-for-Sale Securities, Fair Value Cash, cash equivalents and available-for-sale securities valued at fair value. Short-Term Marketable Securities Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, before Tax Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, before Tax Mergers, Acquisitions and Dispositions Disclosures [Text Block] Mergers, Acquisitions and Dispositions Disclosures [Text Block] Other Liabilities Disclosure [Abstract] Schedule of Other Liabilities [Table] Schedule of Other Liabilities [Table] Schedule of Other Liabilities [Table] Schedule of Other Liabilities [Line Items] Schedule of Other Liabilities [Line Items] [Line Items] for Schedule of Other Liabilities [Table] Accrued lease liability Accrued Rent, Noncurrent Accrued Bonuses Accrued Bonuses Uncertain tax position Liability for Uncertainty in Income Taxes, Noncurrent Deferred Tax Liabilities, Net, Noncurrent Deferred Tax Liabilities, Net, Noncurrent Dividends Payable Dividends Payable Liabilities, Other than Long-term Debt, Noncurrent Liabilities, Other than Long-term Debt, Noncurrent Total Other Long-Term Liabilities Other Liabilities Disclosure [Text Block] Derivative Name [Domain] Cash Flow Hedges [Member] Cash Flow Hedges [Member] Cash Flow Hedges [Member] Gain (loss) reclassified from accumulated OCI into royalty revenue, net of tax Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net Business Combinations [Abstract] Convertible and Non-Recourse Notes Long-term Debt [Text Block] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Schedule of Share Based Compensation Arrangements by Share Based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Award Type [Axis] Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Award Type and Plan Name [Domain] Equity Award [Domain] Stock-Based Incentive Plan [Member] Stock Compensation Plan [Member] Employee Stock Option [Member] Employee Stock Option [Member] Restricted Stock [Member] Restricted Stock [Member] Share Based Compensation Arrangment By Share Based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Decrease in shares available for grant from shares granted Decrease in shares available for grant from shares granted. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Shares Available for Grant, Balance beginning of period (in Shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Restricted Stock Award, Number of Shares, Balance at beginning of period (in Shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Restricted Stock Awards, Number of Shares Granted (in Shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Restricted Stock Awards, Number of Shares, Balance at end of period (in Shares) Restricted Stock Awards, Weighted Average Grant-date Fair Value, Balance at beginning of period (in Dollars per Share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Restricted Stock Awards, Weighted Average Grant-date Fair Value, Granted (in Dollars per Share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Restricted Stock Awards, Weighted Average Grant-date Fair Value, Balance at end of period (in Dollars per Share) Shares Available for Grant, Balance end of period (in Shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations Accounting Changes and Error Corrections [Abstract] Schedule of Error Corrections and Prior Period Adjustment Restatement [Table] Schedule of Error Corrections and Prior Period Adjustment Restatement [Table] Adjustments for Error Corrections [Axis] Adjustments for Error Corrections [Axis] Adjustments for Error Correction [Domain] Adjustments for Error Correction [Domain] Error Corrections and Prior Period Adjustments Restatement [Line Items] Error Corrections and Prior Period Adjustments Restatement [Line Items] Income Tax Disclosure [Abstract] Federal Income Tax Note [Table] Federal Income Tax Note [Table] Investments, Owned, Federal Income Tax Note [Line Items] Investments, Owned, Federal Income Tax Note [Line Items] Income Tax Expense Income Tax Expense (Benefit) Federal income tax rate Federal income tax rate Federal income tax rate Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Accumulated Net Investment Gain (Loss) Attributable to Parent [Member] Accumulated Net Investment Gain (Loss) Attributable to Parent [Member] AOCI Attributable to Parent [Member] AOCI Attributable to Parent [Member] Unrealized gains (losses) on available-for-sale securities Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, before Tax Other Comprehensive Income (Loss), Net of Tax Other Comprehensive Income (Loss), Net of Tax Concentration Risk Disclosure [Text Block] Concentration Risk Disclosure [Text Block] Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Hierarchy [Axis] Fair Value, Hierarchy [Axis] Fair Value Measurements Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Fair Value Level 1 [Member] Fair Value, Inputs, Level 1 [Member] Fair Value Level 2 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value Level 3 [Member] Fair Value, Inputs, Level 3 [Member] Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain] Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Financial and Nonfinancial Liabilities, Fair Value Disclosure Financial and Nonfinancial Liabilities, Fair Value Disclosure Financial assets: Financial assets: Financial assets: Cash and Cash Equivalents, Fair Value Cash and Cash Equivalents, Fair Value Disclosure Available for Sale Securities, Fair Value Available-for-sale Securities Assets, Fair Value Assets, Fair Value Disclosure Warrants and Rights Outstanding Warrants and Rights Outstanding Financial liabilites: Financial liabilites: Financial liabilites: Liabilities, Fair Value Disclosure, Recurring Liabilities, Fair Value Disclosure, Recurring Inventory, Current [Table] Inventory, Current [Table] Inventory [Axis] Inventory [Axis] Inventory [Domain] Inventory [Domain] Inventory [Line Items] Inventory [Line Items] Schedule of Inventory, Current [Table Text Block] Schedule of Inventory, Current [Table Text Block] Stock Repurchase Program, Authorized Amount Stock Repurchase Program, Authorized Amount Treasury Stock, Shares Treasury Stock, Shares Treasury Stock, Value Treasury Stock, Value Goodwill and Intangible Assets Disclosure [Abstract] Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Stockholders' Equity Note [Abstract] Dividends payable quarterly (in Dollars per Share) Dividends Payable, Amount Per Share Payments of Dividends Payments of Dividends Foreign Currency Hedging Derivative Instruments and Hedging Activities Disclosure [Text Block] Segment Reporting [Abstract] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Consolidation Items [Axis] Consolidation Items [Axis] Consolidation Items [Domain] Consolidation Items [Domain] Income generating assets [Member] Income generating assets [Member] Income generating assets [Member] Pharmaceutical [Member] Pharmaceutical [Member] Pharmaceutical [Member] Medical devices [Member] Medical devices [Member] Medical devices [Member] Subsegments [Axis] Subsegments [Axis] Subsegments [Domain] Subsegments [Domain] Subsegments Consolidation Items [Axis] Subsegments Consolidation Items [Axis] Subsegments Consolidation Items [Domain] Subsegments Consolidation Items [Domain] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Long-Lived Assets Long-Lived Assets Net Income (Loss) Attributable to Parent Net Income (Loss) Attributable to Parent Revenues Revenues Accounting Policies [Abstract] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Gains (losses) on sales of available-for-sale securities Available-for-sale Securities, Gross Realized Gain (Loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months Finite-Lived Intangible Assets, Amortization Expense, Year Two Finite-Lived Intangible Assets, Amortization Expense, Year Two Finite-Lived Intangible Assets, Amortization Expense, Year Three Finite-Lived Intangible Assets, Amortization Expense, Year Three Finite-Lived Intangible Assets, Amortization Expense, Year Four Finite-Lived Intangible Assets, Amortization Expense, Year Four Finite-Lived Intangible Assets, Amortization Expense, Year Five Finite-Lived Intangible Assets, Amortization Expense, Year Five Finite-Lived Intangible Assets, Amortization Expense, after Year Five Finite-Lived Intangible Assets, Amortization Expense, after Year Five Finite-Lived Intangible Assets, Net Finite-Lived Intangible Assets, Net Schedule of Segment Reporting Information, by Segment [Table Text Block] Segment Reporting Disclosure [Text Block] Convertible Notes Payable, Carrying Value Notes Payable Summary of cash and available-for-sale securities Schedule of Available-for-sale Securities Reconciliation [Table Text Block] Statement of Cash Flows [Abstract] Cash paid for purchase of noncontrolling interest Cash paid for purchase of noncontrolling interest Cash paid for purchase of noncontrolling interest Repayments of Secured Debt Repayments of Secured Debt Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Assets held for sale reclassified from other assets to intangibles Assets held for sale reclassified from other assets to intangibles Assets held for sale reclassified from other assets to intangibles Gain (Loss) on Disposition of Property Plant Equipment Gain (Loss) on Disposition of Property Plant Equipment Extinguishment of Debt, Amount Extinguishment of Debt, Amount Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Amortization of convertible notes and term loan offering costs Amortization of Debt Issuance Costs Amortization of Acquisition Costs Amortization of Acquisition Costs Impairment of Intangible Assets, Finite-lived Impairment of Intangible Assets, Finite-lived Change in fair value of acquired royalty rights Change in fair value of acquired royalty rights Change in fair value of acquired royalty rights Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Change in Unrealized Gain (Loss) Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Change in Unrealized Gain (Loss) Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Depreciation, Amortization and Accretion, Net Depreciation, Amortization and Accretion, Net Gain (Loss) on Sale of Investments Gain (Loss) on Sale of Investments Inventory Write-down Inventory Write-down Provision for Doubtful Accounts Provision for Doubtful Accounts Stock-based compensation expense Share-based Compensation Deferred income taxes Deferred Income Taxes and Tax Credits Changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Receivables from licensees and other Increase (Decrease) in Accounts Receivable Receivables from licensees and other Increase (Decrease) in Accounts and Other Receivables Prepaid and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Accrued interest on notes receivable Increase (Decrease) in Notes Receivable, Current Increase (Decrease) in Inventories Increase (Decrease) in Inventories Other assets Increase (Decrease) in Other Operating Assets Accounts payable Increase (Decrease) in Accounts Payable, Trade Accrued liabilities Increase (Decrease) in Accrued Liabilities Increase (Decrease) in Deferred Revenue Increase (Decrease) in Deferred Revenue Increase (Decrease) in Income Taxes Payable Increase (Decrease) in Income Taxes Payable Other long-term liabilities Increase (Decrease) in Other Noncurrent Liabilities Net cash provided by (used in) operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Payments to Acquire Investments Payments to Acquire Investments Proceeds from Sale of Available-for-sale Securities, Equity Proceeds from Sale of Available-for-sale Securities, Equity Payments for (Proceeds from) Productive Assets Proceeds from Sale of Productive Assets Proceeds from Sale of Productive Assets Proceeds from Collection of Notes Receivable Proceeds from Collection of Notes Receivable Payments to Acquire Property, Plant, and Equipment Payments to Acquire Property, Plant, and Equipment Net cash provided by investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Cash dividends paid Payments for Repurchase of Common Stock Payments for Repurchase of Common Stock Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Net increase (decrease) in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Cash and cash equivalents at beginning of the period Cash and cash equivalents at end of period Supplemental cash flow information Supplemental Cash Flow Information [Abstract] Cash paid for income taxes Income Taxes Paid, Net Cash paid for interest Assets held for sale reclassified from notes receivable to other assets Assets held for sale reclassified from notes receivable to other assets Assets held for sale reclassified from notes receivable to other assets Supplemental disclosures of non-cash financing activities Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Subsequent Events [Text Block] Subsequent Events [Text Block] Statement Business Segments [Axis] Products [Domain] Preferred stock par value (in Dollars per Share) Preferred Stock, Par or Stated Value Per Share Preferred stock, shares authorized (in Shares) Preferred Stock, Shares Authorized Preferred stock, shares issued (in Shares) Preferred Stock, Shares Issued Preferred stock, shares outstanding (in Shares) Preferred Stock, Shares Outstanding Common stock par value (in Dollars per Share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized (in Shares) Common Stock, Shares Authorized Common stock, shares issued (in Shares) Common Stock, Shares, Issued Common stock, shares outstanding (in Shares) Common Stock, Shares, Outstanding Receivables [Abstract] Schedule Of Accounts Notes Loans And Financing Receivable [Table] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Credit Agreement [Member] Credit Agreement [Member] Credit Agreement [Member] Initial Loan [Member] Initial Loan [Member] Initial Loan [Member] Additional Loan [Member] Additional Loan [Member] Additional Loan [Member] Royalty Agreement [Member] Royalty Agreement [Member] Royalty Agreement [Member] Term loan and interest [Member] Term loan and interest [Member] Term loan and interest [Member] Forbearance principal and interest [Member] Forbearance principal and interest [Member] Forbearance principal and interest [Member] Tranche three [Member] Tranche three [Member] Tranche three [Member] Counterparty Name [Axis] Counterparty Name [Axis] Counterparty Name [Domain] Counterparty Name [Domain] Wellstat Diagnostics [Member] Wellstat Diagnostics [Member] Wellstat Diagnostics [Member] Alphaeon [Member] Alphaeon [Member] Alphaeon [Member] DirectFlow [Member] DirectFlow [Member] DirectFlow [Member] Hyperion [Member] Hyperion [Member] Hyperion [Member] kaleo Note Receivable [Member] kaleo Note Receivable [Member] kaleo Note Receivable [Member] CareView [Member] CareView [Member] CareView [Member] Accounts Notes And Loans Receivable [Line Items] Accounts, Notes, Loans and Financing Receivable [Line Items] Financing receivable, gross Financing Receivable, Gross Premiums, Percentage Assumed to Net Premiums, Percentage Assumed to Net Gain Contingency, Unrecorded Amount Gain Contingency, Unrecorded Amount Financing Receivables, Impaired, Troubled Debt Restructuring, Write-down Financing Receivables, Impaired, Troubled Debt Restructuring, Write-down Proceeds from Sale of Other Assets Proceeds from Sale of Other Assets Investment Warrants, Exercise Price Investment Warrants, Exercise Price Number of payments to be received Number of payments to be received Number of payments to be received Periodic contractual payments Periodic contractual payments Periodic contractual payments Financing Receivable, Modifications, Pre-Modification Recorded Investment Financing Receivable, Modifications, Pre-Modification Recorded Investment Financing Receivable, Net Financing Receivable, Net Interest rate of note receivable (in Percent) Interest rate of note receivable (in Percent) Interest rate of note receivable (in Percent) Investment estimated fair value, per share Investment estimated fair value, per share Investment estimated fair value, per share Reduction in royalty rate (in percent) Reduction in royalty rate (in percent) Reduction in royalty rate (in percent) Repayment of notes receivable Accounts Receivable, Net, Noncurrent Accounts Receivable, Net, Noncurrent Credit agreement, stated interest rate (in Percent) Credit agreement, stated interest rate (in Percent) Stated interest rate of credit agreement. Proceeds received under remedies available for borrower's breach of terms credit agreement Proceeds received under remedies available for borrower's breach of terms credit agreement Proceeds received under remedies available for borrower's breach of terms credit agreement and applied to amounts due under the credit agreement. Amount company has agreed to advance under agreement Amount company has agreed to advance under credit agreement Amount company has agreed to advance under credit agreement. Financing Receivable, Modifications, Post-Modification Recorded Investment Financing Receivable, Modifications, Post-Modification Recorded Investment Investment Owned, Balance, Shares Investment Owned, Balance, Shares Investment Owned, at Cost Investment Owned, at Cost Commitments and Contingencies Tranche 1 of note receivable Tranche 1 of note receivable Tranche 1 of note receivable Tranche 2 of note receivable Tranche 2 of note receivable Tranche 2 of note receivable Class of Warrant or Right, Number of Securities Called by Warrants or Rights Class of Warrant or Right, Number of Securities Called by Warrants or Rights Class of Warrant or Right, Exercise Price of Warrants or Rights Class of Warrant or Right, Exercise Price of Warrants or Rights Equity investment, shares held (shares) Equity investment, shares held (shares) Equity investment, shares held (shares) Financial Instruments, Owned, Other, at Fair Value Financial Instruments, Owned, Other, at Fair Value Revenue from Contracts with Customers [Abstract] Revenue from Contracts with Customers [Abstract] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] North America [Member] North America [Member] Europe [Member] Europe [Member] Asia [Member] Asia [Member] Non-US [Member] Non-US [Member] Contract with Customer, Basis of Pricing [Axis] Contract with Customer, Basis of Pricing [Axis] Contract with Customer, Basis of Pricing [Domain] Contract with Customer, Basis of Pricing [Domain] Contract with Customer, Duration [Axis] Contract with Customer, Duration [Axis] Contract with Customer, Duration [Domain] Contract with Customer, Duration [Domain] Timing of Transfer of Good or Service [Axis] Timing of Transfer of Good or Service [Axis] Timing of Transfer of Good or Service [Domain] Timing of Transfer of Good or Service [Domain] Contract with Customer, Sales Channel [Axis] Contract with Customer, Sales Channel [Axis] Contract with Customer, Sales Channel [Domain] Contract with Customer, Sales Channel [Domain] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Non ASC 606 revenue Non ASC 606 revenue Non ASC 606 revenue Revenue from Contract with Customer, Excluding Assessed Tax Revenue from Contract with Customer, Excluding Assessed Tax DocumentAndEntityInformation [Abstract] DocumentAndEntityInformation [Abstract] Entities [Table] Entities [Table] Entity Information [Line Items] Entity Information [Line Items] Entity Registrant Name Entity Registrant Name Document Type Document Type Current Fiscal Year End Date Current Fiscal Year End Date Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Entity Current Reporting Status Entity Current Reporting Status Entity Voluntary Filers Entity Voluntary Filers Entity Filer Category Entity Filer Category Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Basis of Presentation, Policy Basis of Accounting [Text Block] New Accounting Pronouncements, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] Schedule of carrying value and unamortized discount on December 2021 Notes [Table Text Block] Schedule of carrying value and unamortized discount on December 2021 Notes [Table Text Block] [Table Text Block] for Schedule of carrying value and unamortized discount on December 2021 Notes [Table] Schedule of convertible and non-recourse notes activity Schedule of Debt [Table Text Block] Schedule of carrying value and unamortized discount on February 2018 Notes [Table Text Block] Schedule of carrying value and unamortized discount on February 2018 Notes [Table Text Block] Schedule of carrying value and unamortized discount on February 2018 Notes [Table Text Block] Schedule of interest expense for February 2018 Notes [Table Text Block] Schedule of interest expense for February 2018 Notes [Table Text Block] Schedule of interest expense for February 2018 Notes [Table Text Block] Schedule of interest expense for December 2021 Notes [Table Text Block] Schedule of interest expense for December 2021 Notes [Table Text Block] Schedule of interest expense for December 2021 Notes [Table Text Block] Revenue from Contract with Customers [Abstract] Revenue from Contract with Customers [Abstract] Revenue from Contract with Customer [Text Block] Revenue from Contract with Customer [Text Block] Stock-Based Compensation Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Debt Instrument, Interest Rate, Stated Percentage Debt Instrument, Convertible, Conversion Ratio Convertible Notes, Maturity Date (Date) Debt Instrument, Maturity Date Convertible Notes, Principal Balance Outstanding Convertible Notes Payable, Carrying Value Inventory, Raw Materials, Gross Inventory, Raw Materials, Gross Inventory, Work in Process, Gross Inventory, Work in Process, Gross Inventory, Finished Goods, Gross Inventory, Finished Goods, Gross Inventory, Net Deferred Costs and Other Assets Deferred Costs and Other Assets Inventory Write-down Schedule of Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Property, Plant and Equipment by Type [Axis] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment by Type [Domain] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Indefinite-lived Intangible Assets Acquired as Part of Business Combination [Table] Indefinite-lived Intangible Assets Acquired as Part of Business Combination [Table] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Acquired Indefinite-lived Intangible Assets [Line Items] Acquired Indefinite-lived Intangible Assets [Line Items] Business Acquisition, Pro Forma Revenue Business Acquisition, Pro Forma Revenue Business Combination, Consideration Transferred Business Acquisition, Pro Forma Net Income (Loss) Business Acquisition, Pro Forma Net Income (Loss) Business Acquisition, Pro Forma Earnings Per Share, Basic Business Acquisition, Pro Forma Earnings Per Share, Basic Business Acquisition, Pro Forma Earnings Per Share, Diluted Business Acquisition, Pro Forma Earnings Per Share, Diluted Contractual Obligation Contractual Obligation Accounts and Notes Receivable, Net Accounts and Notes Receivable, Net Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value Gain (Loss) on Investments Gain (Loss) on Investments Commitments and Contingencies Disclosure [Abstract] Schedule of Guarantor Obligations [Table] Schedule of Guarantor Obligations [Table] Duration [Axis] Duration [Axis] Duration [Axis] Duration [Domain] Duration [Domain] [Domain] for Duration [Axis] Next twelve months [Member] Next twelve months [Member] Next twelve months [Member] Next twenty-four months [Member] [Member] Next twenty-four months [Member] [Member] Next twenty-four months [Member] [Member] Next thirty-six months [Member] Next thirty-six months [Member] Next thirty-six months [Member] Guarantor Obligations [Line Items] Guarantor Obligations [Line Items] Debt Instrument, Unamortized Discount Purchase Obligation Purchase Obligation Total lease payments for the duration of the guarantee Guarantor Obligations, Maximum Exposure, Undiscounted Debt Instrument, Convertible, Beneficial Conversion Feature Debt Instrument, Convertible, Beneficial Conversion Feature Interest Expense, Debt Fair Value By Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Wellstat Note Receivable [Member] Wellstat Note Receivable [Member] Wellstat Note Receivable [Member] Fair Value by Balance Sheet Grouping [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Notes receivable, Carrying Value Notes, Loans and Financing Receivable, Gross, Noncurrent Notes receivable, Fair Value Notes Receivable, Fair Value Disclosure Liabilities: Liabilities [Abstract] Notes payable, Fair Value Long-term Debt, Fair Value Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Contractual Rights [Member] Contractual Rights [Member] Customer Relationships [Member] Customer Relationships [Member] Patented Technology [Member] Patented Technology [Member] Trademarks [Member] Trademarks [Member] Acquired Finite-Lived Intangible Assets [Line Items] Acquired Finite-Lived Intangible Assets [Line Items] Fair Value Inputs, Discount Rate Fair Value Inputs, Discount Rate Goodwill and Intangible Asset Impairment Goodwill and Intangible Asset Impairment Finite-Lived Intangible Asset, Useful Life Finite-Lived Intangible Asset, Useful Life Finite-Lived Intangible Assets, Gross Finite-Lived Intangible Assets, Gross Finite-Lived Intangible Assets, Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Finite-Lived Intangible Assets, Net Amortization of Intangible Assets Amortization of Intangible Assets Contract with Customer, Asset, Net Contract with Customer, Asset, Net Contract with Customer, Liability Contract with Customer, Liability Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price Contract with Customer, Liability, Revenue Recognized Contract with Customer, Liability, Revenue Recognized Statement of Comprehensive Income [Abstract] Unrealized gains (losses) on available-for-sale securities, tax Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Tax Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Business Combination, Separately Recognized Transactions, Expenses and Losses Recognized Business Combination, Separately Recognized Transactions, Expenses and Losses Recognized Business Combination, Bargain Purchase, Gain Recognized, Amount Business Combination, Bargain Purchase, Gain Recognized, Amount Net Income per Share Earnings Per Share [Text Block] Payables and Accruals [Abstract] Accrued Liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block] Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block] Income Statement [Abstract] Queen et al. patents [Member] Queen et al. patents [Member] Queen et al. patents [Member] Acquired rights [Member] Acquired rights [Member] Acquired rights [Member] Revenues Revenues [Abstract] Royalty revenues Royalty Revenue Interest revenue Interest revenue Interest revenue Product revenue Sales Revenue, Goods, Net Licenses Revenue Licenses Revenue Total revenues Operating expenses Operating Expenses [Abstract] Cost of Revenue Cost of Revenue General and administrative General and Administrative Expense Selling and Marketing Expense Selling and Marketing Expense Research and Development Expense Research and Development Expense Change in fair value of contingent consideration Change in fair value of contingent consideration Change in fair value of contingent consideration Total operating expenses Operating Expenses Operating income (loss) Operating Income (Loss) Non-operating expense, net Nonoperating Income (Expense) [Abstract] Interest and other income, net Investment Income, Net Interest expense Interest Expense Total non-operating income (expense), net Nonoperating Income (Expense) Income (loss) before income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Income tax expense (benefit) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net Income (Loss) Attributable to Noncontrolling Interest Net Income (Loss) Attributable to Noncontrolling Interest Net income (loss) Net income per share Basic (in Dollars per Share) Earnings Per Share, Basic Net income per diluted share (in Dollars per Share) Earnings Per Share, Diluted Weighted average shares outstanding Weighted Average Number of Shares Outstanding, Diluted [Abstract] Basic (in Shares) Weighted Average Number of Shares Outstanding, Basic Diluted (in Shares) Weighted Average Number of Shares Outstanding, Diluted Business Combination Disclosure [Text Block] Business Combination Disclosure [Text Block] Goodwill and Intangible Assets Disclosure [Text Block] Goodwill and Intangible Assets Disclosure [Text Block] Schedule of other liabilities Schedule of Other Assets and Other Liabilities [Table Text Block] Other comprehensive income (loss), net of tax Other Comprehensive Income (Loss), Net of Tax [Abstract] Change in fair value of investments in available-for-sale securities, net of tax Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax Total change in unrealized gains (losses) on investments in available-for-sale securities, net of tax Total other comprehensive income (loss), net of tax Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Other Long-Term Liabilities [Abstract] Other Long-Term Liabilities [Abstract] Sales Allowances and Accruals [Table Text Block] Sales Allowances and Accruals [Table Text Block] [Table Text Block] for Sales Allowances and Accruals [Table] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Less than one year [Member] Less than one year [Member] Less than one year [Member] Greater than one year [Member] Greater than one year [Member] Greater than one year [Member] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Revenue, Remaining Performance Obligation Revenue, Remaining Performance Obligation Stockholders' Equity Note Disclosure [Text Block] Stockholders' Equity Note Disclosure [Text Block] Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table] Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table] Business Acquisition, Pro Forma Information [Table Text Block] Business Acquisition, Pro Forma Information [Table Text Block] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Schedule of Segment Reporting Information, by Segment [Table Text Block] Schedule of Segment Reporting Information, by Segment [Table Text Block] Cash payment for purchase of royalty right Cash payment for purchase of royalty right Cash payment for purchase of royalty right Purchase of royalty rights Purchase of royalty right Purchase of royalty right Fair value inputs, discount rate (in Percent) Royalty right purchase transaction costs Royalty right purchase transaction costs Royalty right purchase transaction costs Long-Duration Contracts, Assumptions by Product and Guarantee, Discount Rate Long-Duration Contracts, Assumptions by Product and Guarantee, Discount Rate Fair Value Measurements, Sensitivity Analysis, Description Fair Value Measurements, Sensitivity Analysis, Description Litigation Settlement, Amount Awarded from Other Party Litigation Settlement, Amount Awarded from Other Party Revenue Recognition, Milestone Method, Revenue Recognized Revenue Recognition, Milestone Method, Revenue Recognized Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount Transfers from level 1 to level 2, amount Fair Value, Equity, Level 1 to Level 2 Transfers, Amount Transfers from level 2 to level 1, amount Fair Value, Equity, Level 2 to Level 1 Transfers, Amount Percentage of royalty acquired Percentage of royalty acquired Percentage of royalty acquired Maximum amount of additional funds, upon attainment of milestones Maximum amount of additional funds, upon attainment of milestones Maximum amount of additional funds, upon attainment of milestones. Notes Receivable, Fair Value Disclosure Gain (Loss) on Extinguishment of Debt Notes and Other Long-term Receivables Loans, Notes, Trade and Other Receivables Disclosure [Text Block] Schedule of the effect of derivative instruments in the Consolidated Statements of Income and Consolidated Statements of Comprehensive Income Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss) [Table Text Block] Derivative Instruments Gain Loss By Hedging Relationship By Income Statement Location By Derivative Instrument Risk [Table] Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) by Hedging Relationship [Axis] Hedging Relationship [Axis] Hedging Relationship [Domain] Hedging Relationship [Domain] Derivative Instrument Gain Loss [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Disaggregation of Revenue [Table Text Block] Disaggregation of Revenue [Table Text Block] Contract with Customer, Asset and Liability [Table Text Block] Contract with Customer, Asset and Liability [Table Text Block] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block] Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities Name [Domain] Antidilutive Securities, Name [Domain] Option on Securities [Member] Option on Securities [Member] Antidilutive securities excluded from computation of earnings per share (in Shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Compensation Employee-related Liabilities, Current Interest Interest Payable, Current Dividend payable Dividends Payable, Current Legal Accrued Professional Fees, Current Customer Refundable Fees Customer Refundable Fees Customer Advances, Current Customer Advances, Current Other Other Accrued Liabilities, Current Total Deferred Revenue, Current Deferred Revenue, Current Fair Value Measurements Fair Value Disclosures [Text Block] Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block] Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block] Income Taxes Income Tax Disclosure [Text Block] Cash Equivalents and Investments Cash, Cash Equivalents, and Marketable Securities [Text Block] Numerator Net Income (Loss) Available to Common Stockholders, Diluted [Abstract] Income used to compute net income per diluted share Net Income (Loss) Available to Common Stockholders, Diluted Denominator Total weighted-average shares used to compute net income per basic share (in Shares) Award Type [Domain] Additional shares included in the calculation of diluted EPS (in Shares) Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements EX-101.PRE 13 pdli-20180630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 14 pdllogoa01.jpg begin 644 pdllogoa01.jpg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end XML 15 R1.htm IDEA: XBRL DOCUMENT v3.10.0.1
Document And Entity Information - shares
 6 Months Ended
Jun. 30, 2018
Jul. 30, 2018
Entity Information [Line Items]    
Entity Registrant Name PDL BIOPHARMA, INC.  
Document Type 10-Q  
Current Fiscal Year End Date --12-31  
Entity Common Stock, Shares Outstanding   145,400,381
Amendment Flag false  
Entity Central Index Key 0000882104  
Entity Current Reporting Status Yes  
Entity Voluntary Filers No  
Entity Filer Category Accelerated Filer  
Entity Well-known Seasoned Issuer Yes  
Document Period End Date Jun. 30, 2018  
Document Fiscal Year Focus 2018  
Document Fiscal Period Focus Q2  
XML 16 R2.htm IDEA: XBRL DOCUMENT v3.10.0.1
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Revenues        
Interest revenue $ 751 $ 5,460 $ 1,500 $ 10,917
Product revenue 31,761 18,829 55,085 31,410
Licenses Revenue 3 19,536 574 19,636
Total revenues 46,575 143,835 85,093 189,275
Operating expenses        
Cost of Revenue 14,524 4,515 25,090 7,067
Amortization of Intangible Assets 6,384 6,148 12,677 12,163
General and administrative 14,529 11,288 26,190 23,864
Selling and Marketing Expense 5,385 3,616 10,898 6,200
Research and Development Expense 684 4,281 1,477 6,047
Impairment of Intangible Assets, Finite-lived 152,330 0 152,330 0
Change in fair value of contingent consideration (22,135) 1,207 (22,735) 2,649
Total operating expenses 171,701 31,055 205,927 57,990
Operating income (loss) (125,126) 112,780 (120,834) 131,285
Non-operating expense, net        
Interest and other income, net 1,376 276 3,290 488
Interest expense (2,811) (5,015) (6,396) (9,986)
Business Combination, Bargain Purchase, Gain Recognized, Amount 0 6,271 0 6,271
Total non-operating income (expense), net (1,435) 1,532 (3,106) (3,227)
Income (loss) before income taxes (126,561) 114,312 (123,940) 128,058
Income tax expense (benefit) (14,265) 53,873 (13,246) 60,425
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest (112,296) 60,439 (110,694) 67,633
Net Income (Loss) Attributable to Noncontrolling Interest 0 0 0 (47)
Net income (loss) $ (112,296) $ 60,439 $ (110,694) $ 67,680
Net income per share        
Basic (in Dollars per Share) $ (0.76) $ 0.39 $ (0.74) $ 0.42
Net income per diluted share (in Dollars per Share) $ (0.76) $ 0.39 $ (0.74) $ 0.42
Weighted average shares outstanding        
Basic (in Shares) 146,923 155,654 149,186 159,677
Diluted (in Shares) 146,923 156,394 149,186 160,168
Queen et al. patents [Member]        
Revenues        
Royalty revenues $ 1,218 $ 16,285 $ 4,001 $ 30,441
Acquired rights [Member]        
Revenues        
Royalty revenues $ 12,842 $ 83,725 $ 23,933 $ 96,871
XML 17 R3.htm IDEA: XBRL DOCUMENT v3.10.0.1
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest $ (112,296) $ 60,439 $ (110,694) $ 67,633
Other comprehensive income (loss), net of tax        
Change in fair value of investments in available-for-sale securities, net of tax 0 0 (578) 0
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax 0 0 603 0
Total change in unrealized gains (losses) on investments in available-for-sale securities, net of tax [1] 0 0 (1,181) 0
Total other comprehensive income (loss), net of tax 0 0 (1,181) 0
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest (112,296) 60,439 (111,875) 67,633
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest 0 0 0 (47)
Comprehensive income $ (112,296) $ 60,439 $ (111,875) $ 67,680
[1] Net of tax of zero and zero for the three months ended June 30, 2018 and 2017, respectively
XML 18 R4.htm IDEA: XBRL DOCUMENT v3.10.0.1
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parentheticals) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Statement of Comprehensive Income [Abstract]        
Unrealized gains (losses) on available-for-sale securities, tax $ 0 $ 0 $ (314) $ 0
XML 19 R5.htm IDEA: XBRL DOCUMENT v3.10.0.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Jun. 30, 2018
Dec. 31, 2017
Current assets:    
Cash and cash equivalents $ 395,653,000 [1],[2] $ 527,266,000 [3]
Short-term investments 0 [1] 4,848,000 [3]
Accounts receivable, net 19,531,000 [1] 31,183,000 [3]
Notes receivable 58,058,000 [1] 53,613,000 [3]
Prepaid and other current assets 20,628,000 [1] 14,386,000 [3]
Total current assets 508,671,000 [1] 640,443,000 [3]
Property and equipment, net 9,223,000 [1] 7,222,000 [3]
Inventory, Net [1] 14,801,000 9,147,000
Royalty rights 335,163,000 [1] 349,223,000 [3]
Notes and other receivables, long-term 12,829,000 [1] 17,124,000 [3]
Intangible Assets, Net (Excluding Goodwill) [1] 54,472,000 215,823,000
Other assets 25,637,000 [1] 13,288,000 [3]
Total assets 945,995,000 [1] 1,243,123,000 [3]
Current liabilities:    
Accounts payable 11,212,000 [1] 19,785,000 [3]
Accrued liabilities 34,294,000 [1] 45,881,000 [3]
Accrued Income Taxes, Current 217,000 [1] 1,377,000 [3]
Convertible Notes Payable, Current 0 [1] 126,066,000 [3]
Total current liabilities 45,723,000 [1] 193,109,000 [3]
Convertible notes payable 120,945,000 [1] 117,415,000 [3]
Business Combination, Contingent Consideration, Liability, Noncurrent [1] 18,900,000 42,000,000
Other long-term liabilities 47,799,000 [1] 44,709,000 [3]
Total liabilities 233,367,000 [1] 397,233,000 [3]
Commitments and contingencies (Note 12) [1] [3]
Stockholders' deficit:    
Preferred stock, par value $0.01 per share, 10,000 shares authorized; no shares issued and outstanding 0 [1] 0 [3]
Common stock, par value $0.01 per share, 350,000 shares authorized; 145,971 and 153,775 shares issued and outstanding at June 30, 2018 and December 31, 2017, respectively 1,460,000 [1] 1,538,000 [3]
Additional paid-in capital (100,229,000) [1] (102,443,000) [3]
Accumulated other comprehensive income [1] 0 1,181,000 [3]
Retained earnings 811,397,000 [1] 945,614,000 [3]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 712,628,000 845,890,000
Total liabilities and stockholders’ equity $ 945,995,000 [1] $ 1,243,123,000 [3]
[1] unaudited
[2] unaudited
[3] Note 1
XML 20 R6.htm IDEA: XBRL DOCUMENT v3.10.0.1
CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) - $ / shares
shares in Thousands
Jun. 30, 2018
 [1]
Dec. 31, 2017
 [2]
Preferred stock par value (in Dollars per Share) $ 0.01 $ 0.01
Preferred stock, shares authorized (in Shares) 10,000 10,000
Preferred stock, shares issued (in Shares) 0 0
Preferred stock, shares outstanding (in Shares) 0 0
Common stock par value (in Dollars per Share) $ 0.01 $ 0.01
Common stock, shares authorized (in Shares) 350,000 350,000
Common stock, shares issued (in Shares) 145,971 153,775
Common stock, shares outstanding (in Shares) 145,971 153,775
[1] unaudited
[2] Note 1
XML 21 R7.htm IDEA: XBRL DOCUMENT v3.10.0.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Cash paid for purchase of noncontrolling interest $ 0 $ 2,170
Repayments of Secured Debt 126,447 0
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest (110,694) 67,633
Assets held for sale reclassified from other assets to intangibles 1,811 0
Gain (Loss) on Disposition of Property Plant Equipment 66 0
Extinguishment of Debt, Amount 0 43,909
Adjustments to reconcile net income to net cash provided by operating activities:    
Amortization of convertible notes and term loan offering costs 3,911 5,394
Amortization of Acquisition Costs 12,677 12,164
Impairment of Intangible Assets, Finite-lived 152,330 0
Change in fair value of acquired royalty rights (23,933) (96,871)
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Change in Unrealized Gain (Loss) (74) (136)
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability (22,735) 2,649
Depreciation, Amortization and Accretion, Net 2,028 591
Gain (Loss) on Sale of Investments (764) (93)
Inventory Write-down (491) 161
Provision for Doubtful Accounts 43 54
Stock-based compensation expense 2,218 2,075
Deferred income taxes (11,276) 29,223
Changes in assets and liabilities:    
Receivables from licensees and other 10,764 15,058
Receivables from licensees and other (945) (6,000)
Prepaid and other current assets (6,816) (2,700)
Accrued interest on notes receivable (150) 15,263
Increase (Decrease) in Inventories (5,343) (1,823)
Other assets (1,531) 8
Accounts payable (8,679) 993
Accrued liabilities (5,789) 5,542
Increase (Decrease) in Deferred Revenue (5,970) 0
Increase (Decrease) in Income Taxes Payable (1,159) 10,278
Other long-term liabilities 666 (9,851)
Net cash provided by (used in) operating activities (19,756) 61,612
Cash flows from investing activities    
Payments to Acquire Investments 0 19,860
Proceeds from Sale of Available-for-sale Securities, Equity 4,116 29,045
Payments for (Proceeds from) Productive Assets 37,993 48,062
Proceeds from Sale of Productive Assets 0 108,169
Proceeds from Collection of Notes Receivable 0 8,142
Payments to Acquire Property, Plant, and Equipment 3,915 705
Net cash provided by investing activities 38,194 172,853
Cash flows from financing activities    
Cash dividends paid 0 (21)
Payments for Repurchase of Common Stock (23,604) (30,000)
Net cash used in financing activities (150,051) (32,191)
Net increase (decrease) in cash and cash equivalents (131,613) 202,274
Cash and cash equivalents at beginning of the period [1] 527,266 147,154
Cash and cash equivalents at end of period [2],[3] 395,653  
Supplemental cash flow information    
Cash paid for income taxes 3,980 14,205
Cash paid for interest 4,591 4,695
Assets held for sale reclassified from notes receivable to other assets $ 0 $ 10,000
[1] Note 1
[2] unaudited
[3] unaudited
XML 22 R8.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summary of Significant Accounting Policies
 6 Months Ended
Jun. 30, 2018
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies
1. Summary of Significant Accounting Policies
 
Basis of Presentation
 
The accompanying unaudited Condensed Consolidated Financial Statements of PDL Biopharma, Inc. and its subsidiaries (collectively, the “Company” or “PDL”) have been prepared in accordance with Generally Accepted Accounting Principles (United States) (“GAAP”) for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments), that management of the Company believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.
 
The accompanying unaudited Condensed Consolidated Financial Statements and related financial information should be read in conjunction with the Company’s audited Consolidated Financial Statements and the related notes thereto for the year ended December 31, 2017, included in its Annual Report on Form 10-K for the fiscal year ended December 31, 2017, filed with the Securities and Exchange Commission (“SEC”) on March 16, 2018. The Condensed Consolidated Balance Sheet at December 31, 2017, has been derived from the audited Consolidated Financial Statements at that date, but does not include all disclosures required by GAAP.

Significant Accounting Policies

The Company’s significant accounting policies are described in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017. Summarized below are the accounting pronouncements adopted subsequent to December 31, 2017.

Adopted Accounting Pronouncements

In August 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-15, Classification of Certain Cash Receipts and Cash Payments. The new standard provides for specific guidance how certain transactions are classified in the statement of cash flows. Effective January 1, 2018, the Company adopted the requirements of ASU No. 2016-15. The adoption did not have an effect on the Consolidated Financial Statements on the adoption date and no adjustment to prior year Consolidated Financial Statements was required.

In October 2016, the FASB issued ASU No. 2016-16, Intra-Entity Transfers of Assets Other Than Inventory, which requires companies to account for the income tax effects of intercompany sales and transfers of assets other than inventory in the period in which the transfer occurs. Effective January 1, 2018, the Company adopted the requirements of ASU No. 2016-16. The adoption did not have an effect on the Consolidated Financial Statements on the adoption date and no adjustment to prior year Consolidated Financial Statements was required.

In November 2016, the FASB issued ASU No. 2016-18, Restricted Cash, which requires entities to show the changes in total of cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. Effective January 1, 2018, the Company adopted the requirements of ASU No. 2016-18. The adoption did not have an effect on the Consolidated Financial Statements on the adoption date and no adjustment to prior year Consolidated Financial Statements was required.

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). Effective January 1, 2018, the Company adopted the requirements of ASU No. 2014-09 using the modified retrospective method as discussed in Note 2 below. All amounts and disclosures set forth in this Quarterly Report on Form 10-Q reflect these changes.

Recently Issued Accounting Pronouncements

In February 2016, the FASB issued ASU No. 2016-02, Leases, which seeks to increase transparency and comparability among organizations by, among other things, recognizing lease assets and lease liabilities on the balance sheet for leases classified as operating leases under previous GAAP and disclosing key information about leasing arrangements. ASU No. 2016-02 becomes effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the provisions of ASU No. 2016-02 and assessing the impact, if any, it may have on the Company’s Condensed Consolidated Financial Statements.

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments. The new guidance amends the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology, which will result in more timely recognition of losses. ASU No. 2016-13 has an effective date of the fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company is currently evaluating ASU No. 2016-13 and assessing the impact, if any, it may have to the Company’s consolidated results of operations, financial position and cash flows.
XML 23 R9.htm IDEA: XBRL DOCUMENT v3.10.0.1
Net Income per Share
 6 Months Ended
Jun. 30, 2018
Earnings Per Share [Abstract]  
Net Income per Share
. Net Income (loss) per Share
 
 
Three Months Ended
 
Six Months Ended
 
 
June 30,
 
June 30,
Net Income (Loss) per Basic and Diluted Share:
 
2018
 
2017
 
2018
 
2017
 (in thousands except per share amounts)
 
 
 
 
 
 
 
 
Numerator
 
 
 
 
 
 
 
 
Income (loss) attributable to PDL’s shareholders used to compute net income per basic and diluted share
 
$
(112,296
)
 
$
60,439

 
$
(110,694
)
 
$
67,680

 
 
 
 
 
 
 
 
 
Denominator
 
 

 
 

 
 
 
 
Total weighted average shares used to compute net income attributable to PDL’s shareholders, per basic share
 
146,923

 
155,654

 
149,186

 
159,677

Restricted stock outstanding
 
—

 
740

 
—

 
491

Shares used to compute net income (loss) attributable to PDL’s shareholders, per diluted share
 
146,923

 
156,394

 
149,186

 
160,168

 
 
 
 
 
 
 
 
 
Net income (loss) attributable to PDL’s shareholders per share - basic
 
$
(0.76
)
 
$
0.39

 
$
(0.74
)
 
$
0.42

Net income (loss) attributable to PDL’s shareholders per share - diluted
 
$
(0.76
)
 
$
0.39

 
$
(0.74
)
 
$
0.42



The Company computes net income per diluted share using the sum of the weighted-average number of common and common equivalent shares outstanding. Common equivalent shares used in the computation of net income per diluted share include shares that may be issued pursuant to outstanding stock options and restricted stock awards, the 4.0% Convertible Senior Notes due February 1, 2018 (the “February 2018 Notes”) that were repaid on February 1, 2018, and the 2.75% Convertible Senior Notes due December 1, 2021 (the “December 2021 Notes”), in each case, on a weighted average basis for the period that the notes were outstanding, including the effect of adding back interest expense and the underlying shares using the if converted method.

December 2021 Notes Capped Call Potential Dilution

In November 2016, the Company issued $150.0 million in aggregate principal of the December 2021 Notes, which provide in certain situations for the conversion of the outstanding principal amount of the December 2021 Notes into shares of the Company’s common stock at a predefined conversion rate. For additional information on the conversion rates on the Company’s convertible debt, see Note 13. In conjunction with the issuance of the December 2021 Notes, the Company entered into a capped call transaction with a hedge counterparty. The capped call transaction is expected generally to reduce the potential dilution, and/or offset, to an extent, the cash payments the Company may choose to make in excess of the principal amount, upon conversion of the December 2021 Notes. The Company has excluded the capped call transaction from the net income (loss) per diluted share computation as such securities would have an antidilutive effect and those securities should be considered separately rather than in the aggregate in determining whether their effect on net income (loss) per diluted share would be dilutive or antidilutive. For additional information regarding the capped call transaction related to the Company’s December 2021 Notes, see Note 13.

Anti-Dilutive Effect of Restricted Stock Awards and Stock Options

For the three months ended June 30, 2018 and 2017, the Company excluded approximately 1.0 million and 2.2 million shares underlying restricted stock awards, respectively, and for the six months ended June 30, 2018 and 2017, the Company excluded approximately 1.1 million and 2.0 million shares underlying restricted stock awards, respectively, calculated on a weighted average basis, from its net income (loss) per diluted share calculations because their effect was anti-dilutive.

For the three months ended June 30, 2018 and 2017, the Company excluded approximately 4.9 million and zero shares underlying outstanding stock options, respectively, and for the six months ended June 30, 2018 and 2017, the Company excluded approximately 4.9 million and zero shares underlying outstanding stock options, respectively, calculated on a weighted average basis, from its net income (loss) per diluted share calculations because their effect was anti-dilutive.
XML 24 R10.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fair Value Measurements
 6 Months Ended
Jun. 30, 2018
Fair Value Disclosures [Abstract]  
Fair Value Measurements
 4. Fair Value Measurements

The fair value of the Company’s financial instruments are estimates of the amounts that would be received if the Company were to sell an asset or pay to transfer a liability in an orderly transaction between market participants at the measurement date or exit price. The assets and liabilities are categorized and disclosed in one of the following three categories:

Level 1 – based on quoted market prices in active markets for identical assets and liabilities;
 
Level 2 – based on quoted market prices for similar assets and liabilities, using observable market-based inputs or unobservable market-based inputs corroborated by market data; and
 
Level 3 – based on unobservable inputs using management’s best estimate and assumptions when inputs are unavailable.

Assets/Liabilities Measured and Recorded at Fair Value on a Recurring Basis

The following table presents the fair value of the Company’s financial instruments measured at fair value on a recurring basis by level within the valuation hierarchy:
 
 
June 30, 2018
 
December 31, 2017
(in thousands)
 
Level 1
 
Level 2
 
Level 3
 
Total
 
Level 1
 
Level 2
 
Level 3
 
Total
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Financial assets:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Money market funds
 
$
324,105

 
$
—

 
$
—

 
$
324,105

 
$
417,563

 
$
—

 
$
—

 
$
417,563

Corporate securities
 
—

 
—

 
—

 
—

 
4,848

 
—

 
—

 
4,848

Warrants
 
—

 
103

 
—

 
103

 
—

 
29

 
—

 
29

Royalty rights - at fair value
 
—

 
—

 
335,163

 
335,163

 
—

 
—

 
349,223

 
349,223

Total
 
$
324,105

 
$
103

 
$
335,163

 
$
659,371

 
$
422,411

 
$
29

 
$
349,223

 
$
771,663

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Financial liabilities:
 
 

 
 

 
 
 
 

 
 

 
 

 
 
 
 

Contingent consideration, current1
 
$
—

 
$
—

 
$
1,140

 
$
1,140

 
$
—

 
$
—

 
$
—

 
$
—

Contingent consideration, non-current
 
—

 
—

 
18,900

 
18,900

 
—

 
—

 
42,000

 
42,000

Total
 
$
—

 
$
—

 
$
20,040

 
$
20,040

 
$
—

 
$
—

 
$
42,000

 
$
42,000


 ___________________
1 Contingent consideration, current is classified as “Accrued liabilities” on the Condensed Consolidated Balance Sheet. See Note 11 for details.

There have been no transfers between levels during the six month periods ended June 30, 2018 and December 31, 2017. The Company recognizes transfers between levels on the date of the event or change in circumstances that caused the transfer.

Corporate Securities

Corporate securities consisted primarily of U.S. corporate equity holdings. The fair value of corporate securities is estimated using market quoted prices.

Warrants

Warrants consist primarily of purchased call options to buy U.S. corporate equity holdings and derivative assets acquired as part of note receivable investments. The fair value of the warrants is estimated using recently quoted market prices or estimated fair value of the underlying equity security and the Black-Scholes option pricing model.

Royalty Rights - At Fair Value

Depomed Royalty Agreement

On October 18, 2013, the Company entered into the Royalty Purchase and Sale Agreement (the “Depomed Royalty Agreement”) with Depomed, Inc. and Depo DR Sub, LLC (together, “Depomed”), whereby the Company acquired the rights to receive royalties and milestones payable on sales of Type 2 diabetes products licensed by Depomed in exchange for a $240.5 million cash payment. Total consideration was $241.3 million, which was comprised of the $240.5 million cash payment to Depomed and $0.8 million in transaction costs.

The rights acquired include Depomed’s royalty and milestone payments accruing from and after October 1, 2013: (a) from Santarus, Inc. (“Santarus”) (which was subsequently acquired by Salix Pharmaceuticals, Inc. (“Salix”), which itself was acquired by Valeant Pharmaceuticals International, Inc. (which was subsequently acquired by Bausch Health Companies Inc.) (“Bausch Health”)) with respect to sales of Glumetza (metformin HCL extended-release tablets) in the United States; (b) from Merck & Co., Inc. with respect to sales of Janumet® XR (sitagliptin and metformin HCL extended-release tablets); (c) from Janssen Pharmaceutica N.V. with respect to potential future development milestones and sales of its recently approved fixed-dose combination of Invokana® (canagliflozin) and extended-release metformin tablets, marketed as Invokamet XR®; (d) from Boehringer Ingelheim with respect to potential future development milestones and sales of the investigational fixed-dose combinations of drugs and extended-release metformin subject to Depomed’s license agreement with Boehringer Ingelheim, including its recently approved products, Jentadueto XR® and Syngardy XR®; and (e) from LG Life Sciences and Bausch Health for sales of extended-release metformin tablets in Korea and Canada, respectively.

Under the terms of the Depomed Royalty Agreement, the Company receives all royalty and milestone payments due under license agreements between Depomed and its licensees until the Company has received payments equal to two times the cash payment it made to Depomed, after which all net payments received by Depomed will be shared evenly between the Company and Depomed.

The Depomed Royalty Agreement terminates on the third anniversary following the date upon which the later of the following occurs: (a) October 25, 2021, or (b) at such time as no royalty payments remain payable under any license agreement and each of the license agreements has expired by its terms.

As of June 30, 2018 and December 31, 2017, the Company determined that its royalty purchase interest in Depo DR Sub, LLC represented a variable interest in a variable interest entity. However, the Company does not have the power to direct the activities of Depo DR Sub, LLC that most significantly impact Depo DR Sub, LLC’s economic performance and is not the primary beneficiary of Depo DR Sub, LLC; therefore, Depo DR Sub, LLC is not subject to consolidation by the Company.

The financial asset acquired represents a single unit of accounting. The fair value of the financial asset acquired was determined by using a discounted cash flow analysis related to the expected future cash flows to be generated by each licensed product. This financial asset is classified as a Level 3 asset within the fair value hierarchy, as the Company’s valuation utilized significant unobservable inputs, including estimates as to the probability and timing of future commercialization for products not yet approved by regulatory agencies outside of the United States. The discounted cash flows are based upon expected royalties from sales of licensed products over a nine-year period. The discount rates utilized range from 10% to 24%. Significant judgment is required in selecting appropriate discount rates. At June 30, 2018, an evaluation was performed to assess those rates and general market conditions potentially affecting the fair market value, of the financial asset. Should these discount rates increase or decrease by 2.5%, the fair value of the asset could decrease by $12.8 million or increase by $14.7 million, respectively. A third-party expert was engaged to assist management develop its original estimate of the expected future cash flows. The estimated fair value of the asset is subject to variation should those cash flows vary significantly from those estimates. The Company periodically assesses the expected future cash flows and to the extent such payments are greater or less than its initial estimates, or the timing of such payments is materially different than the original estimates, the Company will adjust the estimated fair value of the asset. Should the expected royalties increase or decrease by 2.5%, the fair value of the asset could increase or decrease by $5.4 million, respectively.

When the Company acquired the Depomed royalty rights, Glumetza was marketed by Santarus. In January 2014, Salix acquired Santarus and assumed responsibility for commercializing Glumetza, which was generally perceived to be a positive development because of Salix’s larger sales force and track record in the successful commercialization of therapies. In late 2014, Salix made a number of disclosures relating to an excess of supply at the distribution level of Glumetza and other drugs that it commercialized and the practices leading to this excess of supply which were under review by Salix’s audit committee in relation to the related accounting practices. Because of these disclosures and the Company’s lack of direct access to information as to the levels of inventory of Glumetza in the distribution channels, the Company commenced a review of all public statements by Salix, publicly available historical third-party prescription data, analyst reports and other relevant data sources. The Company also engaged a third-party expert to specifically assess estimated inventory levels of Glumetza in the distribution channel and to ascertain the potential effects those inventory levels may have on expected future cash flows. Salix was acquired by Bausch Health in early April 2015. In mid-2015, Bausch Health implemented two price increases on Glumetza. At year-end 2015, a third-party expert was engaged by the Company to assess the impact of the Glumetza price adjustments and near-term market entrance of generic equivalents to the expected future cash flows. Based on the analysis performed, management revised the underlying assumptions used in the discounted cash flow analysis at year-end 2015. In February and August 2016, a total of three generic equivalents to Glumetza were approved to enter the market. In February 2016, Lupin Pharmaceuticals, Inc. and in August 2017, Teva Pharmaceutical Industries, Ltd., each launched a generic equivalent approved product. To date, the third generic equivalent to Glumetza has not launched.

In May 2017, the Company received notification that a subsidiary of Bausch Health had launched an authorized generic equivalent product in February 2017, and the Company received royalties on such authorized generic equivalent product under the same terms as the branded Glumetza product, retroactive to February 2017.

At December 31, 2017, management re-evaluated, with assistance of a third-party expert, the market share data, the gross-to-net revenue adjustment assumptions and Glumetza demand data, including the delay in launch of additional generic equivalent products and the entry of an authorized generic product by Bausch Health. These data and assumptions are based on available but limited information. At June 30, 2018, management updated the expected future cash flows based on the current period demand and supply data of Glumetza and the authorized generic equivalent product launched by Bausch Health.

As of June 30, 2018, the Company’s discounted cash flow analysis reflects its expectations as to the amount and timing of future cash flows up to the valuation date, including future cash flows for the authorized generic equivalent product. The Company continues to monitor whether the generic competition further affects sales of Glumetza and thus royalties on such sales paid to the Company, and the impact of the launched authorized generic equivalent. Due to the uncertainty around Bausch Health’s marketing and pricing strategy, as well as the recent generic competition and limited historical demand data after generic market entrance, the Company may need to further evaluate future cash flows in the event of more rapid reduction or increase in market share of Glumetza and its authorized generic equivalent product and/or a further erosion in net pricing.

In February 2016, at the Company’s request and pursuant to the Depomed Royalty Agreement, Depomed exercised its audit right with respect to Glumetza royalties. The independent auditor engaged to perform the royalty audit completed it in July 2017, and based upon the results of the audit, Depomed, on behalf of the Company, filed a lawsuit on September 7, 2017, against Bausch Health and one of its subsidiaries, claiming damages for unpaid royalties, fees and interest. Bausch Health, Depomed and the Company entered into a settlement agreement on October 27, 2017 whereby the parties agreed to dismiss the litigation, with prejudice, and Bausch Health agreed to pay to Depomed $13.0 million. The full amount of the settlement payment was transferred to the Company under the terms of the Depomed Royalty Agreement in November 2017.

On May 31, 2016, the Company obtained a notification indicating that the U.S. Food and Drug Administration (“FDA”) approved Jentadueto XR for use in patients with Type 2 diabetes. In June 2016, the Company received a $6.0 million FDA approval milestone pursuant to the terms of the Depomed Royalty Agreement. The product approval was earlier than initially expected. Based on the FDA approval and anticipated timing of the product launch, the Company adjusted the timing of future cash flows and discount rate used in the discounted cash flow model at June 30, 2016. As of December 31, 2017, management re-evaluated, the cash flow assumptions for Jentadueto XR and revised the discounted cash flow model. As of June 30, 2018, the Company’s discounted cash flow analysis reflects its expectations as to the amount and timing of future cash flows up to the valuation date.

On September 21, 2016, the Company obtained a notification indicating that the FDA approved Invokamet XR for use in patients with Type 2 diabetes. The product approval triggered a $5.0 million approval milestone payment to the Company pursuant to the terms of the Depomed Royalty Agreement. Based on the FDA approval and timing of the product launch, the Company adjusted the timing of future cash flows and discount rate used in the discounted cash flow model.

On December 13, 2016, the Company obtained a notification indicating that the FDA approved Synjardy XR for use in patients with Type 2 diabetes. The product approval triggered a $6.0 million approval milestone payment to the Company pursuant to the terms of the Depomed Royalty Agreement. Based on the FDA approval and the April 2017 launch of Synjardy XR by Boehringer Ingelheim, the Company adjusted the timing of future cash flows and discount rate used in the discounted cash flow model.

As of June 30, 2018, the fair value of the asset acquired as reported in the Company’s Condensed Consolidated Balance Sheet was $214.1 million and the maximum loss exposure was $214.1 million.

Viscogliosi Brothers Royalty Agreement

On June 26, 2014, the Company entered into a Royalty Purchase and Sale Agreement (the “VB Royalty Agreement”) with Viscogliosi Brothers, LLC (“VB”), whereby VB conveyed to the Company the right to receive royalties payable on sales of a spinal implant that has received pre-market approval from the FDA held by VB and commercialized by Paradigm Spine, LLC (“Paradigm Spine”), in exchange for a $15.5 million cash payment, less fees.

The royalty rights acquired includes royalties accruing from and after April 1, 2014. Under the terms of the VB Royalty Agreement, the Company receives all royalty payments due to VB pursuant to certain technology transfer agreements between VB and Paradigm Spine until the Company has received payments equal to 2.3 times the cash payment made to VB, after which all rights to receive royalties will be returned to VB. VB’s ability to repurchase the royalty right for as specified amount expired on June 26, 2018.

The fair value of the royalty right at June 30, 2018, was determined by using a discounted cash flow analysis related to the expected future cash flows to be received. This asset is classified as a Level 3 asset, as the Company’s valuation utilized significant unobservable inputs, including estimates as to the probability and timing of future sales of the licensed product. The discounted cash flow was based upon expected royalties from sales of licensed product over a ten-year period. The discount rate utilized was 15.0%. Significant judgment is required in selecting the appropriate discount rate. Should this discount rate increase or decrease by 2.5%, the fair value of this asset could decrease by $1.4 million or increase by $1.6 million, respectively. Should the expected royalties increase or decrease by 2.5%, the fair value of the asset could increase or decrease by $0.4 million, respectively. A third-party expert was engaged to assist management with the development of its estimate of the expected future cash flows, when deemed necessary. The fair value of the asset is subject to variation should those cash flows vary significantly from the Company’s estimates. At each reporting period, an evaluation is performed to assess those estimates, discount rates utilized and general market conditions affecting fair market value.

As of June 30, 2018, the fair value of the asset acquired as reported in the Company’s Condensed Consolidated Balance Sheet was $14.7 million and the maximum loss exposure was $14.7 million.

University of Michigan Royalty Agreement

On November 6, 2014, the Company acquired a portion of all royalty payments of the Regents of the University of Michigan’s (“U-M”) worldwide royalty interest in Cerdelga (eliglustat) for $65.6 million pursuant to the Royalty Purchase and Sale Agreement with U-M (the “U-M Royalty Agreement”). Under the terms of the U-M Royalty Agreement, the Company receives 75% of all royalty payments due under U-M’s license agreement with Genzyme Corporation, a Sanofi company (“Genzyme”) until expiration of the licensed patents, excluding any patent term extension. Cerdelga, an oral therapy for adult patients with Gaucher disease type 1, was developed by Genzyme. Cerdelga was approved in the United States in August 2014, in the European Union in January 2015, and in Japan in March 2015. In addition, marketing applications for Cerdelga are under review by other regulatory authorities. While marketing applications have been approved in the United States, the European Union and Japan, national pricing and reimbursement decisions are delayed in some countries. At December 31, 2017, a third-party expert was engaged by the Company to assess the impact of the delayed pricing and reimbursement decisions to Cerdelga’s expected future cash flows. Based on the analysis performed, management revised the underlying assumptions used in the discounted cash flow analysis at December 31, 2017. As of June 30, 2018, the Company’s discounted cash flow analysis reflects its expectations as to the amount and timing of future cash flows up to the valuation date.

The fair value of the royalty right at June 30, 2018 was determined by using a discounted cash flow analysis related to the expected future cash flows to be received. This asset is classified as a Level 3 asset, as the Company’s valuation utilized significant unobservable inputs, including estimates as to the probability and timing of future sales of the licensed product. The discounted cash flow was based upon expected royalties from sales of licensed product over a four-year period. The discount rate utilized was approximately 12.8%. Significant judgment is required in selecting the appropriate discount rate. Should this discount rate increase or decrease by 2.5%, the fair value of this asset could decrease by $1.2 million or increase by $1.4 million, respectively. Should the expected royalties increase or decrease by 2.5%, the fair value of the asset could increase or decrease by $0.7 million, respectively. A third-party expert is engaged to assist management with the development of its estimate of the expected future cash flows, when deemed necessary. The fair value of the asset is subject to variation should those cash flows vary significantly from the Company’s estimates. An evaluation of those estimates, discount rates utilized and general market conditions affecting fair market value is performed in each reporting period.

As of June 30, 2018, the fair value of the asset acquired as reported in the Company’s Condensed Consolidated Balance Sheet was $26.1 million and the maximum loss exposure was $26.1 million.

AcelRx Royalty Agreement

On September 18, 2015, the Company entered into a royalty interest assignment agreement (the “AcelRx Royalty Agreement”) with ARPI LLC, a wholly owned subsidiary of AcelRx Pharmaceuticals, Inc. (“AcelRx”), whereby the Company acquired the rights to receive a portion of the royalties and certain milestone payments on sales of Zalviso® (sufentanil sublingual tablet system) in the European Union, Switzerland and Australia by AcelRx’s commercial partner, Grünenthal, in exchange for a $65.0 million cash payment. Under the terms of the AcelRx Royalty Agreement, the Company receives 75% of all royalty payments and 80% of the first four commercial milestone payments due under AcelRx’s license agreement with Grünenthal until the earlier to occur of (i) receipt by the Company of payments equal to three times the cash payments made to AcelRx and (ii) the expiration of the licensed patents (expected to be in January of 2032). Zalviso received marketing approval by the European Commission in September 2015. Grünenthal launched Zalviso in the second quarter of 2016 and the Company started to receive royalties in the third quarter of 2016.

As of June 30, 2018, and December 31, 2017, the Company determined that its royalty rights under the AcelRx Royalty Agreement represented a variable interest in a variable interest entity. However, the Company does not have the power to direct the activities of ARPI LLC that most significantly impact ARPI LLC’s economic performance and is not the primary beneficiary of ARPI LLC; therefore, ARPI LLC is not subject to consolidation by the Company.

The fair value of the royalty right at June 30, 2018 was determined by using a discounted cash flow analysis related to the expected future cash flows to be received. This asset is classified as a Level 3 asset, as the Company’s valuation utilized significant unobservable inputs, including estimates as to the probability and timing of future sales of the licensed product. The discounted cash flow was based upon expected royalties from sales of licensed product over a fourteen-year period. The discount rate utilized was approximately 13.4%. Significant judgment is required in selecting the appropriate discount rate. Should this discount rate increase or decrease by 2.5%, the fair value of this asset could decrease by $9.8 million or increase by $12.0 million, respectively. Should the expected royalties increase or decrease by 2.5%, the fair value of the asset could increase or decrease by $1.9 million, respectively. A third-party expert is engaged to assist management with the development of its estimate of the expected future cash flows, when deemed necessary. The fair value of the asset is subject to variation should those cash flows vary significantly from the Company’s estimates. Based on the number of treated patients to date, management adjusted the timing of the expected future cash flows used in the discounted cash flow model at December 31, 2017. At June 30, 2018, management performed an evaluation of those estimates, discount rates utilized and general market conditions to determine the fair market value of the asset, and such an evaluation is performed for each reporting period. As of June 30, 2018, the Company’s discounted cash flow analysis reflects its expectations as to the amount and timing of future cash flows up to the valuation date.

As of June 30, 2018, the fair value of the asset acquired as reported in the Company’s Condensed Consolidated Balance Sheet was $77.4 million and the maximum loss exposure was $77.4 million.

Kybella Royalty Agreement

On July 8, 2016, the Company entered into a royalty purchase and sales agreement with an individual, whereby the Company acquired that individual’s rights to receive certain royalties on sales of KYBELLA® by Allergen plc in exchange for a $9.5 million cash payment and up to $1.0 million in future milestone payments based upon product sales targets. The Company started to receive royalty payments during the third quarter of 2016.

The fair value of the royalty right at June 30, 2018, was determined by using a discounted cash flow analysis related to the expected future cash flows to be received. This asset is classified as a Level 3 asset, as the Company’s valuation utilized significant unobservable inputs, including estimates as to the probability and timing of future sales of the licensed product. The discounted cash flow was based upon expected royalties from sales of a licensed product over a seven-year period. The discount rate utilized was approximately 14.4%. Significant judgment is required in selecting the appropriate discount rate. Should this discount rate increase or decrease by 2.5%, the fair value of this asset could decrease by $0.2 million or increase by $0.3 million, respectively. Should the expected royalties increase or decrease by 2.5%, the fair value of the asset could increase or decrease by $0.1 million, respectively. A third-party expert is engaged to assist management with the development of its estimate of the expected future cash flows, when deemed necessary. The fair value of the asset is subject to variation should those cash flows vary significantly from the Company’s estimates. At each reporting period, an evaluation of those estimates, discount rates utilized and general market conditions affecting fair market value is performed in each reporting period.

As of June 30, 2018, the fair value of the asset acquired as reported in the Company’s Condensed Consolidated Balance Sheet was $2.8 million and the maximum loss exposure was $2.8 million.

The following tables summarize the changes in Level 3 assets and the gains and losses included in earnings for the six months ended June 30, 2018:
Fair Value Measurements Using Significant Unobservable Inputs (Level 3) - Royalty Rights Assets
 
 
 
 
 
 
 
(in thousands)
 
Royalty Rights -
At Fair Value
Fair value as of December 31, 2017
 
 
 
$
349,223

 
 
 
 
 
 
 
 
Total net change in fair value for the period
 
 
 
 
 
 
Change in fair value of royalty rights - at fair value
 
$
23,933

 
 
 
 
Proceeds from royalty rights - at fair value
 
$
(37,993
)
 
 
 
 
Total net change in fair value for the period
 
 
 
(14,060
)
 
 
 
 
 
 
 
Fair value as of June 30, 2018
 


 
$
335,163


Fair Value Measurements Using Significant Unobservable Inputs (Level 3) - Royalty Rights Assets
 
 
 
 
 
 
 
 
 
Fair Value as of
 
Royalty Rights -
 
Fair Value as of
(in thousands)
 
December 31, 2017
 
Change in Fair Value
 
June 30, 2018
 
 
 
 
 
 
 
Depomed
 
$
232,038

 
$
(17,967
)
 
$
214,071

VB
 
14,380

 
284

 
14,664

U-M
 
26,769

 
(620
)
 
26,149

AcelRx
 
72,894

 
4,539

 
77,433

Avinger
 
396

 
(396
)
 
—

KYBELLA
 
2,746

 
100

 
2,846

 
 
$
349,223

 
$
(14,060
)
 
$
335,163

Fair Value Measurements Using Significant Unobservable Inputs (Level 3) - Liabilities
 
 
 
(in thousands)
 
Contingent Consideration
Fair value as of December 31, 2017
 
$
(42,000
)
 
 
 
 
 
 
Total net change in fair value for the period
 
22,735

 
Fair value of financial instruments acquired
 
(1,560
)
 
Settlement of financial instrument
 
785

 
 
 
 
 
Fair value as of June 30, 2018
 
$
(20,040
)


The fair value of the contingent consideration was determined using an income approach derived from revenue estimates and a probability assessment with respect to the likelihood of achieving (a) the level of net sales or (b) generic product launch that would trigger the milestone payments. The key assumptions in determining the fair value are the discount rate and the probability assigned to the potential milestones being achieved. The fair value of the contingent consideration is remeasured each reporting period, with changes in fair value recorded in the Condensed Consolidated Statements of Income. The change in fair value of the contingent consideration during the six months ending June 30, 2018 is due primarily to the changes in the probabilities in the generic entry milestones and the additional contingent consideration acquired as part of the assets acquired by LENSAR from Precision Eye Services, as described in note 9.

Gains and losses from changes in Level 3 assets included in earnings for each period are presented in “Royalty rights - change in fair value” and gains and losses from changes in Level 3 liabilities included in earnings for each period are presented in “Change in fair value of anniversary payment and contingent consideration” as follows:
 
 
Three Months Ended
 
Six Months Ended
 
 
June 30,
 
June 30,
(in thousands)
 
2018
 
2017
 
2018
 
2017
 
 
 
 
 
 
 
 
 
Total change in fair value for the period included in earnings for royalty right assets held at the end of the reporting period
 
$
12,842

 
$
83,725

 
$
23,933

 
$
96,871

 
 
 
 
 
 
 
 
 
Total change in fair value for the period included in earnings for liabilities held at the end of the reporting period
 
$
22,135

 
$
(1,207
)
 
$
22,735

 
$
(2,649
)

Assets/Liabilities Measured and Recorded at Fair Value on a Nonrecurring Basis

The Company remeasures the fair value of certain assets and liabilities upon the occurrence of certain events. Such assets consist of cost-method equity investments and long-lived assets, including property and equipment and intangible assets. During the three months ended June 30, 2018, the Company recorded an impairment charge of $152.3 million for the Noden intangible asset related to the increased probability of a generic version of aliskiren being launched in the United States. As a result of this impairment charge, which was based on the estimated fair value of the assets, the remaining carrying value of the these intangible assets was determined to be $40.1 million. The fair value calculation included level 3 inputs. For additional information on the impairment charge, see note 10.

Assets/Liabilities Not Subject to Fair Value Recognition

The following tables present the fair value of assets and liabilities not subject to fair value recognition by level within the valuation hierarchy:
 
 
June 30, 2018
 
December 31, 2017
(in thousands)
 
Carrying Value
 
Fair Value
Level 2
 
Fair Value
Level 3
 
Carrying Value
 
Fair Value
Level 2
 
Fair Value
Level 3
 
 
 
 
 
 
 
 
 
 
 
 
 
Assets:
 
 
 
 
 
 
 
 
 
 
 
 
Wellstat Diagnostics note receivable
 
$
50,191

 
$
—

 
$
57,224

 
$
50,191

 
$
—

 
$
51,308

Hyperion note receivable
 
1,200

 
—

 
1,200

 
1,200

 
—

 
1,200

CareView note receivable
 
19,496

 
—

 
19,507

 
19,346

 
—

 
18,750

Total
 
$
70,887

 
$
—

 
$
77,931

 
$
70,737

 
$
—

 
$
71,258

 
 
 
 
 
 
 
 
 
 
 
 
 
Liabilities:
 
 

 
 

 
 

 
 

 
 

 
 

February 2018 Notes
 
$
—

 
$
—

 
$
—

 
$
126,066

 
$
126,131

 
$
—

December 2021 Notes
 
120,945

 
139,052

 
—

 
117,415

 
148,028

 
—

Total
 
$
120,945

 
$
139,052

 
$
—

 
$
243,481

 
$
274,159

 
$
—



As of June 30, 2018 and December 31, 2017, the estimated fair values of the Hyperion Catalysis International, Inc. note receivable, and CareView Communications, Inc. (“CareView”) note receivable were determined using one or more discounted cash flow models, incorporating expected payments and the interest rate extended on the notes receivable, with fixed interest rates and incorporating expected payments for notes receivable with a variable rate of return.

When deemed necessary the Company engages a third-party valuation expert to assist in evaluating its investments and the related inputs needed to estimate the fair value of certain investments. The Company determined its notes receivable assets are Level 3 assets as the Company’s valuations utilized significant unobservable inputs, including estimates of future revenues, discount rates, expectations about settlement, terminal values and required yield. To provide support for the estimated fair value measurements, the Company considered forward-looking performance related to the investment and current measures associated with high yield indices, and reviewed the terms and yields of notes placed by specialty finance and venture firms both across industries and in similar sectors.

The CareView note receivable is secured by substantially all assets of, and equity interests in CareView. The Wellstat Diagnostics note receivable is secured by substantially all assets of Wellstat Diagnostics and is supported by a guaranty from the Wellstat Diagnostics Guarantors (as defined in Note 7 below). The estimated fair value of the collateral assets was determined by using an asset approach and discounted cash flow model related to the underlying collateral and was adjusted to consider estimated costs to sell the assets.

On June 30, 2018, the carrying values of several of the Company’s notes receivable differed from their estimated fair value. This is the result of discount rates used when performing a discounted cash flow for fair value valuation purposes.

The fair values of the Company’s convertible notes were determined using quoted market pricing or dealer quotes.

The following table represents significant unobservable inputs used in determining the estimated fair value of impaired notes receivable investments:
Asset
 
Valuation
Technique
 
Unobservable
Input
 
June 30,
2018
 
December 31,
2017
 
 
 
 
 
 
 
 
 
Wellstat Diagnostics
 
 
 
 
 
 
 
 
Wellstat Guarantors Intellectual Property
 
Income Approach
 
 
 
 
 
 
 
 
 
 
Discount rate
 
12%
 
12%
 
 
 
 
Royalty amount
 
$21 million
 
$21 million
Settlement Amount
 
Income Approach
 
 
 
 
 
 
 
 
 
 
Discount rate
 
15%
 
15%
 
 
 
 
Settlement amount
 
$36 million
 
$32 million
 
 
 
 
 
 
 
 
 
Real Estate Property
 
Market Approach
 
 
 
 
 
 
 
 
 
 
Annual appreciation rate
 
4%
 
4%
 
 
 
 
Estimated realtor fee
 
6%
 
6%
 
 
 
 
Estimated disposal date
 
6/30/2019
 
6/30/2019
 
 
 
 
 
 
 
 
 
CareView
 
 
 
 
 
 
 
 
Note receivable cash flows
 
Income Approach
 
 
 
 
 
 
 
 
 
 
Discount rate
 
17.5%
 
17.5%


At June 30, 2018, the Company had three notes receivable investments on non-accrual status with a cumulative investment cost and fair value of approximately $70.9 million and $77.9 million, respectively, compared to three note receivable investments on non-accrual status at December 31, 2017 with a cumulative investment cost and fair value of approximately $70.7 million and $71.3 million, respectively. For the three and six months ended June 30, 2018, the Company recognized $0.8 million and $1.5 million, respectively, of interest revenue for the CareView note receivable investment as a result of cash interest payments made during the period; for the three and six months ended June 30, 2017, the Company did not recognize any interest for note receivable investments on non-accrual status. During the three and six months ended June 30, 2018, the Company recognized losses on extinguishment of notes receivable of zero and zero, respectively, and during the three and six months ended June 30, 2017, the Company recognized losses on extinguishment of notes receivable of $12.2 million and $12.2 million, respectively.
XML 25 R11.htm IDEA: XBRL DOCUMENT v3.10.0.1
Cash Equivalents and Investments
 6 Months Ended
Jun. 30, 2018
Cash and Cash Equivalents [Abstract]  
Cash Equivalents and Investments
5. Cash, Cash Equivalents and Short-term Investments
 
As of June 30, 2018, and December 31, 2017, the Company had invested its excess cash balances primarily in cash, money market funds and a corporate equity security. The Company’s securities are classified as available-for-sale and are carried at estimated fair value, with unrealized gains and losses reported in “Accumulated other comprehensive income” in stockholders’ equity, net of estimated taxes. See Note 4 for fair value measurement information. The cost of securities sold is based on the specific identification method. To date, the Company has not experienced credit losses on investments in these instruments, and it does not require collateral for its investment activities.

The following tables summarize the Company’s cash and available-for-sale securities’ amortized cost, gross unrealized gains and fair value by significant investment category reported as cash and cash equivalents, or short-term investments as of June 30, 2018 and December 31, 2017:
 
 
 
 
 
 
 
 
Reported as:
(in thousands)
 
 Amortized Cost
 
 Unrealized Gains
 
 Estimated Fair Value
 
 Cash and Cash Equivalents
 
Short-Term Investments
 
 
 
 
 
 
 
 
 
 
 
June 30, 2018
 
 
 
 
 
 
 
 
 
 
Cash
 
$
71,548

 
$
—

 
$
71,548

 
$
71,548

 
$
—

Money market funds
 
324,105

 
—

 
324,105

 
324,105

 
—

Total
 
$
395,653

 
$
—

 
$
395,653

 
$
395,653

 
$
—

 
 
 
 
 
 
 
 
 
 
 
December 31, 2017
 
 
 
 
 
 
 
 
 
 
Cash
 
$
109,703

 
$
—

 
$
109,703

 
$
109,703

 
$
—

Money market funds
 
417,563

 
—

 
417,563

 
417,563

 
—

Corporate securities
 
3,353

 
1,495

 
4,848

 
—

 
4,848

Total
 
$
530,619

 
$
1,495

 
$
532,114

 
$
527,266

 
$
4,848



The Company recognized zero and $0.8 million of gains on sales of available-for-sale securities in the three and six months ended June 30, 2018, respectively. The Company did not recognize any gains or losses on sales of available-for-sale securities in the three and six months ended June 30, 2017.

The unrealized gains on investments included in “Other comprehensive income (loss), net of tax” was zero and $1.2 million as of June 30, 2018, and December 31, 2017, respectively.
XML 26 R12.htm IDEA: XBRL DOCUMENT v3.10.0.1
Notes Receivable and Other Long-term Receivables
 6 Months Ended
Jun. 30, 2018
Receivables [Abstract]  
Notes and Other Long-term Receivables
. Notes and Other Long-Term Receivables

Notes and other long-term receivables included the following significant agreements:

Wellstat Diagnostics Note Receivable and Credit Agreement and Related Litigation

On November 2, 2012, the Company and Wellstat Diagnostics entered into a $40.0 million credit agreement pursuant to which the Company was to accrue quarterly interest payments at the rate of 5% per annum (payable in cash or in kind). In addition, the Company was to receive quarterly royalty payments based on a low double-digit royalty rate of Wellstat Diagnostics’ net revenues, generated by the sale, distribution or other use of Wellstat Diagnostics’ products, if any, commencing upon the commercialization of its products. A portion of the proceeds of the $40.0 million credit agreement were used to repay certain notes receivable which Wellstat Diagnostics entered into in March 2012.

In January 2013, the Company was informed that, as of December 31, 2012, Wellstat Diagnostics had used funds contrary to the terms of the credit agreement and breached Sections 2.1.2 and 7 of the credit agreement. The Company sent Wellstat Diagnostics a notice of default on January 22, 2013, and accelerated the amounts owed under the credit agreement. In connection with the notice of default, the Company exercised one of its available remedies and transferred approximately $8.1 million of available cash from a bank account of Wellstat Diagnostics to the Company and applied the funds to amounts due under the credit agreement. On February 28, 2013, the parties entered into a forbearance agreement whereby the Company agreed to refrain from exercising additional remedies for 120 days. During such forbearance period, the Company provided approximately $1.3 million to Wellstat Diagnostics to fund ongoing operations of the business. During the year ended December 31, 2013, approximately $8.7 million was advanced pursuant to the forbearance agreement.

On August 15, 2013, the Company entered into an amended and restated credit agreement with Wellstat Diagnostics. The Company determined that the new agreement should be accounted for as a modification of the existing agreement.

Except as otherwise described herein, the material terms of the amended and restated credit agreement are substantially the same as those of the original credit agreement, including quarterly interest payments at the rate of 5% per annum (payable in cash or in kind). In addition, the Company was to continue to receive quarterly royalty payments based on a low double-digit royalty rate of Wellstat Diagnostics’ net revenues. However, pursuant to the amended and restated credit agreement: (i) the principal amount was reset to approximately $44.1 million, which was comprised of approximately $33.7 million original loan principal and interest, $1.3 million term loan principal and interest and $9.1 million forbearance principal and interest; (ii) the specified internal rates of return increased; (iii) the default interest rate was increased; (iv) Wellstat Diagnostics’ obligation to provide certain financial information increased in frequency to monthly; (v) internal financial controls were strengthened by requiring Wellstat Diagnostics to maintain an independent, third-party financial professional with control over fund disbursements; (vi) the Company waived the existing events of default; and (vii) the owners and affiliates of Wellstat Diagnostics were required to contribute additional capital to Wellstat Diagnostics upon the sale of an affiliate entity. The amended and restated credit agreement had an ultimate maturity date of December 31, 2021 (but has subsequently been accelerated as described below).

In June 2014, the Company received information from Wellstat Diagnostics showing that it was generally unable to pay its debts as they became due, constituting an event of default under the amended and restated credit agreement.

On August 5, 2014, the Company delivered a notice of default (the “Wellstat Diagnostics Borrower Notice”) to Wellstat Diagnostics, which accelerated all obligations under the amended and restated credit agreement and demanded immediate payment in full in an amount equal to approximately $53.9 million, (which amount, in accordance with the terms of the amended and restated credit agreement, included an amount that, together with interest and royalty payments already made to the Company, would generate a specified internal rate of return to the Company), plus accruing fees, costs and interest, and demanded that Wellstat Diagnostics protect and preserve all collateral securing its obligations.

On August 7, 2014, the Company delivered a notice (the “Wellstat Diagnostics Guarantor Notice”) to each of the guarantors of Wellstat Diagnostics’ obligations to the Company (collectively, the “Wellstat Diagnostics Guarantors”) under the credit agreement, which included a demand that the guarantors remit payment to the Company in the amount of the outstanding obligations. The guarantors include certain affiliates and related companies of Wellstat Diagnostics, including Wellstat Therapeutics and Wellstat Diagnostics’ stockholders.

On September 24, 2014, the Company filed an ex-parte petition for appointment of receiver with the Circuit Court of Montgomery County, Maryland (the “Wellstat Diagnostics Petition”), which was granted on the same day. Wellstat Diagnostics remained in operation during the period of the receivership with incremental additional funding from the Company. On May 24, 2017, Wellstat Diagnostics transferred substantially all of its assets to the Company pursuant to a credit bid. The credit bid reduced the outstanding balance of the loan by an immaterial amount.

On September 4, 2015, the Company filed in the Supreme Court of New York a motion for summary judgment in lieu of complaint which requested that the court enter judgment against certain of the Wellstat Diagnostics Guarantors for the total amount due on the Wellstat Diagnostics debt, plus all costs and expenses including lawyers’ fees incurred by the Company in enforcement of the related guarantees. On September 23, 2015, the Company filed in the same court an ex parte application for a temporary restraining order and order of attachment of the Wellstat Diagnostics Guarantor defendants’ assets. Although the court denied the Company’s request for a temporary restraining order at a hearing on September 24, 2015, it ordered that assets of the Wellstat Diagnostics Guarantor defendants should be held in status quo ante and only used in the normal course of business.

On July 29, 2016, the Supreme Court of New York granted the Company’s motion for summary judgment and held that the Wellstat Diagnostics Guarantor defendants are liable for all “Obligations” owed by Wellstat Diagnostics to the Company. After appeal by the Wellstat Diagnostics Guarantor defendants, on February 14, 2017, the Appellate Division of the Supreme Court of New York reversed on procedural grounds a portion of the Memorandum of Decision granting the Company summary judgment in lieu of complaint, but affirmed the portion of the Memorandum of Decision denying the Wellstat Diagnostics Guarantor defendants’ motion for summary judgment in which they sought a determination that the guarantees had been released. As a result, the litigation has been remanded to the Supreme Court of New York to proceed on the Company’s claims as a plenary action. On June 21, 2017, the Supreme Court of New York ordered the Company to file a Complaint, which was filed by the Company on July 20, 2017. The Wellstat Diagnostics Guarantors filed their answer on August 9, 2017, including counterclaims against the Company alleging breach of contract, breach of fiduciary duty, and tortious interference with prospective economic advantage. This case is currently pending and in the pre-trial phase.

On October 14, 2016, the Company sent a notice of default and reference to foreclosure proceedings to certain of the Wellstat Diagnostics Guarantors which are not defendants in the New York action, but which are owners of real estate assets over which a deed of trust in favor of the Company securing the guarantee of the loan to Wellstat Diagnostics had been executed. On March 2, 2017, the Company sent a second notice to foreclose on the real estate assets, and noticed the sale for March 29, 2017. The sale was taken off the calendar by the trustee under the deed of trust and has not been re-scheduled yet. On March 6, 2017, the Company sent a letter to the Wellstat Diagnostics Guarantors seeking information in preparation for a UCC Article 9 sale of some or all of the intellectual property-related collateral of the Wellstat Diagnostics Guarantors. The Wellstat Diagnostics Guarantors did not respond to the Company’s letter, but on March 17, 2017, filed an order to show cause with the Supreme Court of New York to enjoin the Company’s sale of the real estate or enforcing its security interests in the Wellstat Diagnostics Guarantors’ intellectual property during the pendency of any action involving the guarantees at issue. In June 2018, the Delaware Supreme Court largely affirmed a September 2017 decision of the Delaware Chancery Court awarding Wellstat Therapeutics $55.8 million in damages, plus interest, against BTG International, Inc. for breach of contract. In October 2017, the Company had filed a motion with the Supreme Court of New York requesting a pre-judgement attachment of the award. On February 6, 2018, the Supreme Court of New York issued an order from the bench which enjoins the Wellstat Diagnostics Guarantors from selling, encumbering, removing, transferring or altering the collateral pending the outcome of the proceedings before it. The Supreme Court of New York also issued an order precluding the Company from foreclosing on certain of the Wellstat Diagnostics Guarantors’ collateral pending the outcome of the proceedings before it.

On October 22, 2015, certain of the Wellstat Diagnostics Guarantors filed a separate complaint against the Company in the Supreme Court of New York seeking a declaratory judgment that certain contractual arrangements entered into between the parties subsequent to Wellstat Diagnostics’ default, and which relate to a split of proceeds in the event that the Wellstat Diagnostics Guarantors voluntarily monetize any assets that are the Company’s collateral, is of no force or effect. This case has been joined for all purposes, including trial, and consolidated with the pending case filed by the Company.

Effective April 1, 2014, and as a result of the event of default, the Company determined the loan to be impaired and it ceased to accrue interest revenue. At that time and as of June 30, 2018, it has been determined that an allowance on the carrying value of the note was not necessary, as the Company believes the value of the collateral securing Wellstat Diagnostics’ obligations exceeds the carrying value of the asset and is sufficient to enable the Company to recover the current carrying value of $50.2 million. The Company continues to closely monitor the timing and expected recovery of amounts due, including litigation and other matters related to Wellstat Diagnostics Guarantors’ assets. There can be no assurance that an allowance on the carrying value of the notes receivable investment will not be necessary in a future period depending on future developments.

Hyperion Agreement

On January 27, 2012, the Company and Hyperion Catalysis International, Inc. (“Hyperion”) (which is also a Wellstat Diagnostics Guarantor) entered into an agreement whereby Hyperion sold to the Company the royalty streams due from Showa Denko K.K. (“SDK”) related to a certain patent license agreement between Hyperion and SDK dated December 31, 2008. The agreement assigned the patent license agreement royalty stream accruing from January 1, 2012 through December 31, 2013, to the Company in exchange for the lump sum payment to Hyperion of $2.3 million. In exchange for the lump sum payment, the Company was to receive two equal payments of $1.2 million on each of March 5, 2013 and 2014. The first payment of $1.2 million was paid on March 5, 2013, but Hyperion has not made the second payment that was due on March 5, 2014. Effective as of such date and as a result of the event of default, the Company ceased to accrue interest revenue. As of June 30, 2018, the estimated fair value of the collateral was determined to be in excess of the carrying value. There can be no assurance that this will be true in the event of the Company’s foreclosure on the collateral, nor can there be any assurance of realizing value from such collateral.

Avinger Credit and Royalty Agreement

On April 18, 2013, the Company entered into a credit agreement with Avinger, Inc. (the “Avinger Credit and Royalty Agreement”). Under the terms of the Avinger Credit and Royalty Agreement, the Company receives a low, single-digit royalty on Avinger’s net revenues until April 2018. Commencing in October 2015, after Avinger repaid $21.4 million pursuant to its note receivable prior to its maturity date, the royalty on Avinger’s net revenues reduced by 50%, subject to certain minimum payments from the prepayment date until April 18, 2018. The Company has accounted for the royalty rights in accordance with the fair value option. As of April 18, 2018, there are no further obligations owed to PDL.

LENSAR Credit Agreement

On October 1, 2013, the Company entered into a credit agreement with LENSAR, Inc. (“LENSAR”), pursuant to which the Company made available to LENSAR up to $60.0 million to be used by LENSAR in connection with the commercialization of its currently marketed LENSAR™ Laser System. Of the $60.0 million available to LENSAR, an initial $40.0 million, net of fees, was funded by the Company at the close of the transaction. The remaining $20.0 million was never funded. Outstanding borrowings under the loans bore interest at the rate of 15.5% per annum, payable quarterly in arrears.

On May 12, 2015, the Company entered into a forbearance agreement with LENSAR, pursuant to which the Company agreed to refrain from exercising certain remedies available to it resulting from the failure of LENSAR to comply with a liquidity covenant and make interest payments due under the credit agreement. Under the forbearance agreement, the Company agreed to provide LENSAR with up to an aggregate of $8.5 million in weekly increments through the period ended September 30, 2015 plus employee retention amounts of approximately $0.5 million in the form of additional loans, subject to LENSAR meeting certain milestones related to LENSAR obtaining additional capital to fund the business or sell the business and repay outstanding amounts under the credit agreement. In exchange for the forbearance, LENSAR agreed to additional reporting covenants, the engagement of a chief restructuring officer and an increase on the interest rate to 18.5%, applicable to all outstanding amounts under the credit agreement.

On September 30, 2015, the Company agreed to extend the forbearance agreement until October 9, 2015 and provide for up to an additional $0.8 million in funding while LENSAR negotiated a potential sale of its assets. On October 9, 2015, the forbearance agreement expired, but the Company agreed to fund LENSAR’s operations while LENSAR continued to negotiate a potential sale of its assets.

On November 15, 2015, LENSAR, LLC (“LENSAR/Alphaeon”), a wholly owned subsidiary of Alphaeon Corporation (“Alphaeon”), and LENSAR entered into the Asset Purchase Agreement whereby LENSAR/Alphaeon agreed to acquire certain assets of LENSAR and assumed certain liabilities of LENSAR. The acquisition was consummated on December 15, 2015.

In connection with the closing of the acquisition, LENSAR/Alphaeon entered into an amended and restated credit agreement with the Company, assuming $42.0 million in loans as part of the borrowings under the Company’s prior credit agreement with LENSAR. In addition, Alphaeon issued 1.7 million shares of its Class A common stock to the Company.

The Company has estimated a fair value of $3.84 per share for the 1.7 million shares of Alphaeon Class A common stock received in connection with the transactions and recognized this investment as a cost-method investment of $6.6 million included in other long-term assets. The Alphaeon Class A common stock is subject to other-than-temporary impairment assessments in future periods. There is no other-than-temporary impairment charge incurred as of June 30, 2018.

In December 2016, LENSAR, re-acquired the assets from LENSAR/Alphaeon and the Company entered into a second amended and restated credit agreement with LENSAR whereby LENSAR assumed all obligations under the amended and restated credit agreement with LENSAR/Alphaeon. Also in December, LENSAR filed for a voluntary petition under Chapter 11 of the U.S. Bankruptcy Code (“Chapter 11 case”) with the support of the Company. In January 2017, the Company agreed to provide debtor-in-possession financing of up to $2.8 million in new advances to LENSAR so that it could continue to operate its business during the Chapter 11 case. LENSAR filed a Chapter 11 plan of reorganization with the Company’s support under which LENSAR would issue 100% of its equity interests to the Company in exchange for the cancellation of the Company’s claims as a secured creditor in the Chapter 11 case, other than with respect to the debtor-in-possession financing, and would thereby become an operating wholly-owned subsidiary of the Company. On April 26, 2017, the bankruptcy court approved the plan of reorganization.

Pursuant to the plan of reorganization, LENSAR emerged from bankruptcy on May 11, 2017 as a wholly-owned subsidiary of the Company, and the Company started to consolidate LENSAR’s financial statements under the voting interest model beginning May 11, 2017.

For additional information on LENSAR please refer to Note 10 under “Intangible Assets,” Note 19 under “Business Combinations” and Note 20 under “Segment Information.”

Direct Flow Medical Credit Agreement

On November 5, 2013, the Company entered into a credit agreement with Direct Flow Medical, Inc. (“Direct Flow Medical”) under which the Company agreed to provide up to $50.0 million to Direct Flow Medical. Of the $50.0 million available to Direct Flow Medical, an initial $35.0 million (tranche one), net of fees, was funded by the Company at the close of the transaction.

On November 10, 2014, the Company and Direct Flow Medical agreed to an amendment to the credit agreement to permit Direct Flow Medical to borrow the $15.0 million second tranche upon receipt by Direct Flow Medical of a specified minimum amount of proceeds from an equity offering prior to December 31, 2014. In exchange, the parties amended the credit agreement to provide for additional fees associated with certain liquidity events, such as a change of control or the consummation of an initial public offering, and granted the Company certain board of director observation rights. On November 19, 2014, upon Direct Flow Medical satisfying the amended tranche two milestone, the Company funded the $15.0 million second tranche to Direct Flow Medical, net of fees.

Outstanding borrowings under tranche one bore interest at the rate of 15.5% per annum, payable quarterly in arrears, until the occurrence of the second tranche. Upon occurrence of the borrowing of this second tranche, the interest rate applicable to all loans under the credit agreement was decreased to 13.5% per annum, payable quarterly in arrears.

Under the terms of the credit agreement, Direct Flow Medical’s obligation to repay loan principal commenced on the twelfth interest payment date, September 30, 2016. The principal amount outstanding at commencement of repayment was required to be repaid in equal installments until final maturity of the loans. The loans were to mature on November 5, 2018. The obligations under the credit agreement were secured by a pledge of substantially all of the assets of Direct Flow Medical and any of its subsidiaries.

On December 21, 2015, Direct Flow Medical and the Company entered into a waiver to the credit agreement in anticipation of Direct Flow Medical being unable to comply with the liquidity covenant and make interest payments due under the credit agreement, which was subsequently extended on January 14, 2016, and further delayed the timing of the interest payments through the period ending September 30, 2016 while Direct Flow Medical sought additional financing to operate its business.

On January 28, 2016, the Company funded an additional $5.0 million to Direct Flow Medical in the form of a short-term secured promissory note.

On February 26, 2016, the Company and Direct Flow Medical entered into the fourth amendment to the credit agreement that, among other things, (i) converted the $5.0 million short-term secured promissory note into a loan under the credit agreement with substantially the same interest and payment terms as the existing loans, (ii) added a conversion feature whereby the $5.0 million loan would convert into equity of Direct Flow Medical upon the occurrence of certain events and (iii) provided for a second $5.0 million convertible loan tranche commitment, to be funded at the option of the Company. The commitment for the second tranche was not funded and has since expired. In addition, (i) the Company agreed to waive the liquidity covenant and delay the timing of the unpaid interest payments until September 30, 2016 and (ii) Direct Flow Medical agreed to issue to the Company a specified amount of warrants to purchase shares of convertible preferred stock on the first day of each month for the duration of the waiver period at an exercise price of $0.01 per share.

On July 15, 2016, the Company and Direct Flow Medical entered into the fifth amendment and limited waiver to the credit agreement. The Company funded an additional $1.5 million to Direct Flow Medical in the form of a note with substantially the same interest and payment terms as the existing loans and a conversion feature whereby the $1.5 million loan would convert into equity of Direct Flow Medical upon the occurrence of certain events. In addition, Direct Flow Medical agreed to issue to the Company warrants to purchase shares of convertible preferred stock at an exercise price of $0.01 per share.

On September 12, 2016, the Company and Direct Flow Medical entered into the sixth amendment and limited waiver to the credit agreement under which the Company funded an additional $1.5 million to Direct Flow Medical in the form of a note with substantially the same interest and payment terms as the existing loans. In addition, Direct Flow Medical agreed to issue to the Company a specified amount of warrants to purchase shares of convertible preferred stock at an exercise price of $0.01 per share.

On September 30, 2016, the Company and Direct Flow Medical entered into a waiver to the credit agreement where the parties agreed, among other things, to (i) delay payment on all overdue interest payments until October 31, 2016, (ii) waive the initial principal repayment until October 31, 2016 and (iii) continue to waive the liquidity requirements until October 31, 2016. Further, Direct Flow Medical agreed to issue to the Company a specified amount of warrants to purchase shares of convertible preferred stock at an exercise price of $0.01 per share.

On October 31, 2016, the Company agreed to extend the waivers described above until November 30, 2016 and on November 14, 2016, the Company advanced an additional $1.0 million loan while Direct Flow Medical continued to seek additional financing.

On November 16, 2016, Direct Flow Medical advised the Company that its potential financing source had modified its proposal from an equity investment to a loan with a substantially smaller amount and under less favorable terms. Direct Flow Medical shut down its operations in December 2016 and in January 2017 made an assignment for the benefit of creditors. The Company then initiated foreclosure proceedings, resulting in the Company obtaining ownership of most of the Direct Flow Medical assets through the Company’s wholly-owned subsidiary, DFM, LLC. The assets were held for sale and carried at the lower of carrying amount or fair value, less estimated selling costs, which is primarily based on supporting data from market participant sources, and valid offers from third parties.

At December 31, 2016, the Company completed an impairment analysis and concluded that the situation qualified as a troubled debt restructuring and recognized an impairment loss of $51.1 million.

In January 2017, the Company started to actively market the asset held for sale. On January 23, 2017, the Company and DFM, LLC entered into an Intellectual Property Assignment Agreement with Hong Kong Haisco Pharmaceutical Co., Limited (“Haisco”), a Chinese pharmaceutical company, whereby Haisco acquired former Direct Flow Medical clinical, regulatory and commercial information and intellectual property rights exclusively in China for $7.0 million. The Company, through DFM, LLC also sold Haisco certain manufacturing equipment for $450,000 and collected $692,000 on outstanding Direct Flow Medical accounts receivable during the year ended December 31, 2017.

On January 6, 2018, DFM, LLC and HaisThera Advisors Co., Limited (“HaisThera”) entered into a license agreement whereby DFM, LLC granted HaisThera an exclusive license to develop, manufacture and commercialize percutaneously implanting stentless aortic valve in the European Union. The consideration for the license agreement was $500,000 upfront and up to $2.0 million in royalty payments.

kaléo Note Purchase Agreement

On April 1, 2014, the Company entered into a note purchase agreement with Accel 300, LLC (“Accel 300”), a wholly-owned subsidiary of kaléo, Inc. (“kaléo”), pursuant to which the Company acquired $150.0 million of secured notes due 2029 (the “kaléo Note”). The kaléo Note was issued pursuant to an indenture between Accel 300 and U.S. Bank, National Association, as trustee, and was secured by 20% of net sales of its first approved product, Auvi-Q® (epinephrine auto-injection, USP) (known as Allerject® in Canada) and 10% of net sales of kaléo’s second proprietary auto-injector based product, EVZIO (naloxone hydrochloride injection) (the “kaléo Revenue Interests”), and a pledge of kaléo’s equity ownership in Accel 300.

On September 21, 2017, the Company entered into an agreement (the “kaléo Note Sale Agreement”) with MAM-Kangaroo Lender, LLC, a Delaware limited liability company (the “kaléo Purchaser”), pursuant to which the Company sold its entire interest in the kaléo Note.

Pursuant to the kaléo Note Sale Agreement, the kaléo Purchaser paid to the Company an amount equal to 100% of the then outstanding principal, a premium of 1% of such amount and accrued interest under the kaléo Note, for an aggregate cash purchase price of $141.7 million, subject to an 18-month escrow holdback of $1.4 million against certain potential contingencies. For a further discussion on this topic, see Note 12.

CareView Credit Agreement

On June 26, 2015, the Company entered into a credit agreement with CareView, under which the Company made available to CareView up to $40.0 million in two tranches of $20.0 million each. Under the terms of the credit agreement, the first tranche of $20.0 million, net of fees, was funded by the Company upon CareView’s attainment of a specified milestone relating to the placement of CareView Systems®, on October 7, 2015. On October 7, 2015, the Company and CareView entered into an amendment of the credit agreement to modify certain definitions related to the first and second tranche milestones. The second $20.0 million tranche would be funded upon CareView’s attainment of specified milestones relating to the placement of CareView Systems and consolidated earnings before interest, taxes, depreciation and amortization, to be accomplished no later than June 30, 2017. Such milestones were not achieved, and there is no additional funding obligation due from the Company. Outstanding borrowings under the credit agreement will bear interest at the rate of 13.5% per annum and are payable quarterly in arrears.

As part of the transaction, the Company received a warrant to purchase approximately 4.4 million shares of common stock of CareView at an exercise price of $0.45 per share. The Company has accounted for the warrant as derivative asset with an offsetting credit as debt discount. At each reporting period the warrant is marked to market for changes in fair value.

In connection with the October 2015 amendment of the credit agreement, the Company and CareView also agreed to amend the warrant to purchase common stock agreement by reducing the warrant’s exercise price from $0.45 to $0.40 per share.

In February 2018, the Company entered into a modification agreement with CareView whereby the Company agreed, effective as of December 28, 2017, to modify the credit agreement before remedies could otherwise have become available to the Company under the credit agreement in relation to certain obligations of CareView that would potentially not be met, including the requirement to make principal payments. Under the modification agreement the Company agreed that (i) a lower liquidity covenant would be applicable and (ii) principal repayment would be delayed for a period of up to December 31, 2018. In exchange for agreeing to these modifications, among other things, the exercise price of the Company’s warrants to purchase 4.4 million shares of common stock of CareView was repriced from $0.40 to $0.03 per share and, subject to the occurrence of certain events, CareView agreed to grant the Company additional equity interests. At June 30, 2018, the Company determined an estimated fair value of the warrant to be $0.1 million.

Effective October 1, 2017, the Company determined the loan to be impaired and it ceased to accrue interest revenue. At June 30, 2018, it has been determined that an allowance on the carrying value of the note was not necessary.
XML 27 R13.htm IDEA: XBRL DOCUMENT v3.10.0.1
Accrued Liabilities
 6 Months Ended
Jun. 30, 2018
Payables and Accruals [Abstract]  
Accrued Liabilities
. Accrued Liabilities

Accrued liabilities consist of the following:
(in thousands)
 
June 30,
2018
 
December 31,
2017
 
 
 
 
 
Compensation
 
$
7,046

 
$
6,043

Interest
 
344

 
2,451

Deferred revenue
 
4,904

 
9,741

Dividend payable
 
77

 
79

Legal
 
1,027

 
595

Accrued rebates, chargebacks and other revenue reserves
 
16,931

 
19,613

Refund to manufacturer
 
—

 
647

Customer advances
 
—

 
3,198

Contingent consideration, current
 
1,140

 
—

Other
 
2,825

 
3,514

Total
 
$
34,294

 
$
45,881


The following table provides a summary of activity with respect to the Company’s sales allowances and accruals for the six months ended June 30, 2018:
(in thousands)
 
Discount and Distribution Fees
 
Government Rebates and Chargebacks
 
Assistance and Other Discounts
 
Product Return
 
Total
 
 
 
 
 
 
 
 
 
 
 
Balance at December 31, 2017:
 
$
3,422

 
$
8,709

 
$
4,178

 
$
3,304

 
$
19,613

Allowances for current period sales
 
4,749

 
7,859

 
4,174

 
1,291

 
18,073

Allowances for prior period sales
 
—

 
24

 
—

 
65

 
89

Credits/payments for current period sales
 
(2,057
)
 
(2,847
)
 
(2,019
)
 
—

 
(6,923
)
Credits/payments for prior period sales
 
(3,724
)
 
(7,629
)
 
(2,178
)
 
(390
)
 
(13,921
)
Balance at June 30, 2018:
 
$
2,390

 
$
6,116

 
$
4,155

 
$
4,270

 
$
16,931
XML 28 R14.htm IDEA: XBRL DOCUMENT v3.10.0.1
Commitments and Contingencies
 6 Months Ended
Jun. 30, 2018
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies
12. Commitments and Contingencies

Wellstat Litigation

On September 4, 2015, the Company filed in the Supreme Court of New York a motion for summary judgment in lieu of complaint which requested that the court enter judgment against Wellstat Diagnostics Guarantors for the total amount due on the Wellstat Diagnostics debt, plus all costs and expenses including lawyers’ fees incurred by the Company in enforcement of the related guarantees. On July 29, 2016, the court issued its Memorandum of Decision granting the Company’s motion for summary judgment and denying the Wellstat Diagnostics Guarantors’ cross-motion for summary judgment seeking a determination that they were no longer liable under the guarantees. The Supreme Court of New York held that the Wellstat Diagnostics Guarantors are liable for all “Obligations” owed by Wellstat Diagnostics to the Company. It did not set a specific dollar amount due, but ordered that a judicial hearing officer or special referee be designated to determine the amount of the Obligations owing, and awarded the Company its attorneys’ fees and costs in an amount to be determined. On July 29, 2016, the Wellstat Diagnostics Guarantors filed a notice of appeal from the Memorandum of Decision to the Appellate Division of the Supreme Court of New York. On February 14, 2017, the Appellate Division reversed the summary judgment decision of the Supreme Court in the Company’s favor, but affirmed the denial of the Wellstat Guarantors’ cross-motion for summary judgment. The Appellate Division determined that the action was inappropriate for summary judgment pursuant to New York Civil Practice Law & Rules section 3213 on procedural grounds, but specifically made no determination regarding whether the Company was entitled to a judgment on the merits. Pursuant to this decision, the action has been remanded to the Supreme Court for further proceedings on the merits. The proceeding is being conducted as a plenary proceeding, with both parties having the opportunity to take discovery and file dispositive motions in accordance with New York civil procedure.

Noden Pharma DAC v Anchen Pharmaceuticals, Inc. et al

On June 12, 2017, Noden filed a complaint against Anchen Pharmaceuticals, Inc. (“Anchen”) and Par Pharmaceutical (“Par”) for infringement of the 595 Patent based on their submission of an ANDA seeking authorization from the FDA to market a generic version of aliskiren hemifumarate tablets, 150 mg and 300 mg, in the United States. Noden’s suit triggered a 30-month stay of FDA approval of that application under the Hatch Waxman Act. Par filed a counterclaim seeking a declaratory judgment that their proposed generic version of aliskiren hemifumarate hydrochlorothiazide tablets (150 mg eq. base/12.5 mg HCT, 150 mg eq. base/25 mg HCT, 300 mg eq. base/12.5 mg HCT, and 300 mg eq. base/25 mg HCT), described in a separate ANDA submitted by Par to FDA, alleging noninfringement of U.S. Patent No. 8,618,172 (the “‘172 Patent”), also owned by Noden. This case was filed in the United States District Court for the District of Delaware. In March 2018, each of the parties to the proceeding filed a joint stipulation of dismissal of the defendants’ counterclaim seeking a declaratory judgment of non-infringement of the ‘172 Patent. In the stipulation, Anchen and Par agreed that they will not seek, or otherwise join or assist in, any post-grant review, including inter partes review, of the ‘172 Patent or U.S. Patent No. 9,023,893 (the “893 Patent”). The defendants further stipulated that they will not seek approval of Par’s ANDA or submit any other ANDA seeking approval to market aliskiren hemifumarate hydrochlorothiazide prior to the expiration of the ‘172 Patent in July of 2028. Both the ‘172 Patent and the ‘893 Patent are listed in the Orange Book for Tekturna HCT.

On June 8, 2018, Noden and Anchen entered into the Settlement Agreement. Under the Settlement Agreement, the parties agreed to file a stipulation of dismissal with the court to facilitate dismissal of the litigation in its entirety, with prejudice. In the Settlement Agreement, Noden granted Anchen a non-exclusive, royalty free, fully paid up and non-transferable license to manufacture and commercialize in the United States a generic version of aliskiren which is described in Anchen’s ANDA, and Anchen agreed not to commercialize its generic version of aliskiren prior to March 1, 2019. The license grant excludes certain formulations covered by the ‘595 patent which closely relate to the commercial formulation of Tekturna marketed by Noden. The Settlement Agreement includes a release by each party for liabilities associated with the litigation and an acknowledgement from Anchen that the ‘595 patent claims are valid and enforceable. Anchen’s ANDA has not yet been approved by the FDA and any commercialization by Anchen will be subject to their ability to obtain such approval.

Other Legal Proceedings

From time to time, the Company is involved in lawsuits, arbitrations, claims, investigations and proceedings, consisting of intellectual property, commercial, employment and other matters, which arise in the ordinary course of business. The Company makes provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Such provisions are reviewed at least quarterly and adjusted to reflect the impact of settlement negotiations, judicial and administrative rulings, advice of legal counsel, and other information and events pertaining to a particular case. Litigation is inherently unpredictable. If any unfavorable ruling were to occur in any specific period, there exists the possibility of a material adverse impact on the results of the Company’s operations of that period and on its cash flows and liquidity.

Lease Guarantee

In connection with the spin-off (the “Spin-Off”) by the Company of Facet Biotech Corporation (“Facet”), the Company entered into amendments to the leases for the Company’s former facilities in Redwood City, California, under which Facet was added as a co-tenant, and a Co-Tenancy Agreement, under which Facet agreed to indemnify us for all matters related to the leases attributable to the period after the Spin-Off date. As of June 30, 2018, the total lease payments for the duration of the guarantee, which runs through December 2021, are approximately $39.5 million. In April 2010, Abbott Laboratories acquired Facet and later renamed the entity AbbVie Biotherapeutics, Inc. (“AbbVie”). If AbbVie were to default under its lease obligations, the Company could be held liable by the landlord as a co-tenant and, thus, the Company has in substance guaranteed the payments under the lease agreements for the Redwood City facilities.

The Company prepared a discounted, probability weighted cash flow analysis to calculate the estimated fair value of the lease guarantee as of the Spin-Off. The Company was required to make assumptions regarding the probability of Facet’s default on the lease payment, the likelihood of a sublease being executed and the times at which these events could occur. These assumptions are based on information that the Company received from real estate brokers and the then-current economic conditions, as well as expectations of future economic conditions. The fair value of this lease guarantee was charged to additional paid-in capital upon the Spin-Off and any future adjustments to the carrying value of the obligation will also be recorded in additional paid-in capital.

The Company has recorded a liability of $10.7 million on its Condensed Consolidated Balance Sheets as of June 30, 2018 and December 31, 2017, related to this guarantee. In future periods, the Company may adjust this liability for any changes in the ultimate outcome of this matter that are both probable and estimable.

Purchase Obligations

Noden and Novartis entered into a supply agreement pursuant to which Novartis will manufacture and supply to Noden a bulk tableted form of the Noden Products, and for the additional supply of active pharmaceutical ingredient form, for specified periods of time prior to the transfer of manufacturing responsibilities for the Noden Products to another manufacturer. The supply agreement may be terminated by either party for material breach that remains uncured for a specified time period. Noden has placed firm orders for bulk product of $14.4 million, which will be fulfilled within the next twelve months. Under the terms of the supply agreement, Noden is committed to purchase certain minimum quantities of bulk product and active pharmaceutical ingredient that would amount to approximately $114.3 million over the next twenty-four months if fulfilled, of which $61.4 million is committed over the next twelve months. While the supply agreement provides that the parties will agree to reasonable accommodations with respect to changes in firm orders, the Company expects that Noden will meet the requirements of the supply agreement, unless otherwise negotiated. The commitments in the supply agreement terminate upon transfer to another manufacturer.

LENSAR and Coherent, Inc. entered into an Original Equipment Manufacturer agreement pursuant to which Coherent, Inc. will manufacture and supply to LENSAR Staccato Lasers. The supply agreement commits LENSAR to a minimum purchase obligation of approximately $3.5 million over the next twenty-four months, of which $1.2 million is committed over the next twelve months. The Company expects that LENSAR will meet this requirement. For more information about the LENSAR transaction, see Note 19.

Escrow Receivable

On September 21, 2017, the Company entered into the kaléo Note Sale Agreement, pursuant to which the Company sold its entire interest in the kaléo Note.

Pursuant to the kaléo Note Sale Agreement, the purchaser paid to the Company an amount equal to 100% of the then outstanding principal, a premium of 1% of such amount and accrued interest under the kaléo Notes, for an aggregate cash purchase price of $141.7 million.

Pursuant to the terms of the kaléo Note Sale Agreement, $1.4 million of the aggregate purchase price was deposited into an escrow account as a potential payment against certain contingencies, which expires on the 18th month anniversary of the closing date. Upon the expiration of escrow period, the escrow agent is required to release remaining funds to the Company.

The Company does not expect there to be any claims by the purchaser under the escrow agreement. However, in the event that such a claim is made, and if successful, the amount of such a claim up to $1.4 million would be released from the escrow account to the purchaser, which amount would be reduced from the amount released to the Company at the end of the 18-month escrow period. As of June 30, 2018, the Company is not aware of any claims by the purchaser that would reduce the escrow receivable.
XML 29 R15.htm IDEA: XBRL DOCUMENT v3.10.0.1
Convertible Notes
 6 Months Ended
Jun. 30, 2018
Debt Disclosure [Abstract]  
Convertible and Non-Recourse Notes
. Convertible Notes
  
 
 
 
 
Principal Balance Outstanding
 
Carrying Value
 
 
 
 
June 30,
 
June 30,
 
December 31,
Description
 
Maturity Date
 
2018
 
2018
 
2017
(In thousands)
 
 
 
 
 
 
 
 
Convertible Notes
 
 
 
 
 
 
 
 
February 2018 Notes
 
February 1, 2018
 
$
—

 
$
—

 
$
126,066

December 2021 Notes
 
December 1, 2021
 
$
150,000

 
120,945

 
117,415

Total
 
 
 
 

 
$
120,945

 
$
243,481



February 2018 Notes

On February 12, 2014, the Company issued $300.0 million in aggregate principal amount, at par, of the February 2018 Notes in an underwritten public offering, for net proceeds of $290.2 million. The February 2018 Notes were due February 1, 2018, and the Company paid interest at 4.0% on the February 2018 Notes semiannually in arrears on February 1 and August 1 of each year, beginning August 1, 2014. A portion of the proceeds from the February 2018 Notes, net of amounts used for purchased call option transactions and provided by the warrant transactions described below, were used to redeem $131.7 million of the Company’s 2.975% Convertible Senior Notes due February 17, 2016.

On November 20, 2015, the Company’s agent initiated the repurchase of $53.6 million in aggregate principal amount of its February 2018 Notes for $43.7 million in cash in four open market transactions. The closing of these transactions occurred on November 30, 2015. It was determined that the repurchase of the principal amount shall be accounted for as a partial extinguishment of the February 2018 Notes. As a result, a gain on extinguishment of $6.5 million was recorded at closing of the transaction. The $6.5 million gain on extinguishment included the de-recognition of the original issuance discount of $3.1 million, outstanding deferred issuance costs of $0.9 million and agent fees of $0.1 million. In connection with this repurchase of the February 2018 Notes, the Company unwound a portion of the purchased call options related to the notes. As a result of this unwinding, the Company received $0.3 million in cash. The payments received have been recorded as an increase to additional paid-in-capital. In addition, the Company unwound a portion of the warrants for $0.2 million in cash, payable by the Company. The payments have been recorded as a decrease to additional paid-in-capital.

On November 22, 2016, the Company repurchased $120.0 million in aggregate principal amount of its February 2018 Notes for approximately $121.5 million in cash (including $1.5 million of accrued interest) in open market transactions. It was determined that the repurchase of the principal amount shall be accounted for as an extinguishment. The extinguishment included the de-recognition of the original issuance discount of $4.3 million and outstanding deferred issuance costs of $1.3 million. In connection with the repurchase of the February 2018 Notes, the Company unwound a portion of the purchased call options. The unwind transaction of the purchased call option did not result in any cash payments between the parties. In addition, the Company and the counterparties agreed to unwind a portion of the warrants, which also did not result in any cash payments between the parties.

In accordance with the accounting guidance for convertible debt instruments that may be settled in cash or other assets on conversion, the Company was required to separately account for the liability component of the instrument in a manner that reflects the market interest rate for a similar nonconvertible instrument at the date of issuance. As a result, the Company separated the principal balance of the February 2018 Notes between the fair value of the debt component and the fair value of the common stock conversion feature. Using an assumed borrowing rate of 7.0%, which represents the estimated market interest rate for a similar nonconvertible instrument available to the Company on the date of issuance, the Company recorded a total debt discount of $29.7 million, allocated $19.3 million to additional paid-in capital and allocated $10.4 million to deferred tax liability. The discount was being amortized to interest expense over the term of the February 2018 Notes and increases interest expense during the term of the February 2018 Notes from the 4.0% cash coupon interest rate to an effective interest rate of 6.9%.

On February 1, 2018, upon maturity of the February 2018 Notes, the Company repaid a total cash amount of $129.0 million to the custodian, The Bank of New York Mellon Trust Company, N.A., which was comprised of $126.4 million in principal amount and $2.6 million in accrued interest, to retire the February 2018 Notes.

The carrying value and unamortized discount of the February 2018 Notes were as follows:
(In thousands)
 
June 30, 2018
 
December 31, 2017
 
 
 
 
 
Principal amount of the February 2018 Notes
 
$
—

 
$
126,447

Unamortized discount of liability component
 
—

 
(381
)
Net carrying value of the February 2018 Notes
 
$
—

 
$
126,066



Interest expense for the February 2018 Notes on the Company’s Condensed Consolidated Statements of Income was as follows:
 
 
Three Months Ended
 
Six Months Ended
 
 
June 30,
 
June 30,
(In thousands)
 
2018
 
2017
 
2018
 
2017
 
 
 
 
 
 
 
 
 
Contractual coupon interest
 
$
—

 
$
1,264

 
$
421

 
$
2,529

Amortization of debt issuance costs
 
—

 
250

 
88

 
499

Amortization of debt discount
 
—

 
851

 
293

 
1,699

Total
 
$
—

 
$
2,365

 
$
802

 
$
4,727



Purchased Call Options and Warrants

In connection with the issuance of the February 2018 Notes, the Company entered into purchased call option transactions with two hedge counterparties. The Company paid an aggregate amount of $31.0 million for the purchased call options with terms substantially similar to the embedded conversion options in the February 2018 Notes. The purchased call options covered, subject to anti-dilution and certain other customary adjustments substantially similar to those in the February 2018 Notes, approximately 13.8 million shares of the Company’s common stock. The purchased call options expired on February 1, 2018.

In addition, the Company sold to the hedge counterparties warrants exercisable, on a cashless basis, for the sale of rights to receive shares of common stock that will initially underlie the February 2018 Notes at a strike price of $10.3610 per share, which represents a premium of approximately 30% over the last reported sale price of the Company’s common stock of $7.97 on February 6, 2014. The Company received an aggregate amount of $11.4 million for the sale from the two counterparties.

The purchased call options and warrants are considered indexed to the Company stock, require net-share settlement, and met all criteria for equity classification at inception and in subsequent periods. The purchased call options cost of $31.0 million, less deferred taxes of $10.8 million, and the $11.4 million received for the warrants, was recorded as adjustments to additional paid-in capital.

December 2021 Notes

On November 22, 2016, the Company issued $150.0 million in aggregate principal amount, at par, of the December 2021 Notes in an underwritten public offering, for net proceeds of $145.7 million. The December 2021 Notes are due December 1, 2021, and the Company pays interest at 2.75% on the December 2021 Notes semiannually in arrears on June 1 and December 1 of each year, beginning June 1, 2017. A portion of the proceeds from the December 2021 Notes, net of amounts used for the capped call transaction described below, was used to extinguish $120.0 million of the February 2018 Notes.

Upon the occurrence of a fundamental change, as defined in the indenture, holders have the option to require the Company to repurchase their December 2021 Notes at a purchase price equal to 100% of the principal, plus accrued interest.

The December 2021 Notes are convertible under any of the following circumstances:
•
During any fiscal quarter (and only during such fiscal quarter) commencing after the fiscal quarter ended June 30, 2017, if the last reported sale price of Company common stock for at least 20 trading days (whether or not consecutive), in the period of 30 consecutive trading days, ending on, and including, the last trading day of the immediately preceding fiscal quarter, exceeds 130% of the conversion price for the notes on each applicable trading day;
•
During the five business-day period immediately after any five consecutive trading-day period, which the Company refers to as the measurement period, in which the trading price per $1,000 principal amount of notes for each trading day of that measurement period was less than 98% of the product of the last reported sale price of Company common stock and the conversion rate for the notes for each such trading day; or
•
Upon the occurrence of specified corporate events as described in the indenture.

The initial conversion rate for the December 2021 Notes is 262.2951 shares of the Company’s common stock per $1,000 principal amount of December 2021 Notes, which is equivalent to an initial conversion price of approximately $3.81 per share of common stock, subject to adjustments upon the occurrence of certain specified events as set forth in the indenture.

In accordance with the accounting guidance for convertible debt instruments that may be settled in cash or other assets on conversion, the Company was required to separately account for the liability component of the instrument in a manner that reflects the market interest rate for a similar nonconvertible instrument at the date of issuance. As a result, the Company separated the principal balance of the December 2021 Notes between the fair value of the debt component and the fair value of the common stock conversion feature. Using an assumed borrowing rate of 9.5%, which represents the estimated market interest rate for a similar nonconvertible instrument available to the Company on the date of issuance, the Company recorded a total debt discount of $4.3 million, allocated $23.8 million to additional paid-in capital and allocated $12.8 million to deferred tax liability. The discount is being amortized to interest expense over the term of the December 2021 Notes and increases interest expense during the term of the December 2021 Notes from the 2.75% cash coupon interest rate to an effective interest rate of 3.4%. As of June 30, 2018, the remaining discount amortization period is 3.4 years.

The carrying value and unamortized discount of the December 2021 Notes were as follows:
(In thousands)
 
June 30, 2018
 
December 31, 2017
 
 
 
 
 
Principal amount of the December 2021 Notes
 
$
150,000

 
$
150,000

Unamortized discount of liability component
 
(29,055
)
 
(32,585
)
Net carrying value of the December 2021 Notes
 
$
120,945

 
$
117,415



Interest expense for the December 2021 Notes on the Company’s Condensed Consolidated Statements of Income was as follows:
 
 
Three Months Ended
 
Six Months Ended
 
 
June 30,
 
June 30,
(In thousands)
 
2018
 
2017
 
2018
 
2017
 
 
 
 
 
 
 
 
 
Contractual coupon interest
 
$
1,031

 
$
1,032

 
$
2,062

 
$
2,063

Amortization of debt issuance costs
 
19

 
18

 
38

 
36

Amortization of debt discount
 
135

 
131

 
269

 
261

Amortization of conversion feature
 
1,626

 
1,469

 
3,225

 
2,899

Total
 
$
2,811

 
$
2,650

 
$
5,594

 
$
5,259



As of June 30, 2018, the December 2021 Notes are not convertible. At June 30, 2018, the if-converted value of the December 2021 Notes did not exceed the principal amount.

Capped Call Transaction

In connection with the offering of the December 2021 Notes, the Company entered into a privately-negotiated capped call transaction with an affiliate of the underwriter of such issuance. The aggregate cost of the capped call transaction was $14.4 million. The capped call transaction is generally expected to reduce the potential dilution upon conversion of the December 2021 Notes and/or partially offset any cash payments the Company is required to make in excess of the principal amount of converted December 2021 Notes in the event that the market price per share of the Company’s common stock, as measured under the terms of the capped call transaction, is greater than the strike price of the capped call transaction. This initially corresponds to the approximate $3.81 per share conversion price of the December 2021 Notes and is subject to anti-dilution adjustments substantially similar to those applicable to the conversion rate of the December 2021 Notes. The cap price of the capped call transaction was initially $4.88 per share, and is subject to certain adjustments under the terms of the capped call transaction. The Company will not be required to make any cash payments to the option counterparty upon the exercise of the options that are a part of the capped call transaction, but the Company will be entitled to receive from it an aggregate amount of cash and/or number of shares of the Company’s common stock, based on the settlement method election chosen for the related convertible notes, with a value equal to the amount by which the market price per share of the Company’s common stock, as measured under the terms of the capped call transaction, is greater than the strike price of the capped call transaction during the relevant valuation period under the capped call transaction, with such number of shares of the Company’s common stock and/or amount of cash subject to the cap price.

The Company evaluated the capped call transaction under authoritative accounting guidance and determined that they should be accounted for as separate transactions and classified as a net reduction to additional paid-in capital within stockholders’ equity with no recurring fair value measurement recorded.
XML 30 R16.htm IDEA: XBRL DOCUMENT v3.10.0.1
Other Long-Term Liabilities
 6 Months Ended
Jun. 30, 2018
Other Liabilities Disclosure [Abstract]  
Other Long-Term Liabilities
14. Other Long-Term Liabilities

Other long-term liabilities consist of the following:
 
 
June 30,
 
December 31,
(in thousands)
 
2018
 
2017
 
 
 
 
 
Accrued lease liability
 
$
10,700

 
$
10,700

Long-term incentive accrual
 
1,978

 
1,729

Uncertain tax positions
 
31,133

 
30,682

Long-term deferred tax liabilities
 
3,538

 
1,208

Dividend payable
 
45

 
47

Other
 
405

 
343

Total
 
$
47,799

 
$
44,709

 

In connection with the Spin-Off, the Company entered into amendments to the leases for the Company’s former facilities in Redwood City, California, by which the Company has in substance guaranteed the payments under the lease agreements for the Redwood City facilities. For further discussion of the Spin-Off and the lease guarantee, see Note 12. The Company has recorded a liability of $10.7 million on the Company’s Condensed Consolidated Balance Sheets as of June 30, 2018, and December 31, 2017, related to this guarantee.
XML 31 R17.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stock-Based Compensation
 6 Months Ended
Jun. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stock-Based Compensation
15. Stock-Based Compensation

The Company grants restricted stock awards and stock options pursuant to a stockholder approved stock-based incentive plan. This incentive plan is described in further detail in Note 16, Stock-Based Compensation, of Notes to the Condensed Consolidated Financial Statements in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017.

The following table summarizes the Company’s stock option and restricted stock award activity during the six months ended June 30, 2018:
 
 
Stock Options
 
Restricted Stock Awards
(In thousands except per share amounts)
 
Number of Shares Outstanding
 
Weighted Average Exercise Price
 
Number of Shares Outstanding
 
Weighted Average Grant-date Fair Value Per Share
 
 
 
 
 
 
 
 
 
Balance at December 31, 2017
 
961

 
$
3.21

 
2,305

 
$
2.68

Granted
 
3,894

 
$
2.94

 
481

 
$
2.71

Vested or released
 
—

 
$
—

 
(401
)
 
$
2.50

Forfeited or canceled
 
—

 
$
—

 
(119
)
 
$
2.38

Balance at June 30, 2018
 
4,855

 
$
2.99

 
2,266

 
$
2.73
XML 32 R18.htm IDEA: XBRL DOCUMENT v3.10.0.1
Cash Dividends
 6 Months Ended
Jun. 30, 2018
Stockholders' Equity Note [Abstract]  
Stockholders' Equity Note Disclosure [Text Block]
17. Stockholders’ Equity

Stock Repurchase Program

On March 1, 2017, the Company’s board of directors authorized the repurchase through March 2018 of issued and outstanding shares of the Company’s common stock having an aggregate value of up to $30.0 million pursuant to a share repurchase program. The repurchases under the share repurchase program were made from time to time in the open market or in privately negotiated transactions and were funded from the Company’s working capital. All shares of common stock repurchased under the Company’s share repurchase program were retired and restored to authorized but unissued shares of common stock at June 30, 2017. The Company repurchased 13.3 million shares of its common stock under the share repurchase program during the fiscal year ended December 31, 2017, for an aggregate purchase price of $30.0 million, or an average cost of $2.25 per share, including trading commission.

On September 25, 2017, the Company’s board of directors authorized the repurchase of issued and outstanding shares of the Company’s common stock having an aggregate value of up to $25.0 million pursuant to a new share repurchase program. The repurchases under the new share repurchase program are made from time to time in the open market or in privately negotiated transactions and are funded from the Company’s working capital. The amount and timing of such repurchases are dependent upon the price and availability of shares, general market conditions and the availability of cash. Repurchases may also be made under a trading plan under Rule 10b5-1, which would permit shares to be repurchased when the Company might otherwise be precluded from doing so because of self-imposed trading blackout periods or other regulatory restrictions. All shares of common stock repurchased under the Company’s new share repurchase program are expected to be retired and restored to authorized but unissued shares of common stock. The Company repurchased 6.8 million shares of its common stock under the share repurchase program during the three months ended June 30, 2018, for an aggregate purchase price of $19.4 million, or an average cost of $2.87 per share, including trading commissions, and a total of 8.2 million shares of its common stock during the six months ended June 30, 2018, for an aggregate purchase price of $23.6 million, or an average cost of $2.89 per share, including trading commission. All shares repurchased were retired.

From July 1, 2018 to July 5, 2018, the Company completed the $25.0 million share repurchase program by repurchasing approximately 0.6 million shares of its common stock at a weighted average price of $2.44 per share for a total of $1.4 million. The total amounts repurchased by the Company under the share repurchase program equal approximately 8.7 million shares of its common stock for an aggregate purchase price of $25.0 million, or an average cost of $2.89 per share, including trading commissions.
XML 33 R19.htm IDEA: XBRL DOCUMENT v3.10.0.1
Customer Concentration
 6 Months Ended
Jun. 30, 2018
Customer Concentration [Abstract]  
Concentration Risk Disclosure [Text Block]
6. Concentration of Credit Risk

Product Line Concentration

The percentage of total revenue recognized, which individually accounted for 10% or more of the Company’s total revenues, was as follows:
 
 
 
 
Three Months Ended June 30,
 
Six Months Ended June 30,
Licensee
 
Product Name
 
2018
 
2017
 
2018
 
2017
Biogen
 
Tysabri®
 
3%
 
11%
 
5%
 
16%
 
 
 
 
 
 
 
 
 
 
 
Depomed
 
Glumetza, Janumet XR, Jentadueto XR, Synjardy XR and Invokamet XR
 
20%
 
61%
 
20%
 
49%
 
 
 
 
 
 
 
 
 
 
 
N/A
 
Tekturna, Tekturna HCT, Rasilez and Rasilez HCT
 
56%
 
11%
 
52%
 
15%
 
 
 
 
 
 
 
 
 
 
 
LENSAR
 
LENSAR Laser System
 
13%
 
2%
 
13%
 
1%
XML 34 R20.htm IDEA: XBRL DOCUMENT v3.10.0.1
Income Taxes
 6 Months Ended
Jun. 30, 2018
Income Tax Disclosure [Abstract]  
Income Taxes
16. Income Taxes
 
Income tax expense (benefit) for the three months ended June 30, 2018 and 2017, was $(14.3) million and $53.9 million, respectively, and for the six months ended June 30, 2018 and 2017, was $(13.2) million and $60.4 million, respectively, which resulted primarily from applying the federal statutory income tax rate to income before income taxes. The Company’s effective tax rate for the current period differs from the U.S. federal statutory rate of 21% due primarily to the effect of the foreign rate differential related to the impairment of the intangible assets related to the Noden Products.

The uncertain tax positions increased during the three months ended June 30, 2018 and 2017, by zero and $28.9 million, respectively, and for the six months ended June 30, 2018 and 2017, zero and $29.7 million, respectively, resulting from an increase in tax uncertainties and estimated tax liabilities.

On December 22, 2017, the SEC issued Staff Accounting Bulletin No. 118 to address the application of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the 2017 Tax Cuts and Job Act. The accounting for all items is expected to be complete during 2018 as additional guidance related to Global Intangible Low-Taxed Income (“GILTI”) is released. Any differences between what was previously recorded and the final amounts or estimates done for subsequent quarters are not expected to be material.

The Company’s income tax returns are subject to examination by U.S. federal, state and local tax authorities for tax years 2000 forward. The Company is currently under income tax examination by the state of California for the tax years 2009 through 2015 and by the Internal Revenue Service for the tax year 2016. Although the timing of the resolution of income tax examinations is highly uncertain, and the amounts ultimately paid, if any, upon resolution of the issues raised by the taxing authorities may differ materially from the amounts accrued for each year, the Company does not anticipate any material change to the amount of its unrecognized tax benefit over the next 12 months.
XML 35 R21.htm IDEA: XBRL DOCUMENT v3.10.0.1
Accumulated Other Comprehensive Income (Loss)
 6 Months Ended
Jun. 30, 2018
Accumulated Other Comprehensive Income (Loss) [Abstract]  
Comprehensive Income (Loss) Note [Text Block]
18. Accumulated Other Comprehensive Income

Comprehensive income is comprised of net income (loss) and other comprehensive income (loss). The Company includes unrealized net gains (losses) on investments held in its available-for-sale securities in other comprehensive income (loss), and present the amounts net of tax. The Company’s other comprehensive income (loss) is included in the Company’s Condensed Consolidated Statements of Comprehensive Income.

The balance of accumulated other comprehensive income, net of tax, was as follows:
(in thousands)
 
Unrealized gains (losses) on available-for-sale securities
 
Total Accumulated Other Comprehensive Income (Loss)
 
 
 
 
 
Beginning Balance at December 31, 2017
 
$
1,181

 
$
1,181

Activity for the six months ended June 30, 2018
 
(1,181
)
 
(1,181
)
Ending Balance at June 30, 2018
 
$
—

 
$
—
XML 36 R22.htm IDEA: XBRL DOCUMENT v3.10.0.1
Subsequent Events
 6 Months Ended
Jun. 30, 2018
Subsequent Events [Abstract]  
Subsequent Events [Text Block]
21. Subsequent Events

Share Repurchase Program

From July 1, 2018 to July 5, 2018, the Company completed the $25.0 million share repurchase program by repurchasing approximately 0.6 million shares of its common stock at a weighted average price of $2.44 per share for a total of $1.4 million. The total amounts repurchased by the Company under the share repurchase program equal approximately 8.7 million shares of its common stock for an aggregate purchase price of $25.0 million, or an average cost of $2.89 per share, including trading commissions.

Depomed Reversionary Interest Purchase

On August 2, 2018, PDL Investment Holding, LLC (“PDLIH”), a subsidiary of the Company, entered into an amendment of the Depomed Royalty Agreement, pursuant to which PDLIH, as an assignee of the Company, acquired all of Depomed’s remaining rights to royalties and milestones payable on sales of type 2 diabetes products licensed by Depomed for up to $20.0 million. Prior to this amendment of the Depomed Royalty Agreement, the Company would have shared future royalties equally with Depomed after total cash received by the Company reached $481.0 million, or two times the Company’s original investment, which the Company expects to occur by October 2020.

On August 2, 2018, under the terms of the amendment, the Company made an initial payment of $10.0 million to Depomed. On August 7, 2018, an additional $10.0 million payment was made to Depomed, as certain conditions specified in the amendment were met.
XML 37 R23.htm IDEA: XBRL DOCUMENT v3.10.0.1
Business Combinations (Notes)
 6 Months Ended
Jun. 30, 2018
Business Combinations [Abstract]  
Business Combination Disclosure [Text Block]
19. Business Combinations

LENSAR TRANSACTION

Description of the LENSAR Transaction

In December 2016, LENSAR filed the Chapter 11 case with the support of the Company, as its largest senior secured creditor under a credit agreement, as amended, that the Company and LENSAR had entered into in 2013. For more information regarding the credit agreement between the Company and LENSAR, please see Note 7. In January 2017, the Company agreed to provide debtor-in-possession financing of up to $2.8 million in new advances to LENSAR so that it could continue to operate its business during the remainder of the Chapter 11 case. As part of the Chapter 11 case, LENSAR filed a Chapter 11 plan of reorganization, with the Company’s support, under which LENSAR would issue 100% of its equity securities to the Company in exchange for the cancellation of the Company’s claims as a secured creditor in the Chapter 11 case. Following consummation of the Plan, LENSAR would become an operating subsidiary of the Company and the Company provided LENSAR a new, senior-secured, first-priority term loan facility (the “Exit Facility”).

On April 26, 2017, the bankruptcy court approved the plan of reorganization. On May 11, 2017, LENSAR and the Company consummated the plan of reorganization and LENSAR emerged from bankruptcy. Pursuant to the plan of reorganization, the Company obtained control of 100% of the outstanding voting shares of LENSAR. All assets of the LENSAR bankruptcy estate re-vested in reorganized LENSAR free and clear of all liens, claims or charges. The consummation of the plan of reorganization related transactions effect binding and valid transfers to reorganized LENSAR with all rights, title and interest in the acquired assets. Upon consummation of the plan of reorganization, all debt owed to the Company was eliminated other than the Exit Facility. Liabilities to other creditors, including general unsecured creditors, were satisfied through the plan of reorganization. 

The Company concluded that the LENSAR transaction shall be accounted in accordance with ASC 805 that do not involve a transfer of consideration (“combinations by contract”) by applying the acquisition method.

Fair Value of Consideration Transferred

Contemporaneously with the cancellation of the Company’s notes receivable with a carrying value of $43.9 million, the Company acquired 100% equity interests in LENSAR, at fair value, for $31.7 million, resulting in a loss on extinguishment of notes receivable of $10.6 million. The fair value of the equity interest in LENSAR was determined primarily using the “income method,” which starts with a forecast of all expected future cash flows of the acquired business. The acquisition resulted in a gain on bargain purchase because the fair value of assets acquired and liabilities assumed exceeded the total of the fair value of the equity interest in LENSAR by approximately $9.3 million, which was recorded in the Consolidated Statement of Income for the year ended December 31, 2017.

Assets Acquired and Liabilities Assumed

The following table summarizes the fair values of the identifiable intangible assets acquired and liabilities assumed at the acquisition date (in thousands):
Cash
 
$
1,983

Tangible assets
 
18,647

Intangible assets (1)
 
11,970

Net deferred tax assets
 
25,723

Total identifiable assets
 
58,323

Current liabilities
 
(6,673
)
Total liabilities assumed
 
(6,673
)
 
 
 
Net loss on derecognition of notes receivables
 
(10,615
)
Gain on bargain purchase, net of loss on extinguishment of notes receivable
 
(9,309
)
Total fair value of consideration
 
$
31,726

______________
(1) As of the effective date of the transaction, identifiable intangible assets are required to be measured at fair value.  The fair value measurement is based on significant inputs that are unobservable in the market and thus represents a Level 3 measurement. The Company used an income approach to estimate the preliminary fair value of the intangibles which includes technology, trademarks and customer relationships. The assumptions used to estimate the cash flows of the business included a discount rate of 16%, estimated gross margins ranging from 37-72%, income tax rate of 35%, and operating expenses consisting of direct costs based on the anticipated level of revenues.  The intangible assets have a weighted-average useful life of approximately 15.0 years. The intangible assets for acquired technology and trademarks are being amortized over their estimated useful lives using the straight-line method of amortization. The intangible assets for customer relationship are being amortized using a double-declining method of amortization as such method better represents the economic benefits to be obtained.

Pro Forma Impact of Business Combination

The following table represents the unaudited consolidated financial information for the Company on a pro forma basis for the three and six months ended June 30, 2018 and 2017, assuming that the LENSAR transaction had closed on January 1, 2016. The historical financial information has been adjusted to give effect to pro forma items that are directly attributable to the acquisitions and are expected to have a continuing impact on the consolidated results. Additionally, the following table sets forth unaudited financial information and has been compiled from historical financial statements and other information, but is not necessarily indicative of the results that actually would have been achieved had the transactions occurred on the dates indicated or that may be achieved in the future.
 
 
Three Months Ended
 
Six Months Ended
 
 
June 30,
 
June 30,
(in thousands)
 
2018
 
2017
 
2018
 
2017
 
 
 
 
 
 
 
 
 
Pro forma revenues
 
$
46,575

 
$
145,554

 
$
85,093

 
$
194,820

Pro forma net income (loss)
 
$
(112,296
)
 
$
59,351

 
$
(110,694
)
 
$
64,124

Pro forma net income (loss) per share - basic
 
$
(0.76
)
 
$
0.38

 
$
(0.74
)
 
$
0.40

Pro forma net income (loss) per share - diluted
 
$
(0.76
)
 
$
0.38

 
$
(0.74
)
 
$
0.40



The unaudited pro forma consolidated results include historical revenues and expenses of assets acquired in the LENSAR Transaction with the following adjustments:
•
Adjustment to recognize incremental amortization expense based on the fair value of intangibles acquired;
•
Elimination of non-recurring charges directly related to the acquisition that were included in the historical results of operations for the Company; and
•
Adjustment to recognize pro forma income tax based on income tax benefit on the amortization of intangible asset at the statutory tax rate of the United States, at such time (35.0%), and the income tax benefit on the interest expense at the statutory tax rate of the United States, at such time (35.0%).
XML 38 R24.htm IDEA: XBRL DOCUMENT v3.10.0.1
Intangibles and Goodwill (Notes)
 6 Months Ended
Jun. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets Disclosure [Text Block]
. Intangible Assets

Intangible Assets, Net

On June 8, 2018, Noden Pharma DAC (“Noden DAC”), a wholly owned subsidiary of the Company, entered into a Settlement Agreement (the “Settlement Agreement”) with Anchen Pharmaceuticals, Inc. and its affiliates (“Anchen”) to resolve the patent litigation relating to infringement of U.S. Patent No. 8,617,595 (the “595 Patent”) based on their submission of an Abbreviated New Drug Application (“ANDA”) seeking authorization from the U.S. FDA to market a generic version of aliskiren, the active ingredient in the Tekturna and Tekturna HCT drug. Under the Settlement Agreement, Anchen, the sole ANDA filer of which the Company is aware, agreed to not commercialize its generic version of aliskiren prior to March 1, 2019. Per the Settlement Agreement, Anchen may commercialize their formulation of aliskiren, but is not permitted to commercialize a copy of Tekturna.

Accordingly, management evaluated the ongoing value of the Noden DAC asset group based upon the probability of Anchen’s market entry of a generic version of aliskiren in the United States and the associated cash flows and conducted a test for impairment. Due to the increased probability of a generic version of aliskiren being launched in the United States the Company revised its estimates of future cash flows and as a result of this analysis determined that the sum of undiscounted cash flows was not greater than the carrying value of the assets. Therefore, the Company performed a discounted cash flow analysis to estimated the fair value of the asset group in accordance with ASC Topic 360, Impairment or Disposal of Long-lived Assets. The cash flows are those expected to be generated by market participants, discounted to reflect an appropriate amount of risk, which was determined to be 21%. The Company concluded that the Noden DAC acquired product rights and customer relationship long-lived assets, with a carrying amount of $192.5 million, were no longer recoverable and wrote them down to their estimated fair value of $40.1 million, resulting in an impairment charge of $152.3 million as of June 30, 2018. This write-down is included in “Impairment of intangible assets” in the Condensed Consolidated Statements of Income and the Condensed Consolidated Statements of Cash Flows. The remaining Noden DAC intangible asset balance, part of the Pharmaceutical reportable segment, of $40.1 million will be amortized straight-line over the remaining useful life of 8 years.

The components of intangible assets as of June 30, 2018 and December 31, 2017 were as follows:
 
 
June 30, 2018
 
December 31, 2017
(in thousands)
 
Gross Carrying Amount
 
Accumulated Amortization
 
Net Carrying Amount
 
Gross Carrying Amount
 
Accumulated Amortization
 
Net Carrying Amount
 
 
 
 
 
 
 
 
 
 
 
 
 
Finite-lived intangible assets:
 
 
 
 
 
 
 
 
 
 
 
 
Acquired products rights(1)
 
$
36,143

 
$
—

 
$
36,143

 
$
216,690

 
$
(32,503
)
 
$
184,187

Customer relationships(1) (2)
 
8,028

 
(341
)
 
7,687

 
26,080

 
(3,729
)
 
22,351

Acquired technology(2) (3)
 
11,011

 
(806
)
 
10,205

 
9,200

 
(409
)
 
8,791

Acquired trademarks(2)
 
570

 
(133
)
 
437

 
570

 
(76
)
 
494

 
 
$
55,752

 
$
(1,280
)
 
$
54,472

 
$
252,540

 
$
(36,717
)
 
$
215,823

________________
(1) The Company acquired certain intangible assets as part of the Noden Transaction. They are amortized on a straight-line basis over a weighted average period of 8.0 years.
(2) The Company acquired certain intangible assets as part of the LENSAR transaction, as described further in Note 19. They are amortized over a weighted average period of 15.0 years. The intangible assets for acquired technology and trademarks are being amortized over their estimated useful lives using the straight-line method of amortization. The intangible assets for customer relationships are being amortized using a double-declining method of amortization as such method better represents the economic benefits to be obtained.
(3)
The Company acquired certain intangible assets as part of the foreclosure on certain of Direct Flow Medical assets, as described further in Note 7. They are amortized over a weighted average period of 10.0 years. The intangible assets for acquired technology are being amortized over their estimated useful lives using the straight-line method of amortization.

For the three and six months ended June 30, 2018, amortization expense was $6.4 million and $12.7 million, respectively, and for the three and six months ended June 30, 2017, amortization expense was $6.1 million and $12.2 million, respectively.

Based on the intangible assets recorded at June 30, 2018, and assuming no subsequent additions to or impairment of the underlying assets, the remaining estimated amortization expense is expected to be as follows (in thousands):
Fiscal Year
 
Amount
 
 
 
2018 (Remaining six months)
 
$
3,154

2019
 
6,275

2020
 
6,240

2021
 
6,209

2022
 
6,104

2023
 
6,040

Thereafter
 
20,450

Total remaining estimated amortization expense
 
$
54,472
XML 39 R25.htm IDEA: XBRL DOCUMENT v3.10.0.1
Segment Information (Notes)
 6 Months Ended
Jun. 30, 2018
Segment Reporting Information [Line Items]  
Schedule of Segment Reporting Information, by Segment [Table Text Block]
20. Segment Information

In connection with acquiring 100% of the equity interests of LENSAR in May 2017, the Company added a third reportable segment, “Medical Devices” and renamed the previous product sales segment “Pharmaceutical”.

Information regarding the Company’s segments for the three and six months ended June 30, 2018 and 2017 is as follows:
Revenues by segment
 
Three Months Ended
 
Six Months Ended
 
 
June 30,
 
June 30,
(in thousands)
 
2018
 
2017
 
2018
 
2017
 
 
 
 
 
 
 
 
 
Pharmaceutical
 
$
25,879

 
$
16,212

 
44,221

 
28,794

Medical devices
 
5,882

 
2,617

 
10,864

 
2,617

Income generating assets
 
14,814

 
125,006

 
30,008

 
157,864

Total revenues
 
$
46,575

 
$
143,835

 
$
85,093

 
$
189,275


Income (loss) by segment
 
Three Months Ended
 
Six Months Ended
 
 
June 30,
 
June 30,
(in thousands)
 
2018
 
2017
 
2018
 
2017
 
 
 
 
 
 
 
 
 
Pharmaceutical
 
$
(111,335
)
 
$
(891
)
 
(113,048
)
 
(4,624
)
Medical devices
 
(1,904
)
 
(1,195
)
 
(2,491
)
 
(1,195
)
Income generating assets
 
943

 
62,525

 
4,845

 
73,499

Total net income (loss)
 
$
(112,296
)
 
$
60,439

 
$
(110,694
)
 
$
67,680


Information regarding the Company’s segments as of June 30, 2018 and December 31, 2017 is as follows:
Long-lived assets by segment
 
 
 
 
(in thousands)
 
June 30,
2018
 
December 31,
2017
 
 
 
 
 
Pharmaceutical
 
$
3,474

 
$
822

Medical devices
 
5,606

 
6,263

Income generating assets
 
143

 
137

Total long-lived assets
 
$
9,223

 
$
7,222



The operations for the Company’s Pharmaceutical and Medical Devices segments are primarily located in Ireland and the United Stated, respectively.
XML 40 R26.htm IDEA: XBRL DOCUMENT v3.10.0.1
Inventory (Notes)
 6 Months Ended
Jun. 30, 2018
Inventory [Abstract]  
Inventory Disclosure [Text Block]
8. Inventories

Inventories consisted of the following:
 
 
June 30,
 
December 31,
(in thousands)
 
2018
 
2017
 
 
 
 
 
Raw materials
 
$
1,771

 
$
1,717

Work in process
 
1,677

 
1,119

Finished goods
 
11,353

 
6,311

Total inventory
 
$
14,801

 
$
9,147



As of June 30, 2018 and December 31, 2017, the Company deferred approximately $0.2 million and $1.3 million, respectively, of costs associated with inventory transfers made under the Company’s third party logistic provider service arrangement. These costs have been recorded as other assets on the Company’s Condensed Consolidated Balance Sheet as of June 30, 2018 and December 31, 2017. The Company will recognize the cost of product sold as inventory is transferred from its third-party logistics provider to the Company’s customers.

During the three and six months ended June 30, 2018, the Company recognized a reduction in the inventory provision of $0.6 million and $0.5 million, respectively, and during the three and six months ended June 30, 2017, the Company recognized an inventory write-down of $0.1 million and $0.2 million, respectively, related to Tekturna®, Tekturna HCT®, Rasilez® and Rasilez HCT® (collectively, the “Noden Products” or “Tekturna”) that the Company would not be able to sell prior to their expiration.
XML 41 R27.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stockholders' Equity (Notes)
 6 Months Ended
Jun. 30, 2018
Stockholders' Equity Attributable to Parent [Abstract]  
Stockholders' Equity Note Disclosure [Text Block]
17. Stockholders’ Equity

Stock Repurchase Program

On March 1, 2017, the Company’s board of directors authorized the repurchase through March 2018 of issued and outstanding shares of the Company’s common stock having an aggregate value of up to $30.0 million pursuant to a share repurchase program. The repurchases under the share repurchase program were made from time to time in the open market or in privately negotiated transactions and were funded from the Company’s working capital. All shares of common stock repurchased under the Company’s share repurchase program were retired and restored to authorized but unissued shares of common stock at June 30, 2017. The Company repurchased 13.3 million shares of its common stock under the share repurchase program during the fiscal year ended December 31, 2017, for an aggregate purchase price of $30.0 million, or an average cost of $2.25 per share, including trading commission.

On September 25, 2017, the Company’s board of directors authorized the repurchase of issued and outstanding shares of the Company’s common stock having an aggregate value of up to $25.0 million pursuant to a new share repurchase program. The repurchases under the new share repurchase program are made from time to time in the open market or in privately negotiated transactions and are funded from the Company’s working capital. The amount and timing of such repurchases are dependent upon the price and availability of shares, general market conditions and the availability of cash. Repurchases may also be made under a trading plan under Rule 10b5-1, which would permit shares to be repurchased when the Company might otherwise be precluded from doing so because of self-imposed trading blackout periods or other regulatory restrictions. All shares of common stock repurchased under the Company’s new share repurchase program are expected to be retired and restored to authorized but unissued shares of common stock. The Company repurchased 6.8 million shares of its common stock under the share repurchase program during the three months ended June 30, 2018, for an aggregate purchase price of $19.4 million, or an average cost of $2.87 per share, including trading commissions, and a total of 8.2 million shares of its common stock during the six months ended June 30, 2018, for an aggregate purchase price of $23.6 million, or an average cost of $2.89 per share, including trading commission. All shares repurchased were retired.

From July 1, 2018 to July 5, 2018, the Company completed the $25.0 million share repurchase program by repurchasing approximately 0.6 million shares of its common stock at a weighted average price of $2.44 per share for a total of $1.4 million. The total amounts repurchased by the Company under the share repurchase program equal approximately 8.7 million shares of its common stock for an aggregate purchase price of $25.0 million, or an average cost of $2.89 per share, including trading commissions.
XML 42 R28.htm IDEA: XBRL DOCUMENT v3.10.0.1
Revenue from Contracts with Customers (Notes)
 6 Months Ended
Jun. 30, 2018
Revenue from Contract with Customers [Abstract]  
Revenue from Contract with Customer [Text Block]
 2. Revenue from Contracts with Customers

Adoption of New Revenue Standard

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers that supersedes Accounting Standards Codification (“ASC”) Topic 605, Revenue Recognition. Subsequently, the FASB issued several updates to ASU No. 2014-09, which are pending content or otherwise codified in ASC Topic 606 (“ASC 606”). ASC 606 also includes new guidance on costs related to a contract, which is codified in ASC Subtopic 340-40. The Company adopted ASC 606 on January 1, 2018 using the modified retrospective method for all contracts not substantially completed as of the date of adoption. The cumulative impact of the adoption ASC 606 was not material to the Company therefore the Company did not record any adjustments to retained earnings. The reported results for 2018 reflect the application of ASC 606 guidance while the reported results for 2017 were prepared under the guidance of ASC Topic 605, which is also referred to herein as “legacy GAAP” or the “previous guidance”.

Revenue

A. Significant Accounting Policy

In accordance with ASC 606, revenue is recognized when a customer obtains control of promised products and services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these products and services. A five-step model is utilized to achieve the core principle and includes the following steps: (1) identify the customer contract; (2) identify the contract’s performance obligation; (3) determine the transactions price; (4) allocate the transactions price to the performance obligation; and (5) recognize revenue when the performance obligation is satisfied.

B. Practical Expedients

Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from revenue.

Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost and are included in cost of revenues.

Sales commissions and other incremental costs of obtaining contracts are expensed as incurred as the amortization periods are less than one year.

C. Nature of Goods and Services

The following is a description of principal activities - separated by reportable segments - from which the Company generates its revenue. For more detailed information about reportable segments, see Note 20.

i. Pharmaceutical

The pharmaceutical segment of the Company principally generates revenue from products sold to wholesalers and distributors. Customer orders are generally fulfilled within a few days of receipt resulting in minimal order backlog. Contractual performance obligations are usually limited to transfer of the product to the customer. The transfer occurs either upon shipment or upon receipt of the product in certain non-U.S. countries after considering when the customer obtains control of the product. In addition, for some non-U.S. countries, the Company sells product on a consignment basis where control is not transferred until the customer resells the product to an end user. At these points, customers are able to direct the use of and obtain substantially all of the remaining benefits of the product.

Sales to customers are initially invoiced at contractual list prices. Payment terms are typically 30 to 90 days based on customary practice in each country. Revenue is reduced from the list price at the time of recognition for expected charge-backs, discounts, rebates, sales allowances and product returns, which are referred to as gross-to-net adjustments. These reductions are attributed to various commercial agreements, managed healthcare organizations and government programs such as Medicare, Medicaid, and the 340B Drug Pricing Program containing various pricing implications such as mandatory discounts, pricing protection below wholesaler list price and other discounts when Medicare Part D beneficiaries are in the coverage gap. These various reductions in the transaction price have been estimated using either a most likely amount or expected value method depending on their nature and have been reflected as liabilities and are settled through cash payments, typically within time periods ranging from a few months to one year. Significant judgment is required in estimating gross-to-net adjustments considering legal interpretations of applicable laws and regulations, historical experience, payer channel mix, current contract prices under applicable programs, unbilled claims, processing time lags and inventory levels in the distribution channel.

ii. Medical Devices

The medical devices segment of the Company principally generates revenue from the sale and lease of the LENSAR® Laser System (“LLS”), related procedure devices and licenses, and service agreements.

For bundled packages, the Company accounts for individual products and services separately if they are distinct - i.e. if a product or service is separately identifiable from other items in the bundled package and if the customer can benefit from it on its own or with other resources that are readily available to the customer. As the Company both sells and leases the LLS, the consideration (including any discounts) is first allocated between lease and non-lease components and then allocated between the separate products and services based on their stand-alone selling prices. The consideration (including any discounts) is allocated between separate products and services in a bundle based on their stand-alone selling prices. The stand-alone selling prices for the Patient Interface Devices (“PIDs”) and procedure licenses are determined based on the prices at which the Company separately sells the PIDs and procedure licenses. The LLS system and warranty stand-alone selling prices are determined using the expected cost plus a margin approach.

The Company sells and leases the LLS to customers. For LSS sales, the Company recognizes revenue in products revenue when a customer takes possession of the system. This usually occurs after the customer signs a contract, LENSAR installs the system, and LENSAR performs the requisite training for use of the system. For LLS leases, the Company recognizes revenue in products revenue over the length of the lease in products revenue in accordance with ASC Topic 840, Leases.

The LLS requires both a consumable, a PID, and a procedure license to perform each procedure. The Company recognizes revenue for PIDs in products revenue when the customer takes possession of the PID. PIDs are sold by the case. The Company recognizes revenue for procedure licenses in products revenue when a customer purchases a procedure license from the web portal. Typically, consideration for PIDs and procedure licenses is considered fixed consideration except as noted below. Certain customer agreements provide for variable consideration through tiered volume discount pricing.

The Company provides an extended warranty that provides additional services beyond the standard warranty. The Company recognizes revenue in products revenue over the warranty period. Customers have the option of renewing the warranty period, which is considered a new and separate contract.

iii. Income Generating Assets

Licenses of intellectual property: If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license.

In January 2018, DFM, LLC, a wholly-owned subsidiary of the Company, granted an exclusive license related to certain Direct Flow Medical assets in exchange for $0.5 million in cash and up to $2.0 million in royalty payments. The $0.5 million payment was accounted for in accordance with ASC 606 under which the full cash payment was recognized as revenue in the first quarter of 2018 as DFM, LLC had fulfilled its performance obligation under the agreement.

Royalties: The Company recognizes royalty revenues related to the sale of products by its licensees that incorporate the Company's technologies. Royalties qualify for the sales-and-usage exemption under Topic 606 as (i) royalties are based strictly on the sales-and-usage by the licensee; and (ii) a license of IP is the sole or predominant item to which such royalties relate. Based on this exemption, these royalties are earned under the terms of a license agreement in the period the products are sold by the Company's partner and the Company has a present right to payment.

D. Disaggregation of Revenue

The Company disaggregates its revenue from contracts with customers by segment and geographic location, as the Company believes it best depicts how the nature, amount, timing and uncertainty of its revenue and cash flows are affected by economic factors. In the following table, revenue is disaggregated by segment and primary geographical market for the three and six months ended June 30, 2018:
 
 
Three Months Ended
 
Six Months Ended
 
 
June 30, 2018
 
June 30, 2018
(in thousands)
 
Medical Devices
 
Pharmaceutical
 
Medical Devices
 
Pharmaceutical
 
 
 
 
 
 
 
 
 
Primary geographical markets:
 
 
 
 
 
 
 
 
North America
 
$
615

 
$
10,776

 
$
2,319

 
$
21,707

Europe
 
679

 
6,371

 
1,294

 
12,362

Asia
 
1,643

 
8,732

 
2,757

 
10,152

Other
 
107

 
—

 
220

 
—

Total revenue from contracts with customers1
 
$
3,044

 
$
25,879

 
$
6,590

 
$
44,221

_______________
1 The table above does not include Medical Device lease revenue of $2.8 million and $4.3 million for the three and six months ended June 30, 2018, respectively.

E. Contract Balances

The following table provides information about receivables, contract assets and contract liabilities from contracts with customers:
(in thousands)
 
June 30, 2018
 
January 1, 2018
 
 
 
 
 
Receivables, current and non-current, net
 
$
19,970

 
$
30,771

Contract assets
 
$
3,235

 
$
—

Contract liabilities
 
$
5,114

 
$
10,084


Receivables, Net—Receivables, net, include amounts billed and currently due from customers. The amounts due are stated at their net estimated realizable value. The Company maintains an allowance for doubtful accounts to provide for the estimated amount of receivables that will not be collected. The allowance is based upon an assessment of customer creditworthiness, historical payment experience, the age of outstanding receivables and collateral to the extent applicable.

Contract assets—The Company’s contract assets represent revenue recognized for performance obligations completed before an unconditional right to payment exists, and therefore invoicing or associated reporting from the customer regarding the computation of the net product sales has not yet occurred. The Company classifies contract assets as current based on the timing of when it expects to receive payment and is included in prepaid and other current assets in the Company’s consolidated balance sheets.
(in thousands)
 
Medical Devices
 
Pharmaceutical
 
Total
 
 
 
 
 
 
 
Contract assets at January 1, 2018
 
$
—

 
$
—

 
$
—

Contract assets recognized
 
—

 
3,235

 
3,235

Contract assets at June 30, 2018
 
$
—

 
$
3,235

 
$
3,235


Contract Liabilities—The Company’s contract liabilities consist of deferred revenue for products sold to customers for which the performance obligation has not been completed by the Company. The Company classifies deferred revenue as current or noncurrent based on the timing of when it expects to recognize revenue. The noncurrent portion of deferred revenue is included in other long-term liabilities in the Company’s consolidated balance sheets.
(in thousands)
 
Medical Devices
 
Pharmaceutical
 
Total
 
 
 
 
 
 
 
Contract liabilities at January 1, 2018
 
$
1,391

 
$
8,693

 
$
10,084

Additions
 
547

 
3,880

 
4,427

Amounts recognized into revenue
 
(704
)
 
(8,693
)
 
(9,397
)
Contract liabilities at June 30, 2018
 
$
1,234

 
$
3,880

 
$
5,114



F. Transaction Price Allocated to Future Performance Obligations

The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period.
 
 
Six Months Ended
 
 
 
 
(in thousands)
 
December 31, 2018
 
Thereafter
 
Total
 
 
 
 
 
 
 
Pharmaceutical product sales
 
$
1,000

 
$
—

 
$
1,000

Medical device product sales
 
$
1,878

 
$
2,352

 
$
4,230



The Company does not disclose the value of unsatisfied performance obligations for (i) contracts with original expected lengths of one year or less or (ii) contracts for which the Company recognizes revenue at the amount to which it has the right to invoice for the products delivered or services performed.
XML 43 R29.htm IDEA: XBRL DOCUMENT v3.10.0.1
Asset Acquisitions (Notes)
 6 Months Ended
Jun. 30, 2018
Business Acquisition [Line Items]  
Mergers, Acquisitions and Dispositions Disclosures [Text Block]
9. Asset Acquisition

On January 8, 2018, LENSAR entered into an Asset Purchase Agreement with Precision Eye Services (“PES”) to purchase assets used in PES’ laser-assisted cataract surgery business. The assets purchased include equipment, inventory and PES’ customer contracts. No workforce was transferred as part of the transaction.

The Company assessed the acquisition of PES assets under ASC Topic 805, Business Combinations (“ASC 805”). Under ASC 805, the Company determined that the acquired assets did not constitute a business and that the transaction would be accounted for as an asset acquisition.

The following table summarizes the fair values of the identifiable assets acquired and liabilities assumed at the acquisition date (in thousands):
Equipment and inventory
 
$
848

Fixed assets
 
67

Intangible assets (customer relationships)
 
1,845

Total identifiable assets
 
$
2,760

 
 
 
Consideration paid at closing, cash
 
$
1,200

Conversion consideration
 
920

Contingent consideration
 
640

Total fair value of consideration
 
$
2,760
XML 44 R30.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summary of Significant Accounting Policies (Policies)
 6 Months Ended
Jun. 30, 2018
Accounting Policies [Abstract]  
Basis of Presentation, Policy
Basis of Presentation
 
The accompanying unaudited Condensed Consolidated Financial Statements of PDL Biopharma, Inc. and its subsidiaries (collectively, the “Company” or “PDL”) have been prepared in accordance with Generally Accepted Accounting Principles (United States) (“GAAP”) for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments), that management of the Company believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.
 
The accompanying unaudited Condensed Consolidated Financial Statements and related financial information should be read in conjunction with the Company’s audited Consolidated Financial Statements and the related notes thereto for the year ended December 31, 2017, included in its Annual Report on Form 10-K for the fiscal year ended December 31, 2017, filed with the Securities and Exchange Commission (“SEC”) on March 16, 2018. The Condensed Consolidated Balance Sheet at December 31, 2017, has been derived from the audited Consolidated Financial Statements at that date, but does not include all disclosures required by GAAP.

Significant Accounting Policies

The Company’s significant accounting policies are described in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017. Summarized below are the accounting pronouncements adopted subsequent to December 31, 2017.
New Accounting Pronouncements, Policy [Policy Text Block]
Adopted Accounting Pronouncements

In August 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-15, Classification of Certain Cash Receipts and Cash Payments. The new standard provides for specific guidance how certain transactions are classified in the statement of cash flows. Effective January 1, 2018, the Company adopted the requirements of ASU No. 2016-15. The adoption did not have an effect on the Consolidated Financial Statements on the adoption date and no adjustment to prior year Consolidated Financial Statements was required.

In October 2016, the FASB issued ASU No. 2016-16, Intra-Entity Transfers of Assets Other Than Inventory, which requires companies to account for the income tax effects of intercompany sales and transfers of assets other than inventory in the period in which the transfer occurs. Effective January 1, 2018, the Company adopted the requirements of ASU No. 2016-16. The adoption did not have an effect on the Consolidated Financial Statements on the adoption date and no adjustment to prior year Consolidated Financial Statements was required.

In November 2016, the FASB issued ASU No. 2016-18, Restricted Cash, which requires entities to show the changes in total of cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. Effective January 1, 2018, the Company adopted the requirements of ASU No. 2016-18. The adoption did not have an effect on the Consolidated Financial Statements on the adoption date and no adjustment to prior year Consolidated Financial Statements was required.

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). Effective January 1, 2018, the Company adopted the requirements of ASU No. 2014-09 using the modified retrospective method as discussed in Note 2 below. All amounts and disclosures set forth in this Quarterly Report on Form 10-Q reflect these changes.

Recently Issued Accounting Pronouncements

In February 2016, the FASB issued ASU No. 2016-02, Leases, which seeks to increase transparency and comparability among organizations by, among other things, recognizing lease assets and lease liabilities on the balance sheet for leases classified as operating leases under previous GAAP and disclosing key information about leasing arrangements. ASU No. 2016-02 becomes effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the provisions of ASU No. 2016-02 and assessing the impact, if any, it may have on the Company’s Condensed Consolidated Financial Statements.

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments. The new guidance amends the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology, which will result in more timely recognition of losses. ASU No. 2016-13 has an effective date of the fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company is currently evaluating ASU No. 2016-13 and assessing the impact, if any, it may have to the Company’s consolidated results of operations, financial position and cash flows.
XML 45 R31.htm IDEA: XBRL DOCUMENT v3.10.0.1
Net Income per Share (Tables)
 6 Months Ended
Jun. 30, 2018
Earnings Per Share [Abstract]  
Schedule of calculation of numerator and denominator in earnings per share
 
 
Three Months Ended
 
Six Months Ended
 
 
June 30,
 
June 30,
Net Income (Loss) per Basic and Diluted Share:
 
2018
 
2017
 
2018
 
2017
 (in thousands except per share amounts)
 
 
 
 
 
 
 
 
Numerator
 
 
 
 
 
 
 
 
Income (loss) attributable to PDL’s shareholders used to compute net income per basic and diluted share
 
$
(112,296
)
 
$
60,439

 
$
(110,694
)
 
$
67,680

 
 
 
 
 
 
 
 
 
Denominator
 
 

 
 

 
 
 
 
Total weighted average shares used to compute net income attributable to PDL’s shareholders, per basic share
 
146,923

 
155,654

 
149,186

 
159,677

Restricted stock outstanding
 
—

 
740

 
—

 
491

Shares used to compute net income (loss) attributable to PDL’s shareholders, per diluted share
 
146,923

 
156,394

 
149,186

 
160,168

 
 
 
 
 
 
 
 
 
Net income (loss) attributable to PDL’s shareholders per share - basic
 
$
(0.76
)
 
$
0.39

 
$
(0.74
)
 
$
0.42

Net income (loss) attributable to PDL’s shareholders per share - diluted
 
$
(0.76
)
 
$
0.39

 
$
(0.74
)
 
$
0.42
XML 46 R32.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fair Value Measurements (Tables)
 6 Months Ended
Jun. 30, 2018
Fair Value Disclosures [Abstract]  
Fair Value Inputs, Assets, Quantitative Information [Table Text Block]
The following table represents significant unobservable inputs used in determining the estimated fair value of impaired notes receivable investments:
Asset
 
Valuation
Technique
 
Unobservable
Input
 
June 30,
2018
 
December 31,
2017
 
 
 
 
 
 
 
 
 
Wellstat Diagnostics
 
 
 
 
 
 
 
 
Wellstat Guarantors Intellectual Property
 
Income Approach
 
 
 
 
 
 
 
 
 
 
Discount rate
 
12%
 
12%
 
 
 
 
Royalty amount
 
$21 million
 
$21 million
Settlement Amount
 
Income Approach
 
 
 
 
 
 
 
 
 
 
Discount rate
 
15%
 
15%
 
 
 
 
Settlement amount
 
$36 million
 
$32 million
 
 
 
 
 
 
 
 
 
Real Estate Property
 
Market Approach
 
 
 
 
 
 
 
 
 
 
Annual appreciation rate
 
4%
 
4%
 
 
 
 
Estimated realtor fee
 
6%
 
6%
 
 
 
 
Estimated disposal date
 
6/30/2019
 
6/30/2019
 
 
 
 
 
 
 
 
 
CareView
 
 
 
 
 
 
 
 
Note receivable cash flows
 
Income Approach
 
 
 
 
 
 
 
 
 
 
Discount rate
 
17.5%
 
17.5%
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]
The following tables summarize the changes in Level 3 assets and the gains and losses included in earnings for the six months ended June 30, 2018:
Fair Value Measurements Using Significant Unobservable Inputs (Level 3) - Royalty Rights Assets
 
 
 
 
 
 
 
(in thousands)
 
Royalty Rights -
At Fair Value
Fair value as of December 31, 2017
 
 
 
$
349,223

 
 
 
 
 
 
 
 
Total net change in fair value for the period
 
 
 
 
 
 
Change in fair value of royalty rights - at fair value
 
$
23,933

 
 
 
 
Proceeds from royalty rights - at fair value
 
$
(37,993
)
 
 
 
 
Total net change in fair value for the period
 
 
 
(14,060
)
 
 
 
 
 
 
 
Fair value as of June 30, 2018
 


 
$
335,163


Fair Value Measurements Using Significant Unobservable Inputs (Level 3) - Royalty Rights Assets
 
 
 
 
 
 
 
 
 
Fair Value as of
 
Royalty Rights -
 
Fair Value as of
(in thousands)
 
December 31, 2017
 
Change in Fair Value
 
June 30, 2018
 
 
 
 
 
 
 
Depomed
 
$
232,038

 
$
(17,967
)
 
$
214,071

VB
 
14,380

 
284

 
14,664

U-M
 
26,769

 
(620
)
 
26,149

AcelRx
 
72,894

 
4,539

 
77,433

Avinger
 
396

 
(396
)
 
—

KYBELLA
 
2,746

 
100

 
2,846

 
 
$
349,223

 
$
(14,060
)
 
$
335,163

Fair Value Measurements Using Significant Unobservable Inputs (Level 3) - Liabilities
 
 
 
(in thousands)
 
Contingent Consideration
Fair value as of December 31, 2017
 
$
(42,000
)
 
 
 
 
 
 
Total net change in fair value for the period
 
22,735

 
Fair value of financial instruments acquired
 
(1,560
)
 
Settlement of financial instrument
 
785

 
 
 
 
 
Fair value as of June 30, 2018
 
$
(20,040
)
Schedule of fair value of financial instruments measured on recurring basis
 
 
June 30, 2018
 
December 31, 2017
(in thousands)
 
Level 1
 
Level 2
 
Level 3
 
Total
 
Level 1
 
Level 2
 
Level 3
 
Total
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Financial assets:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Money market funds
 
$
324,105

 
$
—

 
$
—

 
$
324,105

 
$
417,563

 
$
—

 
$
—

 
$
417,563

Corporate securities
 
—

 
—

 
—

 
—

 
4,848

 
—

 
—

 
4,848

Warrants
 
—

 
103

 
—

 
103

 
—

 
29

 
—

 
29

Royalty rights - at fair value
 
—

 
—

 
335,163

 
335,163

 
—

 
—

 
349,223

 
349,223

Total
 
$
324,105

 
$
103

 
$
335,163

 
$
659,371

 
$
422,411

 
$
29

 
$
349,223

 
$
771,663

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Financial liabilities:
 
 

 
 

 
 
 
 

 
 

 
 

 
 
 
 

Contingent consideration, current1
 
$
—

 
$
—

 
$
1,140

 
$
1,140

 
$
—

 
$
—

 
$
—

 
$
—

Contingent consideration, non-current
 
—

 
—

 
18,900

 
18,900

 
—

 
—

 
42,000

 
42,000

Total
 
$
—

 
$
—

 
$
20,040

 
$
20,040

 
$
—

 
$
—

 
$
42,000

 
$
42,000
Schedule of fair value of assets and liabilities not subject to fair value recognition by level within the valuation hierarchy
ollows:
 
 
Three Months Ended
 
Six Months Ended
 
 
June 30,
 
June 30,
(in thousands)
 
2018
 
2017
 
2018
 
2017
 
 
 
 
 
 
 
 
 
Total change in fair value for the period included in earnings for royalty right assets held at the end of the reporting period
 
$
12,842

 
$
83,725

 
$
23,933

 
$
96,871

 
 
 
 
 
 
 
 
 
Total change in fair value for the period included in earnings for liabilities held at the end of the reporting period
 
$
22,135

 
$
(1,207
)
 
$
22,735

 
$
(2,649
)

Assets/Liabilities Measured and Recorded at Fair Value on a Nonrecurring Basis

The Company remeasures the fair value of certain assets and liabilities upon the occurrence of certain events. Such assets consist of cost-method equity investments and long-lived assets, including property and equipment and intangible assets. During the three months ended June 30, 2018, the Company recorded an impairment charge of $152.3 million for the Noden intangible asset related to the increased probability of a generic version of aliskiren being launched in the United States. As a result of this impairment charge, which was based on the estimated fair value of the assets, the remaining carrying value of the these intangible assets was determined to be $40.1 million. The fair value calculation included level 3 inputs. For additional information on the impairment charge, see note 10.

Assets/Liabilities Not Subject to Fair Value Recognition

The following tables present the fair value of assets and liabilities not subject to fair value recognition by level within the valuation h
XML 47 R33.htm IDEA: XBRL DOCUMENT v3.10.0.1
Cash Equivalents and Investments (Tables)
 6 Months Ended
Jun. 30, 2018
Cash and Cash Equivalents [Abstract]  
Summary of cash and available-for-sale securities
 
 
 
 
 
 
 
 
Reported as:
(in thousands)
 
 Amortized Cost
 
 Unrealized Gains
 
 Estimated Fair Value
 
 Cash and Cash Equivalents
 
Short-Term Investments
 
 
 
 
 
 
 
 
 
 
 
June 30, 2018
 
 
 
 
 
 
 
 
 
 
Cash
 
$
71,548

 
$
—

 
$
71,548

 
$
71,548

 
$
—

Money market funds
 
324,105

 
—

 
324,105

 
324,105

 
—

Total
 
$
395,653

 
$
—

 
$
395,653

 
$
395,653

 
$
—

 
 
 
 
 
 
 
 
 
 
 
December 31, 2017
 
 
 
 
 
 
 
 
 
 
Cash
 
$
109,703

 
$
—

 
$
109,703

 
$
109,703

 
$
—

Money market funds
 
417,563

 
—

 
417,563

 
417,563

 
—

Corporate securities
 
3,353

 
1,495

 
4,848

 
—

 
4,848

Total
 
$
530,619

 
$
1,495

 
$
532,114

 
$
527,266

 
$
4,848
XML 48 R34.htm IDEA: XBRL DOCUMENT v3.10.0.1
Accrued Liabilities (Tables)
 6 Months Ended
Jun. 30, 2018
Sales Allowances and Accruals [Abstract]  
Sales Allowances and Accruals [Table Text Block]
The following table provides a summary of activity with respect to the Company’s sales allowances and accruals for the six months ended June 30, 2018:
(in thousands)
 
Discount and Distribution Fees
 
Government Rebates and Chargebacks
 
Assistance and Other Discounts
 
Product Return
 
Total
 
 
 
 
 
 
 
 
 
 
 
Balance at December 31, 2017:
 
$
3,422

 
$
8,709

 
$
4,178

 
$
3,304

 
$
19,613

Allowances for current period sales
 
4,749

 
7,859

 
4,174

 
1,291

 
18,073

Allowances for prior period sales
 
—

 
24

 
—

 
65

 
89

Credits/payments for current period sales
 
(2,057
)
 
(2,847
)
 
(2,019
)
 
—

 
(6,923
)
Credits/payments for prior period sales
 
(3,724
)
 
(7,629
)
 
(2,178
)
 
(390
)
 
(13,921
)
Balance at June 30, 2018:
 
$
2,390

 
$
6,116

 
$
4,155

 
$
4,270

 
$
16,931
XML 49 R35.htm IDEA: XBRL DOCUMENT v3.10.0.1
Convertible Notes (Tables)
 6 Months Ended
Jun. 30, 2018
Debt Disclosure [Abstract]  
Schedule of carrying value and unamortized discount on December 2021 Notes [Table Text Block]
The carrying value and unamortized discount of the December 2021 Notes were as follows:
(In thousands)
 
June 30, 2018
 
December 31, 2017
 
 
 
 
 
Principal amount of the December 2021 Notes
 
$
150,000

 
$
150,000

Unamortized discount of liability component
 
(29,055
)
 
(32,585
)
Net carrying value of the December 2021 Notes
 
$
120,945

 
$
117,415
Schedule of convertible and non-recourse notes activity
 
 
 
 
Principal Balance Outstanding
 
Carrying Value
 
 
 
 
June 30,
 
June 30,
 
December 31,
Description
 
Maturity Date
 
2018
 
2018
 
2017
(In thousands)
 
 
 
 
 
 
 
 
Convertible Notes
 
 
 
 
 
 
 
 
February 2018 Notes
 
February 1, 2018
 
$
—

 
$
—

 
$
126,066

December 2021 Notes
 
December 1, 2021
 
$
150,000

 
120,945

 
117,415

Total
 
 
 
 

 
$
120,945

 
$
243,481
Schedule of carrying value and unamortized discount on February 2018 Notes [Table Text Block]
The carrying value and unamortized discount of the February 2018 Notes were as follows:
(In thousands)
 
June 30, 2018
 
December 31, 2017
 
 
 
 
 
Principal amount of the February 2018 Notes
 
$
—

 
$
126,447

Unamortized discount of liability component
 
—

 
(381
)
Net carrying value of the February 2018 Notes
 
$
—

 
$
126,066
Schedule of interest expense for February 2018 Notes [Table Text Block]
Interest expense for the February 2018 Notes on the Company’s Condensed Consolidated Statements of Income was as follows:
 
 
Three Months Ended
 
Six Months Ended
 
 
June 30,
 
June 30,
(In thousands)
 
2018
 
2017
 
2018
 
2017
 
 
 
 
 
 
 
 
 
Contractual coupon interest
 
$
—

 
$
1,264

 
$
421

 
$
2,529

Amortization of debt issuance costs
 
—

 
250

 
88

 
499

Amortization of debt discount
 
—

 
851

 
293

 
1,699

Total
 
$
—

 
$
2,365

 
$
802

 
$
4,727
Schedule of interest expense for December 2021 Notes [Table Text Block]
Interest expense for the December 2021 Notes on the Company’s Condensed Consolidated Statements of Income was as follows:
 
 
Three Months Ended
 
Six Months Ended
 
 
June 30,
 
June 30,
(In thousands)
 
2018
 
2017
 
2018
 
2017
 
 
 
 
 
 
 
 
 
Contractual coupon interest
 
$
1,031

 
$
1,032

 
$
2,062

 
$
2,063

Amortization of debt issuance costs
 
19

 
18

 
38

 
36

Amortization of debt discount
 
135

 
131

 
269

 
261

Amortization of conversion feature
 
1,626

 
1,469

 
3,225

 
2,899

Total
 
$
2,811

 
$
2,650

 
$
5,594

 
$
5,259
XML 50 R36.htm IDEA: XBRL DOCUMENT v3.10.0.1
Other Long-Term Liabilities (Tables)
 6 Months Ended
Jun. 30, 2018
Other Liabilities Disclosure [Abstract]  
Schedule of other liabilities
 
 
June 30,
 
December 31,
(in thousands)
 
2018
 
2017
 
 
 
 
 
Accrued lease liability
 
$
10,700

 
$
10,700

Long-term incentive accrual
 
1,978

 
1,729

Uncertain tax positions
 
31,133

 
30,682

Long-term deferred tax liabilities
 
3,538

 
1,208

Dividend payable
 
45

 
47

Other
 
405

 
343

Total
 
$
47,799

 
$
44,709
XML 51 R37.htm IDEA: XBRL DOCUMENT v3.10.0.1
Customer Concentration (Tables)
 6 Months Ended
Jun. 30, 2018
Customer Concentration [Abstract]  
Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]
The percentage of total revenue recognized, which individually accounted for 10% or more of the Company’s total revenues, was as follows:
 
 
 
 
Three Months Ended June 30,
 
Six Months Ended June 30,
Licensee
 
Product Name
 
2018
 
2017
 
2018
 
2017
Biogen
 
Tysabri®
 
3%
 
11%
 
5%
 
16%
 
 
 
 
 
 
 
 
 
 
 
Depomed
 
Glumetza, Janumet XR, Jentadueto XR, Synjardy XR and Invokamet XR
 
20%
 
61%
 
20%
 
49%
 
 
 
 
 
 
 
 
 
 
 
N/A
 
Tekturna, Tekturna HCT, Rasilez and Rasilez HCT
 
56%
 
11%
 
52%
 
15%
 
 
 
 
 
 
 
 
 
 
 
LENSAR
 
LENSAR Laser System
 
13%
 
2%
 
13%
 
1%
XML 52 R38.htm IDEA: XBRL DOCUMENT v3.10.0.1
Business Combinations (Tables)
 6 Months Ended
Jun. 30, 2018
Acquired Finite-Lived Intangible Assets [Line Items]  
Business Acquisition, Pro Forma Information [Table Text Block]
 
 
Three Months Ended
 
Six Months Ended
 
 
June 30,
 
June 30,
(in thousands)
 
2018
 
2017
 
2018
 
2017
 
 
 
 
 
 
 
 
 
Pro forma revenues
 
$
46,575

 
$
145,554

 
$
85,093

 
$
194,820

Pro forma net income (loss)
 
$
(112,296
)
 
$
59,351

 
$
(110,694
)
 
$
64,124

Pro forma net income (loss) per share - basic
 
$
(0.76
)
 
$
0.38

 
$
(0.74
)
 
$
0.40

Pro forma net income (loss) per share - diluted
 
$
(0.76
)
 
$
0.38

 
$
(0.74
)
 
$
0.40
XML 53 R39.htm IDEA: XBRL DOCUMENT v3.10.0.1
Business Combinations Fair Value of Intangible Assets Acquired and Liabilities Assumed (Tables)
 6 Months Ended
Jun. 30, 2018
Business Acquisition [Line Items]  
Schedule of Business Acquisitions, by Acquisition [Table Text Block]
The following table summarizes the fair values of the identifiable assets acquired and liabilities assumed at the acquisition date (in thousands):
Equipment and inventory
 
$
848

Fixed assets
 
67

Intangible assets (customer relationships)
 
1,845

Total identifiable assets
 
$
2,760

 
 
 
Consideration paid at closing, cash
 
$
1,200

Conversion consideration
 
920

Contingent consideration
 
640

Total fair value of consideration
 
$
2,760

The following table summarizes the fair values of the identifiable intangible assets acquired and liabilities assumed at the acquisition date (in thousands):
Cash
 
$
1,983

Tangible assets
 
18,647

Intangible assets (1)
 
11,970

Net deferred tax assets
 
25,723

Total identifiable assets
 
58,323

Current liabilities
 
(6,673
)
Total liabilities assumed
 
(6,673
)
 
 
 
Net loss on derecognition of notes receivables
 
(10,615
)
Gain on bargain purchase, net of loss on extinguishment of notes receivable
 
(9,309
)
Total fair value of consideration
 
$
31,726

______________
(1) As of the effective date of the transaction, identifiable intangible assets are required to be measured at fair value.  The fair value measurement is based on significant inputs that are unobservable in the market and thus represents a Level 3 measurement. The Company used an income approach to estimate the preliminary fair value of the intangibles which includes technology, trademarks and customer relationships. The assumptions used to estimate the cash flows of the business included a discount rate of 16%, estimated gross margins ranging from 37-72%, income tax rate of 35%, and operating expenses consisting of direct costs based on the anticipated level of revenues.  The intangible assets have a weighted-average useful life of approximately 15.0 years. The intangible assets for acquired technology and trademarks are being amortized over their estimated useful lives using the straight-line method of amortization. The intangible assets for customer relationship are being amortized using a double-declining method of amortization as such method better represents the economic benefits to be obtained.
XML 54 R40.htm IDEA: XBRL DOCUMENT v3.10.0.1
Intangibles and Goodwill (Tables)
 6 Months Ended
Jun. 30, 2018
Acquired Finite-Lived Intangible Assets [Line Items]  
Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]
The components of intangible assets as of June 30, 2018 and December 31, 2017 were as follows:
 
 
June 30, 2018
 
December 31, 2017
(in thousands)
 
Gross Carrying Amount
 
Accumulated Amortization
 
Net Carrying Amount
 
Gross Carrying Amount
 
Accumulated Amortization
 
Net Carrying Amount
 
 
 
 
 
 
 
 
 
 
 
 
 
Finite-lived intangible assets:
 
 
 
 
 
 
 
 
 
 
 
 
Acquired products rights(1)
 
$
36,143

 
$
—

 
$
36,143

 
$
216,690

 
$
(32,503
)
 
$
184,187

Customer relationships(1) (2)
 
8,028

 
(341
)
 
7,687

 
26,080

 
(3,729
)
 
22,351

Acquired technology(2) (3)
 
11,011

 
(806
)
 
10,205

 
9,200

 
(409
)
 
8,791

Acquired trademarks(2)
 
570

 
(133
)
 
437

 
570

 
(76
)
 
494

 
 
$
55,752

 
$
(1,280
)
 
$
54,472

 
$
252,540

 
$
(36,717
)
 
$
215,823

________________
(1) The Company acquired certain intangible assets as part of the Noden Transaction. They are amortized on a straight-line basis over a weighted average period of 8.0 years.
(2) The Company acquired certain intangible assets as part of the LENSAR transaction, as described further in Note 19. They are amortized over a weighted average period of 15.0 years. The intangible assets for acquired technology and trademarks are being amortized over their estimated useful lives using the straight-line method of amortization. The intangible assets for customer relationships are being amortized using a double-declining method of amortization as such method better represents the economic benefits to be obtained.
(3)
The Company acquired certain intangible assets as part of the foreclosure on certain of Direct Flow Medical assets, as described further in Note 7. They are amortized over a weighted average period of 10.0 years. The intangible assets for acquired technology are being amortized over their estimated useful lives using the straight-line method of amortization.
XML 55 R41.htm IDEA: XBRL DOCUMENT v3.10.0.1
Intangibles and Goodwill Remaining Amortization Expense (Tables)
 6 Months Ended
Jun. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]
Based on the intangible assets recorded at June 30, 2018, and assuming no subsequent additions to or impairment of the underlying assets, the remaining estimated amortization expense is expected to be as follows (in thousands):
Fiscal Year
 
Amount
 
 
 
2018 (Remaining six months)
 
$
3,154

2019
 
6,275

2020
 
6,240

2021
 
6,209

2022
 
6,104

2023
 
6,040

Thereafter
 
20,450

Total remaining estimated amortization expense
 
$
54,472
XML 56 R42.htm IDEA: XBRL DOCUMENT v3.10.0.1
Segment Information (Tables)
 6 Months Ended
Jun. 30, 2018
Segment Reporting Information [Line Items]  
Schedule of Segment Reporting Information, by Segment [Table Text Block]
Information regarding the Company’s segments for the three and six months ended June 30, 2018 and 2017 is as follows:
Revenues by segment
 
Three Months Ended
 
Six Months Ended
 
 
June 30,
 
June 30,
(in thousands)
 
2018
 
2017
 
2018
 
2017
 
 
 
 
 
 
 
 
 
Pharmaceutical
 
$
25,879

 
$
16,212

 
44,221

 
28,794

Medical devices
 
5,882

 
2,617

 
10,864

 
2,617

Income generating assets
 
14,814

 
125,006

 
30,008

 
157,864

Total revenues
 
$
46,575

 
$
143,835

 
$
85,093

 
$
189,275


Income (loss) by segment
 
Three Months Ended
 
Six Months Ended
 
 
June 30,
 
June 30,
(in thousands)
 
2018
 
2017
 
2018
 
2017
 
 
 
 
 
 
 
 
 
Pharmaceutical
 
$
(111,335
)
 
$
(891
)
 
(113,048
)
 
(4,624
)
Medical devices
 
(1,904
)
 
(1,195
)
 
(2,491
)
 
(1,195
)
Income generating assets
 
943

 
62,525

 
4,845

 
73,499

Total net income (loss)
 
$
(112,296
)
 
$
60,439

 
$
(110,694
)
 
$
67,680


Information regarding the Company’s segments as of June 30, 2018 and December 31, 2017 is as follows:
Long-lived assets by segment
 
 
 
 
(in thousands)
 
June 30,
2018
 
December 31,
2017
 
 
 
 
 
Pharmaceutical
 
$
3,474

 
$
822

Medical devices
 
5,606

 
6,263

Income generating assets
 
143

 
137

Total long-lived assets
 
$
9,223

 
$
7,222
XML 57 R43.htm IDEA: XBRL DOCUMENT v3.10.0.1
Inventory (Tables)
 6 Months Ended
Jun. 30, 2018
Inventory [Line Items]  
Schedule of Inventory, Current [Table Text Block]
Inventories consisted of the following:
 
 
June 30,
 
December 31,
(in thousands)
 
2018
 
2017
 
 
 
 
 
Raw materials
 
$
1,771

 
$
1,717

Work in process
 
1,677

 
1,119

Finished goods
 
11,353

 
6,311

Total inventory
 
$
14,801

 
$
9,147
XML 58 R44.htm IDEA: XBRL DOCUMENT v3.10.0.1
Revenue from Contracts with Customers (Tables)
 6 Months Ended
Jun. 30, 2018
Revenue from Contracts with Customers [Abstract]  
Disaggregation of Revenue [Table Text Block]
disaggregates its revenue from contracts with customers by segment and geographic location, as the Company believes it best depicts how the nature, amount, timing and uncertainty of its revenue and cash flows are affected by economic factors. In the following table, revenue is disaggregated by segment and primary geographical market for the three and six months ended June 30, 2018:
 
 
Three Months Ended
 
Six Months Ended
 
 
June 30, 2018
 
June 30, 2018
(in thousands)
 
Medical Devices
 
Pharmaceutical
 
Medical Devices
 
Pharmaceutical
 
 
 
 
 
 
 
 
 
Primary geographical markets:
 
 
 
 
 
 
 
 
North America
 
$
615

 
$
10,776

 
$
2,319

 
$
21,707

Europe
 
679

 
6,371

 
1,294

 
12,362

Asia
 
1,643

 
8,732

 
2,757

 
10,152

Other
 
107

 
—

 
220

 
—

Total revenue from contracts with customers1
 
$
3,044

 
$
25,879

 
$
6,590

 
$
44,221

_______________
1 The table above does not include Medical Device lease revenue of $2.8 million and $4.3 million for the three and six months ended June 30, 2018, respectively.
Contract with Customer, Asset and Liability [Table Text Block]
The following table provides information about receivables, contract assets and contract liabilities from contracts with customers:
(in thousands)
 
June 30, 2018
 
January 1, 2018
 
 
 
 
 
Receivables, current and non-current, net
 
$
19,970

 
$
30,771

Contract assets
 
$
3,235

 
$
—

Contract liabilities
 
$
5,114

 
$
10,084


Receivables, Net—Receivables, net, include amounts billed and currently due from customers. The amounts due are stated at their net estimated realizable value. The Company maintains an allowance for doubtful accounts to provide for the estimated amount of receivables that will not be collected. The allowance is based upon an assessment of customer creditworthiness, historical payment experience, the age of outstanding receivables and collateral to the extent applicable.

Contract assets—The Company’s contract assets represent revenue recognized for performance obligations completed before an unconditional right to payment exists, and therefore invoicing or associated reporting from the customer regarding the computation of the net product sales has not yet occurred. The Company classifies contract assets as current based on the timing of when it expects to receive payment and is included in prepaid and other current assets in the Company’s consolidated balance sheets.
(in thousands)
 
Medical Devices
 
Pharmaceutical
 
Total
 
 
 
 
 
 
 
Contract assets at January 1, 2018
 
$
—

 
$
—

 
$
—

Contract assets recognized
 
—

 
3,235

 
3,235

Contract assets at June 30, 2018
 
$
—

 
$
3,235

 
$
3,235


Contract Liabilities—The Company’s contract liabilities consist of deferred revenue for products sold to customers for which the performance obligation has not been completed by the Company. The Company classifies deferred revenue as current or noncurrent based on the timing of when it expects to recognize revenue. The noncurrent portion of deferred revenue is included in other long-term liabilities in the Company’s consolidated balance sheets.
(in thousands)
 
Medical Devices
 
Pharmaceutical
 
Total
 
 
 
 
 
 
 
Contract liabilities at January 1, 2018
 
$
1,391

 
$
8,693

 
$
10,084

Additions
 
547

 
3,880

 
4,427

Amounts recognized into revenue
 
(704
)
 
(8,693
)
 
(9,397
)
Contract liabilities at June 30, 2018
 
$
1,234

 
$
3,880

 
$
5,114
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]
The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period.
 
 
Six Months Ended
 
 
 
 
(in thousands)
 
December 31, 2018
 
Thereafter
 
Total
 
 
 
 
 
 
 
Pharmaceutical product sales
 
$
1,000

 
$
—

 
$
1,000

Medical device product sales
 
$
1,878

 
$
2,352

 
$
4,230
XML 59 R45.htm IDEA: XBRL DOCUMENT v3.10.0.1
Asset Acquisitions (Tables)
 6 Months Ended
Jun. 30, 2018
Business Acquisition [Line Items]  
Schedule of Business Acquisitions, by Acquisition [Table Text Block]
The following table summarizes the fair values of the identifiable assets acquired and liabilities assumed at the acquisition date (in thousands):
Equipment and inventory
 
$
848

Fixed assets
 
67

Intangible assets (customer relationships)
 
1,845

Total identifiable assets
 
$
2,760

 
 
 
Consideration paid at closing, cash
 
$
1,200

Conversion consideration
 
920

Contingent consideration
 
640

Total fair value of consideration
 
$
2,760

The following table summarizes the fair values of the identifiable intangible assets acquired and liabilities assumed at the acquisition date (in thousands):
Cash
 
$
1,983

Tangible assets
 
18,647

Intangible assets (1)
 
11,970

Net deferred tax assets
 
25,723

Total identifiable assets
 
58,323

Current liabilities
 
(6,673
)
Total liabilities assumed
 
(6,673
)
 
 
 
Net loss on derecognition of notes receivables
 
(10,615
)
Gain on bargain purchase, net of loss on extinguishment of notes receivable
 
(9,309
)
Total fair value of consideration
 
$
31,726

______________
(1) As of the effective date of the transaction, identifiable intangible assets are required to be measured at fair value.  The fair value measurement is based on significant inputs that are unobservable in the market and thus represents a Level 3 measurement. The Company used an income approach to estimate the preliminary fair value of the intangibles which includes technology, trademarks and customer relationships. The assumptions used to estimate the cash flows of the business included a discount rate of 16%, estimated gross margins ranging from 37-72%, income tax rate of 35%, and operating expenses consisting of direct costs based on the anticipated level of revenues.  The intangible assets have a weighted-average useful life of approximately 15.0 years. The intangible assets for acquired technology and trademarks are being amortized over their estimated useful lives using the straight-line method of amortization. The intangible assets for customer relationship are being amortized using a double-declining method of amortization as such method better represents the economic benefits to be obtained.
XML 60 R46.htm IDEA: XBRL DOCUMENT v3.10.0.1
Net Income per Share (Narrative) (Detail) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Dec. 31, 2017
Nov. 22, 2016
Nov. 20, 2015
Restricted Stock [Member]              
Debt Instrument [Line Items]              
Antidilutive securities excluded from computation of earnings per share (in Shares) 1,000,000 2,200,000 1,100,000 2,000,000      
Option on Securities [Member]              
Debt Instrument [Line Items]              
Antidilutive securities excluded from computation of earnings per share (in Shares) 4,900,000 0 4,900,000 0      
December 2021 Notes [Member]              
Debt Instrument [Line Items]              
Convertible notes $ 120,945   $ 120,945   $ 117,415 $ 150,000 $ 150,000
XML 61 R47.htm IDEA: XBRL DOCUMENT v3.10.0.1
Net Income per Share (Net Income Per Basic and Diluted Share) (Detail) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Numerator        
Income used to compute net income per diluted share $ (112,296) $ 60,439 $ (110,694) $ 67,680
Denominator        
Total weighted-average shares used to compute net income per basic share (in Shares) 146,923 155,654 149,186 159,677
Diluted (in Shares) 146,923 156,394 149,186 160,168
Basic (in Dollars per Share) $ (0.76) $ 0.39 $ (0.74) $ 0.42
Net income per diluted share (in Dollars per Share) $ (0.76) $ 0.39 $ (0.74) $ 0.42
Restricted Stock [Member]        
Debt Instrument [Line Items]        
Additional shares included in the calculation of diluted EPS (in Shares) 0 740 0 491
XML 62 R48.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fair Value Measurements (Narrative) (Detail) - USD ($)
 3 Months Ended 6 Months Ended
Oct. 28, 2017
Dec. 13, 2016
Sep. 21, 2016
Jul. 08, 2016
Jun. 02, 2016
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Jun. 29, 2018
Dec. 31, 2017
Jul. 09, 2016
Sep. 18, 2015
Nov. 06, 2014
Jun. 26, 2014
Oct. 18, 2013
Goodwill and Intangible Asset Impairment               $ 152,300,000                
Accounts and Notes Receivable, Net           $ 70,900,000   $ 70,900,000     $ 70,700,000          
Cash payment for purchase of royalty right                           $ 65,600,000    
Fair value inputs, discount rate (in Percent)               21.00%                
Litigation Settlement, Amount Awarded from Other Party $ 13,000,000                              
Revenue Recognition, Milestone Method, Revenue Recognized   $ 6,000,000 $ 5,000,000   $ 6,000,000                      
Royalty rights           335,163,000 [1]   $ 335,163,000 [1]     349,223,000 [2]          
Transfers from level 1 to level 2, amount           0   0     0          
Transfers from level 2 to level 1, amount           0   0     0          
Percentage of royalty acquired                           75.00%    
Notes Receivable, Fair Value Disclosure           77,900,000   77,900,000     71,300,000          
Interest revenue           751,000 $ 5,460,000 1,500,000 $ 10,917,000              
Gain (Loss) on Extinguishment of Debt           0 $ 12,200,000 0 $ 12,200,000              
Finite-Lived Intangible Assets, Gross           $ 55,752,000   $ 55,752,000   $ 192,500,000 $ 252,540,000          
Depomed [Member]                                
Cash payment for purchase of royalty right                               $ 240,500,000
Purchase of royalty rights                               241,300,000
Royalty right purchase transaction costs                               $ 800,000
Long-Duration Contracts, Assumptions by Product and Guarantee, Discount Rate           10.00%   10.00%                
Fair Value Measurements, Sensitivity Analysis, Description               Should these discount rates increase or decrease by 2.5%, the fair value of the asset could decrease by $12.8 million or increase by $14.7 million, respectively. A third-party expert was engaged to assist management develop its original estimate of the expected future cash flows. The estimated fair value of the asset is subject to variation should those cash flows vary significantly from those estimates. The Company periodically assesses the expected future cash flows and to the extent such payments are greater or less than its initial estimates, or the timing of such payments is materially different than the original estimates, the Company will adjust the estimated fair value of the asset. Should the expected royalties increase or decrease by 2.5%, the fair value of the asset could increase or decrease by $5.4 million, respectively.                
Royalty rights           $ 214,100,000   $ 214,100,000                
Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount           $ 214,100,000   $ 214,100,000                
VB [Member]                                
Purchase of royalty rights                             $ 15,500,000  
Fair value inputs, discount rate (in Percent)           15.00%                    
Fair Value Measurements, Sensitivity Analysis, Description               Should this discount rate increase or decrease by 2.5%, the fair value of this asset could decrease by $1.4 million or increase by $1.6 million, respectively. Should the expected royalties increase or decrease by 2.5%, the fair value of the asset could increase or decrease by $0.4 million, respectively.                
Royalty rights           $ 14,700,000   $ 14,700,000                
Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount           $ 14,700,000   $ 14,700,000                
University of Michigan [Member]                                
Long-Duration Contracts, Assumptions by Product and Guarantee, Discount Rate           12.80%   12.80%                
Fair Value Measurements, Sensitivity Analysis, Description           Should this discount rate increase or decrease by 2.5%, the fair value of this asset could decrease by $1.2 million or increase by $1.4 million, respectively. Should the expected royalties increase or decrease by 2.5%, the fair value of the asset could increase or decrease by $0.7 million, respectively.                    
Royalty rights           $ 26,100,000   $ 26,100,000                
Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount           $ 26,100,000   $ 26,100,000                
AcelRx [Member]                                
Purchase of royalty rights                         $ 65,000,000      
Long-Duration Contracts, Assumptions by Product and Guarantee, Discount Rate           13.40%   13.40%                
Fair Value Measurements, Sensitivity Analysis, Description           Should this discount rate increase or decrease by 2.5%, the fair value of this asset could decrease by $9.8 million or increase by $12.0 million, respectively. Should the expected royalties increase or decrease by 2.5%, the fair value of the asset could increase or decrease by $1.9 million, respectively                    
Royalty rights           $ 77,400,000   $ 77,400,000                
Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount           $ 77,400,000   $ 77,400,000                
Percentage of royalty acquired                         75.00%      
Kybella [Member]                                
Purchase of royalty rights                       $ 9,500,000        
Long-Duration Contracts, Assumptions by Product and Guarantee, Discount Rate           14.40%   14.40%                
Fair Value Measurements, Sensitivity Analysis, Description           Should this discount rate increase or decrease by 2.5%, the fair value of this asset could decrease by $0.2 million or increase by $0.3 million, respectively. Should the expected royalties increase or decrease by 2.5%, the fair value of the asset could increase or decrease by $0.1 million, respectively                    
Royalty rights           $ 2,800,000   $ 2,800,000                
Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount           2,800,000   2,800,000                
Maximum amount of additional funds, upon attainment of milestones       $ 1,000,000                        
CareView [Member]                                
Interest revenue           800,000   1,500,000                
Noden [Member]                                
Finite-Lived Intangible Assets, Gross           $ 40,100,000   $ 40,100,000                
[1] unaudited
[2] Note 1
XML 63 R49.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fair Value Measurements (Financial Instruments Measured at Fair Value on a Recurring Basis) (Detail) - USD ($)
$ in Thousands
Jun. 30, 2018
Jan. 06, 2018
Dec. 31, 2017
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Business Combination, Contingent Consideration, Liability, Current $ 1,140 $ 920 $ 0
Royalty rights 335,163 [1]   349,223 [2]
Financial assets:      
Assets, Fair Value 659,371   771,663
Warrants and Rights Outstanding 103   29
Financial liabilites:      
Business Combination, Contingent Consideration, Liability, Noncurrent 18,900 [1] $ 640 42,000 [1]
Liabilities, Fair Value Disclosure, Recurring 20,040   42,000
Money Market Funds [Member]      
Financial assets:      
Cash and Cash Equivalents, Fair Value 324,105   417,563
Equity Securities [Member]      
Financial assets:      
Available for Sale Securities, Fair Value 0   4,848
Fair Value Level 1 [Member]      
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Financial and Nonfinancial Liabilities, Fair Value Disclosure 0   0
Financial assets:      
Assets, Fair Value 324,105   422,411
Fair Value Level 1 [Member] | Money Market Funds [Member]      
Financial assets:      
Cash and Cash Equivalents, Fair Value 324,105   417,563
Fair Value Level 1 [Member] | Equity Securities [Member]      
Financial assets:      
Available for Sale Securities, Fair Value 0   4,848
Fair Value Level 2 [Member]      
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Financial and Nonfinancial Liabilities, Fair Value Disclosure 0   0
Financial assets:      
Assets, Fair Value 103   29
Warrants and Rights Outstanding 103   29
Fair Value Level 2 [Member] | Money Market Funds [Member]      
Financial assets:      
Cash and Cash Equivalents, Fair Value 0   0
Fair Value Level 2 [Member] | Equity Securities [Member]      
Financial assets:      
Available for Sale Securities, Fair Value 0   0
Fair Value Level 3 [Member]      
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Business Combination, Contingent Consideration, Liability, Current 1,140    
Financial and Nonfinancial Liabilities, Fair Value Disclosure 20,040   42,000
Royalty rights 335,163   349,223
Financial assets:      
Assets, Fair Value 335,163   349,223
Warrants and Rights Outstanding 0    
Financial liabilites:      
Business Combination, Contingent Consideration, Liability, Noncurrent $ 18,900   $ 42,000
[1] unaudited
[2] Note 1
XML 64 R50.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fair Value Measurements (Schedule of Fair Value of Assets and Liabilities not Subject to Fair Value Recognition) (Detail) - USD ($)
$ in Thousands
Jun. 30, 2018
Dec. 31, 2017
Assets    
Notes receivable, Carrying Value $ 70,887 $ 70,737
Notes receivable, Fair Value 77,900 71,300
Liabilities:    
Convertible Notes Payable, Carrying Value 120,945 243,481
February 2018 Notes [Member]    
Liabilities:    
Convertible Notes Payable, Carrying Value   126,066
December 2021 Notes [Member]    
Liabilities:    
Convertible Notes Payable, Carrying Value 120,945 117,415
Wellstat Note Receivable [Member]    
Assets    
Notes receivable, Carrying Value 50,191 50,191
Hyperion [Member]    
Assets    
Notes receivable, Carrying Value 1,200 1,200
CareView [Member]    
Assets    
Notes receivable, Carrying Value 19,496 19,346
Fair Value Level 2 [Member]    
Liabilities:    
Notes payable, Fair Value 139,052 274,159
Fair Value Level 2 [Member] | February 2018 Notes [Member]    
Liabilities:    
Notes payable, Fair Value   126,131
Fair Value Level 2 [Member] | December 2021 Notes [Member]    
Liabilities:    
Notes payable, Fair Value 139,052 148,028
Fair Value Level 2 [Member] | Hyperion [Member]    
Assets    
Notes receivable, Fair Value 0 0
Fair Value Level 2 [Member] | CareView [Member]    
Assets    
Notes receivable, Fair Value 0 0
Fair Value Level 3 [Member]    
Assets    
Notes receivable, Fair Value 77,931 71,258
Fair Value Level 3 [Member] | Wellstat Note Receivable [Member]    
Assets    
Notes receivable, Fair Value 57,224 51,308
Fair Value Level 3 [Member] | Hyperion [Member]    
Assets    
Notes receivable, Fair Value 1,200 1,200
Fair Value Level 3 [Member] | CareView [Member]    
Assets    
Notes receivable, Fair Value $ 19,507 $ 18,750
XML 65 R51.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fair Value Measurements Level 3 Unobservable Input Reconciliation (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Dec. 31, 2017
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Sales     $ (1,560)    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements     785    
Change in fair value of acquired royalty rights, Level 3 Rollforward $ 12,842 $ 83,725 23,933 $ 96,871  
Payments for (Proceeds from) Productive Assets     (37,993) (48,062)  
Change in fair value included in earnings for liabilities 22,135 $ (1,207) 22,735 $ (2,649)  
Contingent Consideration [Member]          
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value (20,040)   (20,040)   $ (42,000)
Change in fair value of acquired royalty rights     22,735    
Royalty right [Member]          
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
Beginning balance     349,223    
Change in fair value of acquired royalty rights, Level 3 Rollforward     23,933    
Ending balance 335,163   335,163    
Payments for (Proceeds from) Productive Assets     (37,993)    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings     (14,060)    
Depomed [Member] | Royalty right [Member]          
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
Beginning balance     232,038    
Ending balance 214,071   214,071    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings     (17,967)    
VB [Member] | Royalty right [Member]          
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
Beginning balance     14,380    
Ending balance 14,664   14,664    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings     284    
University of Michigan [Member] | Royalty right [Member]          
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
Beginning balance     26,769    
Ending balance 26,149   26,149    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings     (620)    
AcelRx [Member] | Royalty right [Member]          
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
Beginning balance     72,894    
Ending balance 77,433   77,433    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings     4,539    
Avinger [Member] | Royalty right [Member]          
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
Beginning balance     396    
Ending balance 0   0    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings     (396)    
Kybella [Member] | Royalty right [Member]          
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
Beginning balance     2,746    
Ending balance $ 2,846   2,846    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings     $ 100    
XML 66 R52.htm IDEA: XBRL DOCUMENT v3.10.0.1
Cash Equivalents and Investments (Narrative) (Detail) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Dec. 31, 2017
 [2]
Cash and Cash Equivalents [Abstract]          
Gains (losses) on sales of available-for-sale securities $ 0 $ 0 $ 764,000 $ 0  
Accumulated Other Comprehensive Income (Loss), Net of Tax [1] $ 0   $ 0   $ 1,181,000
[1] unaudited
[2] Note 1
XML 67 R53.htm IDEA: XBRL DOCUMENT v3.10.0.1
Cash Equivalents and Investments (Summary of Cash and Available-For-Sale Securities) (Detail) - USD ($)
$ in Thousands
Jun. 30, 2018
Dec. 31, 2017
Mar. 31, 2017
 [2]
Dec. 31, 2016
 [3]
Schedule of Available-For-Sale Securities [Line Items]        
Adjusted Cost $ 395,653 $ 530,619    
Cash, Cash Equivalents and Available-for-Sale Securities, Fair Value 395,653 532,114    
Cash and cash equivalents 395,653 [1],[2] 527,266 [3] $ 349,428 $ 147,154
Short-Term Marketable Securities 0 [1] 4,848 [3]    
Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, before Tax 0 1,495    
Cash [Member]        
Schedule of Available-For-Sale Securities [Line Items]        
Adjusted Cost 71,548 109,703    
Cash, Cash Equivalents and Available-for-Sale Securities, Fair Value 71,548 109,703    
Cash and cash equivalents 71,548 109,703    
Short-Term Marketable Securities 0 0    
Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, before Tax 0 0    
Money Market Funds [Member]        
Schedule of Available-For-Sale Securities [Line Items]        
Adjusted Cost 324,105 417,563    
Cash, Cash Equivalents and Available-for-Sale Securities, Fair Value 324,105 417,563    
Cash and cash equivalents 324,105 417,563    
Short-Term Marketable Securities 0 0    
Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, before Tax $ 0 0    
Equity Securities [Member]        
Schedule of Available-For-Sale Securities [Line Items]        
Adjusted Cost   3,353    
Cash, Cash Equivalents and Available-for-Sale Securities, Fair Value   4,848    
Cash and cash equivalents   0    
Short-Term Marketable Securities   4,848    
Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, before Tax   $ 1,495    
[1] unaudited
[2] unaudited
[3] Note 1
XML 68 R54.htm IDEA: XBRL DOCUMENT v3.10.0.1
Notes Receivable and Other Long-term Receivables (Narrative) (Detail)
$ / shares in Units, $ in Thousands, shares in Millions
 1 Months Ended 6 Months Ended 12 Months Ended 58 Months Ended
Sep. 21, 2017
USD ($)
Feb. 14, 2017
USD ($)
Feb. 09, 2017
USD ($)
Feb. 06, 2017
USD ($)
Dec. 30, 2016
USD ($)
Jul. 16, 2016
$ / shares
Sep. 22, 2015
USD ($)
Jun. 26, 2015
USD ($)
$ / shares
shares
Nov. 10, 2014
USD ($)
Nov. 05, 2013
USD ($)
Oct. 03, 2013
USD ($)
Aug. 15, 2013
USD ($)
Jan. 31, 2013
USD ($)
Jun. 30, 2018
USD ($)
Jun. 30, 2017
USD ($)
Dec. 31, 2013
USD ($)
Apr. 30, 2018
Feb. 02, 2018
$ / shares
shares
Dec. 31, 2017
USD ($)
 [2]
Nov. 14, 2016
USD ($)
Sep. 29, 2016
$ / shares
Sep. 12, 2016
USD ($)
$ / shares
Jul. 15, 2016
USD ($)
Dec. 31, 2015
USD ($)
$ / shares
Dec. 15, 2015
USD ($)
shares
Oct. 07, 2015
$ / shares
Sep. 29, 2015
USD ($)
May 12, 2015
USD ($)
Sep. 30, 2014
USD ($)
Apr. 01, 2014
USD ($)
Nov. 06, 2013
USD ($)
Jun. 28, 2013
USD ($)
Mar. 05, 2013
USD ($)
Nov. 02, 2012
USD ($)
Jan. 27, 2012
USD ($)
Accounts Notes And Loans Receivable [Line Items]                                                                      
Premiums, Percentage Assumed to Net 1.00%                                                                    
Investment Warrants, Exercise Price | $ / shares           $ 0.01                                                          
Repayment of notes receivable                           $ 0 $ 8,142                                        
Accounts Receivable, Net, Noncurrent [1]                           1,400                                          
Investment Owned, Balance, Shares | shares                                                 1.7                    
Investment Owned, at Cost                           6,600                                          
Commitments and Contingencies                           [1]                 $ 500       $ 8,500              
Equity investment, shares held (shares) | shares                                   4.4                                  
Wellstat Diagnostics [Member]                                                                      
Accounts Notes And Loans Receivable [Line Items]                                                                      
Financing receivable, gross                                                         $ 53,900            
Gain Contingency, Unrecorded Amount                           55,800                                          
Financing Receivable, Net                           50,200                                          
Interest rate of note receivable (in Percent)                       5.00%                                              
Avinger [Member]                                                                      
Accounts Notes And Loans Receivable [Line Items]                                                                      
Repayment of notes receivable             $ 21,400                                                        
LENSAR [Member]                                                                      
Accounts Notes And Loans Receivable [Line Items]                                                                      
Financing receivable, gross                     $ 40,000                           $ 42,000                    
Interest rate of note receivable (in Percent)                     15.50%                                 18.50%              
Amount company has agreed to advance under agreement                     $ 60,000                                                
Alphaeon [Member]                                                                      
Accounts Notes And Loans Receivable [Line Items]                                                                      
Investment estimated fair value, per share | $ / shares                                               $ 3.84                      
DirectFlow [Member]                                                                      
Accounts Notes And Loans Receivable [Line Items]                                                                      
Financing receivable, gross                                       $ 1,000   $ 1,500 $ 1,500               $ 35,000        
Financing Receivables, Impaired, Troubled Debt Restructuring, Write-down         $ 51,100                                                            
Proceeds from Sale of Other Assets   $ 700 $ 500 $ 7,000                                                              
Interest rate of note receivable (in Percent)                                                             15.50%        
Amount company has agreed to advance under agreement                 $ 15,000 $ 50,000                                                  
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares                                         $ 0.01 $ 0.01                          
Hyperion [Member]                                                                      
Accounts Notes And Loans Receivable [Line Items]                                                                      
Financing receivable, gross                                                                     $ 2,300
Number of payments to be received                                                                     2
Periodic contractual payments                                                                 $ 1,200    
kaleo Note Receivable [Member]                                                                      
Accounts Notes And Loans Receivable [Line Items]                                                                      
Financing receivable, gross                                                           $ 150,000          
Repayment of notes receivable $ 141,700                                                                    
CareView [Member]                                                                      
Accounts Notes And Loans Receivable [Line Items]                                                                      
Interest rate of note receivable (in Percent)               13.50%                                                      
Amount company has agreed to advance under agreement               $ 40,000                                                      
Tranche 1 of note receivable               20,000                                                      
Tranche 2 of note receivable               $ 20,000                                                      
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares               4.4                                                      
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares               $ 0.45                   $ 0.03               $ 0.40                  
Financial Instruments, Owned, Other, at Fair Value                           $ 100                                          
Credit Agreement [Member] | Wellstat Diagnostics [Member]                                                                      
Accounts Notes And Loans Receivable [Line Items]                                                                      
Financing receivable, gross                                                                   $ 40,000  
Credit agreement, stated interest rate (in Percent)                                                                   5.00%  
Proceeds received under remedies available for borrower's breach of terms credit agreement                         $ 8,100                                            
Amount company has agreed to advance under agreement                               $ 8,700                                      
Financing Receivable, Modifications, Post-Modification Recorded Investment                       $ 44,100                                              
Credit Agreement [Member] | LENSAR [Member]                                                                      
Accounts Notes And Loans Receivable [Line Items]                                                                      
Amount company has agreed to advance under agreement       $ 2,800                                                              
Initial Loan [Member] | Wellstat Diagnostics [Member]                                                                      
Accounts Notes And Loans Receivable [Line Items]                                                                      
Financing Receivable, Modifications, Pre-Modification Recorded Investment                       33,700                                              
Additional Loan [Member]                                                                      
Accounts Notes And Loans Receivable [Line Items]                                                                      
Commitments and Contingencies                                                     $ 800                
Additional Loan [Member] | Wellstat Diagnostics [Member]                                                                      
Accounts Notes And Loans Receivable [Line Items]                                                                      
Financing receivable, gross                                                               $ 1,300      
Additional Loan [Member] | LENSAR [Member]                                                                      
Accounts Notes And Loans Receivable [Line Items]                                                                      
Amount company has agreed to advance under agreement                     $ 20,000                                                
Royalty Agreement [Member] | Avinger [Member]                                                                      
Accounts Notes And Loans Receivable [Line Items]                                                                      
Reduction in royalty rate (in percent)                                 50.00%                                    
Term loan and interest [Member] | Wellstat Diagnostics [Member]                                                                      
Accounts Notes And Loans Receivable [Line Items]                                                                      
Financing Receivable, Modifications, Pre-Modification Recorded Investment                       1,300                                              
Forbearance principal and interest [Member] | Wellstat Diagnostics [Member]                                                                      
Accounts Notes And Loans Receivable [Line Items]                                                                      
Financing Receivable, Modifications, Pre-Modification Recorded Investment                       $ 9,100                                              
Tranche three [Member] | DirectFlow [Member]                                                                      
Accounts Notes And Loans Receivable [Line Items]                                                                      
Financing receivable, gross                                                 $ 5,000                    
[1] unaudited
[2] Note 1
XML 69 R55.htm IDEA: XBRL DOCUMENT v3.10.0.1
Accrued Liabilities (Narrative) (Detail) - USD ($)
$ in Thousands
Jun. 30, 2018
Dec. 31, 2017
Sales Allowances and Accruals [Abstract]    
Discount and Distribution Fees $ 2,390 $ 3,422
Government rebates and chargebacks 6,116 8,709
Assistance and Other Discounts 4,155 4,178
Product return 4,270 3,304
Accrued liabilities, amounts received in advance of revenue recognition $ 16,931 $ 19,613
XML 70 R56.htm IDEA: XBRL DOCUMENT v3.10.0.1
Accrued Liabilities (Accrued Liabilities) (Detail) - USD ($)
$ in Thousands
Jun. 30, 2018
Jan. 06, 2018
Dec. 31, 2017
Payables and Accruals [Abstract]      
Compensation $ 7,046   $ 6,043
Interest 344   2,451
Dividend payable 77   79
Legal 1,027   595
Accrued liabilities, amounts received in advance of revenue recognition 16,931   19,613
Customer Refundable Fees 0   647
Customer Advances, Current 0   3,198
Business Combination, Contingent Consideration, Liability, Current 1,140 $ 920 0
Other 2,825   3,514
Total 34,294 [1]   45,881 [2]
Deferred Revenue, Current $ 4,904   $ 9,741
[1] unaudited
[2] Note 1
XML 71 R57.htm IDEA: XBRL DOCUMENT v3.10.0.1
Commitments and Contingencies (Narrative) (Detail) - USD ($)
$ in Thousands
 6 Months Ended
Sep. 21, 2017
Jun. 30, 2018
Jun. 30, 2017
Dec. 31, 2017
Nov. 22, 2016
Nov. 20, 2015
Feb. 12, 2014
Guarantor Obligations [Line Items]              
Premiums, Percentage Assumed to Net 1.00%            
Proceeds from Collection of Notes Receivable   $ 0 $ 8,142        
Accounts Receivable, Net, Noncurrent [1]   1,400          
Total lease payments for the duration of the guarantee   39,500          
Accrued lease liability   10,700   $ 10,700      
February 2018 Notes [Member]              
Guarantor Obligations [Line Items]              
Debt Instrument, Unamortized Discount   0   $ 381 $ 4,300 $ 3,100 $ 29,700
kaleo Note Receivable [Member]              
Guarantor Obligations [Line Items]              
Proceeds from Collection of Notes Receivable $ 141,700            
Noden [Member] | Next twelve months [Member]              
Guarantor Obligations [Line Items]              
Purchase Obligation   114,300          
Noden [Member] | Next thirty-six months [Member]              
Guarantor Obligations [Line Items]              
Purchase Obligation   61,400          
LENSAR [Member] | Next twelve months [Member]              
Guarantor Obligations [Line Items]              
Purchase Obligation   3,500          
LENSAR [Member] | Next twenty-four months [Member] [Member]              
Guarantor Obligations [Line Items]              
Purchase Obligation   $ 1,200          
[1] unaudited
XML 72 R58.htm IDEA: XBRL DOCUMENT v3.10.0.1
Convertible Notes (Narrative) (Detail)
$ / shares in Units, shares in Millions
 3 Months Ended 6 Months Ended
Feb. 02, 2018
USD ($)
Nov. 21, 2016
USD ($)
Nov. 20, 2015
USD ($)
Feb. 11, 2014
USD ($)
Feb. 05, 2014
USD ($)
Jun. 30, 2018
USD ($)
$ / shares
shares
Jun. 30, 2017
USD ($)
Jun. 30, 2018
USD ($)
$ / shares
shares
Jun. 30, 2017
USD ($)
Dec. 31, 2017
USD ($)
Nov. 22, 2016
USD ($)
$ / shares
Feb. 12, 2014
USD ($)
Feb. 06, 2014
USD ($)
$ / shares
Debt Instrument [Line Items]                          
Principal amount a $5 incentive cash payment per each to convert debt               $ 1,000          
Convertible note rate conversion trading days (in days)               0          
Convertible Notes rate conversion consecutive trading days (in days)               $ 30          
Minimum conversion price percent for note conversion (in Percent)               130.00%          
Interest Paid               $ 4,591,000 $ 4,695,000        
Gain on conversion of convertible notes           $ 0 $ (12,200,000) 0 $ (12,200,000)        
Share Price | $ / shares                         $ 7.97
Repayments of Debt $ 129,000,000                        
Debt Instrument, Periodic Payment, Principal 126,400,000                        
Debt Instrument, Periodic Payment, Interest $ 2,600,000                        
February 2018 Notes [Member]                          
Debt Instrument [Line Items]                          
Convertible notes           0   0   $ 126,066,000   $ 300,000,000  
Debt instrument, interest rate (in Percent)                       4.00%  
Unamortized discount of liability component     $ (3,100,000)     0   0   (381,000) $ (4,300,000) $ (29,700,000)  
Deferred issuance costs     900,000               1,300,000    
Purchase call option unwind     270,000                    
Warrant unwind     170,000                    
Fees and Commissions, Transfer Agent     100,000                    
Debt discount recorded to additional paid in capital                       19,300,000  
Debt discount recorded to deferred tax liability                       $ 10,400,000  
Debt Instrument, Interest Rate, Effective Percentage                       6.90%  
Estimated market interest rate for similar nonconvertible instrument                       7.00%  
Net proceeds from the issuance of convertible notes       $ 290,200,000                  
Debt Instrument, Repurchase Amount     53,600,000               120,000,000    
Debt instrument, repurchase amount paid     43,700,000               121,500,000    
Interest Paid   $ 1,500,000                      
Debt Instrument, Face Amount           $ 0   $ 0   126,447,000      
Gain on conversion of convertible notes     (6,500,000)                    
February 2018 Note Warrant [Member]                          
Debt Instrument [Line Items]                          
Convertible notes, conversion price (in Dollars per Share) | $ / shares           $ 10.3610   $ 10.3610          
Proceeds from Issuance of Warrants         $ 11,400,000                
December 2021 Notes [Member]                          
Debt Instrument [Line Items]                          
Convertible notes     $ 150,000,000     $ 120,945,000   $ 120,945,000   117,415,000 $ 150,000,000    
Debt instrument, interest rate (in Percent)                     2.80%    
Unamortized discount of liability component           (29,055,000)   $ (29,055,000)   (32,585,000) $ (4,300,000)    
Debt discount recorded to additional paid in capital                     23,800,000    
Debt discount recorded to deferred tax liability                     $ 12,800,000    
Maximum percent of common stock closing price and conversion rate to convert note (in Percent)               98.00%          
Debt Instrument, Interest Rate, Effective Percentage                     3.40%    
Convertible notes, conversion price (in Dollars per Share) | $ / shares                     $ 3.81    
Estimated market interest rate for similar nonconvertible instrument                     9.50%    
Debt instrument, convertible, remaining amortization period (in Duration)               3 years 5 months 5 days          
Net proceeds from the issuance of convertible notes   $ 145,700,000                      
Debt Instrument, Face Amount           $ 150,000,000   $ 150,000,000   $ 150,000,000      
Conversion Rate per $1,000 Principal Amount (in Ratio)   262.2951                      
Proceeds from Issuance of Warrants   $ 14,400,000                      
February 2018 Note Purchase Call Option [Member]                          
Debt Instrument [Line Items]                          
Purchased call options cost       31,000,000                  
Number of shares of common stock covered by the purchased call options purchased (in Shares) | shares           13.8   13.8          
Deferred taxes included in purchased call options cost       $ 10,800,000                  
Purchased Call Options [Member]                          
Debt Instrument [Line Items]                          
Convertible notes, conversion price (in Dollars per Share) | $ / shares           $ 4.88   $ 4.88          
Series 2012 Notes [Member]                          
Debt Instrument [Line Items]                          
Convertible notes                         $ 131,700,000
XML 73 R59.htm IDEA: XBRL DOCUMENT v3.10.0.1
Convertible Notes (Summary of Convertible Notes) (Detail)
 6 Months Ended
Nov. 21, 2016
Jun. 30, 2018
USD ($)
Dec. 31, 2017
USD ($)
Nov. 22, 2016
$ / shares
Feb. 12, 2014
Debt Instrument [Line Items]          
Principal amount a $5 incentive cash payment per each to convert debt   $ 1,000      
Convertible Notes Payable, Carrying Value   $ 120,945,000 $ 243,481,000    
February 2018 Notes [Member]          
Debt Instrument [Line Items]          
Debt Instrument, Interest Rate, Stated Percentage         4.00%
Convertible Notes, Maturity Date (Date)   Feb. 01, 2018      
Convertible Notes, Principal Balance Outstanding   $ 0 126,447,000    
Convertible Notes Payable, Carrying Value     126,066,000    
December 2021 Notes [Member]          
Debt Instrument [Line Items]          
Debt Instrument, Interest Rate, Stated Percentage       2.80%  
Debt Instrument, Convertible, Conversion Ratio 262.2951        
Convertible notes, conversion price (in Dollars per Share) | $ / shares       $ 3.81  
Convertible Notes, Maturity Date (Date)   Dec. 01, 2021      
Convertible Notes, Principal Balance Outstanding   $ 150,000,000 150,000,000    
Convertible Notes Payable, Carrying Value   $ 120,945,000 $ 117,415,000    
XML 74 R60.htm IDEA: XBRL DOCUMENT v3.10.0.1
Convertible Notes (Summary of Series 2012 Notes) (Detail) - USD ($)
$ in Thousands
Jun. 30, 2018
Dec. 31, 2017
Debt Instrument [Line Items]    
Convertible Notes Payable, Carrying Value $ 120,945 $ 243,481
XML 75 R61.htm IDEA: XBRL DOCUMENT v3.10.0.1
Convertible Notes (Summary of May 2015 Notes) (Detail) - USD ($)
$ in Thousands
Jun. 30, 2018
Dec. 31, 2017
Debt Instrument [Line Items]    
Convertible Notes Payable, Carrying Value $ 120,945 $ 243,481
XML 76 R62.htm IDEA: XBRL DOCUMENT v3.10.0.1
Convertible Notes Convertible Notes (Summary of February 2018 Notes) (Detail) (Details) - February 2018 Notes [Member] - USD ($)
$ in Thousands
Jun. 30, 2018
Dec. 31, 2017
Nov. 22, 2016
Nov. 20, 2015
Feb. 12, 2014
Debt Instrument [Line Items]          
Debt Instrument, Unamortized Discount $ 0 $ (381) $ (4,300) $ (3,100) $ (29,700)
Convertible notes 0 126,066     $ 300,000
Debt Instrument, Face Amount $ 0 $ 126,447      
XML 77 R63.htm IDEA: XBRL DOCUMENT v3.10.0.1
Convertible Notes Convertible Notes (Interest Expense for February 2018 Notes) (Detail) (Details) - February 2018 Notes [Member] - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Debt Instrument [Line Items]        
Contractual coupon interest $ 0 $ 1,264 $ 421 $ 2,529
Amortization of debt issuance costs 0 250 88 499
Amortization of debt discount 0 851 293 1,699
Total $ 0 $ 2,365 $ 802 $ 4,727
XML 78 R64.htm IDEA: XBRL DOCUMENT v3.10.0.1
Convertible Notes Convertible Notes (Summary of December 2021 Notes) (Details) - December 2021 Notes [Member] - USD ($)
$ in Thousands
Jun. 30, 2018
Dec. 31, 2017
Nov. 22, 2016
Nov. 20, 2015
Debt Instrument [Line Items]        
Debt Instrument, Face Amount $ 150,000 $ 150,000    
Debt Instrument, Unamortized Discount (29,055) (32,585) $ (4,300)  
Convertible notes $ 120,945 $ 117,415 $ 150,000 $ 150,000
XML 79 R65.htm IDEA: XBRL DOCUMENT v3.10.0.1
Convertible Notes Convertible Notes (Interest Expense for December 2021 Notes) (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Debt Instrument [Line Items]        
Debt Instrument, Convertible, Beneficial Conversion Feature $ 1,626 $ 1,469 $ 3,225 $ 2,899
December 2021 Notes [Member]        
Debt Instrument [Line Items]        
Contractual coupon interest 1,031 1,032 2,062 2,063
Amortization of debt issuance costs 19 18 38 36
Amortization of debt discount 135 131 269 261
Interest Expense, Debt $ 2,811 $ 2,650 $ 5,594 $ 5,259
XML 80 R66.htm IDEA: XBRL DOCUMENT v3.10.0.1
Other Long-Term Liabilities (Narrative) (Detail) - USD ($)
$ in Thousands
Jun. 30, 2018
Dec. 31, 2017
Schedule of Other Liabilities [Line Items]    
Accrued lease liability $ 10,700 $ 10,700
XML 81 R67.htm IDEA: XBRL DOCUMENT v3.10.0.1
Other Long-Term Liabilities (Other Long-Term Liabilities) (Detail) - USD ($)
$ in Thousands
Jun. 30, 2018
Dec. 31, 2017
Schedule of Other Liabilities [Line Items]    
Accrued lease liability $ 10,700 $ 10,700
Accrued Bonuses 1,978 1,729
Uncertain tax position 31,133 30,682
Deferred Tax Liabilities, Net, Noncurrent 3,538 1,208
Dividends Payable 45 47
Liabilities, Other than Long-term Debt, Noncurrent 405 343
Total $ 47,799 [1] $ 44,709 [2]
[1] unaudited
[2] Note 1
XML 82 R68.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stock-Based Compensation (Summary of Stock Option and Restricted Stock Award Activity) (Detail) - $ / shares
shares in Thousands
 6 Months Ended
Jun. 30, 2018
Dec. 31, 2017
Share Based Compensation Arrangment By Share Based Payment Award [Line Items]    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 401  
Employee Stock Option [Member]    
Share Based Compensation Arrangment By Share Based Payment Award [Line Items]    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number 4,855 961
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3,894  
Restricted Stock Awards, Weighted Average Grant-date Fair Value, Granted (in Dollars per Share) $ 2.94  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price $ 2.99 $ 3.21
Restricted Stock [Member]    
Share Based Compensation Arrangment By Share Based Payment Award [Line Items]    
Restricted Stock Award, Number of Shares, Balance at beginning of period (in Shares) 2,305  
Restricted Stock Awards, Number of Shares Granted (in Shares) 481  
Restricted Stock Awards, Number of Shares, Balance at end of period (in Shares) 2,266  
Restricted Stock Awards, Weighted Average Grant-date Fair Value, Balance at beginning of period (in Dollars per Share) $ 2.68  
Restricted Stock Awards, Weighted Average Grant-date Fair Value, Granted (in Dollars per Share) 2.71  
Restricted Stock Awards, Weighted Average Grant-date Fair Value, Balance at end of period (in Dollars per Share) 2.73  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value 2.50  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value $ 2.38  
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations (119)  
XML 83 R69.htm IDEA: XBRL DOCUMENT v3.10.0.1
Cash Dividends (Narrative) (Detail) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Stockholders' Equity Note [Abstract]    
Payments of Dividends $ 0 $ 21
XML 84 R70.htm IDEA: XBRL DOCUMENT v3.10.0.1
Customer Concentration (Percentage of Total Revenue From Licenses Over 10% of Revenue) (Detail)
 3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Elan [Member] | Tysabri [Member]        
Revenue, Major Customer [Line Items]        
Concentration Risk, Percentage 3.00% 11.00% 5.00% 16.00%
Depomed [Member]        
Revenue, Major Customer [Line Items]        
Concentration Risk, Percentage 20.00% 61.00% 20.00% 49.00%
Noden [Member]        
Revenue, Major Customer [Line Items]        
Concentration Risk, Percentage 56.00%     15.00%
Noden [Member] | Tysabri [Member]        
Revenue, Major Customer [Line Items]        
Concentration Risk, Percentage   11.00% 52.00%  
LENSAR [Member] | Interest revenues [Member]        
Revenue, Major Customer [Line Items]        
Concentration Risk, Percentage 13.00% 2.00% 13.00% 1.00%
XML 85 R71.htm IDEA: XBRL DOCUMENT v3.10.0.1
Income Taxes (Narrative) (Detail) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Investments, Owned, Federal Income Tax Note [Line Items]        
Income Tax Expense $ (14,265) $ 53,873 $ (13,246) $ 60,425
Federal income tax rate     21.00%  
Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions $ 0 $ 0 $ 28,900 $ 29,700
XML 86 R72.htm IDEA: XBRL DOCUMENT v3.10.0.1
Accumulated Other Comprehensive Income (Loss) (Schedule of Balances of Accumulated Other Comprehensive Income (Loss)) (Detail) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Dec. 31, 2017
Accumulated other comprehensive income [1] $ 0   $ 0   $ 1,181,000 [2]
Unrealized gains (losses) on available-for-sale securities [3] 0 $ 0 (1,181,000) $ 0  
Other Comprehensive Income (Loss), Net of Tax 0 $ 0 (1,181,000) $ 0  
Accumulated Net Investment Gain (Loss) Attributable to Parent [Member]          
Accumulated other comprehensive income 0   0   1,181,000
AOCI Attributable to Parent [Member]          
Accumulated other comprehensive income $ 0   0   $ 1,181,000
Other Comprehensive Income (Loss), Net of Tax     $ (1,181,000)    
[1] unaudited
[2] Note 1
[3] Net of tax of zero and zero for the three months ended June 30, 2018 and 2017, respectively
XML 87 R73.htm IDEA: XBRL DOCUMENT v3.10.0.1
Subsequent Events (Narrative) (Detail) - USD ($)
$ / shares in Units, $ in Thousands, shares in Millions
 3 Months Ended 4 Months Ended 6 Months Ended 12 Months Ended
Aug. 02, 2018
Jul. 05, 2018
Jun. 30, 2018
Jul. 05, 2018
Jun. 30, 2018
Dec. 31, 2017
May 08, 2018
Jan. 06, 2018
Subsequent Event [Line Items]                
Stock Repurchased During Period, Shares     6.8 8.7 8.2 13.3    
Treasury Stock Acquired, Average Cost Per Share     $ 2.87 $ 2.89 $ 2.89 $ 2.25    
Stock Repurchased During Period, Value     $ 19,400 $ 25,000 $ 23,600 $ 30,000    
Stock Repurchase Program, Remaining Authorized Repurchase Amount             $ 25,000  
Acquisition Costs, Period Cost $ 20,000              
Business Combination, Contingent Consideration, Liability, Current     1,140   1,140 $ 0   $ 920
Subsequent Event [Member]                
Subsequent Event [Line Items]                
Stock Repurchased During Period, Shares   0.6            
Treasury Stock Acquired, Average Cost Per Share   $ 2.44            
Stock Repurchased During Period, Value   $ 1,400            
Royalty trigger amount     $ 481,000   $ 481,000      
Payments to Acquire Productive Assets 10,000              
Business Combination, Contingent Consideration, Liability, Current $ 10,000              
XML 88 R74.htm IDEA: XBRL DOCUMENT v3.10.0.1
Business Combinations (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended
Jan. 08, 2018
May 13, 2017
May 11, 2017
Jun. 30, 2018
Jun. 30, 2017
Jan. 06, 2018
Dec. 31, 2017
Jan. 20, 2017
Acquired Indefinite-lived Intangible Assets [Line Items]                
Business Acquisition, Pro Forma Revenue       $ 46,575 $ 145,554      
Business Combination, Consideration Transferred $ 1,200              
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets           $ 2,760    
Business Acquisition, Pro Forma Net Income (Loss)       $ (112,296) $ 59,351      
Business Acquisition, Pro Forma Earnings Per Share, Basic       $ (0.76) $ 0.38      
Business Acquisition, Pro Forma Earnings Per Share, Diluted       $ (0.76) $ 0.38      
Accounts and Notes Receivable, Net       $ 70,900     $ 70,700  
Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value     $ 31,700          
LENSAR [Member]                
Acquired Indefinite-lived Intangible Assets [Line Items]                
Business Combination, Consideration Transferred   $ 31,726            
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets     58,323          
Contractual Obligation               $ 2,800
Accounts and Notes Receivable, Net     43,900          
Gain (Loss) on Investments   $ 9,300 $ 10,600          
XML 89 R75.htm IDEA: XBRL DOCUMENT v3.10.0.1
Business Combinations Proforma (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Business Combinations [Abstract]    
Business Acquisition, Pro Forma Revenue $ 46,575 $ 145,554
Business Acquisition, Pro Forma Net Income (Loss) $ (112,296) $ 59,351
Business Acquisition, Pro Forma Earnings Per Share, Basic $ (0.76) $ 0.38
Business Acquisition, Pro Forma Earnings Per Share, Diluted $ (0.76) $ 0.38
XML 90 R76.htm IDEA: XBRL DOCUMENT v3.10.0.1
Business Combinations Asset and Liabilities Acquired (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jan. 08, 2018
May 13, 2017
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Jan. 06, 2018
May 11, 2017
Business Acquisition [Line Items]                
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill             $ 1,845  
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets             $ 2,760  
Business Combination, Separately Recognized Transactions, Expenses and Losses Recognized   $ (10,615)            
Business Combination, Bargain Purchase, Gain Recognized, Amount     $ 0 $ 6,271 $ 0 $ 6,271    
Business Combination, Consideration Transferred $ 1,200              
LENSAR [Member]                
Business Acquisition [Line Items]                
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents               $ 1,983
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment               18,647
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill [1]               11,970
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets               25,723
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets               58,323
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities               $ (6,673)
Business Combination, Bargain Purchase, Gain Recognized, Amount   (9,309)            
Business Combination, Consideration Transferred   $ 31,726            
[1] (1) As of the effective date of the transaction, identifiable intangible assets are required to be measured at fair value. The fair value measurement is based on significant inputs that are unobservable in the market and thus represents a Level 3 measurement. The Company used an income approach to estimate the preliminary fair value of the intangibles which includes technology, trademarks and customer relationships. The assumptions used to estimate the cash flows of the business included a discount rate of 16%, estimated gross margins ranging from 37-72%, income tax rate of 35%, and operating expenses consisting of direct costs based on the anticipated level of revenues. The intangible assets have a weighted-average useful life of approximately 15.0 years. The intangible assets for acquired technology and trademarks are being amortized over their estimated useful lives using the straight-line method of amortization. The intangible assets for customer relationship are being amortized using a double-declining method of amortization as such method better represents the economic benefits to be obtained.
XML 91 R77.htm IDEA: XBRL DOCUMENT v3.10.0.1
Intangibles and Goodwill (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Jun. 29, 2018
Dec. 31, 2017
Acquired Finite-Lived Intangible Assets [Line Items]            
Fair Value Inputs, Discount Rate     21.00%      
Goodwill and Intangible Asset Impairment     $ 152,300      
Finite-Lived Intangible Asset, Useful Life     8 years      
Finite-Lived Intangible Assets, Gross $ 55,752   $ 55,752   $ 192,500 $ 252,540
Finite-Lived Intangible Assets, Accumulated Amortization (1,280)   (1,280)     (36,717)
Finite-Lived Intangible Assets, Net 54,472   54,472     215,823
Amortization of Intangible Assets 6,384 $ 6,148 12,677 $ 12,163    
Contractual Rights [Member]            
Acquired Finite-Lived Intangible Assets [Line Items]            
Finite-Lived Intangible Assets, Gross 36,143   36,143     216,690
Finite-Lived Intangible Assets, Accumulated Amortization 0   0     (32,503)
Finite-Lived Intangible Assets, Net 36,143   36,143     184,187
Customer Relationships [Member]            
Acquired Finite-Lived Intangible Assets [Line Items]            
Finite-Lived Intangible Assets, Gross 8,028   8,028     26,080
Finite-Lived Intangible Assets, Accumulated Amortization (341)   (341)     (3,729)
Finite-Lived Intangible Assets, Net 7,687   7,687     22,351
Patented Technology [Member]            
Acquired Finite-Lived Intangible Assets [Line Items]            
Finite-Lived Intangible Assets, Gross 11,011   11,011     9,200
Finite-Lived Intangible Assets, Accumulated Amortization (806)   (806)     (409)
Finite-Lived Intangible Assets, Net 10,205   10,205     8,791
Trademarks [Member]            
Acquired Finite-Lived Intangible Assets [Line Items]            
Finite-Lived Intangible Assets, Gross 570   570     570
Finite-Lived Intangible Assets, Accumulated Amortization (133)   (133)     (76)
Finite-Lived Intangible Assets, Net 437   437     $ 494
Noden [Member]            
Acquired Finite-Lived Intangible Assets [Line Items]            
Finite-Lived Intangible Assets, Gross $ 40,100   $ 40,100      
XML 92 R78.htm IDEA: XBRL DOCUMENT v3.10.0.1
Intangibles and Goodwill Schedule of Finite-Lived Intangible Asset Amortization Expense (Details) - USD ($)
$ in Thousands
Jun. 30, 2018
Dec. 31, 2017
Finite-Lived Intangible Assets [Line Items]    
Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year $ 3,154  
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months 6,275  
Finite-Lived Intangible Assets, Amortization Expense, Year Two 6,240  
Finite-Lived Intangible Assets, Amortization Expense, Year Three 6,209  
Finite-Lived Intangible Assets, Amortization Expense, Year Four 6,104  
Finite-Lived Intangible Assets, Amortization Expense, Year Five 6,040  
Finite-Lived Intangible Assets, Amortization Expense, after Year Five 20,450  
Finite-Lived Intangible Assets, Net $ 54,472 $ 215,823
XML 93 R79.htm IDEA: XBRL DOCUMENT v3.10.0.1
Segment Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Dec. 31, 2017
Segment Reporting Information [Line Items]          
Long-Lived Assets $ 9,223   $ 9,223   $ 7,222
Net Income (Loss) Attributable to Parent (112,296) $ 60,439 (110,694) $ 67,680  
Revenues 46,575 143,835 85,093 189,275  
Income generating assets [Member]          
Segment Reporting Information [Line Items]          
Long-Lived Assets 143   143   137
Net Income (Loss) Attributable to Parent 943 62,525 4,845 73,499  
Revenues 14,814 125,006 30,008 157,864  
Pharmaceutical [Member]          
Segment Reporting Information [Line Items]          
Long-Lived Assets 3,474   3,474   822
Net Income (Loss) Attributable to Parent (111,335) (891) (113,048) (4,624)  
Revenues 25,879 16,212 44,221 28,794  
Medical devices [Member]          
Segment Reporting Information [Line Items]          
Long-Lived Assets 5,606   5,606   $ 6,263
Net Income (Loss) Attributable to Parent (1,904) (1,195) (2,491) (1,195)  
Revenues $ 5,882 $ 2,617 $ 10,864 $ 2,617  
XML 94 R80.htm IDEA: XBRL DOCUMENT v3.10.0.1
Inventory (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2018
Dec. 31, 2017
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Inventory [Line Items]          
Inventory, Raw Materials, Gross $ 1,771 $ 1,717   $ 1,771  
Inventory, Work in Process, Gross 1,677 1,119   1,677  
Inventory, Finished Goods, Gross 11,353 6,311   11,353  
Inventory, Net [1] 14,801 9,147   14,801  
Deferred Costs and Other Assets 200 1,300   200  
Inventory Write-down $ 600 $ 500 $ (100) $ 491 $ (161)
[1] unaudited
XML 95 R81.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stockholders' Equity (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
 3 Months Ended 4 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2018
Jul. 05, 2018
Jun. 30, 2018
Dec. 31, 2017
Sep. 25, 2017
Mar. 02, 2017
Stockholders' Equity Attributable to Parent [Abstract]            
Stock Repurchase Program, Authorized Amount         $ 25.0 $ 30.0
Stock Repurchased During Period, Shares 6.8 8.7 8.2 13.3    
Stock Repurchased During Period, Value $ 19.4 $ 25.0 $ 23.6 $ 30.0    
Treasury Stock Acquired, Average Cost Per Share $ 2.87 $ 2.89 $ 2.89 $ 2.25    
XML 96 R82.htm IDEA: XBRL DOCUMENT v3.10.0.1
Revenue from Contracts with Customers (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2018
Jun. 30, 2017
Medical devices [Member]      
Disaggregation of Revenue [Line Items]      
Non ASC 606 revenue $ 2,800 $ 4,300  
Revenue from Contract with Customer, Excluding Assessed Tax 3,044 6,590 $ 44,221
Medical devices [Member] | North America [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 615 2,319  
Medical devices [Member] | Europe [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 679 1,294  
Medical devices [Member] | Asia [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 1,643 2,757  
Medical devices [Member] | Non-US [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 107 $ 220 0
Pharmaceutical [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 25,879    
Pharmaceutical [Member] | North America [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 10,776   21,707
Pharmaceutical [Member] | Europe [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 6,371   12,362
Pharmaceutical [Member] | Asia [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 8,732   $ 10,152
Pharmaceutical [Member] | Non-US [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax $ 0    
XML 97 R83.htm IDEA: XBRL DOCUMENT v3.10.0.1
Revenue from Contracts with Customers Contract Assets and Liabilities (Details) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2018
Jan. 01, 2018
Dec. 31, 2017
Disaggregation of Revenue [Line Items]      
Contract with Customer, Asset, Net $ 19,970 $ 30,771  
Contract with Customer, Liability 5,114 $ 10,084 $ 10,084
Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price 4,427    
Contract with Customer, Liability, Revenue Recognized (9,397)    
Medical devices [Member]      
Disaggregation of Revenue [Line Items]      
Contract with Customer, Liability 1,234   1,391
Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price 547    
Contract with Customer, Liability, Revenue Recognized (704)    
Pharmaceutical [Member]      
Disaggregation of Revenue [Line Items]      
Contract with Customer, Liability 3,880   $ 8,693
Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price 3,880    
Contract with Customer, Liability, Revenue Recognized $ (8,693)    
XML 98 R84.htm IDEA: XBRL DOCUMENT v3.10.0.1
Revenue from Contracts with Customers Transaction Price Allocated to the Remaining Performance Obligations (Details)
$ in Thousands
Jun. 30, 2018
USD ($)
Pharmaceutical [Member]  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue, Remaining Performance Obligation $ 1,000
Pharmaceutical [Member] | Less than one year [Member]  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue, Remaining Performance Obligation 1,000
Pharmaceutical [Member] | Greater than one year [Member]  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue, Remaining Performance Obligation 0
Medical devices [Member]  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue, Remaining Performance Obligation 4,230
Medical devices [Member] | Less than one year [Member]  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue, Remaining Performance Obligation 1,878
Medical devices [Member] | Greater than one year [Member]  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue, Remaining Performance Obligation $ 2,352
XML 99 R85.htm IDEA: XBRL DOCUMENT v3.10.0.1
Asset Acquisitions Asset Acquisition Details (Details) - USD ($)
$ in Thousands
Jan. 08, 2018
Jun. 30, 2018
Jan. 06, 2018
Dec. 31, 2017
Business Acquisition [Line Items]        
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory     $ 848  
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Equipment     67  
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill     1,845  
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets     2,760  
Business Combination, Consideration Transferred $ 1,200      
Business Combination, Contingent Consideration, Liability, Current   $ 1,140 920 $ 0
Business Combination, Contingent Consideration, Liability, Noncurrent   $ 18,900 [1] $ 640 $ 42,000 [1]
[1] unaudited
EXCEL 100 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 102 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 104 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 293 362 1 true 75 0 false 4 false false R1.htm 0001000 - Document - Document And Entity Information Sheet http://www.pdl.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 1001000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) Sheet http://www.pdl.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) Statements 2 false false R3.htm 1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) Sheet http://www.pdl.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) Statements 3 false false R4.htm 1002501 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parentheticals) Sheet http://www.pdl.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParentheticals CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parentheticals) Statements 4 false false R5.htm 1003000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.pdl.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 5 false false R6.htm 1003501 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) Sheet http://www.pdl.com/role/CondensedConsolidatedBalanceSheetsParentheticals CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) Statements 6 false false R7.htm 1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://www.pdl.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Statements 7 false false R8.htm 2102100 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.pdl.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 2103100 - Disclosure - Net Income per Share Sheet http://www.pdl.com/role/NetIncomePerShare Net Income per Share Notes 9 false false R10.htm 2104100 - Disclosure - Fair Value Measurements Sheet http://www.pdl.com/role/FairValueMeasurements Fair Value Measurements Notes 10 false false R11.htm 2105100 - Disclosure - Cash Equivalents and Investments Sheet http://www.pdl.com/role/CashEquivalentsAndInvestments Cash Equivalents and Investments Notes 11 false false R12.htm 2107100 - Disclosure - Notes Receivable and Other Long-term Receivables Notes http://www.pdl.com/role/NotesReceivableAndOtherLongTermReceivables Notes Receivable and Other Long-term Receivables Notes 12 false false R13.htm 2111100 - Disclosure - Accrued Liabilities Sheet http://www.pdl.com/role/AccruedLiabilities Accrued Liabilities Notes 13 false false R14.htm 2112100 - Disclosure - Commitments and Contingencies Sheet http://www.pdl.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 14 false false R15.htm 2113100 - Disclosure - Convertible Notes Notes http://www.pdl.com/role/ConvertibleNotes Convertible Notes Notes 15 false false R16.htm 2115100 - Disclosure - Other Long-Term Liabilities Sheet http://www.pdl.com/role/OtherLongTermLiabilities Other Long-Term Liabilities Notes 16 false false R17.htm 2116100 - Disclosure - Stock-Based Compensation Sheet http://www.pdl.com/role/StockBasedCompensation Stock-Based Compensation Notes 17 false false R18.htm 2117100 - Disclosure - Cash Dividends Sheet http://www.pdl.com/role/CashDividends Cash Dividends Notes 18 false false R19.htm 2118100 - Disclosure - Customer Concentration Sheet http://www.pdl.com/role/CustomerConcentration Customer Concentration Notes 19 false false R20.htm 2119100 - Disclosure - Income Taxes Sheet http://www.pdl.com/role/IncomeTaxes Income Taxes Notes 20 false false R21.htm 2120100 - Disclosure - Accumulated Other Comprehensive Income (Loss) Sheet http://www.pdl.com/role/AccumulatedOtherComprehensiveIncomeLoss Accumulated Other Comprehensive Income (Loss) Notes 21 false false R22.htm 2122100 - Disclosure - Subsequent Events Sheet http://www.pdl.com/role/SubsequentEvents Subsequent Events Notes 22 false false R23.htm 2125100 - Disclosure - Business Combinations (Notes) Notes http://www.pdl.com/role/BusinessCombinationsNotes Business Combinations (Notes) Notes 23 false false R24.htm 2126100 - Disclosure - Intangibles and Goodwill (Notes) Notes http://www.pdl.com/role/IntangiblesAndGoodwillNotes Intangibles and Goodwill (Notes) Notes 24 false false R25.htm 2127100 - Disclosure - Segment Information (Notes) Notes http://www.pdl.com/role/SegmentInformationNotes Segment Information (Notes) Notes 25 false false R26.htm 2128100 - Disclosure - Inventory (Notes) Notes http://www.pdl.com/role/InventoryNotes Inventory (Notes) Notes 26 false false R27.htm 2129100 - Disclosure - Stockholders' Equity (Notes) Notes http://www.pdl.com/role/StockholdersEquityNotes Stockholders' Equity (Notes) Notes 27 false false R28.htm 2130100 - Disclosure - Revenue from Contracts with Customers (Notes) Notes http://www.pdl.com/role/RevenueFromContractsWithCustomersNotes Revenue from Contracts with Customers (Notes) Notes 28 false false R29.htm 2131100 - Disclosure - Asset Acquisitions (Notes) Notes http://www.pdl.com/role/AssetAcquisitionsNotes Asset Acquisitions (Notes) Notes 29 false false R30.htm 2202201 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.pdl.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.pdl.com/role/SummaryOfSignificantAccountingPolicies 30 false false R31.htm 2303301 - Disclosure - Net Income per Share (Tables) Sheet http://www.pdl.com/role/NetIncomePerShareTables Net Income per Share (Tables) Tables http://www.pdl.com/role/NetIncomePerShare 31 false false R32.htm 2304301 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.pdl.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.pdl.com/role/FairValueMeasurements 32 false false R33.htm 2305301 - Disclosure - Cash Equivalents and Investments (Tables) Sheet http://www.pdl.com/role/CashEquivalentsAndInvestmentsTables Cash Equivalents and Investments (Tables) Tables http://www.pdl.com/role/CashEquivalentsAndInvestments 33 false false R34.htm 2311301 - Disclosure - Accrued Liabilities (Tables) Sheet http://www.pdl.com/role/AccruedLiabilitiesTables Accrued Liabilities (Tables) Tables http://www.pdl.com/role/AccruedLiabilities 34 false false R35.htm 2313301 - Disclosure - Convertible Notes (Tables) Notes http://www.pdl.com/role/ConvertibleNotesTables Convertible Notes (Tables) Tables http://www.pdl.com/role/ConvertibleNotes 35 false false R36.htm 2315301 - Disclosure - Other Long-Term Liabilities (Tables) Sheet http://www.pdl.com/role/OtherLongTermLiabilitiesTables Other Long-Term Liabilities (Tables) Tables http://www.pdl.com/role/OtherLongTermLiabilities 36 false false R37.htm 2318301 - Disclosure - Customer Concentration (Tables) Sheet http://www.pdl.com/role/CustomerConcentrationTables Customer Concentration (Tables) Tables http://www.pdl.com/role/CustomerConcentration 37 false false R38.htm 2325301 - Disclosure - Business Combinations (Tables) Sheet http://www.pdl.com/role/BusinessCombinationsTables Business Combinations (Tables) Tables http://www.pdl.com/role/BusinessCombinationsNotes 38 false false R39.htm 2325302 - Disclosure - Business Combinations Fair Value of Intangible Assets Acquired and Liabilities Assumed (Tables) Sheet http://www.pdl.com/role/BusinessCombinationsFairValueOfIntangibleAssetsAcquiredAndLiabilitiesAssumedTables Business Combinations Fair Value of Intangible Assets Acquired and Liabilities Assumed (Tables) Tables 39 false false R40.htm 2326301 - Disclosure - Intangibles and Goodwill (Tables) Sheet http://www.pdl.com/role/IntangiblesAndGoodwillTables Intangibles and Goodwill (Tables) Tables http://www.pdl.com/role/IntangiblesAndGoodwillNotes 40 false false R41.htm 2326302 - Disclosure - Intangibles and Goodwill Remaining Amortization Expense (Tables) Sheet http://www.pdl.com/role/IntangiblesAndGoodwillRemainingAmortizationExpenseTables Intangibles and Goodwill Remaining Amortization Expense (Tables) Tables 41 false false R42.htm 2327301 - Disclosure - Segment Information (Tables) Sheet http://www.pdl.com/role/SegmentInformationTables Segment Information (Tables) Tables http://www.pdl.com/role/SegmentInformationNotes 42 false false R43.htm 2328301 - Disclosure - Inventory (Tables) Sheet http://www.pdl.com/role/InventoryTables Inventory (Tables) Tables http://www.pdl.com/role/InventoryNotes 43 false false R44.htm 2330301 - Disclosure - Revenue from Contracts with Customers (Tables) Sheet http://www.pdl.com/role/RevenueFromContractsWithCustomersTables Revenue from Contracts with Customers (Tables) Tables http://www.pdl.com/role/RevenueFromContractsWithCustomersNotes 44 false false R45.htm 2331301 - Disclosure - Asset Acquisitions (Tables) Sheet http://www.pdl.com/role/AssetAcquisitionsTables Asset Acquisitions (Tables) Tables http://www.pdl.com/role/AssetAcquisitionsNotes 45 false false R46.htm 2403402 - Disclosure - Net Income per Share (Narrative) (Detail) Sheet http://www.pdl.com/role/NetIncomePerShareNarrativeDetail Net Income per Share (Narrative) (Detail) Details http://www.pdl.com/role/NetIncomePerShareTables 46 false false R47.htm 2403403 - Disclosure - Net Income per Share (Net Income Per Basic and Diluted Share) (Detail) Sheet http://www.pdl.com/role/NetIncomePerShareNetIncomePerBasicAndDilutedShareDetail Net Income per Share (Net Income Per Basic and Diluted Share) (Detail) Details http://www.pdl.com/role/NetIncomePerShareTables 47 false false R48.htm 2404402 - Disclosure - Fair Value Measurements (Narrative) (Detail) Sheet http://www.pdl.com/role/FairValueMeasurementsNarrativeDetail Fair Value Measurements (Narrative) (Detail) Details http://www.pdl.com/role/FairValueMeasurementsTables 48 false false R49.htm 2404403 - Disclosure - Fair Value Measurements (Financial Instruments Measured at Fair Value on a Recurring Basis) (Detail) Sheet http://www.pdl.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetail Fair Value Measurements (Financial Instruments Measured at Fair Value on a Recurring Basis) (Detail) Details http://www.pdl.com/role/FairValueMeasurementsTables 49 false false R50.htm 2404404 - Disclosure - Fair Value Measurements (Schedule of Fair Value of Assets and Liabilities not Subject to Fair Value Recognition) (Detail) Sheet http://www.pdl.com/role/FairValueMeasurementsScheduleOfFairValueOfAssetsAndLiabilitiesNotSubjectToFairValueRecognitionDetail Fair Value Measurements (Schedule of Fair Value of Assets and Liabilities not Subject to Fair Value Recognition) (Detail) Details http://www.pdl.com/role/FairValueMeasurementsTables 50 false false R51.htm 2404405 - Disclosure - Fair Value Measurements Level 3 Unobservable Input Reconciliation (Details) Sheet http://www.pdl.com/role/FairValueMeasurementsLevel3UnobservableInputReconciliationDetails Fair Value Measurements Level 3 Unobservable Input Reconciliation (Details) Details 51 false false R52.htm 2405402 - Disclosure - Cash Equivalents and Investments (Narrative) (Detail) Sheet http://www.pdl.com/role/CashEquivalentsAndInvestmentsNarrativeDetail Cash Equivalents and Investments (Narrative) (Detail) Details http://www.pdl.com/role/CashEquivalentsAndInvestmentsTables 52 false false R53.htm 2405403 - Disclosure - Cash Equivalents and Investments (Summary of Cash and Available-For-Sale Securities) (Detail) Sheet http://www.pdl.com/role/CashEquivalentsAndInvestmentsSummaryOfCashAndAvailableForSaleSecuritiesDetail Cash Equivalents and Investments (Summary of Cash and Available-For-Sale Securities) (Detail) Details http://www.pdl.com/role/CashEquivalentsAndInvestmentsTables 53 false false R54.htm 2407401 - Disclosure - Notes Receivable and Other Long-term Receivables (Narrative) (Detail) Notes http://www.pdl.com/role/NotesReceivableAndOtherLongTermReceivablesNarrativeDetail Notes Receivable and Other Long-term Receivables (Narrative) (Detail) Details http://www.pdl.com/role/NotesReceivableAndOtherLongTermReceivables 54 false false R55.htm 2411403 - Disclosure - Accrued Liabilities (Narrative) (Detail) Sheet http://www.pdl.com/role/AccruedLiabilitiesNarrativeDetail Accrued Liabilities (Narrative) (Detail) Details http://www.pdl.com/role/AccruedLiabilitiesTables 55 false false R56.htm 2411404 - Disclosure - Accrued Liabilities (Accrued Liabilities) (Detail) Sheet http://www.pdl.com/role/AccruedLiabilitiesAccruedLiabilitiesDetail Accrued Liabilities (Accrued Liabilities) (Detail) Details http://www.pdl.com/role/AccruedLiabilitiesTables 56 false false R57.htm 2412402 - Disclosure - Commitments and Contingencies (Narrative) (Detail) Sheet http://www.pdl.com/role/CommitmentsAndContingenciesNarrativeDetail Commitments and Contingencies (Narrative) (Detail) Details http://www.pdl.com/role/CommitmentsAndContingencies 57 false false R58.htm 2413402 - Disclosure - Convertible Notes (Narrative) (Detail) Notes http://www.pdl.com/role/ConvertibleNotesNarrativeDetail Convertible Notes (Narrative) (Detail) Details http://www.pdl.com/role/ConvertibleNotesTables 58 false false R59.htm 2413403 - Disclosure - Convertible Notes (Summary of Convertible Notes) (Detail) Notes http://www.pdl.com/role/ConvertibleNotesSummaryOfConvertibleNotesDetail Convertible Notes (Summary of Convertible Notes) (Detail) Details http://www.pdl.com/role/ConvertibleNotesTables 59 false false R60.htm 2413404 - Disclosure - Convertible Notes (Summary of Series 2012 Notes) (Detail) Notes http://www.pdl.com/role/ConvertibleNotesSummaryOfSeries2012NotesDetail Convertible Notes (Summary of Series 2012 Notes) (Detail) Details http://www.pdl.com/role/ConvertibleNotesTables 60 false false R61.htm 2413406 - Disclosure - Convertible Notes (Summary of May 2015 Notes) (Detail) Notes http://www.pdl.com/role/ConvertibleNotesSummaryOfMay2015NotesDetail Convertible Notes (Summary of May 2015 Notes) (Detail) Details http://www.pdl.com/role/ConvertibleNotesTables 61 false false R62.htm 2413408 - Disclosure - Convertible Notes Convertible Notes (Summary of February 2018 Notes) (Detail) (Details) Notes http://www.pdl.com/role/ConvertibleNotesConvertibleNotesSummaryOfFebruary2018NotesDetailDetails Convertible Notes Convertible Notes (Summary of February 2018 Notes) (Detail) (Details) Details 62 false false R63.htm 2413409 - Disclosure - Convertible Notes Convertible Notes (Interest Expense for February 2018 Notes) (Detail) (Details) Notes http://www.pdl.com/role/ConvertibleNotesConvertibleNotesInterestExpenseForFebruary2018NotesDetailDetails Convertible Notes Convertible Notes (Interest Expense for February 2018 Notes) (Detail) (Details) Details 63 false false R64.htm 2413410 - Disclosure - Convertible Notes Convertible Notes (Summary of December 2021 Notes) (Details) Notes http://www.pdl.com/role/ConvertibleNotesConvertibleNotesSummaryOfDecember2021NotesDetails Convertible Notes Convertible Notes (Summary of December 2021 Notes) (Details) Details 64 false false R65.htm 2413411 - Disclosure - Convertible Notes Convertible Notes (Interest Expense for December 2021 Notes) (Details) Notes http://www.pdl.com/role/ConvertibleNotesConvertibleNotesInterestExpenseForDecember2021NotesDetails Convertible Notes Convertible Notes (Interest Expense for December 2021 Notes) (Details) Details 65 false false R66.htm 2415402 - Disclosure - Other Long-Term Liabilities (Narrative) (Detail) Sheet http://www.pdl.com/role/OtherLongTermLiabilitiesNarrativeDetail Other Long-Term Liabilities (Narrative) (Detail) Details http://www.pdl.com/role/OtherLongTermLiabilitiesTables 66 false false R67.htm 2415403 - Disclosure - Other Long-Term Liabilities (Other Long-Term Liabilities) (Detail) Sheet http://www.pdl.com/role/OtherLongTermLiabilitiesOtherLongTermLiabilitiesDetail Other Long-Term Liabilities (Other Long-Term Liabilities) (Detail) Details http://www.pdl.com/role/OtherLongTermLiabilitiesTables 67 false false R68.htm 2416405 - Disclosure - Stock-Based Compensation (Summary of Stock Option and Restricted Stock Award Activity) (Detail) Sheet http://www.pdl.com/role/StockBasedCompensationSummaryOfStockOptionAndRestrictedStockAwardActivityDetail Stock-Based Compensation (Summary of Stock Option and Restricted Stock Award Activity) (Detail) Details http://www.pdl.com/role/StockBasedCompensation 68 false false R69.htm 2417402 - Disclosure - Cash Dividends (Narrative) (Detail) Sheet http://www.pdl.com/role/CashDividendsNarrativeDetail Cash Dividends (Narrative) (Detail) Details http://www.pdl.com/role/CashDividends 69 false false R70.htm 2418403 - Disclosure - Customer Concentration (Percentage of Total Revenue From Licenses Over 10% of Revenue) (Detail) Sheet http://www.pdl.com/role/CustomerConcentrationPercentageOfTotalRevenueFromLicensesOver10OfRevenueDetail Customer Concentration (Percentage of Total Revenue From Licenses Over 10% of Revenue) (Detail) Details http://www.pdl.com/role/CustomerConcentrationTables 70 false false R71.htm 2419402 - Disclosure - Income Taxes (Narrative) (Detail) Sheet http://www.pdl.com/role/IncomeTaxesNarrativeDetail Income Taxes (Narrative) (Detail) Details http://www.pdl.com/role/IncomeTaxes 71 false false R72.htm 2420403 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Schedule of Balances of Accumulated Other Comprehensive Income (Loss)) (Detail) Sheet http://www.pdl.com/role/AccumulatedOtherComprehensiveIncomeLossScheduleOfBalancesOfAccumulatedOtherComprehensiveIncomeLossDetail Accumulated Other Comprehensive Income (Loss) (Schedule of Balances of Accumulated Other Comprehensive Income (Loss)) (Detail) Details http://www.pdl.com/role/AccumulatedOtherComprehensiveIncomeLoss 72 false false R73.htm 2422401 - Disclosure - Subsequent Events (Narrative) (Detail) Sheet http://www.pdl.com/role/SubsequentEventsNarrativeDetail Subsequent Events (Narrative) (Detail) Details http://www.pdl.com/role/SubsequentEvents 73 false false R74.htm 2425403 - Disclosure - Business Combinations (Details) Sheet http://www.pdl.com/role/BusinessCombinationsDetails Business Combinations (Details) Details http://www.pdl.com/role/BusinessCombinationsTables 74 false false R75.htm 2425404 - Disclosure - Business Combinations Proforma (Details) Sheet http://www.pdl.com/role/BusinessCombinationsProformaDetails Business Combinations Proforma (Details) Details 75 false false R76.htm 2425405 - Disclosure - Business Combinations Asset and Liabilities Acquired (Details) Sheet http://www.pdl.com/role/BusinessCombinationsAssetAndLiabilitiesAcquiredDetails Business Combinations Asset and Liabilities Acquired (Details) Details 76 false false R77.htm 2426403 - Disclosure - Intangibles and Goodwill (Details) Sheet http://www.pdl.com/role/IntangiblesAndGoodwillDetails Intangibles and Goodwill (Details) Details http://www.pdl.com/role/IntangiblesAndGoodwillTables 77 false false R78.htm 2426404 - Disclosure - Intangibles and Goodwill Schedule of Finite-Lived Intangible Asset Amortization Expense (Details) Sheet http://www.pdl.com/role/IntangiblesAndGoodwillScheduleOfFiniteLivedIntangibleAssetAmortizationExpenseDetails Intangibles and Goodwill Schedule of Finite-Lived Intangible Asset Amortization Expense (Details) Details 78 false false R79.htm 2427402 - Disclosure - Segment Information (Details) Sheet http://www.pdl.com/role/SegmentInformationDetails Segment Information (Details) Details http://www.pdl.com/role/SegmentInformationTables 79 false false R80.htm 2428402 - Disclosure - Inventory (Details) Sheet http://www.pdl.com/role/InventoryDetails Inventory (Details) Details http://www.pdl.com/role/InventoryTables 80 false false R81.htm 2429402 - Disclosure - Stockholders' Equity (Details) Sheet http://www.pdl.com/role/StockholdersEquityDetails Stockholders' Equity (Details) Details http://www.pdl.com/role/StockholdersEquityNotes 81 false false R82.htm 2430402 - Disclosure - Revenue from Contracts with Customers (Details) Sheet http://www.pdl.com/role/RevenueFromContractsWithCustomersDetails Revenue from Contracts with Customers (Details) Details http://www.pdl.com/role/RevenueFromContractsWithCustomersTables 82 false false R83.htm 2430403 - Disclosure - Revenue from Contracts with Customers Contract Assets and Liabilities (Details) Sheet http://www.pdl.com/role/RevenueFromContractsWithCustomersContractAssetsAndLiabilitiesDetails Revenue from Contracts with Customers Contract Assets and Liabilities (Details) Details 83 false false R84.htm 2430404 - Disclosure - Revenue from Contracts with Customers Transaction Price Allocated to the Remaining Performance Obligations (Details) Sheet http://www.pdl.com/role/RevenueFromContractsWithCustomersTransactionPriceAllocatedToRemainingPerformanceObligationsDetails Revenue from Contracts with Customers Transaction Price Allocated to the Remaining Performance Obligations (Details) Details 84 false false R85.htm 2431403 - Disclosure - Asset Acquisitions Asset Acquisition Details (Details) Sheet http://www.pdl.com/role/AssetAcquisitionsAssetAcquisitionDetailsDetails Asset Acquisitions Asset Acquisition Details (Details) Details 85 false false All Reports Book All Reports pdli-20180630.xml pdli-20180630.xsd pdli-20180630_cal.xml pdli-20180630_def.xml pdli-20180630_lab.xml pdli-20180630_pre.xml http://fasb.org/us-gaap/2017-01-31 http://xbrl.sec.gov/dei/2014-01-31 http://xbrl.sec.gov/invest/2013-01-31 true true ZIP 106 0000882104-18-000091-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000882104-18-000091-xbrl.zip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end

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�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